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Glossary 
Acute HIV infection (AHI) The first 30 days following HIV infection. Clinically 
identified by a HIV test interval ≤30 days or by laboratory 
evidence of AHI (absence of HIV antibody with either 
detectable p24 antigen, or HIV RNA). 
Agency Defined by Bandura as "the capacity to exercise control 
over nature and the quality of one's life" 1.  
Casual partner A partner with whom the index has had sex with once 
only. 
ChemSex The use of specific illegal substances immediately before 
or during sex to increase the pleasure, duration and 
intensity of sex. The exact illegal substances included in 
the definition vary according to the study but almost 
always include the following three drugs: 
methamphetamine (crystal/crystal 
meth/meth/ice/glass/Tina), mephedrone 
(meph/drone/meow meow/plant food/MCAT) and GHB 
(Gammahydroxybutyrate) or GBL (Gammabutyrolactone). 
Early ART Initiation of ART during early HIV infection; either as 
short-course ART initiated during PHI or long term ART at 
CD4 count>350. 
Early HIV infection (EHI) The first 12 months of HIV infection. 
Enacted stigma Defined by Scambler as the experience of discrimination 
from others based on a personal characteristic2, for 
example being HIV positive. Also known as external 
stigma or discrimination. 
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Felt stigma Defined by Scambler as the experience of feelings of 
shame due to a personal characteristic, or the fear of 
experiencing enacted stigma 2. Also known as internal 
stigma or self-stigmatisation. 
HIV test interval The time interval elapsed between HIV antibody negative 
and positive tests. This is 0 if the patient presents with 
laboratory evidence of AHI (absence of HIV antibody with 
either detectable p24 antigen, or HIV RNA) or is RITA 
incident. 
HIV treatment optimism  The belief that HIV is less serious due to the availability of 
ART. It can be further categorised into health optimism, 
the belief that ART improves personal health, and 
transmission optimism, the belief that ART reduces risk of 
HIV transmission3. 
Primary HIV infection (PHI) The first 6 months following HIV infection. 
Regular partner A partner with whom the index has had sex with more 
than once. 
Risk compensation Increased engagement in sexual behaviours that carry a 
high risk of HIV transmission, due to a perceived lower 
risk of HIV acquisition or transmission. 
Self-efficacy Defined by Bandura as "the belief in one’s capabilities to 
organize and execute the courses of action required to 
manage prospective situations."1. 
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Sero-adaptive behaviours Modification of sexual practices to reduce HIV 
transmission, based on the known HIV status of one's 
sexual partner. Examples include serosorting and 
strategic positioning. 
Seroconcordant sex Sex with a partner who is known to have the same HIV 
status as oneself. 
Seroconversion date Estimated as the midpoint date in the HIV test interval 
(see definition above), or the date RITA incident, or the 
date tested p24/HIV RNA positive and antibody negative. 
Seroconversion date is commonly used as a proxy for 
date of HIV infection. 
Serodiscordant sex Sex with a partner who is known to have the opposite 
HIV status as the index partner. In the analyses included 
in this thesis serodiscordant sex is also considered to 
have occurred if the partner's HIV status was unknown. 
Serosorting Intentional selection of sexual partners known to have 
the same HIV-status as the index, for example, an HIV-
positive MSM practises exclusive serosorting if he only 
has sex with men he knows to be HIV positive.  
Short-course ART ART initiated in PHI with the intention of stopping at 
some point in the future, usually, but not exclusively, 
after 3-12 months.  
Strategic positioning Intentional selection of sexual positioning to minimise 
HIV transmission risk with partners who are known to be 
serodiscordant, or have unknown HIV status as the index.   
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Transient ART See short-course ART. 
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Abstract 
High viraemia in early HIV infection (EHI) may contribute disproportionately to onward 
transmission in men who have sex with men (MSM) but early antiretroviral therapy (ART) 
could minimise risk of transmission. The effectiveness of this strategy depends on viral load 
(VL) at presentation, sexual behaviour and ART acceptability, which are unknown. This 
thesis combines quantitative and qualitative methods to understand the acceptability and 
utility of early ART to reduce HIV transmission in UK MSM.  
Using UK Register of HIV Seroconverters data I examined temporal trends in ART initiation 
and VL at presentation, using Kaplan-Meier and logistic regression. An in-depth interview 
and cross-sectional survey explored and quantified men’s attitudes, beliefs and 
acceptability of early ART and sexual behaviour. Using logistic regression I examined factors 
associated with early ART initiation and high-risk sex post diagnosis. 
VL peaked in men presenting ~30 days post-seroconversion, plateauing ~day 100. 
Median(95% CI) time from seroconversion to ART initiation decreased, from 3.7(3.2,4.9) 
years pre-2000 to 1.4(1.3,1.7) in 2010-11. Early ART was acceptable; 67%(76/114) would 
have accepted it at diagnosis and 47%(55/116) had initiated it. ART initiation was more 
likely if men believed it had health benefits or their clinician recommended it. It was 
perceived to reduce transmission anxiety and provide holistic health benefits, but fear of 
toxicities and stigma were potential barriers to initiation. Transmission risk was low post-
diagnosis; 32%(37/117) abstained from sex and 21%(24/117) exclusively used condoms. 
However, 35%(41/117) reported high-risk sex, associated with treatment optimism, 
ChemSex and higher partner numbers pre-diagnosis.  
Early ART was acceptable to MSM to prevent transmission, and for perceived holistic health 
benefits. It is unlikely, however, to be effective in reducing transmission risk during peak 
viraemia given the low proportion presenting at that stage. Expansion of HIV testing is 
required to identify MSM during that stage. 
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Thesis Overview 
This multidisciplinary mixed-methods PhD sought to use a combination of epidemiological 
and social science approaches to answer the overarching research question:  
“Is early antiretroviral therapy acceptable to men who have sex with 
men (MSM) with early HIV infection attending UK HIV clinics, and could it 
be used in this population to reduce HIV transmission?” 
 
In chapter 1, I provide a background to the thesis by first situating the research idea in the 
context of the state of knowledge about treatment as prevention (TasP) when I embarked 
on the PhD. I then give an outline of the global and UK HIV epidemic and describe the 
natural history and life cycle of HIV. I discuss the virological and immunological events 
which occur in early HIV infection (EHI) in more detail and outline the methods used to 
identify recent seroconverters. Finally, I provide an overview of the factors important in 
determining onward transmission of HIV. 
Chapter 2 contains the results from two scoping literature reviews, designed to answer the 
following questions: “What role does EHI play in the secondary transmission of HIV?” and 
“What is the rationale for initiation of ART in EHI?”. For this part of the thesis I designed the 
search strategies, reviewed the identified article titles and abstracts for inclusion, charted 
the data and wrote the reviews. The first literature review presents data published up until 
the end of 2009, when I finalised my research question, to illustrate the role that recent HIV 
seroconverters may play in onward transmission of HIV. The second presents a scoping 
review of literature outlining the rationale for initiation of early ART, including literature 
published , or presented at key conferences, up until the end of 2010 when I upgraded from 
MPhil to PhD. Relevant literature published after these dates are included in the discussion, 
chapter 7. At the end of this chapter I outline the rationale for my thesis and present the 
overarching research question.  
In chapter 3 I outline the methodology and methods I employed during my PhD. A brief 
description of mixed methods research is presented with a rationale for the selection of this 
approach to answer the overarching research question. I outline the study design and 
present the overall aims and research questions for each part of the PhD: workstream 1, 
which involved statistical analysis of UK Register of HIV Seroconverters (UK Register) data; 
and workstream 2, comprising of both phase A, the in-depth interview study; and phase B, 
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the cross-sectional survey.  I then provide the full methods for these three parts which 
combine to address the overarching research question.  
In chapter 4 I provide the results of workstream 1, the statistical analysis of data from the 
UK Register. Here I aimed to examine how high viral load is when HIV seroconverters 
present to clinic in the UK, what the median time to ART initiation is and whether these 
have changed over time. For these analyses I was responsible for determining and refining 
the research questions, downloading and cleaning the data from the UK Register database 
and operationalising the dependent, and independent, variables of interest. I designed and 
conducted the statistical analyses and interpreted the results. I presented this work as a 
poster at the British HIV Association (BHIVA) Spring conference, Liverpool, in April 2009 
(appendix 1), at the Conference on Retroviruses and Opportunistic Infections (CROI), 
Boston in March 2014 (appendix 2), and as an oral presentation at the BHIVA Spring 
conference, Liverpool, in April 2014 (appendix 3). Selected results were also published in a 
review article by Hamlyn et al, of which I was a co-author 4. 
In chapter 5 I provide the results from workstream 2, phase A, the in-depth interview study. 
The aim of this part of the PhD was to explore the experience of MSM with EHI around the 
time of HIV infection and diagnosis, to understand their priorities at this time and their 
attitudes and beliefs in relation to early ART. I was responsible for designing the study, 
writing the protocol, developing the topic guide and applying for NHS permission to 
conduct the study. I liaised with staff at the recruitment clinic to initiate the study and 
recruited the men for the study. I co-ordinated the study for the duration and conducted all 
of the in-depth interviews. I then coded and analysed the data using a framework 
approach, facilitated through use of NVivo, interpreted the results, and developed attitude 
and belief statements and questions for the cross-sectional survey questionnaire in phase 
B, the cross-sectional survey. I presented the findings from this qualitative work as a poster 
at the HIV Therapy conference, Glasgow, in November 2014 (appendix 4).  
In chapter 6 I present the results from the cross-sectional survey of MSM recruited to the 
UK Register. This study aimed to estimate the prevalence of certain attitudes and beliefs 
towards early ART in a UK-wide population of MSM with EHI and was informed by the 
qualitative study presented in the previous chapter. It also aimed to examine ART 
acceptability and uptake in this population and the factors associated with early ART 
initiation, along with sexual behaviour after HIV diagnosis, and factors associated with 
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behaviours which carried a high risk of HIV transmission. For this phase, I was responsible 
for designing the sub-study and refining the research questions. I designed and developed 
the questionnaire using a combination of previously validated questions from other 
questionnaires designed for use by HIV-positive MSM and newly-developed questions, and 
newly developed items based on findings from my in-depth interview study. I then piloted 
the questionnaire and validated the questions and statements through conducting 
cognitive interviews with MSM with EHI. I refined the questionnaire design and item 
wording based on the results of those interviews. I designed and formatted the layout of 
the final questionnaire using Microsoft Word and co-ordinated the professional printing of 
the questionnaires. I completed the necessary paperwork to gain NHS ethics approval to 
conduct the survey as a sub-study, and worked with the UK Register study manager Louise 
Walker-Nthenda, to obtain NHS research and development (R&D) approval for each of the 
participating HIV clinics. I liaised with participating centres, presenting the study in person 
to clinic staff and investigators where necessary, and co-ordinated the running of the 
survey for its duration. I designed a Microsoft Access database in which to enter the data 
from the questionnaires and performed the data entry. I cleaned the final dataset, merged 
it with clinical and demographic data downloaded from the UK Register database, 
determined eligible respondents, then cleaned and recoded the final dataset ready for 
analysis. I designed and performed the statistical analyses of the survey data and 
interpreted the results. I presented this work as a poster at the International Workshop of 
HIV Observational Databases (IWHOD), Catania, in March 2015 (appendix 5) and BHIVA 
Spring conference, Brighton, in April 2015 (appendix 6).  
Chapter 7 contains the overall discussion for the thesis. Here, I discuss the overall findings 
from the two workstreams in relation to the overall research question, highlighting where 
they complement and contrast each other, and in the context of work which was published 
from 2010 onwards, i.e. (after my literature review and research question were finalised). 
Whilst the strengths and limitations of the individual workstreams and phases of the study 
are discussed at the end of the individual results chapters (4, 5 and 6), here I provide an 
overview of the strengths and limitations of adopting a mixed-methods approach, along 
with some of the difficulties encountered during the process. Finally, I highlight areas in 
need of future research and provide implications for policy.  
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1 Background 
This chapter forms a background to the thesis, first giving a flavour of the research focus on 
TasP when I first started this PhD, in October 2008. I then give an overview of the global 
and UK epidemiology of HIV infection, the natural history of HIV and AIDS, the life-cycle of 
the HIV virion and how it interacts with the host’s immune system, and how ART interrupts 
this life-cycle. I then focus on early HIV infection (EHI), defined here as the first year 
following infection, and the immunological events which occur at this time, outlining the 
various methods of identifying EHI. Finally, I provide an overview of the factors influencing 
HIV transmission.  
 A bold statement 1.1
In January 2008, the Swiss National AIDS Commission released a statement written in 
French and German by four prominent doctors in Swiss HIV medicine for circulation to 
Swiss clinicians. This statement has since become so internationally renowned now it is 
now known simply as “The Swiss Statement”. It stated that:  
"An HIV-infected person on antiretroviral therapy with completely 
suppressed viraemia (“effective ART”) is not sexually infectious, i.e. 
cannot transmit HIV through sexual contact.”. 
Vernazza et al (2008) 5 
 
With a further qualification that the statement was valid as long as all of the following three 
circumstances held true;  
1. “The person adheres to antiretroviral therapy, the effects of which 
must be evaluated regularly by the treating physician.”  
2. “The viral load has been suppressed below the limits of detection 
(i.e. below 40 copies/mL) for at least six months.” 
3. “There are no other sexually transmitted infections.” 
Vernazza et al (2008) 5 
 
By releasing the statement authors wished for as many as possible of the 17,000 people 
living with HIV (PLWH) in Switzerland to have a “normal sexual life”.  In short, the paper 
was intended to guide the management of individual risk of HIV transmission between 
serodiscordant monogamous partners. However, global circulation of the paper over the 
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internet meant it swiftly became one of the most hotly debated topics in HIV research, as it 
had major implications for public health 6,7. Did the reduced transmission risk afforded by 
effective ART, have the potential to reduce the global pandemic if rolled out at a population 
level?  
Whilst few healthcare professionals and researchers doubted that undetectable viral load 
meant less chance of transmission, many were reticent to claim zero risk of transmission 7. 
At this time the HPTN-052 trial was under way to address whether ART can reduce the risk 
of HIV transmission in serodiscordant couples, though the results were not expected for a 
number of years. Further questions were asked about the relevance of the Swiss Statement 
to MSM, as the scientific evidence underlying the statement was largely from studies 
conducted with heterosexual couples. Some HIV advocacy and prevention groups insisted 
that the three stipulations that needed to be met for an individual to be classed as 
“uninfectious” were too nuanced and complicated to be communicated to people living 
with HIV PLWH in a way that could be understood and incorporated into everyday life. 
Furthermore, there were concerns that risk compensation may occur (whereby high-risk 
sexual behaviour increases due to a perceived lower risk of HIV transmission), enacted 
primarily by abandonment of condom use. On the other hand, other groups welcomed the 
statement as liberating, citing the stigma reduction, the potential effect on HIV 
criminalisation laws and the addition of a new method risk-reduction for men to use as 
major benefits 7.  
At the time of the Swiss Statement’s release, ART was being recommended by BHIVA for 
PLWH before CD4 count fell below 350 cells/mm3, or specifically in primary HIV infection 
(PHI) if they had an AIDS defining illness or neurological involvement. Under these 
guidelines any potential public health benefit of TasP would be limited to partners of these 
individuals, unless expansion of the number of PLWH on ART occurred through earlier 
initiation. As yet, there was no randomised clinical trial evidence of additional clinical 
benefit afforded by earlier ART initiation (specifically in PHI or at higher CD4 counts), 
although trials to rectify this were already underway. The International Network for 
Strategic Initiatives in Global HIV Trials (INSIGHT) study group were planning the Strategic 
Timing for Antiretroviral Therapy (START) trial which would compare clinical outcomes 
between individuals randomised to initiate ART at CD4≥500 cells/mm3 and those 
randomised to defer therapy to CD4≤350. For some years there had been research 
investigating the use of immediate short-course ART during PHI, with the UK-run Short-
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Course Antiretroviral Therapy in Primary HIV Infection (SPARTAC) trial underway to address 
the question as to whether it could delay disease progression.  
In October 2008, amid international research focus on both the potential public health 
impact of TasP and the health benefits of early HIV treatment, I started this PhD. I had been 
awarded a Medical Research Council studentship to investigate the acceptability of early 
ART amongst recent HIV seroconverters in the UK, by using a mixed methods approach and 
existing data from the UK Register of HIV seroconverters.  
 Epidemiology of HIV 1.2
Since the first cases of AIDS were described in the USA in 1981, HIV has spread rapidly 
across the world so that  at the time of embarking on this thesis, an estimated 33.3 million 
people were living with HIV worldwide 8. As can be seen in figure 1.1, the largest burden of 
HIV is in sub-Saharan Africa, where 68% of all PLWH reside, equating to a prevalence of 5% 
of the adult population (15-49 years). In sub-Saharan countries, the HIV epidemic is largely 
generalised with the main route of transmission through heterosexual sex. Comparatively, 
Western Europe has a much lower burden of HIV with 820,000 cases estimated in 2009, 
equating to a prevalence of 0.2% in the adult population. The epidemic in Western Europe 
is more diverse than that of sub-Saharan Africa, with a large proportion of transmissions 
attributable to unprotected sex between men and, to a lesser extent, injecting drug use 
(IDU), as well as sex between men and women 8.  
In the UK in 2009, the estimated number of people living with HIV was 86,500 with a 
disproportionate number of MSM represented in these statistics 9. Of 6,630 individuals 
newly diagnosed in 2009, 2,760 (41.6%) were within this risk group (see figure 1.2). Whilst a 
year on year decline in the number of newly diagnosed PLWH have been observed in the 
UK since 2005, this is largely due to the decline in heterosexually acquired infections abroad 
with no comparable decrease observed amongst MSM 9.  Furthermore, a higher proportion 
of recent infections in 2009 was also observed amongst MSM, compared to heterosexuals, 
with 1 in 6 infections identified as probably contracted in the last 4-5 months amongst 
MSM compared to 1 in 16 for heterosexual PLWH 9. 
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Figure 1.1 Global HIV prevalence in 2009 
 
Source: UNAIDS (2009) 8 
Figure 1.2 Number of new HIV diagnoses in the UK by prevention group: 2000-2009 
 
Source: Health Protection Agency (2009) 9 
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 HIV and ART 1.3
HIV is a retrovirus 10–12 which is transmitted between humans through sexual  
intercourse 13–15, contact between broken skin or mucosa and blood or other bodily 
secretions for example through the sharing of contaminated needles 16, blood or organ 
transfusion 17, and through mother to child (vertical) transmission in the womb, during birth 
18,19 or through breastfeeding 20,21. Without treatment, HIV eventually depletes the host’s 
immune system leaving them susceptible to a range of opportunistic infections and AIDS-
defining conditions, followed by death.  
HIV can be categorised into two types HIV-1 and HIV-2 22,23, with HIV-1 being the 
predominant virus globally and HIV-2 accounting for comparably few infections which are 
mostly geographically limited to West Africa 8. Within HIV-1, the virus can be arranged into 
four groups (see figure 1.3) which are thought to correspond to four isolated introductions 
of simian immunodeficiency virus into the human population. The majority of HIV infections 
globally are group “M” viruses, though there are nine subtypes within this group: A, B, C, D, 
F, G, H, J, K, as well as numerous hybrid combinations of subtypes, known as CRFs 
(circulating recombinant forms), a product of viral reproduction in the cells of a host 
infected with two subtypes 24. Whilst the original distribution of subtypes showed distinct 
patterns by risk group and geographic region, immigration and sexual mixing have now 
blended these somewhat 25,26. The predominant subtype found in the UK remains subtype 
B, accounting for around 40% of all HIV infections acquired in the UK 27.  Whilst historically 
this subtype was associated solely with MSM, a recent analysis reported that heterosexual 
HIV exposures now accounted for 22% of subtype B infections in the UK 27.  
 The natural course of HIV infection and its clinical manifestations 1.3.1
A schematic overview of the full natural history of HIV infection is depicted in figure 1.4, 
which shows HIV viral dynamics alongside the host’s immunological changes over the 
course of infection, as measured by CD4 count. Broadly speaking, HIV infection is typically 
described as having three phases: the acute phase, comprising the first month of infection; 
the latent phase, which is sometimes described as asymptomatic infection; and AIDS, or 
late stage disease, when the immune system is too damaged to function efficiently.   
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Figure 1.3 HIV types, groups and subtypes 
 
Source: http://www.aids.info/symptomstypes/HIV-types-groups-and-subtypes 28 
  
Figure 1.4 Schematic representation of the natural history of HIV infection 
 
Source: Fauci (2007) 29  
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HIV, identified in the form of HIV-RNA most commonly through polymerase chain reaction 
(PCR), but also branched DNA (B-DNA) or nucleic acid sequence based amplification 
(NASBA) assays, is detectable in blood plasma on average between 4 and 11 days following 
infection 30. Viral replication occurs at a very rapid rate at this time with blood plasma viral 
load documented to rise to over 1 million (6 log10) copies/mL whilst the virus remains 
largely unrecognised by the host’s immune system 31, see figure 1.4.  A rapid decline in 
plasma viraemia occurs around the same time as seroconversion as the immune system 
mounts a full scale attack on the virus. Eventually, viral load falls to a point where it reaches 
a plateau; this is termed the viral “set point” or “steady state”.   
Much variation in the timing and titre of peak viral load and set point has been 
demonstrated between individuals. Using a mathematical modelling approach Pilcher et al  
estimated peak viraemia was reached at approximately day 20 after infection with set point 
occurring around day 54 32. Conversely, set point has been demonstrated to occur much 
later when estimated using data from large epidemiological cohorts; the  
CASCADE collaboration estimated set point to be reached at around 10 months post-
seroconversion 33.  The titre at which viral set-point occurs varies between individuals and 
has been linked to disease progression rates, with those at higher risk of rapid progression 
if viral set point is higher 34,35. After reaching set-point, viral load increases gradually and is 
accompanied by a corresponding decrease in the host’s CD4 count which eventually, 
reduces the capacity of the immune system to such a level the host becomes susceptible to 
AIDS defining conditions. 
Shortly after infection, an immune response is mounted by the host. This involves 
activation of CD4+ CCR5+ T cells (CD4 cells), before the development of HIV specific 
antibody. The development of HIV-specific antibodies is termed seroconversion. These 
antibodies have been shown to be detectable a median of 2.4 months following the 
appearance of HIV-DNA in the blood plasma 36. Some individuals exhibit symptoms around 
the time of seroconversion, termed acute retroviral syndrome or seroconversion illness, 
though many remain asymptomatic. It is currently unknown whether acute retroviral 
syndrome is caused by the high viraemia experienced at this time or the actual immune 
response to infection. The proportion of newly infected individuals who report experiencing 
acute retroviral syndrome varies considerably and has been documented to be between 40-
85% amongst cohorts of recently infected individuals 30,37,38. If acute retroviral syndrome 
develops, symptoms are usually non-specific and vary considerably between individuals, 
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the most commonly reported symptoms being fever, fatigue and a macro-papular rash 30,39. 
Of note, the majority of the work performed examining acute retroviral syndrome has been 
amongst cohorts of recent seroconverters diagnosed early in infection and the lack of 
control data in these studies, in addition to potentially long recall periods, introduces the 
possibility of bias in the estimation of the proportion of individuals who experience 
symptoms. 
In the absence of HIV-treatment, over time the host’s CD4 cells are depleted to such a low 
level that the immune system can no longer fulfil its function to protect from opportunistic 
infections and illnesses.  Advanced HIV infection occurs when CD4 count falls below 200 
cells/mm3, and may be accompanied by an AIDS diagnosis if one or more AIDS defining 
illnesses are also present. The average time elapsed between exposure to HIV and the 
diagnosis of AIDS is known as the incubation period, and the has been estimated to last 
around 9 years; ranging between 8.3 years to 9.8 years 40,41. Individual variation is vast, 
however, and incubation period duration has been demonstrated to decrease with 
increasing age at HIV infection 42–44. 
In the absence of ART, median survival time following AIDS diagnosis has been estimated at 
11 months 45. Older age at AIDS diagnosis has been shown to be associated with shorter 
survival and higher CD4 counts at AIDS diagnosis predict longer survival 45.  Estimated 
survival post-AIDS diagnosis also depends on AIDS defining conditions; ranging from 3 
months for HIV neurological AIDS defining conditions to 31 months for candidiasis 46. In 
developed countries where ART is available and accessible, these survival estimates are 
largely irrelevant as intervention with ART increases survival markedly. In the UK, Ewings et 
al 47 described a 97% reduction in the risk of death amongst those seroconverting in 2004-6 
(the HAART era) compared to prior to 1996 (the pre-HAART era); over this time the 
proportion of seroconverters surviving for 10 years after their estimated date of 
seroconversion increased from 50% prior to 1996 to 94% in 2004-2006.  
Preventing disease progression to AIDS is not the only goal of ART; analysis of data from the 
Strategic Management of Antiretroviral Therapy (SMART) study also highlighted a high risk 
of death from non-AIDS defining renal, hepatic and cardiovascular conditions 48.  
Associations have subsequently been found between uncontrolled viraemia and biomarkers 
of coagulation and inflammation 49, underlining the importance of virological control 
through use of ART.  
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 HIV life cycle and the influence of ART 1.3.2
Whilst it is important to understand the typical disease course of HIV and progression to 
AIDS the availability of sensitive and specific diagnostic tests for HIV, coupled with the 
widespread availability of effective ART, has altered the typical course of HIV progression in 
treated individuals. ART has dramatically decreased the morbidity and mortality caused by 
HIV/AIDS 35,50–52 and extended life expectancy for PLWH to near that of their HIV negative 
counterparts 53.  As the focus of my PhD is on MSM with recent HIV infection in the UK, 
where PLWH currently have access to ART free at the point of use, the next section details 
the natural life cycle of a HIV virion including how and when the different ART classes 
disrupt viral reproduction (see figure 1.5). 
Since the US Food and Drug Administration (FDA) approved the use of the first 
antiretroviral agent Zidovudine (AZT) in 1987, there have been a multitude of new drugs 
licensed to treat HIV. These can be grouped into different drug classes according to which 
part of the HIV life cycle they affect.  There are currently six therapeutic classes of anti-HIV 
medication available: CCR5 inhibitors, fusion inhibitors, non-nucleoside reverse 
transcriptase inhibitors (NNRTI), nucleoside reverse transcriptase inhibitors (NRTI), 
integrase inhibitors and protease inhibitors.  
After permeating the mucosa and entering the host organism, a HIV virion will bind with 
the CCR5 receptors on the surface of a CD4+ T-lymphocytes (CD4) cells. The viral envelope 
and the CD4 cell membrane fuse and allow the viral RNA and reverse transcriptase to enter 
the CD4 cell cytoplasm. Two drug classes act at this point of the life cycle: CCR5 inhibitors 
act by effectively blocking the CCR5 receptor, so that the virion may not bind with the CD4 
cell to begin with 54; and fusion inhibitors prevent a bound virion from fusing to the CD4 cell 
and permeating the cell membrane 55. 
In the absence of any therapy, the reverse transcriptase in the virion’s cytoplasm is used by 
the virus to convert HIV RNA to HIV DNA. The NRTI and NNRTI drug classes act at this point 
to interrupt the conversion of HIV RNA to DNA. In the absence of these drugs however the 
newly created HIV DNA passes through the CD4 cell nucleus membrane and, once inside, 
integrase is used by HIV to integrate viral DNA into the CD4 cell DNA thus allowing use of 
the protein creating capabilities of the CD4 cell to make HIV protein chains. The fifth drug 
class integrase inhibitors act here to prevent the integration of CD4 and HIV DNA. HIV 
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infected CD4 cells where the HIV DNA has successfully fused with the cell DNA are called 
proviral cells, and these cells can lie dormant for weeks and even years.  
The HIV protein chains and HIV RNA created in the CD4 cytoplasm migrate to the cell 
surface membrane where they assemble and prepare to exit the CD4 cell as immature and 
uninfectious HIV. Protease is then released within the immature viral particle which serves 
to break up the long protein chains to smaller proteins. These proteins combine to form 
mature, and now infectious, HIV which bind with further CD4 cells so that the process 
repeats. The final class of anti-HIV medication are the protease inhibitors and these act to 
block the effect of the protease enzyme, which prevents the immature HIV virion from 
maturing and becoming infectious.  
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Figure 1.5 HIV virion life cycle including target areas for antiretroviral therapy 
 
Source: https://aidsinfo.nih.gov/education-materials/fact-sheets/19/73/the-hiv-life-cycle 56 
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 Early HIV infection 1.4
So far I have presented a brief overview of the natural course of HIV infection, however as 
the population under focus in this thesis are individuals with EHI, it is important to delve 
deeper into the events occurring over this initial period. In order to do this, it is necessary 
to clarify the nomenclature of this early period of HIV infection as the terms “early 
infection”, “primary infection” and “acute infection” are often used inter-changeably in the 
literature. For the purpose of this thesis I will define early infection as the first year 
following HIV infection, primary infection as the 6 month period following infection and 
acute infection as the first 30 days following HIV infection. The main focus of this thesis is 
early infection, the one-year period following infection, which encompasses both the acute 
and primary infection phases. Where I reference literature which adopts different 
nomenclature to that outlined above I will report the author’s definitions.  
 The stages of early HIV infection 1.4.1
Early HIV infection (the first year of infection) can be sub-divided into 7 stages: the eclipse 
phase; which is then followed by the 6 Fiebig stages sequentially, Fiebig I-VI, see figure 1.6. 
In this section I present an overview of these stages of EHI as presented by Fiebig et al 57, 
outlining in detail the immunological and virological changes that occur over this period.  
Fiebig et al illustrate that the eclipse phase spans from the point of infection to the time 
HIV-RNA first becomes detectable by laboratory assays 57. During this phase it is not 
possible to identify whether an individual is infected with HIV. The Fiebig stages I-VI are 
laboratory stages of EHI defined by the emergence of viral and immunological markers 
which occur in a consistent sequence following HIV infection.  As illustrated in figure 1.6, 
Fiebig stage I corresponds to the appearance of HIV in blood samples as detected by HIV 
RNA assays and typically spans 5 days (95% CI 3-8) 57. The authors estimate HIV RNA levels 
on average increase by 2.0 log10 copies/mL between Fiebig stages I to II (p<0.001).  In stage 
II p24 antigen first becomes detectable alongside HIV RNA, typically occurring 10 days 
following infection (95% CI 7-14). Stage III typically occurs 14 days after infection (95% CI 
10-17) and corresponds with the detectability of HIV RNA, p24 antigen and HIV antibody on 
IgM sensitive enzyme immunoassays (3rd generation EIA) and no HIV-specific bands are 
present on Western Blot. HIV RNA is known to peak during stage III, around the time of HIV 
seroconversion. Stage IV is defined by detectability of HIV RNA and HIV antibody on 3rd 
generation EIA, though p24 antigen may no longer be observed and an indeterminate 
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Western Blot. The typical duration of each of the first 4 Fiebig stages is very short at 3-5 
days each, amounting to a cumulative duration of 19 days (95% CI 15-23). By stage V, HIV 
RNA and HIV antibody is detectable on 3rd and potentially 2nd generation EIA and Western 
Blot is reactive but without p31 reactivity. HIV RNA decline is observable by this stage which 
typically occurs 89 days after infection (95% CI 47-130 days). These phases typically 
comprise the period of primary infection.  
Figure 1.6 Detailed schematic representation of the period of “acute” and “early chronic” 
HIV infection 
 
Source: McMichael et al (2010) 58. 
 
The final Fiebig stage VI, sometimes termed “early chronic infection”, corresponds with HIV 
RNA and antibody detection (on 2nd, 3rd and 4th generation EIA) and full Western Blot 
reactivity (including p31).  This stage can be further sub-divided according to the 
detectability of antibody using low and high sensitivity EIAs compared using recent testing 
algorithms. Laboratory techniques collectively known RITA (Recent Infection Testing 
Algorithm) or STARHS (Serological Testing Algorithm for Recent HIV Seroconversion) have 
been developed to identify these early infections. RITA approaches exploit the properties of 
evolving HIV antibody responses by measuring the avidity, isotype, concentration or 
proportion of antibodies and are predominantly used for the calculation of incidence 
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estimates in large populations. Since 2008, PHE (formerly the Health Protection Agency) 
have been phasing in the use of RITA assays to their routine surveillance programme to 
estimate HIV incidence in the UK 9. In addition to allowing incidence calculations the assays 
facilitate the identification of recent seroconverters for research into acquisition and 
onward transmission in EHI. 
Concerns have been expressed over the sensitivity and specificity of some of the RITA 
assays, however. In a systematic review of serological assays for detection of recent 
infection Guy et al 59 reported the median sensitivity across 13 RITA assays to be 89% 
(ranging from 42%-100% depending on the assay).  The median specificity across all 13 
assays for detecting established infection was 86.8%, though this ranged from 49.5% to 
100%.  The window period for identifying recent infection using any given RITA technique 
varies greatly across individuals and assays, so misclassifications are inevitable. The window 
periods are estimated as means, which by definition results in a large proportion of the 
sample being above and below the exact window period cut off. These types of 
misclassifications tend to cancel each other out in overall incidence calculations, or can be 
adjusted for by the use of correcting factors. They are more problematic however when 
RITA assays are used as a diagnostic tool in identifying individuals with recent infection as it 
is not possible to use a correcting factor. In addition to individual variation in window 
periods, misclassification can also occur with some of the assays when RITA is applied to 
patients with advanced disease stage, AIDS or in those who are taking or have taken ART. 
Currently, the majority of RITA assays are designed to detect recent HIV-1 subtype B 
infection, so may not apply to HIV-2 or other HIV-1 subtypes. 
Whilst the Fiebig stages are useful in identifying the key events of early infection, it should 
be noted that identification of earlier Fiebig stages is highly dependent on the sensitivity of 
laboratory assays used, with older less sensitive assays detecting markers at a later time 
point than their newer counterparts. More recently, the development of fourth generation 
EIA assays (which detect p24 antigen as well as HIV antibody) has led to proposed 
modifications to the Fiebig staging system to incorporate the increased sensitivity provided 
by these assays and the reduced window period of HIV detection 60. Perhaps the most 
limiting factor of the use of the Fiebig staging system, however, is the typical delay between 
HIV infection and presentation to medical services observed amongst recently infected 
individuals resulting in only a small minority of patients presenting before Fiebig stage III.  
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 Transmission of HIV 1.5
Whilst it is important to understand the natural history of HIV and how the virus interacts 
with the host on an individual level, it is the transmission dynamics of the virus which 
dictate the spread of the disease throughout a population. In this section I present a simple 
model of transmission, proposed by May and Anderson 61 which can be used to assess the 
rate at which HIV will persist in a susceptible population. 
R0=βcD 
This equation facilitates the prediction of the average number of secondary cases of HIV 
originating from a single infection in a totally susceptible population (R0) and is a product of 
the following three parameters:  
 the transmission co-efficient or per-contact transmission probability (β), 
 the average rate of acquisition of new sexual partners (c), 
 the duration of infectiousness (D). 
Whilst May and Anderson’s model provides a useful starting point from which to 
understand transmission dynamics, a number of limitations exist in its application to HIV 
epidemics in general populations. Firstly, R0 relates to the average number of secondary 
cases amongst a totally susceptible population, which does not apply in the case of a 
mature epidemic like that under study in this thesis, where a proportion of the population 
has HIV and a proportion is susceptible. In this scenario the net reproductive number (Rn) is 
used to describe the number of new cases arising from an infectious population, and is 
equal to R0 multiplied by the proportion of the population susceptible 
62. Secondly, it is 
problematic to assume homogenous rates of acquisition of new sexual partners; 
mathematical modelling studies of HIV and other STIs have demonstrated that 
heterogeneity in the rate of acquisition of sexual partners between sub-populations can 
affect the overall population rate of secondary transmission, and that rates of mixing 
between these sub-populations also affects epidemic spread 63,64.  
Building on May and Anderson’s simple model of transmission, Boerma and Weir 
deconstructed the three biological parameters βcd into a theoretical framework outlining 
the proximate determinants of HIV transmission, with the proximate determinants acting 
as an interface between the underlying social determinants of HIV transmission and the 
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biological determinants which make up the transmission model as described above 65. It is 
notable that Boerma and Weir’s framework broadens the c parameter from “the average 
rate of acquisition of new partners” in May and Anderson’s model to “exposure of 
susceptible to infected persons”. In doing this, they implicitly incorporate the proportion 
susceptible, in addition to the rate of new sexual partner acquisition, into the biological 
parameter. To acknowledge the importance of sexual mixing and background prevalence, in 
addition to the rate of partner acquisition, on the c parameter I will henceforth adopt 
Boerma and Weir’s terminology and refer to the c parameter as “exposure of susceptible to 
infected persons” for the remainder of the thesis. The proximate determinants that 
influence β, c and d are demonstrated in figure 1.7 and those relevant to this thesis are 
described in more detail in the following section. 
Figure 1.7 Boerma and Weir’s conceptual framework of the proximate determinants of 
sexual transmission of HIV  
 
Source: Boerma and Weir (2005) 65 
 
43 
 
 Factors affecting the transmission coefficient (β) 1.5.1
The transmission coefficient (β) is defined as the per-contact transmission probability and is 
dependent on both the infectiousness of the host individual and the susceptibility of the 
uninfected partner to HIV 61. Factors that have been shown to be associated with the 
infectiousness of an individual include: HIV viral load, typically measured as plasma viral 
load; the presence of a sexually transmitted infection (STI); HIV type and subtype; and the 
type of sexual act. Though not so integral to this thesis, factors associated with HIV 
susceptibility have also been identified as: mucosal integrity, presence of STI, as well as 
innate and acquired natural resistance to HIV infection. An overview of these factors now 
follows. 
1.5.1.1 HIV viral load 
The period of elevated viraemia during acute infection is thought to translate to a period of 
increased infectiousness in the individual as blood serum viral load has been shown to be 
highly correlated with HIV transmission. In a seminal piece of research, Quinn et al 66 
followed up 415 monogamous couples from Rakai Uganda, who were initially 
serodiscordant for HIV. Biological and behavioural factors were studied in relation to 
incident infection in the susceptible partner. Overall HIV incidence was estimated as 11.88 
per 100 person years, with no significant differences between male-to-female and female-
to-male transmission rates. A strong dose-response effect was found between log-
transformed blood serum HIV-1 RNA levels and transmission rates leading the authors to 
conclude that viral load is a key predictor of heterosexual transmission of HIV-1. Figure 1.8 
shows the changes in transmission rates with increasing blood viral load. Also of interest 
was the finding that no transmission events were observed amongst persons with viral load 
less than 1500 copies/mL. The same data from the Rakai Project were also used by Gray et 
al 67 to highlight differences in HIV transmission probability per coital act at varying HIV viral 
load quantities. The probability of transmission per sexual act was 0.0001, 0.0013, 0.0014 
and 0.0023 at viral loads of <1700, 1700-12499, 12500-38500 and >38500 copies/mL, 
respectively.  
The reduction in blood plasma viral load afforded by ART effectively prevents mother-to-
child transmission 68, and led researchers to speculate there is a decreased transmission risk 
from individuals with undetectable viral load 5. The HTPN-052 trial was under way at the 
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time of writing to establish whether ART can reduce the risk of HIV transmission in 
serodiscordant couples. 
 
Although blood plasma viraemia is unlikely to be directly responsible for sexual 
transmission of HIV in the majority of cases, it has been shown to be highly correlated to 
HIV-RNA in the genital fluids. Pilcher et al 69 prospectively studied HIV RNA titre in different 
body fluids amongst 17 people with primary HIV infection (defined as 8-70 days following 
onset of acute retroviral syndrome symptoms). The authors found that HIV-RNA levels in 
semen and saliva were statistically correlated with that of blood plasma amongst 
individuals with primary infection, though both at a lower titre than blood plasma. 
Longitudinal analysis of blood and plasma samples provided by men recently infected with 
HIV attending the University of Washington Primary Infection Clinic between 1993 and 
Figure 1.8 Transmission rate per 100 person years by blood HIV-1 RNA level and sex and 
of the index partner 
 
Source: Quinn et al (2000) 66 
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2005 has also shown a moderate correlation between levels of HIV-1 RNA in seminal 
plasma and in blood plasma, with a lower concentration in seminal plasma 70. Evidence of a 
correlation between seminal viral load and HIV transmission has also been demonstrated 
by Chakraborty et al by using epidemiological data fitted to a probabilistic empiric model to 
examine male-to-female transmission risk per sexual contact at different seminal viral  
loads 71.  
1.5.1.2 Co-infection with STI 
For an HIV-positive individual, genital tract infections have been shown to be associated 
with spikes in genital viral load.  Pilcher et al 69 observed genital viral loads exceeding that 
of their blood plasma in three individuals of 17 with primary infection, all of whom 
presented with at least one other STI. More recently, Fisher et al 72 used phylogenetic 
sequencing of the pol gene to establish transmission clusters amongst 859 men recruited 
from an HIV clinic in Brighton. The rate of transmission in men diagnosed with an STI in the 
past 3 months was 5.64 times that of those not diagnosed with an STI 72.  Whilst these 
studies indicate higher transmission probabilities from individuals with STI co-infection and 
not on ART, Kelley et al found no evidence of an association between rectal HIV shedding 
and presence of a rectal STI amongst MSM on ART with an undetectable viral load 73.  
1.5.1.3 HIV type and subtype 
The variation of HIV subtypes in different HIV risk groups observed early in the epidemic led 
to speculation that different subtypes were more infectious than others or more suited to 
transmission via certain routes. For example, the high prevalence of subtype B amongst 
MSM in Northern Europe, US and Australia led to speculation that this clade was more 
suited to transmission via the rectal lining 74. Whilst this theory has not been disproven, 
recent data indicating a growing proportion of non-B subtypes circulating in MSM in the UK 
may indicate the dominance of certain subtypes amongst particular risk groups in early 
infection may in fact have been due to assortative sexual mixing 27. Evidence of higher 
transmissibility has been observed, however, for subtype A compared to D amongst 
heterosexual serodiscordant couples in Rakai 75, and compared to C in an in vitro study in 
India 76. Conversely, no evidence was found in the risk of vertical transmission between 
subtypes B and C in Brazil 77. Differences in infectivity between HIV strains are also 
hypothesised, with HIV-1 believed to be more infectious than HIV-2 due to higher viral load 
concentrations in the blood and semen of HIV-1 infected individuals 78. HIV-1 subtype has 
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been shown to significantly influence CD4 count at seroconversion with the rate of CD4 
decline slowest in subtypes A, C, and CRF02_AG 79. 
1.5.1.4 Type of sex  
The fact that some sexual acts result in a higher transmission coefficient was established 
fairly early on in the epidemic. The range of average per-contact risk of transmission for 
other sexual acts reported in the literature to date may be found in table 1.1. Receptive 
anal intercourse (AI) with an HIV-positive partner with ejaculation and without a condom 
carries by far the largest risk of transmission at all disease stages. In the UK, a recent case-
control study showed MSM attending HIV testing clinics in London, Manchester and 
Brighton who seroconverted in the last 18 months to have 3.9 times the odds of engaging 
in receptive condomless anal intercourse (UAI) since their last HIV negative test than those 
who did not seroconvert 80. Higher still was the risk of engaging in receptive UAI with MSM 
not known to be HIV negative; OR 5.6 (95% CI 2.88-10.81). Seroconverters were also more 
likely to report insertive UAI with an HIV-positive or unknown status partner than non-
seroconverters, OR 2.1 (95% CI 1.1-3.8), though this was less of a risk factor for HIV 
acquisition.  
Table 1.1 Average per-contact probability of HIV transmission for different sexual acts 
Study population Transmission route 
Transmission 
probability  
(95% CI) 
Reference 
Heterosexual – Europe Male to female 
0.0005  
(0.0003-0.0007) 
Downs et al (1996) 
81
  
Heterosexual - Europe Female to male 
0.0003  
(0.0002-0.0005) 
Downs et al (1996) 
81
 
MSM 
Unprotected insertive 
anal intercourse 
0.0006 
Vittinghoff et al 
(1999) 
82
 
MSM - US 
Unprotected receptive 
anal intercourse 
0.005-0.03 
De-Gruttola et al 
(1989) 
83
 
MSW & MSM 
Receptive oral 
intercourse 
0.0004 
Vittinghoff et al 
(1999) 
82
 
 
Alongside condom use, several risk-reduction strategies have been adopted by MSM to 
reduce the transmission probability, including engagement in condomless oral sex only, 
withdrawal prior to ejaculation and “strategic positioning” (defined as taking the receptive 
position if HIV-positive, and the insertive position if HIV-negative) 84.    
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1.5.1.5 Factors affecting susceptibility to HIV 
The factors above affect the efficiency of transmission from the HIV-positive partner, 
however a number of factors can influence the potential to acquire HIV infection. As these 
are of less interest in the context of this thesis they will be briefly outlined in this section 
below.   
The presence of STIs especially ulcerative STIs such as Herpes Simplex Virus (HSV), have 
been demonstrated to increase the probability of HIV acquisition. Modelling studies have 
indicated that genital ulceration has been a key co-factor in the spread of HIV throughout 
sub-Saharan Africa 85. This is proposed to be due to mechanical and immunological reasons; 
the presence of ulcerative STIs is thought to increase immune system activation at the point 
of infection therefore increasing the number of cells present in the genital tract for the 
virus to bind to 86. In addition to mucosal compromise through presence of ulcerative STIs, 
rough sex without adequate lubrication has also been hypothesised to increase the risk of 
HIV acquisition as it may cause small rips in the mucosa which would allow the virus to pass 
more easily through the membrane.  
The study of individuals who have been repeatedly exposed to HIV but yet remain sero-
negative has led to the discovery of mechanisms for natural protection to HIV. Such 
individuals have been identified amongst high-risk cohorts of commercial sex workers, 
serodiscordant couples who engage in condomless sex and infants of women living with HIV 
and have resulted in the identification of both innate genetic and acquired immunological 
mechanisms of protection 87. Genetic mutations are known to exist within chemokine 
receptors, and homozygosity for Δ32 in the CCR5 co-receptor gene has been linked to a 
decreased susceptibility to HIV, as the receptor is not expressed on the cell surface 88.  
Heterozygosity for the Δ32 allele appears to provide less HIV-1 resistance but is associated 
with significantly slower disease progression 89. In addition to these mechanisms of innate 
genetic immunity, a number of immunological changes, postulated to be acquired after 
repeated exposure to HIV-1, have been shown to be present in people with natural 
resistance to HIV infection. These changes include cytotoxic T cell responses, helper T-cell 
responses, humoral immune responses and soluble inhibitory factors, though definitive 
data to prove these immune changes are responsible for the resistance to HIV acquisition 
are lacking 87.  
48 
 
Most recently, evidence of the efficacy of pre-exposure prophylaxis (PrEP) to prevent HIV 
acquisition has increased interest in a biomedical method with which to prevent HIV 
acquisition 90.  
 Factors affecting the exposure of infected to susceptible individuals (c) 1.5.2
The second parameter important in determining R0,as described by May and Anderson, is 
the average rate of acquisition of new partners (c) 61. As mentioned in the introduction of 
section 1.5, whilst the c parameter is often cited as the most important factor influencing R0 
in a totally susceptible population 61,91,92, in a general population where some individuals 
are not susceptible as they have HIV, background prevalence must also be considered. In 
addition, heterogeneous rates of partner change between population sub-groups, and 
importantly the interaction between rate of partner change and sexual mixing, can also 
lead to substantial variation in epidemic patterns 93. For these reasons, Boerma and Weir 
adopt the term “exposure of susceptible to infected partners” instead of “average rate of 
acquisition of new partners” to describe the c parameter in their proximal determinants 
framework 65. They proposed several proximal determinants which influence this 
parameter, namely the rate of new partner acquisition, sexual mixing, concurrency, and 
coital frequency. 
1.5.2.1 Rate of new partner acquisition 
Sexual transmission of HIV prevails in populations where there is a high rate of partner 
change, though the background prevalence of HIV within the population will dictate the 
spread of infection 61. For individuals infected with HIV, higher rate of partner change 
means coming into contact with a larger number of susceptible individuals, certainly at the 
beginning of the epidemic when the majority are susceptible to the virus. As background 
prevalence increases in a fixed population, however, the number individuals who are 
susceptible decreases and so does the influence of rate of partner change.  
1.5.2.2 Sexual mixing 
Any population can be divided into different sub-groups by demographic factors, such as 
ethnicity, age and gender; as well as by risk behaviours, such as the annual number of sex 
partners or engagement in condomless sex. In a given population, mixing between these 
sub-groups can occur in different ways and to different extents. Sexual mixing can be 
categorised into three extreme types: assortative (often called like with like), disassortative 
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(exclusive between group mixing) and random mixing. Variations in the type of sexual 
mixing in a population can alter transmission dynamics considerably and lead to different 
patterns of HIV spread throughout a population. Mixing patterns are dynamic and 
interchangeable, with different patterns dominating in different social settings and at 
different stages of an epidemic. Epidemic growth in a predominantly disassortative mixing 
framework will be slower but will eventually reach a much higher prevalence across all 
populations 94. An epidemic in a population exhibiting assortative mixing, results in a rapid 
increase in prevalence in one risk group, as individuals from different populations do not 
tend to mix. Assortative mixing of MSM in the highest sexual risk class was observed to be 
one of the important drivers of the early HIV epidemic in the US 94.  
One concept arising from the study of sexual mixing, is that of core groups, which can be 
defined as a subpopulation with a high rate of partner change and high background 
prevalence. It is proposed that core-groups have a vital role in the persistence of HIV, 
especially in situations where HIV prevalence in the general population is relatively low 95. 
In these situations core-groups serve to maintain a high reproductive number through the 
many “bridges” between the core-groups and general population in which there is a larger 
number of susceptible individuals.   
1.5.2.3 Sexual networks, concurrency and partnership type 
A social network is defined by Morris et al 96 as “a set of relations (links) among persons 
(nodes) where the relations can range from kinship and exchange, to affection or physical 
contact”. A sexual network will constitute only a small subset of an individual’s social 
network.  In a sexual network it is not only the behaviour of an individual that determines 
transmission risk but also the behaviour of their partners. Within a sexual network many 
partnership types will prevail, though most sexual behaviour studies tend to dichotomise 
partnership types into regular and casual. Gorbach et al 97 outline seven different sexual 
partner types from qualitative data in their analysis of sexual behaviour in MSM recently 
diagnosed with HIV in California, USA (see table 1.2).  Different partnership types are 
associated with different sexual behaviour, as factors such as trust, power balance and 
communication between partners will dictate the level of intimacy and ability to negotiate 
the use of risk reduction strategies.  
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Table 1.2 Seven types of sexual partner, as defined by Gorbach et al (2006)97 
Partner type Description 
Unknown Someone you have never met before you had sexual contact and never plan to 
see again 
1-time Someone you had sexual contact with only 1 time, but could find again if 
necessary 
Acquaintance Someone you have had sexual contact with more than once but not on a regular 
basis and who you don’t socialise with 
Friend Someone you have had sexual contact with more than once but not on a regular 
basis and who you normally socialise with 
Regular Someone who you have sex with on a regular basis 
Main Someone who is your primary sexual partner 
Trade Someone who you gave sex to for money or other goods, or someone who gave 
you sex for money or other goods. 
 
Monogamy and concurrency both describe the timing of relationships within a network. 
Serial monogamy is when an individual has multiple partners but none of the relationships 
overlap temporally. Concurrent partnerships are less easily defined, most likely due to the 
many possible nuances of concurrency. For example, Gorbach and Holmes defined 
concurrency as “a sexual partnership in which one or more of the partnership members 
have other partners whilst continuing sexual activity with the original partner” 98 but 
Koumans et al expanded this definition to someone who “had sex with two or more 
partners during 1 week in the previous month, [or] has overlapping partners if she/he had 
partners with overlapping dates of sexual exposure” 99.  
Mathematical modelling has indicated that longer monogamous partnerships result in slow 
progression of the epidemic and lower peak prevalence 96. Serial monogamous 
relationships also follow a “protective” sequence, meaning that earlier partners of the 
index case are not placed at risk from infection acquired in a later partnership. Conversely, 
concurrency was highlighted early on in the epidemic as a potential driver of epidemic 
growth, and has subsequently been demonstrated to increase the growth of an epidemic 
exponentially by acting as a bridge across sexual networks 100. It places any given 
concurrent partner of the index case at direct risk of infection from the index, but also, at 
indirect risk of infection from the other concurrent sexual partners of the index 96. 
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1.5.2.4 Coital frequency 
In a serodiscordant partnership, the probability of transmission from an index case to a 
susceptible partner increases with the number of sex acts between partners. This pattern of 
increase follows a binomial distribution, with the probability increasing to a maximum of 1. 
Variation in the per sex act probability will dictate the trajectory of the transmission 
probability per partnership curve, with sex acts which carry a high risk of transmission 
warranting a steeper trajectory over the course of a partnership 101, see figure 1.9.  Hence, 
individuals may mediate the risk of HIV acquisition or transmission by reducing the number 
of sexual exposures within a partnership, or adopting risk reduction techniques to reduce 
the probability of transmission (β) per exposure, by using the methods outlined in section 
1.5.1.4.  
Figure 1.9 Changes in per partnership transmission probability with increasing number of 
sex acts, and variable per contact transmission probabilities 
 
Source: Garnett (2008) 101 
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 Duration of infectiousness (D) 1.5.3
The third parameter which influences secondary transmission of HIV is duration of 
infectiousness. Estimates of the duration of HIV infection vary dramatically and depend on 
the population under study and whether ART is initiated. As will be reviewed in detail in the 
next chapter, infectiousness is unlikely to be constant over the course of HIV infection with 
the elevated viraemia of primary infection and again during end-stage HIV/AIDS, likely 
resulting in increased transmission potential. The average life course of HIV infection in the 
UK is estimated to be 8-10 years in the absence of ART 102. The duration of infection is vastly 
increased however for those treated with ART 47, and in some cases the estimated life 
expectancy is likely to be the same as their uninfected equivalent 53. This increased life 
expectancy for PLWH on ART has resulted in a longer duration of HIV infection during which 
time a higher number of sexual partners and larger number of sex acts can be accumulated. 
However, the goal of ART is to achieve undetectable viral load which likely renders the 
individual less infectious for the duration viral load remains undetectable 66.   
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2 Literature review 
In this chapter I present the results of the two scoping literature reviews I conducted. Due 
to the multidisciplinary, mixed methods nature of this thesis conducting a systematic 
review of the literature was neither appropriate, nor possible given the time constraints. 
Instead multiple scoping reviews were conducted, using systematic searches to identify 
potentially relevant literature. The first review examines the role that individuals with EHI 
play in secondary transmission, and includes research published or presented at 
conferences up to April 2009. The second review covers literature published or presented 
at conferences up to March 2010, assessing the rationale for initiation of ART in EHI, 
focussing on short-course ART in PHI, ART initiation at CD4>350cells/mm3 and TasP. All 
relevant research published after these reviews were conducted are included in the thesis 
discussion, chapter 7. At the end of this chapter I outline the rationale for my thesis and 
present the overarching research question.  
2.1 What role does early HIV infection play in the secondary 
transmission of HIV? 
The simple model for HIV transmission (R0=βcD) as presented in section 1.5, is typically 
applied over the whole duration of HIV infection but equally can be applied to each stage of 
infection if the parameters β (the per-contact risk of transmission), c (rate of exposure of 
susceptible to infected individuals) and D (the duration of infectiousness) are thought to 
vary enough by disease stage to impact on R0 (the basic reproductive number). Whether 
recent seroconverters contribute disproportionally to secondary transmission can therefore 
be assessed by examining changes in the parameters β, c, and D between HIV stages and 
the corresponding impact of such changes on R0. In this section I use the simple model of 
HIV transmission as a framework to help summarise the research performed to date 
examining secondary transmission from individuals with EHI. 
 Literature review scope and search strategy  2.1.1
This review aimed to examine the literature to establish the role individuals with EHI play in 
the onward sexual transmission of HIV. To do this I searched PubMed (which includes 
Medline) and Ovid (which includes PsychINFO, EMBASE), for English language articles 
published up until April 2009, using the search terms in table 2.1, in this case formatted for 
Ovid.  I reviewed all identified article titles and abstracts to identify any studies which 
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estimated either the per-contact risk of transmission, the proportion of HIV transmissions 
by HIV disease stage, or sexual behaviour over EHI. In line with the scoping review methods 
outlined by Arksey and O’Malley 103, no a-priori restrictions were placed on the methods 
used in studies or the quality of the studies as the aim was to summarise the full range of 
published information to enable the identification of gaps in knowledge. I first reviewed the 
abstracts and then the full papers or conference proceedings for studies identified as 
potentially relevant, charting their findings according to outcome (estimated per-contact 
HIV transmission, the proportion of infections attributable to each disease stage or sexual 
behaviour during EHI) as well as the study design (mathematical models, phylogenetic 
studies or observational studies). The reference lists of relevant articles were manually 
checked for publications which met the above criteria and may not have been picked up in 
the database searches. 
Table 2.1 Database search strategy formatted for Ovid 
Boolean operator Search term Field 
 "HIV" OR "Human immunodeficiency" OR 
"Human immuno-deficiency" OR "AIDS" OR 
"Acquired immunodeficiency" 
Title/abstract 
AND "seroconver*" or "early" or "primary" or "acute" 
OR "HIV stage" OR "disease stage" OR "HIV 
phase" OR "HIV stage" 
Title/abstract 
AND "infecti*" OR "transmi*" OR "spread" Title/abstract 
AND "probabilit*" OR "risk" OR "rate" OR 
"proportion" 
Any 
AND "sex*" OR "men who have sex with men" OR 
"MSM" OR "gay" OR "homosexual" OR 
"heterosexual" OR "MSW" OR "partner*" 
Any 
AND NOT "perinatal" or "mother to child" or "mother-to-
child" or "vertical" 
Title/abstract 
 
 Transmission probability per sexual contact (β) by HIV disease stage 2.1.2
As presented in the background chapter, the association between blood plasma viral load 
and HIV transmission 66, in conjunction with the high viraemia demonstrated in EHI 31,32,57, 
has led researchers to postulate that people with recent HIV infection contribute 
disproportionally to onward transmission of HIV. Cohen used the term “amplified 
transmission” to describe the likely increase in probability of transmission from individuals 
with EHI 104.   
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The majority of research conducted amongst heterosexuals in this area has used empirical 
data collected from partner studies where the date of infection of the index partner is 
known or can be well estimated, and follow-up of the susceptible partner occurs to 
establish whether a transmission event has occurred. In some studies, behavioural data 
collected at these follow-up visits is then used to estimate the average risk of transmission 
per contact through the use of mathematical models. A summary of per-contact 
transmission probabilities by disease stage can be found in table 2.2.  
 
Table 2.2 Estimates of the transmission probability per sexual contact acquired from the 
literature 
   HIV stage: 
Author (year) 
Risk group 
(sexual act) Location Early Asymptomatic Symptomatic 
Ahlgren et al  
(1990) 
105
 
MSM 
(any penile-
anal) 
San 
Francisco 
0.0323
a
 0.000578 
Jacquez et al  
(1994) 
106
 
MSM 
 (any penile-
anal) 
US  0.1-0.3
b
 0.0001-0.001 0.001-0.01 
Leynaert et al  
(1998) 
107
 
MSW 
 (any penile-
anal) 
Europe 0.1261
c
 0.0167 0.3213 
Leynaert et al  
(1998) 
107
 
MSW (all) Europe 0.0029
c
 0.0009 0.0013 
Wawer et al  
(2005) 
108
 
MSW/WSM 
(all) 
Rakai 0.0082
d
 0.0015 0.0007 
Rapatski et al  
(2005) 
109
 
MSM and 
MSW 
(insertive 
penile sex) 
San 
Francisco 
0.024
e
 0.002 0.299 
Pinkerton (2008) 
110
 MSW/WSM 
(all) 
Rakai 0.03604
f
 0.00084 
Boily et al (2009) 
111
 MSW/WSM 
(all) 
Various 0.0066
g
 0.0007 0.0055 
a=early infection duration 11-19 weeks; b=early infection duration 2 months; c=early infection duration 3 months; d=early 
infection duration  2.5 months; e=early infection duration 6 months; f=early infection duration 49 days ;g=estimated from a 
meta-analysis including studies with differing definitions of early infection 
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Leynaert et al 107 fitted data from the European Study of Heterosexual Transmission of HIV, 
a retrospective study of 499 serodiscordant partners conducted in 9 European countries 
between 1987 and 1992, to their probabilistic model to estimate per-contact transmission 
risk. They assumed a 3 month duration of PHI (modelling it also as 2 and 6 months in a 
sensitivity analysis), after which time the infected individual entered the second 
“asymptomatic” period where they stayed until clinical signs of HIV infection manifested or 
CD4 count fell below 200 cells/mm3 and they moved into the third stage. The authors 
categorised sexual contacts into two risk groups: type 1, male-female penile-vaginal sex and 
sex outside of menstruation; and type 2, penile-anal sex when the male partner was HIV-
positive and sex during menses when the female was the HIV-positive partner. There was 
no variation in the male-female penile-vaginal transmission probability over the three 
disease stages, however penile-anal transmission risks were higher in primary and 
symptomatic stages when compared to the asymptomatic stage, with probabilities of 
0.1261, 0.3213 and 0.0167, respectively. There was no significant variation across stages 
when data from the two risk strata were combined with probabilities of 0.0029, 0.0009 and 
0.0013 in primary, asymptomatic and symptomatic phases. Calculation of an estimate for 
female-male risk of transmission in primary infection was not possible due to lack of data, 
however transmission risks were highest at 0.0063 when the index partner was 
menstruating and had symptomatic HIV infection, and lowest at 0.0003 when not 
menstruating and in the asymptomatic stage. The lack of certainty around the date of 
infection and seroconversion is one potential weakness of this study. For each individual 
with unknown infection date, the probability of infection at each possible date was 
estimated using a continuous-time Markov process based on CD4 count at presentation 
compared to empirical CD4 decline from seroconversion to AIDS, whilst controlling for 
country-specific population prevalence. The authors did not seem to assess the accuracy of 
this method in estimating infection dates. Given the short 3-month duration of primary 
infection used in the final model, any loss of accuracy around the estimate may have 
resulted in under or over-estimation of transmission probabilities. 
Evidence in support of the concept of amplified transmission probability in primary 
infection amongst heterosexual couples was found by Wawer et al 108. The authors used 
data from monogamous serodiscordant and seroconcordant negative couples identified 
retrospectively from the Rakai study, Uganda, estimating and comparing the risk of HIV 
acquisition per coital act for different stages of HIV infection. Importantly, none of the 
study participants reported anal intercourse, blood transfusion, IDU, or sex between men, 
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and in all couples the initially uninfected partner reported monogamy for the duration of 
follow-up. In couples where both members were initially HIV negative and both went on to 
seroconvert within a single 10 month follow-up period, the index case was defined as the 
partner who reported extra-marital sexual activity. The risk of transmission per coital act at 
each stage of infection was 0.0082 (95% CI 0.0039-0.0150), 0.0015 (95% CI 0.0002-0.0055), 
0.0007 (95% CI 0.0006-0.0011) and 0.0028 (95% CI 0.0015-0.0041) approximately 2.5 
months after seroconversion, 6-15 months after seroconversion, during chronic infection 
and 6-25 months before death, respectively. The adjusted risk ratio for HIV transmission 
per coital act after controlling for covariates (presence of genital ulcer disease and age 
group) remained highest during incident infection at 7.25 (3.05-17.25) times the risk in the 
chronic stage.  
Pinkerton  110 performed a secondary analysis on Rakai project data, estimating per coital 
act and per partnership transmission probabilities in 23 couples where both members 
seroconverted during follow-up. Couples were grouped into early and chronic groups 
depending on the 10 month follow-up period in which the non-index couple seroconverted, 
i.e. early transmission occurred if both couples seroconverted within the same 10 month 
period, middle in the period after the period the index-partner seroconverted and late 
transmission 2 to 3 periods after the index couple. Per coital act transmission probabilities 
were estimated as 0.03604 and 0.00084 for early and chronic transmission groups amongst 
the incident couples, respectively.  
A sub-analysis of transmission probabilities by disease stage was performed by Boily et  
al 111 in a meta-analysis of risk of heterosexual HIV-1 transmission per sexual act. The 
pooled HIV-1 transmission probability in early infection was estimated to be 0.658% (95% CI 
0.283-1.152%), in the asymptomatic stage 0.072% (0.053-0.097%) and in the late stage 
0.553% (0.200-1.525%). The final per-act transmission risk ratios compared to the 
asymptomatic stage were 9.17 (4.47-18.81) in early infection and 7.27 (4.45-11.88) in late 
stage infection. 
In contrast to models of transmission amongst heterosexuals, those estimating per contact 
transmission by disease stage amongst MSM have little empirical data on transmission 
events upon which to base model parameter estimates 105,106,109. In these studies, observed 
epidemic curves are modelled in addition to behavioural data, if available, with the 
transmission parameters β and D permitted to vary and maximum likelihood used to 
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establish the best fit to epidemic data.  Nonetheless, these studies also conclude that 
transmission probabilities are amplified in early infection, ranging from 0.024-0.3 in EHI, 
compared to 0.0001-0.002 in the asymptomatic stage (see table 2.2).  
 Proportion of infections attributable to each disease stage 2.1.3
The studies presented above provide support for the concept of amplified transmission in 
EHI, however increased per-contact transmission probabilities alone cannot predict the 
extent to which it contributes to onward transmission. To assess this it is also necessary to 
account for the duration of primary infection (D) and rate and nature of sexual partner 
formation over this time (c). As presented in the background, the duration of elevated 
viraemia seen in EHI is relatively short, lasting weeks to months in comparison to the 
asymptomatic stage HIV 32,33. Logically, the number of sexual partners experienced over the 
short duration of early infection is likely to be smaller than that of the asymptomatic stage 
which lasts for a number of years and this may mediate the increased infectivity over this 
time. Two methods have been used in the literature to estimate which stage of disease 
dominates transmission dynamics: mathematical modelling and phylogenetic analysis. 
2.1.3.1 Mathematical modelling of HIV transmission by disease stage 
With certain assumptions, deterministic models can be fitted to clinical, epidemiological 
and behavioural data from observational studies, and population surveillance data, to 
elucidate whether a particular disease stage is responsible for a greater proportion of 
onward transmissions. Early mathematical models were somewhat simplistic due to a lack 
of empiric data available for use as parameter values and limitations in computing power, 
they also predominantly modelled MSM. More recently a shift towards studies modelling 
heterosexual transmission has occurred largely due to the availability of extensive 
transmission data collected as part of the previously mentioned Rakai study in Uganda.  
Table 2.3 summarises the proportion of secondary HIV infections as estimated from 
mathematical modelling studies.  
One of the first models to investigate secondary transmission by stage of infection was 
reported by Koopman et al 112. They used two compartmental deterministic models to 
estimate the proportion of infections transmitted during EHI in a hypothetical population of 
MSM in the early stages of an HIV epidemic. The authors used “hypothesised” transmission 
probabilities per partner of 0.2, 0.001 and 0.076 for early infection (defined as the first 1.5 
months after infection), middle stage (duration 104 months) and late stage (duration 14.5
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Table 2.3 Mathematical modelling studies estimating the proportion of HIV infections attributable to early HIV infection 
    
Proportion of infections attributable to: 
Authors (year) Risk group (assumptions) Population 
EHI
duration 
Early 
HIV 
Asymptomatic 
HIV 
Symptomatic 
HIV 
Not early 
HIV 
Abu-Raddad & Longini 
(2008) 
113
 
MSW/WSM (generalised epidemic) Rakai 2.5 
months 
25.0% 44.0% 31.0% 0.0% 
Abu-Raddad & Longini 
(2008) 
113
 
MSW/WSM (hyper-endemic situation) Rakai 2.5 
months 
13.0% 51.0% 32.0% 0.0% 
Coutinho et al (2001) 
114
 Unspecified (modelling  VL, age mixing in 1 
year increments, age-declining sexual activity 
in 5 year increments, peak sexual activity at 
20 years) 
Hypothetical 6-7 weeks 88.5% 9.0% 2.5% 0.0% 
Coutinho et al (2001) 
114
 Unspecified (modelling  VL, age mixing in 10 
year increments, age-declining sexual activity 
in 15 year increments, peak sexual activity at 
25 years) 
Hypothetical 6-7 weeks 32.5% 12.8% 54.8% 0.0% 
Coutinho et al (2001) 
114
 Unspecified (modelling VL, no age mixing, no 
age-declining sexual activity, no age defined 
peak sexual activity) 
Hypothetical 6-7 weeks 21.4% 7.1% 71.5% 0.0% 
Coutinho et al (2001) 
114
 Unspecified (modelling log 10 VL, age mixing 
in 1 year increments, age-declining sexual 
activity in 5 year increments, peak sexual 
activity at 20 years) 
Hypothetical 6-7 weeks 13.4% 86.2% 0.5% 0.0% 
Coutinho et al (2001) 
114
 Unspecified (modelling log 10 VL, age mixing 
in 10 year increments, age-declining sexual 
activity in 15 year increments, peak sexual 
activity at 25 years) 
Hypothetical 6-7 weeks 3.8% 78.5% 17.7% 0.0% 
EHI= Early HIV infection        
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Table 2.3 (continued) 
    
Proportion of infections attributable to: 
Authors (year) Risk group (assumptions) Population 
EHI 
duration 
EHI 
Asymptomatic 
HIV 
Symptomatic HIV Not early HIV 
Coutinho et al (2001) 
114
 Unspecified (modelling log 10 VL, no age 
mixing, no age-declining sexual activity, 
no age defined peak sexual activity) 
Hypothetical 6-7 
weeks 
2.0% 81.6% 16.4% 0.0% 
Hollingsworth (2006) 
115
 MSW/WSM (random mixing) Rakai 2.9 
months 
31.0% 42.0% 27.0% 0.0% 
Hollingsworth (2006) 
115
 MSW/WSM (serial monogamy) Rakai 2.9 
months 
9.0% 71.0% 20.0% 0.0% 
Koopman et al (1997) 
112
 MSM (assortative age mixing) Hypothetical 1.5 
months 
20.0% 7.0% 73.0% 0.0% 
Koopman et al (1997) 
112
 MSM (assortative age mixing & transient 
high-risk behaviour) 
Hypothetical 1.5 
months 
10.0% 40.0% 50.0% 0.0% 
Pinkerton (2008) 
110
 MSW/WSM Rakai 49 days 46.5% 0.0% 0.0% 53.5% 
Rapatski et al (2005) 
109
 MSM San 
Francisco 
2-6 
months 
1.3% 2.0% 97.2% 0.0% 
Xiridou et al (2004) 
116
 MSM Amsterdam 1-5 
months 
11.2% 0.0% 0.0% 88.8% 
EHI= Early HIV infection 
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months), respectively. They then adapted the model to include a homogenous contact rate 
of two partners per month, age-preferred sexual mixing where 80% of partnerships are 
formed within the partner’s own age-group (a figure derived from US wide survey data), 
and age-peaked sexual contact forming. The proportion of cumulative transmissions 
accountable to the early, mid and late infection were: 20.0%, 6.7% and 73.3%, in the crude 
model; 36%, 8% and 56% in the model incorporating ageing, homogenous contact patterns 
and proportionate mixing; and 47.4%, 8.4% and 44.2% in the model incorporating ageing, 
age-peaked contact rates and proportionate mixing. The second model presented in this 
paper 112, compared mid and late infection to early infection, modelled as a 6 month stage 
stratified into 3 periods: latent, primary and post-primary, lasting 0.5, 0.5 and 5 months, 
respectively. The transmission probabilities used in this model were 0.0, 0.2, 0.04, 0.012 
and 0.1 for each respective stage with the corresponding proportion of transmission 
assigned to each stage estimated at 0.0% 3.3%, 6.7%, 40% and 50%, respectively.  
Xiridou et al 116 also estimated the proportion of HIV transmissions occurring during primary 
HIV infection amongst MSM in Amsterdam. Unlike previous models which modelled 
behaviour using very simplistic assumptions, their model included detailed sexual 
behaviour data collected from the Amsterdam cohort study of young MSM. In addition to 
incorporating acquisition rate of both steady and casual partnerships, and frequency of 
receptive and insertive UAI, the authors included more comprehensive behavioural 
parameters such as percentage reduction in risky behaviour by use of negotiated safety 
methods and percentage reduction in risky behaviour due to HIV diagnosis in chronic 
infection. Uncertainty analysis with a sample of values selected from probability density 
distributions of each parameter were used where parameter estimates were unclear, for 
example PHI duration and infectivity in PHI relative to chronic HIV infection. In total, the 
percentage of new infections estimated as attributable to transmission in PHI was 11.21%. 
Transmission in casual partnerships where the index partner had PHI was higher than in 
steady partnerships, 6.42% compared to 4.79%.  Increasing the level of risky behaviour by 
50% amongst casual partnerships in the model resulted in an estimated 25% of new 
infections transmitted during PHI. When risky behaviour was doubled amongst steady 
partners the estimated contribution of PHI to onward transmission reduced to 10%. The 
results led the authors to conclude that in Amsterdam, where the epidemic has matured 
and the majority of transmission events are between regular partners, the proportion of 
transmission events attributable to PHI is very small in comparison to the chronic and late 
stages. The explanation given for this finding is that the average duration of a steady 
 62 
 
relationship is longer than the duration of primary HIV infection; therefore, fewer contacts 
are exposed to infection in PHI in communities where steady relationships dominate. 
Rapatski et al 109 modelled data from the San Francisco Clinic Cohorts Study to demonstrate 
that late stage disease is responsible for driving the HIV epidemic amongst MSM in San 
Francisco between 1978 and 1984. The duration of the primary, asymptomatic and 
symptomatic stages were modelled as 6 months, 7 years and 3 years, respectively. The 
authors fitted retrospectively ascertained antibody prevalence and sexual behaviour data 
to their deterministic model. They modelled behaviour in six risk groups depending on the 
number of contacts per year, ranging from 231 in group 1 to 0 in group 6. All contacts were 
assumed to be casual and promiscuous under what the authors term “the bathhouse 
assumption” and sexual behaviour was said to be constant over time. Under these 
assumptions, they estimated per contact transmission risks at 0.024, 0.002 and 0.299 for 
primary, asymptomatic and symptomatic stages, respectively. This translated to 1.3%, 1.5% 
and 97.2% of infections observed in the study period occurring in primary, asymptomatic 
and symptomatic infection. The authors conceded that the initial wave of the epidemic was 
likely to have been driven by men in the highest risk group with primary HIV infection. Over 
the full course of the epidemic and in the later stages when equilibrium is reached, it is the 
symptomatic stage that accounts for the majority of transmissions. 
The large proportion of infections attributable to the symptomatic disease stage proposed 
by Rapatski et al has led to criticism over the behavioural assumptions incorporated into 
the model.  Koopman and Simon questioned how representative the San Francisco City 
Clinic Cohort was of the wider MSM population, adding that the partnership formation 
assumptions of random mixing, no clustering of partnerships and no ongoing partnerships 
were unfeasible within this population 117. Finally, they queried the assumption that 
partnership formation rates remain constant over the study period, and do not fluctuate 
with illness, death or any other social factors 117.  
2.1.3.2 Heterosexual populations 
As was the case with studies estimating transmission probability per sexual act (β), the 
majority of the work to date in heterosexual populations is based on data from the Rakai 
study. Hollingsworth et al fitted a probabilistic model to the Rakai study data and estimated 
the likely stage duration and probability of transmission in a monogamous relationship for 
each HIV stage (primary, asymptomatic and late) 118. PHI and late-stage infection were 
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estimated to be 26 and 7 times more infectious, respectively, than asymptomatic infection, 
with an estimated 276 (95% CI 131-509) transmissions per 100 person years for PHI and 76 
(41.3-128) in late stage, and 10.6 (7.61-13.3) in asymptomatic infection. A number of 
methodological improvements were made on the model used by Wawer et al  to estimate 
per contact risk of transmission by disease stage 108. Instead of using the midpoint of each 
10 month follow-up period in the estimations when a seroconversion or death occurred, 
they assumed there was an equal probability that these events could occur on any day in 
the follow-up period. In addition, the model used by Hollingsworth et al made no 
assumption regarding the duration of each HIV stage, instead they allowed the durations to 
vary to achieve the best fit to the Rakai data using maximum likelihood. The duration of PHI 
using this method was estimated as 2.90 months (95% CI 1.23-6.00) and the duration of 
high transmission risk before death (late HIV stage) was 9.00 months (95% CI 4.81-14.00). 
The authors went on to use the estimated rates and stage durations to model the likely 
proportion of new infections amongst two hypothetical populations with extremes of 
sexual behaviours: those who practised serial monogamy and those who practised random 
mixing. The percentage of new infections attributable to PHI in serial monogamous scenario 
was estimated at 9% in comparison to 31% in a situation of random mixing. In both 
populations, the majority of infections were estimated to have occurred in the 
asymptomatic stage due to its long duration (71% in the serial monogamy model and 42% 
in the random mixing). 
The HIV stage-specific transmission risks presented by Wawer et al 108 were also 
incorporated by Abu-Raddad and Longini 113 in a deterministic compartmental model to 
ascertain the proportion of infections between 1980 and 2007 that were attributable to 
index cases in each HIV stage. Data from two different Sub-Saharan African populations 
were modelled separately representing the hyper-endemic situation in Kisumu, Kenya and 
the generalised but non-hyper-endemic epidemic in Yaounde, Cameroon.  Adopting the 
same definition of acute, latent and late disease stages as Wawer et al, and including non-
random population mixing between four sexual-risk classes they estimated that acute 
infection was responsible for 13% of all infections acquired between 1980 and 2007 in 
Kisumu, with 51% attributed to latent stage and 32% to late stage. In Yaounde, the 
cumulative proportion of infections was 25%, 44% and 31% in the acute, latent and late 
stages, respectively.  The authors conclude that, in both epidemic scenarios, acute infection 
contributes disproportionally to onward transmission in the early stages of an epidemic 
only, when transmission occurs predominantly amongst high-risk sexual behaviour groups. 
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The latent stage accounted for the largest proportion of incident infections despite having 
the lowest transmission risk per coital act. This was likely due to the long duration of the 
latent stage and the potential increased number of sexual contacts during this period. 
Pinkerton 110 also estimated the proportion of all infections transmitted during the acute 
phase using data from the Rakai study. An average number of transmission events were 
estimated from the first and second follow-up periods by calculating the mean number of 
transmission events in each 10 month period. Adjusting for a latent period of 9 days, during 
which no transmission events could occur, and using an estimated acute infection period of 
49 days, Pinkerton’s model predicted 46.5% of the 23 incident infections observed in this 
cohort were transmitted in the acute stage of infection. 
2.1.3.3 Influence of behavioural assumptions on mathematical models 
Models that predict HIV transmission in different disease stages can assume homogenous 
behaviours in the population regardless of infection status.  Coutinho et al (2001) 119 neatly 
demonstrated the effect of different assumptions regarding sexual behaviour on 
transmission models predicting the proportion of infections attributable to primary, 
asymptomatic and symptomatic disease stages. The authors developed two transmission 
models: the first was based on a directly proportional increase in transmissibility with 
increased viraemia; the second on a directly proportional increase in transmissibility with 
increase in log-viraemia. The primary, asymptomatic and symptomatic stage durations 
were held constant across all simulations at 6 weeks, 10 years and 2 years. The age at which 
an individual became sexually active was also held constant at 15 years. The authors varied 
the following parameters: preferences in the acquisition of new partners from no age-
preference to within 1 or 10 years of the individual’s age, age-declining sexual activity from 
none exhibited to 5 or 15 years post peak, and the age of peak sexual activity at 20 or 25 
years. The results vary markedly as can be seen in table 2.3.  In the model where increased 
transmissibility is directly proportional to increased log-viraemia the dominant stage of 
infection is typically the asymptomatic stage no matter how behavioural parameters are 
varied. Due to a lack of epidemiological data it is unknown as to whether the normal or log 
viraemia model is more representative of the actual relationship between transmissibility 
and viraemia.  
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2.1.3.4 Caveats surrounding modelling estimates 
Mathematical models are heavily dependent on generalising assumptions governing 
partnership formation rates, relationship durations, risk-taking behaviour, sexual mixing 
and partnership concurrency. Thus they may predict transmission probabilities and rates in 
populations where these assumptions hold true, but may not be generalisable to different 
populations. For example Rapatski et al’s 109 model was formed using data from the early 
San Francisco epidemic amongst MSM and is most likely not generalisable to the situation 
in Sub-Saharan Africa where the epidemic is generalised.  Extrapolation from a modelling 
study using data from one population can only be done with caution and an appreciation 
that assumptions which hold in one population may not be true in another. 
To date, the majority of models comparing HIV transmission probability by stage of HIV 
infection model Rakai study data. These models are based entirely on transmission 
probabilities from monogamous heterosexual couples in a developing country.  Rapatski et 
al 120 argue that a partial immunity can be acquired through multiple contacts with an HIV-
positive partner, and this may help to explain the higher transmission probabilities 
observed during primary infection in comparison to late-stage infection. This acquired 
immunity would result in reduced susceptibility to HIV infection over time and could 
explain why more infections were estimated to be attributable to primary infection in 
models using Rakai study data. The monogamous heterosexual couples enrolled in the 
Rakai study are likely not representative of the individuals driving the epidemic in Western 
countries. This serves to highlight the importance of modelling behavioural assumptions 
specific to the population under study, and where basing these assumptions on empiric 
data. 
2.1.3.5 Phylogenetic studies estimating the proportion of infections attributable to 
each disease stage 
Phylogenetic studies use molecular and epidemiological techniques to determine 
transmission clusters amongst HIV-positive individuals. They typically involve sequencing of 
the pol region of the HIV genome from plasma virus or pro-viral DNA. These sequences are 
then matched across samples collected from other HIV-positive individuals to form clusters 
of individuals who share statistically similar sequences.  Using the estimated date of HIV 
infection amongst individuals in these clusters it is possible to construct likely chains of 
transmission where, due to the timing of infection, one person is likely to have transmitted 
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to another. With various assumptions, estimation of the proportion of HIV infections 
attributable to individuals with EHI is then possible. 
In the UK, Pao et al identified 103 recently HIV-positive individuals presenting to a 
genitourinary medicine (GUM) clinic during PHI between 1999 and 2003 121. Recruited 
individuals were predominantly male and MSM. PHI was diagnosed if the individual had a 
HIV test interval of 18 months or less, an evolving Western Blot or antibody response, or 
tested incident using a RITA assay. Fifteen transmission clusters were found, with 34% of 
the 103 PHI infections falling into these clusters. The authors found that individuals in 11 
out of 15 clusters had PHI diagnosis within 12 months of each other; possibly showing 
enhanced transmission during PHI when viral load is elevated. They found younger age, 
higher CD4 count and higher number of sexual contacts in the 3 months preceding 
seroconversion to be associated with being in a PHI cluster. The presence of an STI at time 
of PHI diagnosis was not found to be significantly associated with clustering, though the risk 
of STI infection was higher amongst individuals within a cluster. Interestingly plasma viral 
load at diagnosis was not found to be predictive of clustering. The authors suggested that 
transmission amongst MSM may be more correlated with seminal viral load rather than 
blood plasma viral load. 
More recently, Fisher et al 72 isolated the Pol sequence from samples of 859 MSM recruited 
from a large cohort attending an HIV treatment centre in Brighton. Of these 859, 159 (19%) 
were found to have been recently infected, defined in this study as a negative HIV antibody 
test in the past 6 months, laboratory evidence of seroconversion or testing incident with 
RITA if subtype B. From these 159 recently infected individuals, 47(29.6%) fell into 
transmission clusters, with a single likely transmitter identified for 41 (26%) individuals. 
Likely transmitters had to share a cluster with a recently infected individual, and be 
diagnosed HIV positive prior to them. Of these likely transmitters it was estimated that 24% 
had recent infection at the time of transmission (as per the above definition), with the 
remaining 76% in chronic stage of infection.  
Brenner et al also used phylogenetic linking to assess the proportion of individuals with 
primary HIV infection (defined as seroconversion within the 6 months before genotyping) in 
Quebec who fell into clustered transmission groups 122. The authors found that 49.4% of the 
sequences from individuals with PHI fell into 75 chains of transmission, however, within 
these chains the mean transmission interval (time between HIV acquisition and 
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transmission) was 15.2 months (standard deviation 9.5 months; range 1-37 months) so 
whilst those diagnosed in PHI were likely involved in more transmission events, a number of 
these events would have occurred outside the period of PHI.  
2.1.3.6 Caveats surrounding phylogenetic studies 
Phylogenetic linkage studies are useful as they assess actual transmission events amongst 
known contacts in a sexual network. One problem with phylogenetic linking however is the 
assumption that people within a cluster have directly infected each other. In reality, there 
may be an individual outside of the study population who is responsible for infecting some 
or all of the people in the cluster but who was not included in the study themselves. Brown 
et al 123 also highlighted the importance of the use of full and adequate definitions as well 
as known dates of seroconversion when performing phylogenetic reconstructions of 
transmissions to demonstrate amplified transmission in acutely infected individuals. Using 
165 individuals with well estimated infection dates from the CASCADE Collaboration of 
recent seroconverters they conducted a phylogenetic analysis on the HIV pol sequence. 
Nine phylogenetic clusters were found amongst the sequences, containing 11% of the 165 
sequences. Only two of the nine clusters could have occurred during acute infection though 
due to the timing of infections exceeding the duration of PHI. The authors concluded that 
individuals with transmission intervals which exceed the duration of PHI should be excluded 
from force of infection calculations for those in that HIV stage. 
 Factors affecting exposure of susceptible to infected individuals (c) across HIV 2.1.4
stages 
As infection with HIV is asymptomatic or, in the case of acute retroviral syndrome, very 
non-specific, it can remain undiagnosed for long periods in the absence of routine HIV 
testing. A key concept in the hypothesis that individuals with recent HIV infection account 
for a disproportionate number of sexual HIV transmissions is that any risky sexual 
behaviour that may have led to primary infection of the index case continues until that 
individual is diagnosed with HIV. Awareness of HIV status is therefore of great importance, 
and may act as an important pivot point for behaviour change in PLWH.  
A meta-analysis conducted by Marks et al showed that knowledge of HIV-positive status 
was associated with a reduction of 53% (95% CI 45-60%) in the prevalence of unprotected 
vaginal or anal intercourse with any partner 124. After adjusting for the proportion of sexual 
partners who were at risk of HIV, the effect of awareness of personal HIV-positive status on 
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prevalence on UVAI reduced by 68% (95% CI 59-76%) 124. In a subsequent paper, the 
authors went on to use the relative reduction in UVAI afforded by awareness of HIV status 
estimated from the above meta-analysis in a model assessing the number of new HIV 
infections attributable to those unaware of their HIV status 125. This model accounted for 
undetectable/low viral loads and subsequent low biological risk of transmission amongst 
aware HIV-positive people but no adjustment was made for unaware individuals due to 
them not being on ART to control viraemia. As an estimate of the ratio of HIV-positive to 
HIV-negative sex partners that unaware HIV-positive individuals have was unavailable, the 
authors used three arbitrary values (1:1, 1.5:1 and 2:1) modelling each of the three ratios. 
They concluded that even when the number of partners was equal between aware and 
unaware individuals, secondary sexual transmission from the unaware group accounted for 
54% of the new infections. When the number of susceptible partners was double that of 
the aware individuals, transmission from those unaware of their positive status accounted 
for 70% of new infections 125.  
Pinkerton also investigated the role that awareness of HIV status has on secondary 
transmission across all disease stages and, specifically, in the acute stage using 
epidemiological data from the USA 126. Acute infection in this model was assumed to last for 
49 days, ranging between 42 and 56 days in sensitivity analysis.  The model used estimates 
of transmission probability ratios for acute to asymptomatic infection derived from studies 
in different risk populations; these ranged from 4.2 (representative of male-female 
transmission) to 12.0 (calculated from male-male transmission). A 3.7 risk ratio for 
transmission from individuals unaware of their HIV status compared to those who were 
aware was modelled, as estimated from the Marks et al meta-analysis 124.  The final model 
predicted 8.6% of 32,000 annual infections sexually acquired in the USA were attributable 
to acute infection. However, 48.5% of the remaining infections were attributable to 
individuals with undiagnosed chronic infection, indicating a markedly higher contribution of 
undiagnosed infection to onward transmission compared to acute infection. 
To date, three studies have examined behaviour change following HIV diagnosis amongst 
cohorts of recently infected MSM in the US and UK. Gorbach et al 97 studied transmission 
behaviours in 106 MSM from Southern California who were infected with HIV in the last 12 
months. They conducted baseline and 3 month follow-up interviews to determine sexual 
behaviour in the 3 months prior to interview and found that 46.9% of the sexually active 
MSM reported a reduction in number of partners between baseline and follow-up. A 
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significant reduction in the mean number of all, one-time and acquaintance partners was 
also observed from 7.9 to 5.2, 1.9 to 0.8, and 1.1 to 0.5 between baseline and follow-up, 
respectively.  There was also a significant reduction in UAI with reported HIV negative or 
status unknown partners from 82% at baseline to 48% at follow-up. Unfortunately no 
further rounds of follow up data were collected to examine whether observed changes 
persisted.  
Colfax et al 127 also observed a reduction in risky sexual behaviour amongst 66 MSM 
recruited to the HIVNET vaccine cohort who seroconverted within a 6 month test window. 
Baseline data were collected prior to positive result notification, and follow-up interviews 
were conducted at 1, 3, 6, 9 and 12 months after positive test. A reduction in the 
proportion of MSM reporting insertive UAI with HIV negative or unknown status partners 
was observed between baseline and one month follow up from 39% to 2%. Unfortunately, 
this proportion then steadily increased to 8%, 6%, 13% and 12% at 3, 6, 9 and 12 months 
following the positive test. The authors also observed that MSM who continued to engage 
in UAI after HIV diagnosis were significantly more likely to continue to do so at 6 and 9 
months post diagnosis but not 12 months.  
Most recently, Fox et al 128 followed up a cohort of 98 MSM diagnosed with primary HIV 
infection enrolled in an ART intervention study to assess changes in sexual behaviour after 
HIV diagnosis. Men completed a survey at diagnosis enquiring about sexual behaviour in 
the 12 weeks prior to diagnosis and at 12 week follow-up. Recreational drug use was high 
amongst study participants at 71% pre diagnosis, and 62% reported UAI with a casual male 
partner. By 12 weeks after diagnosis, prevalence of drug use had fallen to 25% and condom 
use had increased amongst men reporting sex with casual partners. Notably, 76% of the 
men had eliminated any transmission risk over the follow-up period, defined as UAI with a 
regular partner of unknown or negative HIV status, UAI with casual male partners or 
incident STI. Even amongst men presenting with continued transmission risk, the median 
number of partners in the 12 weeks since diagnosis was significantly lower. The 22 men 
who continued to pose a transmission risk after PHI diagnosis reported more sexual 
partners in the 12 weeks prior to their diagnosis than those who posed no apparent risk. 
They also had almost 3 times the odds of reporting ketamine use and 2.7 times the odds of 
having an STI at diagnosis. 
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One factor which may also mediate sexual behaviour during early infection is the presence 
of acute retroviral syndrome which, if experienced, coincides with the time of peak 
infectivity and may lower libido. Celum et al found that 70 out of the 103 seroconverters in 
their cohort reported changes in their usual activities because of acute retroviral illness 
lasting for 3 days or more; moreover 59/103 took time off work over this period 37. The 
severity and number of acute retroviral syndrome symptoms experienced in PHI has been 
shown to be positively correlated with viral load at this time 129. Gray et al 67 observed from 
the Rakai data that sex was most frequent amongst couples where the infected partner had 
a HIV viral load <1700 copies/mL at 10.4 acts per month, and less frequent amongst couples 
where the infected partner had a HIV viral load >38500 copies/mL at 7.91 acts per month. 
The true extent to which individuals engage in unsafe sexual behaviour at this time of peak 
viraemia is currently unknown.  
The duration of the high viraemia in EHI is much shorter in comparison to the 
asymptomatic and symptomatic stages; estimated to be weeks or months in EHI 32,57, as 
opposed to years for asymptomatic and symptomatic stages 40,41,45. In a hypothetical 
situation, when the rate of sexual contact formation and transmission probability stays 
constant throughout infection, the shorter duration of elevated infectiousness seen in 
primary infection should result in fewer sexual contacts and therefore fewer transmission 
events in comparison to the long asymptomatic period which lasts for years. The 
assumption of a constant rate of sexual contact formation over this time period may not be 
valid however. One view is that partner formation rates and risky behaviour are higher 
throughout early infection, as any risky behaviour that may have led to the primary 
infection may remain unmodified whilst the individuals is unaware of their positive status. 
In high-risk populations where partner formation rates are high and UAI remains frequent 
over early infection, primary infection likely plays an important role as the high number of 
contacts achieved in the short period would be ample to transmit the virus. In this period, 
concurrency of partners will also fuel a faster growing epidemic.  However, in populations 
where relationships are long lasting and monogamous in nature, the duration of the 
primary infection plays less of a role as relationships are likely to last longer than the short 
duration of primary infection, therefore only exposing one partner to the high infectivity 
over that time period. 
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 Conclusions 2.1.5
Partner studies and indirect estimates from mathematical models have unilaterally shown 
the HIV transmission coefficient (β) to be elevated in early infection, a finding which 
supports the theory of increased infectiousness as a result of the elevated viraemia during 
this period. Deterministic models combine these stage-specific transmission coefficients 
with data summarising sexual behaviour (c) in the population and disease stage durations 
(D) to provide estimates of the proportion of infections attributable to early infection, 
however the resulting estimates are varied ranging from 1% to 89%. This variation is due 
primarily to differences in model assumptions across study settings, mainly involving sexual 
behaviour parameters, which can undermine the validity and generalisability of model 
findings. Phylogenetic studies have the advantage of tracking actual transmission events in 
real sexual networks but must be performed with rigorous definitions. Though phylogenetic 
analyses have provided evidence that EHI may contribute to a large proportion of 
secondary transmissions the most recent study in the UK demonstrated that undiagnosed 
infection across all disease stages contributes to a larger proportion of transmission events 
than recent infection. To date, there is limited data on the sexual behaviour of MSM 
diagnosed during with EHI in the UK from which to understand their role in secondary 
transmission in this country. Empiric estimates of the number of sexual partners accrued 
over EHI, alongside their HIV status is crucial to facilitate modelling of the role of recent 
seroconverters in onward transmission of HIV in the UK.  
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2.2 What is the rationale for initiation of ART in early HIV infection? 
 Literature review methods 2.2.1
This scoping literature review aimed to summarise the literature published up until March 
2010 examining the rationale for initiation of ART in early ART, specifically: 
1. The clinical benefit of initiating ART in EHI in terms of: 
 immunological benefits of ART in PHI 
 virological benefits of ART in PHI 
 clinical benefits of ART initiation at CD4>350 cells/mm3 
2. The role of early ART in reducing HIV transmission 
3. Acceptability and potential barriers towards early ART. 
The scoping review approach as outlined by Arksey and O’Malley 103, and used for the 
previous review, was adopted for this scoping review, with one change. Due to the wider 
range of topics to be covered in this review, it was necessary to perform a number of 
searches on the online bibliographic databases PubMed and Ovid (see appendix 7 for 
search strategies). Studies were charted according to the three themes listed above, and 
according to the research methods each employed. In addition to searching bibliographic 
databases, the reference lists of articles found to be relevant were hand checked and 
conference abstracts of UK and international HIV conferences between 2008 and 2010 
were also checked to ensure inclusion of relevant recent studies that were not likely to be 
published yet.  
 Does initiating ART in early HIV infection confer clinical benefit? 2.2.2
At the time of writing this literature review, the optimum time to start ART in asymptomatic 
HIV-positive individuals was unknown. Historically the perceived optimum time to start ART 
has varied over the years. The “hit hard and early” approach, advocated soon after the 
advent of ART 130, was followed by a more cautious “deferred therapy” approach resulting 
in recommendations of ART for those with CD4 counts of 200 cells/mm3 or less 131. In recent 
years, the recommendations have shifted back towards starting ART earlier in infection, 
with UK guidelines changed from CD4 count of 200 to 350 cells/mm3 in 2008 132.  
HIV treatment initiation in the UK is currently predominantly guided by immune deficiency 
as measured by CD4 count, though specific guidelines also exist for PHI. At the time of 
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writing, BHIVA guidelines recommended commencement of HIV treatment in PHI if the 
patient had neurological involvement, CD4≤350 cells/mm3 or AIDS diagnosis, and in 
asymptomatic HIV-positive patients at CD4≤350 cells/mm3 132.  However, there is a rationale 
to start treatment earlier in infection than current BHIVA guidelines recommend, as aside 
from possibly conferring clinical benefits, earlier initiation of ART could also reduce 
infectiousness and hence the extent of onward transmission. If HIV treatment were to be 
used to reduce onward HIV transmission the largest reduction in infectiousness would be 
amongst individuals who have high viral loads, which is particularly the case in EHI. In 
addition to the reduction in infectiousness, individuals with high CD4 counts, and/or PHI, 
may also benefit clinically from initiation of ART at this time point. This section of the 
literature review outlines the rationale for early initiation of ART from a clinical and public 
health perspective.  
Over the years, several clinical rationales have been proposed for ART in EHI. Before 
investigating these further it is important to clarify the definition of early ART as there are 
separate rationales to treat primary HIV infection (usually defined as the first 6 months of 
HIV infection) and early-chronic infection (where CD4 count is likely still >350 cells/mm3 but 
patients are still asymptomatic). Both of these scenarios apply to the population under 
study in this thesis, individuals with EHI, as the vast majority still have CD4 count >500 
within a year of seroconversion 133. In this section, I provide an overview of the research 
performed to date and where possible synthesise the evidence for and against early 
initiation of ART, focussing foremost on those with PHI and secondly individuals with 
chronic asymptomatic infection and high CD4 count.  
2.2.2.1 Immunological benefits of ART in PHI 
Several studies have investigated the effectiveness of ART initiated specifically in PHI, the 
majority of which are observational, or clinical, cohorts of individuals with laboratory 
confirmed dates of seroconversion. As recent seroconverters are identified and recruited to 
studies in the very early stages of HIV infection, it is expensive and impractical to follow up 
large cohorts until AIDS events or death. Instead, measures of viral load and CD4 counts, 
which are known to be predictive of disease progression and AIDS 134, are used to reduce 
the necessary study follow-up duration. Uncertainty exists, however, in whether the 
apparent short term improvements in these surrogate markers, as demonstrated in studies 
investigating transient ART in PHI, translate into clinical benefits in later infection. 
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There is a rationale for starting treatment specifically in PHI to lessen the extent of immune 
depletion that occurs in the weeks following HIV infection. T-cell activation is very high in 
acute infection, and the extent of activation has been shown to be associated with CD4+ T-
cell depletion 135. ART initiated in PHI, ideally as early as possible after infection, has been 
shown to reduce the duration of T-cell activation and lessen the extent of depletion of 
CD8+ and CD4+ T-cells 136–143, and preserves a higher level of immune function for longer 
than individuals not treated in PHI 144,145.  
It is important to note, however, that it may be possible to initiate ART too soon. Younes et 
al 146 demonstrated that in individuals who start ART within 1 month of seroconversion, the 
short exposure to HIV does not allow the generation of significant detectable frequencies of 
HIV-specific CD4+ memory T-cells. The authors suggest balance must therefore be reached 
between initiating ART in PHI late enough that HIV-specific immunity can first be developed 
but early enough to avoid the depletion of CD4+ T-cell numbers and functionality observed 
in chronic infection.  
2.2.2.2 Virological benefits of ART in PHI 
Viral load “set point”, the point at which blood viral load levels off after the initial rise and 
fall following HIV infection, has been shown to be a strong predictor of long term disease 
progression with a higher set point associated with faster disease progression 34,35. This 
makes it an ideal surrogate marker to use as an outcome in the assessment of virological 
benefits of ART in PHI. There have been conflicting results to date from studies assessing 
the effect of ART in EHI on viral set point following drug cessation, with six studies having 
shown a significant difference between individuals treated in EHI versus their  
controls 140,147–151 and three studies showing no difference 143,152,153. The lack of agreement 
of these studies is likely due to variation between the observational studies in the key 
variables of interest such as the definition of EHI, the timing, duration and formulation of 
ART and importantly the way viral set point has been defined, which has no standard 
definition. What is evident from these studies however, is that any viral control achieved 
through early ART is very rarely attenuated for any length of time following cessation of 
treatment. This is due to the re-emergence of the virus post-treatment from a latent 
reservoir of HIV-infected CD4 cells, which is established in EHI 154 and this is known to 
persist even amongst individuals on ART whose blood plasma viral load is undetectable 155. 
There is however some evidence that initiation of immediate ART in acute infection, results 
in a significantly smaller latent viral reservoir compared to individuals who initiated therapy 
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in chronic infection 156 and even compared to those initiating later in EHI (over 180 days 
following infection) 157. The small reservoir size reported by Pires et al was comparable to 
that found in the cohort of long term non-progressors, prompting cautious speculation that 
an early ART strategy could be used to provide a functional cure 156.  
At the time of writing, only data from observational studies were available to assess 
whether initiation of combination ART earlier in infection benefits the individual in terms of 
preservation of immune function, delaying onset of opportunistic infections or death and 
these have found no consensus. In addition, observational studies, whilst logistically and 
financially more convenient to conduct, are prone to unmeasured confounding. Well 
designed, adequately powered, randomised controlled clinical trials provide the highest 
quality evidence of the clinical efficacy of ART initiated in PHI. The SPARTAC (Short Pulse 
Anti-Retroviral Therapy At Seroconversion) trial is one such trial and was in the follow up 
phase at the time of writing. The aim of SPARTAC was to elucidate whether a transient 
short (12-week) or longer (48-week) course of ART given to individuals with PHI can delay 
the time taken for CD4 count to fall below 350 cells/mm3 on two consecutive occasions, or 
time to clinically indicated initiation of ART 158. The findings of SPARTAC apply specifically to 
individuals with PHI and, as they were reported in 2013, are not included in this literature 
review but are included in the thesis discussion, chapter 7. 
Even if the existence of immunological or virological benefits through use of transient ART 
in PHI are demonstrated, it would not necessarily result in an immediate change in BHIVA 
recommendations. Results from the SMART (Strategies for Management of Antiretroviral 
Therapy) study, a large clinical trial examining structured treatment interruptions in 
chronically infected individuals, have shown that CD4 guided ART interruptions resulted in 
higher risk of AIDS and death from any cause 48. Whilst those initiating ART in early infection 
may be a sufficiently different population from those enrolled in the SMART study there 
may still be an underlying risk associated with transient treatment in PHI. The act of starting 
ART in PHI, stopping, then restarting it later in the disease course when clinically indicated 
could increase the risk of cardiovascular events, AIDS and/or death as demonstrated in the 
SMART study 48.  
2.2.2.3 Earlier CD4-guided ART initiation for clinical benefit 
Two very large cohort collaborations have recently reported findings from studies assessing 
higher CD4 guided ART start points, than the current recommended threshold of 350 
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cells/mm3. The first was run by NA-ACCORD (North American AIDS Cohort Collaboration on 
Research and Design), a collaboration of 22 research groups in North America 159. Data from 
17,517 asymptomatic patients were used to run two comparison analyses. The first used 
data from 8,362 patients to compare mortality between those who initiated ART at CD4 
351 to 500 cells/mm3 (n=2084) to those who had deferred treatment until their CD4 was 
350 cells/mm3 or less. After controlling for differences in calendar year, demographic 
factors and clinical characteristics between the two groups, the findings showed an 
increased risk of death in the deferred treatment group of 69% compared to the earlier 
treatment group (risk ratio: 1.69, 95% CI: 1.26-2.26). The second analysis presented used 
data from 9,155 patients to show an increase in mortality of 94% (RR=1.94; 95% CI=1.37-
2.79) amongst the group that deferred ART until CD4 count was less than 500 cells/mm3 
(n=6,935) when compared to those who started at CD4>500 cells/mm3 159.  
The second large cohort study addressing the issue of earlier commencement of ART is the 
When to Start Consortium of HIV Cohort Studies 160. By combining data on 21,247 AIDS-
free, non-IDU, patients from 15 cohort studies across North America and Europe and using 
novel statistical methods to account for unobserved events in the deferred treatment arm 
the ART-CC (Antiretroviral Treatment Cohort Collaboration) compared deferring ART across 
a range of different CD4 counts, to initiating it at those counts. They found that deferring 
ART until CD4 was less than 350 cells/mm3 resulted in a 28% (HR=1.28, 95% CI=1.04-1.57) 
increase in AIDS or death when compared to starting it at CD4 351-450 cells/mm3. No 
significant differences in mortality or AIDS events were observed between those who 
started and those who deferred. 
The findings from the observational analyses above are not directly comparable due to the 
different end points used, and study populations.  In addition, results from any cohort study 
must be treated with caution as the nature of the methodology makes the results 
susceptible to confounding from unmeasured factors though efforts were made to control 
for bias and potential confounders. ART-CC used novel statistical techniques to estimate 
distributions of lead-time and unseen events prior to the deferred group starting ART by 
using pre-ART data. This method relies on the assumption that the course of infection in the 
pre-ART era is representative of the current course of infection, i.e. that the rate of disease 
progression in the absence of ART has not increased. NA-ACCORD controlled for 
demographic and clinical confounders in their analyses, though unmeasured confounders 
may have persisted.  
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Despite the lack of randomised evidence indicating clinical benefit of initiation of ART at 
CD4>350, the US DHHS released new guidelines in December 2009 recommending ART 
initiation amongst asymptomatic individuals diagnosed with HIV and who have a CD4 
between 350 and 500 cells/mm3 161. The START (Strategic Timing of Anti-Retroviral 
Treatment) clinical trial, which at the time of writing was recruiting, aims to examine 
whether starting HIV treatment at CD4 of 500 cells/mm3 delays progression to AIDS and 
reduces mortality, compared to deferring it until CD4 count reaches 350 cells/mm3. Whilst 
the study population is not specifically recent seroconverters, the findings will apply to the 
majority of recent seroconverters by default given that the high CD4 counts that determine 
eligibility are typically observed in EHI.  
 Early ART to reduce transmission 2.2.3
Antiretroviral therapy has long been known to be effective at reducing blood viral load in 
PLWH.  This has led researchers to hypothesise that the reduction of viral load in the blood 
brought about by ART may also reduce sexual transmission at the individual level 5.  A 
recent systematic review and meta-analysis of studies examining transmission amongst 
serodiscordant heterosexual couples appeared to confirm this hypothesis showing 
transmission rate to be 0.46 per 100 person-years in studies where the HIV-positive partner 
was on ART compared to 5.64 per 100 person-years 162. Furthermore, no transmission 
events were identified amongst couples where the HIV-positive partner’s viral load was 
<400 copies/mL in the studies included in the meta-analysis.  
Most recently, results from the “Partners in Prevention” study, the primary objective of 
which was to assess whether treatment of herpes with acyclovir reduced HIV transmission, 
aimed to assess the effect of ART on HIV transmission amongst 3381 serodiscordant 
couples as a secondary objective 163.  The study team observed a far lower rate of HIV 
transmission amongst couples where the HIV-positive partner self-reported taking ART: 
0.39 (95% CI 0.09-2.18) per 100 person years, compared to 2.23 (1.84-2.70) per 100 person 
years in those who were not on ART. This equated to a 92% reduction in HIV transmission 
afforded by ART, after controlling for CD4 count at initiation and the time enrolled in the 
study. One transmission event occurred in the ART cohort, however in this case it was 
plausible that the transmission event had occurred prior to the index partner initiating ART.  
In North America, Central and Western Europe the dominant mode of HIV transmission is 
between sex between men 8, however, there is a notable lack of published partner studies 
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examining transmission in this population. As a result, concern exists over the extent to 
which findings from heterosexual studies can be extrapolated to MSM.  Also though 
observational evidence exists that ART decreases transmission risk, transient ART during 
PHI carries the possibility of a delay in the hyper-viraemia observed during AHI until after 
treatment discontinuation, as demonstrated by Rieder et al 164. The authors carried out 
phylogenetic analyses of the sequences from the env and pol region of the HIV genome 
sampled from 111 MSM enrolled in the Zurich Primary HIV Infection study who were 
diagnosed with acute or primary infection revealed and 18% to be involved in 6 
transmission clusters with other MSM in this study and the Swiss HIV Cohort Study. The 111 
MSM were followed up for a median of 3.3 years, during which time 93 MSM initiated early 
ART (with 47 stopping treatment after a year of viral load being suppressed to below 
50copies/mL).  Within the 6 transmission clusters, only 1 transmission was likely to have 
occurred in the acute period, 1 in the recent infection period and 5 transmissions were 
likely to have occurred in the period following cessation of transient ART. The 
corresponding rate of transmission prior to early ART initiation was 3.5 transmissions per 
person-year (95% CI 0.9-13.5) compared to 1.8 for the period after treatment cessation 
(95% CI 0.5-5.8). Interestingly, one cluster contained a potential transmission from an index 
patient stable on ART with an undetectable viral load at the time, however the authors 
dismissed this as highly unlikely as upon updating the analysis it appeared there were 
another possible 3 transmitters in the cluster 164. 
Whilst the observational evidence to date appears to indicate transmission whilst 
undetectable on ART is unlikely, these studies are susceptible to unmeasured confounders. 
At the time of writing the randomised HPTN-052 trial was ongoing with the primary 
objective of assessing the effectiveness of ART in preventing HIV transmission amongst 
1,750 serodiscordant couples 165. Both heterosexual and MSM couples are eligible, with the 
index (HIV-positive partner) of each couple randomised to one of two arms: to receive 
immediate ART, or defer ART initiation to when CD4 count falls below 200-250 cells/mm3.  
At a population level, the impact of ART on HIV transmission has been assessed through 
mathematical modelling and ecological studies.  Ecological analyses of HIV incidence 
amongst MSM following the widespread rollout of ART in Amsterdam, San Francisco, 
Taiwan and British Columbia have yielded mixed results. Dukers et al used unlinked 
anonymous samples from 3090 MSM attending an Amsterdam STI  clinic, to estimate HIV 
incidence between 1991-2001 166. The authors observed an increase in HIV incidence, and 
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concurrent STI infection over time which was particularly evident amongst MSM aged >34 
years. Katz et al used routine surveillance data from San Francisco to demonstrate that HIV 
incidence has remained stable between 1996 and 1999, despite rapidly increasing uptake of 
ART over this time period 167. Both of these studies concluded that any decrease in 
infectiousness afforded by increased ART use was likely mediated by population-wide 
increases in unprotected sex. Conversely, Porco et al observed a 60% reduction in HIV 
incidence following the widespread use of ART amongst MSM enrolled in the Young Men’s 
Health Study between 1994-1999 168, the same period as the study by Katz et al 167. Fang et 
al conducted an ecological analysis of national surveillance data in Taiwan and 
demonstrated a 53% decrease in HIV transmission rate following the introduction of a 
national policy of free ART access to all HIV-positive individuals 169. Notably there was no 
observed increase in the incidence of syphilis over the same time period, inferring no 
increase in high-risk sexual behaviour. 
Recent analysis of routine data from San Francisco by Das et al used estimates of 
community viral load (calculated as the mean or the total of the most recent viral load test 
for all HIV-positive individuals in a given geographical population) as a proxy of population 
infectiousness, instead of the previously used proxy of ART uptake 170. These data suggest 
an association between decreasing community viral load over time and decreasing 
incidence between 2006 and 2007, following the introduction of an expanded test and treat 
strategy in 2006 170. In British Columbia, Canada, the increase in ART rollout at a population 
level has also been associated with a decrease in the annual number of new HIV diagnoses 
between 1999 and 2009 following a concentrated effort to expand testing and access to 
ART 171. This was delivered alongside several other community strategies which aimed to: 
improve linkage to care; promote condom use; distribute free condoms; and provide free 
ART to those who are HIV-positive and have no health insurance. Whilst these more recent 
studies appear to indicate decreasing incidence occurring in combination with expanded 
test and treat strategies, it is important to acknowledge the risk of ecological fallacy; as the 
outcomes and risk factors are measured as an aggregate across the entire population, any 
decreases in HIV incidence cannot be directly attributed to test and treat initiatives. 
Mathematical modelling studies have also provided insight into the role ART can play in 
reducing transmission at a population level, though opinions on its potential efficacy are 
divided.  Months after the release of the Swiss statement, Wilson et al published a paper 
highlighting the potentially negative public health impact the Swiss Statement could have if 
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condoms were subsequently abandoned and ART solely relied upon to reduce transmission 
in serodiscordant partnerships 172. The authors’ model estimated the cumulative risk of HIV 
transmission from HIV-positive individuals undetectable on ART (viral load <10 copies/mL) 
and in monogamous serodiscordant partnerships. Using the correlation between viral load 
and per contact transmission risk estimated in the Rakai study 66, Wilson et al modelled 
male-to-female, female-to-male and male-male transmission, estimating annual cumulative 
risk of transmission to be 0.0043, 0.0022 and 0.043, respectively, assuming couples engage 
in 100 sexual acts per year. This translated to 10 year cumulative number of 
seroconversions of 425 from male-female transmission, 215 from female-male and 3524 
amongst MSM, in hypothetical populations of 10,000 partnerships over a 10 year period in 
the total absence of condom use.  Applying the assumption of 80% condom use, with a 95% 
efficacy per act, in addition to ART, decreased the number of seroconversions substantially 
to 104, 52, and 990, respectively. Central to the model were the assumptions that the log-
linear association between viral load and per contact transmission risk was applicable in 
different transmission scenarios (male-to-female, female-male and male-male), that the 
correlation held even at undetectable viral loads and in the presence of ART. There is no 
evidence published to date to confirm or refute these assumptions, and it is conceivable 
that a threshold effect operates, rendering transmission below a particular viral titre 
unfeasible. 
Several other models have endorsed the use of TasP at a population level. Granich et al 
predicted that the prevalence of HIV in South Africa could be reduced to less than 1% 
within 50 years if universal HIV testing followed by immediate HIV treatment initiation was 
implemented 173. This estimated decrease in prevalence is caused by the reduction in 
population viral load afforded by early HIV treatment, along with a decrease in the 
proportion of HIV-positive individuals who remain unaware of their HIV infection. However, 
the study has faced criticism for its “utopian” assumptions of very optimistic ART rollout, 
uptake and adherence rates 174; 90% of South Africans were assumed to have ART and 
follow-up care accessible to them within the next 8 years, and adherence was assumed to 
remain high after ART initiation.  
Other modelling studies have corroborated the idea that TasP can be used to reduce HIV 
incidence. Dodd et al used a more detailed deterministic model, acknowledging that 
epidemiological variations in epidemic stage, survival rates, stage of infection and sexual 
behaviour can vastly influence model predictions 175.  They found that in certain epidemic 
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situations, for example in a population with homogenous risk distribution testing 80% of 
the population every 2-3 years could generate an 95% reduction in incidence over 30 years, 
however this reduces to 85% reduction in epidemics where sexual mixing is random and 
risk is heterogeneous. They conclude that test and treat models should be fitted to specific 
populations, and ideally include local sexual behaviour data to enable the most accurate 
prediction of TasP impact. Similarly, Lima et al modelled the effect of varying ART coverage, 
adherence, recommended CD4 initiation thresholds in British Columbia, Canada 176.  The 
authors concluded a decrease in HIV incidence would be seen if a minimum of 75% of 
individuals who were clinically eligible for ART were treated, and that this can be optimised 
by recommending ART at higher CD4 counts as well as achieving high rates of coverage and 
maintaining high adherence amongst those who are clinically eligible.  
At the time of writing this literature review, the Population effects of Antiretroviral Therapy 
(PopART) trial was being developed to examine whether universal testing and treatment for 
all HIV-positive individuals, irrespective of CD4 count, would reduce HIV incidence at a 
population level in a real world setting 177. The study aims to estimate HIV incidence 
amongst 21 community clusters, each recruiting a random selection of 2500 adults, in 
South Africa and Zambia. Communities will be randomised to one of three arms: arm 1 will 
receive the combination prevention package comprised of annual home testing with 
immediate ART for all testing HIV positive, and promotion of male circumcision for HIV-
negative men; arm 2 will receive the package but with HIV treatment as per current 
national guidelines; arm 3 will receive standard of care.  
 Barriers to early ART 2.2.4
If ART were to be offered earlier in infection to those with EHI in the UK to reduce 
transmission, there is no guarantee that it would be taken up. There has been no work 
published to date on the acceptability of early ART initiation amongst individuals with EHI. 
With no RCT evidence indicating clinical benefit of early ART, individuals would be asked to 
initiate purely to reduce transmission, almost as an altruistic act.  No published literature 
was available on the concept of altruism in relation to ART use, though the broader concept 
of HIV “prevention altruism” had been explored. Nimmons defined the term “prevention 
altruism” as the values, motivations and practices of caretaking towards one’s sexual 
partners to avoid the transmission of HIV 178. O’Dell et al observed high levels of prevention 
altruism, as measured on a seven-item likert scale, in a cross-sectional survey of HIV-
positive MSM in the US 179. Univariate analysis showed MSM in the highest tertile of 
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prevention altruism were half as likely to report serodiscordant UAI than those in the 
lowest. However, when disinhibitive factors such as crystal meth or Viagra use were 
adjusted for the association did not remain statistically significant 179. 
Even if the trials do show a clinical benefit of earlier ART, taking medication in the absence 
of symptoms or illness may introduce adherence problems. Drug resistance, both 
transmitted and acquired, is also of major concern when considering the drawbacks of 
expanding ART for prevention. The reported decrease in the detection of drug resistance in 
British Columbia where the “Seek and Treat” strategy is currently in place, from a rate of 
1.73 to 0.13 cases per 100 person-months of therapy between 1997 and 2008 is 
encouraging though 180. This decrease has occurred alongside an increase in the proportion 
of HIV-positive individuals with suppressed viraemia (<50 copies/mL) of 65% in 2000, to 
87% in 2008. Though causal associations cannot be made from observational studies, it is 
encouraging that at a time of expanded access in this population, detected drug resistance 
appears to have decreased 180.  
Risk compensation, is also a very real possibility should early ART be widely adopted to 
prevent transmission in the absence of condom use.  Mathematical modelling has 
estimated that a 50% increase in condomless sex amongst Australian MSM will completely 
offset any decrease in infectiousness afforded by ART, and result in increased incidence in 
the population 181. An increase in high-risk sexual behaviour during EHI may also occur if 
individuals on ART feel better.  A population wide increase in condomless sex could not only 
directly increase HIV incidence, but also facilitate the spread of other STIs. Any increase in 
the prevalence of STIs amongst HIV-positive individuals could in turn indirectly facilitate 
transmission as viral load in the genital fluids of HIV-positive people is known to increase 
with the presence of another STI 69. 
At the time of writing this review, there were no published data to indicate whether 
initiation of treatment in EHI results in risk compensation; however, data do exist from 
studies investigating the relationship between attitudes to treatment, viral load and sexual 
behaviour in MSM who were not recently infected. Crepaz et al performed a meta-analytic 
review of studies examining the relationship between ART and sexual risk behaviour 182. 
Their review included studies amongst heterosexuals, MSM and IDU. Their random effects 
model included 21 effect estimates form 16 studies and concluded that there was no 
significant difference in unprotected sexual intercourse between HIV-positive people who 
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were on ART and those who were not (OR, 0.92; 95% CI, 0.65-1.31). Their random effects 
model of data from 12 studies examining whether undetectable viral load was associated 
with unprotected sex also showed no evidence of an association (OR, 0.99; 95% CI, 0.82-
1.21). Interestingly, meta-analysis of the 18 effect sizes from the 10 studies investigating 
beliefs about ART or viral load and unprotected sex amongst HIV-positive, negative and 
unknown individuals showed the likelihood of unprotected sexual behaviour was 
significantly higher in people who believed ART reduces HIV transmission or who were less 
concerned about unsafe sex because of the availability of ART (OR, 1.82; 95% CI, 1.52-2.17).  
It is important to note that this meta-analysis covered studies published up until 2003 only. 
Since then, improvements in drug technology and subsequent reduction in pill burden and 
toxicities, in addition to the increased publicity given to the effect of ART on infectiousness 
may have resulted in shifts in attitudes and beliefs associated with ART and resulted in 
higher treatment optimism and reduced concern about transmission.  
Finally, perhaps the biggest factor to limit the utility of early ART to reduce HIV transmission 
will be the rate of HIV testing 173,175. For this reason, many of the population-based 
programmes assessing the impact of early ART involve plans to scale up HIV testing, for 
example the previously mentioned “Test and Treat” programme in San Francisco 170 and 
“Seek and Treat” in British Columbia 180 as well as the PopART trial 177. The benefits of 
increasing HIV-testing are two-fold; it decreases the number of individuals unaware of their 
HIV status and increases the number who may initiate early ART and achieve undetectable 
viral load. In the UK at the time of writing, BHIVA recommended annual HIV testing for 
MSM, or more regularly if HIV symptoms are present or individuals engage in high risk 
sexual behaviour 132.  Surveillance data collected from sexual health clinics has indicated an 
increase in HIV testing over time across the UK 183 with UK national surveillance figures 
estimating that 93% of GUM clinic attendees received an HIV test in 2008 9. Whilst testing 
amongst sexual health clinic attenders may be high, data from the second National Survey 
of Sexual Attitudes and Lifestyles, a weighted probability sample survey conducted in the 
general population, found only 44% of MSM to have ever tested for HIV, out of whom only 
1 in 3 had tested in the last year 184. Increasing the proportion of MSM who have ever 
tested for HIV, and encouraging MSM to test regularly thereafter, is a crucial precursor to 
any role early treatment could play in curbing onward transmission.  
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 Conclusion 2.2.5
At the time of writing this review, there was clinical equipoise over whether early ART, both 
when initiated at high CD4 counts (>350 cells/mm3) and when given as short-course 
therapy in PHI, conferred significant clinical benefits to the individual. Whilst, in both cases, 
observational studies to date have reported potential benefits to earlier initiation, they are 
subject to bias and the effect of unmeasured confounders. Large randomised controlled 
trials are currently underway to address these gaps in the evidence: START to assess 
whether initiation of ART at CD4>500 cells/mm3 confers clinical benefit compared to 
starting at ≤350; and SPARTAC to assess whether short-course ART of 12 or 48-week 
duration initiated in PHI could delay the time to treatment re-initiation, compared to no 
ART in PHI. Meanwhile, there is mounting evidence from observational and mathematical 
modelling studies that ART, often in combination with expanded HIV testing, can play a role 
in reducing HIV transmission at both the individual and population level. The HPTN-052 trial 
is currently underway and aims to address whether ART can reduce risk of HIV transmission 
amongst serodiscordant partners, whilst the PopART cluster randomised trial is currently in 
planning phase and seeks to assess whether a universal test and treat policy can reduce HIV 
incidence at the population level.   
The success of the widespread rollout of TasP depends not only on the efficacy of ART in 
the prevention of transmission, but also the identification of undiagnosed individuals at an 
early stage of infection, good linkage to care to enable ART initiation and retention in care 
for monitoring of adherence and viral load. There are also concerns as to whether risk 
compensation may occur if TasP were to be adopted as a prevention strategy, whereby 
high-risk sexual behaviour increases due to a perceived decrease in the risk of transmitting 
or acquiring HIV. In addition, there is no research to date on the acceptability of early ART 
to reduce transmission, particularly in the current scenario where there is no randomised 
evidence of clinical benefit to the individual.  
2.3 PhD Rationale and research question 
In this chapter I have summarised the findings from the literature showing that the 
elevated viral load during EHI likely results in disproportionally high transmission risk over 
this disease stage. This has been shown in several modelling and phylogenetic studies, 
though the proportion of infections attributable to EHI varies greatly (from 1.3 to 88.5%) 
according to the populations under study, stage of the epidemic, model assumptions and 
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definitions adopted by the researchers.  Sexual behaviour studies have also indicated that 
lack of awareness of HIV infection and subsequent continued high-risk sexual behaviours 
over EHI, may also be responsible for high transmission potential during this stage.  
Individuals with EHI are likely to present with high CD4 counts, most likely above the 
current BHIVA recommended threshold for treatment initiation of 350 cells/mm3 132. 
Evidence from observational studies indicates that initiation of life-long therapy at CD4>350 
cells/mm3, or specifically in PHI, may confer clinical benefit, though randomised evidence is 
currently lacking. There is also a growing body of observational evidence supporting the use 
of ART as a method of reducing sexual transmission of HIV, at the individual and public 
health level, though again, randomised trial data are still awaited. 
MSM in the UK carry a disproportionate burden of HIV, with 2760 newly diagnosed with 
HIV in 2009, comprising 42% of all new diagnoses in the UK 185. As 1 in 6 MSM presented 
with evidence of a recent infection, and 4 out of 5 were likely to have contracted HIV in the 
UK 185, it is evident that TasP could play a role in reducing transmission amongst this risk 
group.  As MSM with EHI are known to have higher viral loads than those with chronic 
infection, early initiation of ART in this population could reduce the high infectivity 
associated with elevated viral loads, help reduce community viral load, and may also 
provide clinical benefits to the individual. The rollout of TasP in the UK would result in HIV-
positive MSM being offered ART at a much earlier time point in the course of HIV infection 
than they are under the current guidelines.  However, at the time of this literature review, 
there was no work to date investigating the acceptability of early ART to prevent HIV 
transmission amongst MSM with EHI. Whether MSM would accept early ART to prevent 
transmission is a particularly salient question, given the absence of randomised evidence of 
individual clinical benefit.  
Due to the short duration of elevated infectiousness in early infection, early presentation to 
health services for HIV diagnosis at peak viraemia is crucial in dictating the utility of TasP. 
However, currently no data exist characterising viral load at clinic presentation amongst 
MSM with EHI in the UK. Similarly, the success of TasP in reducing secondary transmission 
during EHI is dependent on sexual behaviour over this time period.  Studies from the US, 
and one study conducted in a central London HIV clinic, indicated attenuation of HIV-
transmission risk-behaviours after HIV diagnosis amongst MSM with EHI, but no recent data 
exist to address this question amongst a wider population of MSM in the UK.  
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This thesis attempts to bridge the gaps in the knowledge and understanding of acceptability 
of early ART amongst MSM with EHI in the UK, and how TasP could be used in this 
population to reduce HIV transmission. The overarching research question this thesis seeks 
to address is:  
“Is early antiretroviral therapy acceptable to MSM with early HIV infection 
attending UK HIV clinics, and could it be used in this population to reduce 
HIV transmission risk?” 
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3 Methodology and methods 
In this chapter I first give a brief introduction to mixed methods research, outlining its origin 
and underlying methodology. I then provide my rationale for selecting this approach, 
framing this decision within the context of my worldview and philosophical assumptions on 
the nature of research.  The study design is then outlined in full, with the aims and 
objectives of the two PhD workstreams presented, and the methods for each of their 
comprising phases described in detail.   
 The mixed methods approach 3.1
Mixed methods research has been defined by Tashakkori and Creswell as “research in 
which the investigator collects and analyses data, integrates the findings, and draws 
inferences using both qualitative and quantitative approaches or methods in a single study 
or programme of inquiry” 186. Greene went on to add a further layer to this definition by 
stating that mixed methods research invites us “to participate in dialogue about multiple 
ways of seeing and hearing, multiple ways of making sense of the social world, and multiple 
standpoints on what is important and to be valued and cherished” 187.  
The first studies demonstrating the use of mixed methods, by merging qualitative and 
quantitative data using data triangulation techniques, can be traced back to 1970’s 
psychology. However, mixed methods research in its current guise, as a methodology in its 
own right, is a far more recent development, dating from the late 1980s and early 1990s. 
Researchers in the UK, US and Canada from very different backgrounds in sociology, 
psychology, management, evaluation, education and nursing began by independently, then 
collaboratively, refining the definition of mixed methods and developing a typology of 
different mixed methods approaches. The culmination was a formal classification of mixed 
methods design types defined by a number of factors including: the sequence in which the 
qualitative and quantitative components are conducted, the relative weight, emphasis and 
aim of each component and how, and at what point in the study, the results are  
integrated 188.  
Mixed methods research can be employed for many reasons. Greene et al defined a 
typology of five reasons for using a mixed methods approach, namely: triangulation, 
complementarity, development, initiation and expansion 189. Triangulation enables 
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corroboration of results between the methods, whilst complementarity seeks enhancement 
and clarification of findings. Development refers to the use of one method to inform the 
other, either from a sampling, data capture or implementation perspective. Initiation refers 
to the discovery of contradictions in findings between the methods, and expansion is the 
ability of mixed methods to reveal a greater depth and breadth of a subject using different 
study components. By combining qualitative and quantitative methods, it is possible to 
capitalise on the benefits of both approaches, whilst minimising the bias and limitations 
each approach is renowned for.   
Arguably, the most dominant worldview in health research today is the positivist 
perspective, which assumes that an external reality exists in a fixed state, all phenomena 
can be measured objectively and that knowledge can be gained through hypothesis testing.  
The positivist worldview derives from the natural sciences and generally assumes the 
researcher is independent from the phenomenon under study.  Interpretivism on the other 
hand is deeply rooted in the social sciences and recognises that the researcher and the 
phenomenon under study can influence each other. It is for this reason that qualitative 
research findings are often regarded as subjective. From an interpretivist perspective, social 
reality is viewed as being less constant as it is based on human thoughts and behaviour, 
which are not governed by the “law-like” regularities seen in the natural world 190. The 
integration of qualitative and quantitative methods, with their fundamentally distinct 
ontology, axiology and epistemology, into a mixed methods approach has led to resistance 
from methodological purists over the years.  However, the development of mixed methods 
methodology brought with it a new research paradigm in the shape of a pragmatist 
worldview, which is generally now regarded as the “paradigm of choice” amongst mixed 
methods researchers. Pragmatism in this context is defined by Creswell and Plano Clark as 
focussing on “the consequences of research, on the primary importance of the question 
asked rather than the methods, and on the use of multiple methods of data collection to 
inform problems under study whilst valuing both objective and subjective knowledge” 191.  
Despite the opposition to mixed methods research from positivist and interpretivist purists, 
it is hard to argue that there is no place for it in today’s research world. In health research, 
where research questions are often complex and multifaceted, the use of mixed methods 
has risen exponentially and funding calls now often specify the need for a qualitative 
component in the study design. This is reflected in the observed increase in US National 
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Institute of Health funded projects with mixed methods designs which increased from 1 in 
1997 to 60 in 2007 192.   
 Philosophical assumptions and personal characteristics 3.2
Whilst quantitative research lends itself to a positivist worldview, qualitative research is 
reflexive in nature with the researcher playing an integral part in the research process.  As 
such, an appreciation of my philosophical assumptions is important to assist in 
understanding my position and how this affects my chosen study design and interpretation 
of the resulting data.  
I have a very multidisciplinary background as a researcher and have worked on a number of 
studies over the years, ranging from clinical observational cohorts and a randomised trial of 
computer aided sexual health interviewing techniques for clinicians, to an international 
longitudinal study on health, and various cross-sectional sexual behaviour surveys in 
between. The majority of my work to date, has involved a combination of epidemiology and 
social epidemiology. I believe that there is a difference between the fixed state of the 
natural world and the ever-changing landscape of the social world. As such, I hold a 
pragmatic worldview and believe that whilst a positivist approach to research may be 
acceptable in certain basic science circumstances where elements can be artificially 
controlled, such as in a laboratory context, the nature of the social world is far more 
complex and difficult to control.  I believe the close interaction between the researcher and 
the participants in a face-to-face in-depth interview situation means that, while a social 
reality may exist outside of the interview context for the participant, the relationship 
between the researcher and participant will dictate how much of that reality is presented 
to the researcher within the interview context.  Furthermore, my philosophical 
assumptions, research motivations and personal characteristics are entwined within the 
research itself, and may be enacted subconsciously. 
 The mixed methods study design of the thesis 3.3
 Rationale for using mixed methods approach for this thesis 3.3.1
As demonstrated in the background chapter by May and Anderson’s simple model of HIV 
transmission, the global HIV epidemic is a product of the relationship between the virus, 
the host and a range of psychological and societal factors which dictate human  
 90 
 
behaviour 61. As such, immunology, virology, epidemiology, sociology and psychology all 
have a play a part in assessing, and attenuating, onward transmission of HIV. We live in 
world where dependence on biomedical intervention is high, and as such, clinical practice 
has a propensity to focus on clinical outcomes, sometimes to the detriment of psychological 
and social factors which are often also important. After all, a biomedical intervention is of 
no use if it is not accepted, adopted and used as intended by those whom it was designed 
to help. The decision that an intervention is acceptable, and the subsequent adoption of it, 
are dependent on an individual’s attitudes and beliefs about the intervention which are 
moulded by psychological and societal factors. 
In this thesis, where the goal is to understand how useful early ART could be in reducing 
transmission amongst MSM with EHI, assessing the acceptability of the intervention, and 
understanding the underlying attitudes, beliefs, and experiences of the men who would 
take it, is as crucial a step as examining the biological factors changes in infectiousness over 
EHI. By adopting a multi-disciplinary mixed-methods approach, I hope to provide a 
comprehensive understanding of where early ART fits into the lives of MSM with EHI, how 
acceptable it is and whether it could be useful in preventing secondary transmission in this 
group.  
 Study design 3.3.2
In this thesis, I describe the use of a multi-phase mixed-methods study design which 
combines 2 concurrent workstreams, as illustrated in figure 3.1, to answer the overarching 
research question:  
“Is early antiretroviral therapy acceptable to MSM with early HIV infection 
attending UK HIV clinics, and could it be used in this population to reduce 
HIV transmission risk?” 
As an overview: workstream 1 involved secondary analysis of data from the UK Register of 
HIV Seroconverters to examine temporal changes in ART uptake amongst individuals with 
EHI and viral load at first clinic presentation amongst MSM with EHI. In workstream 2, I 
designed and conducted an exploratory sequential mixed methods study 191, also known as 
the quantitative follow-up design 193. This involved a qualitative component (phase A), an 
in-depth interview study to explore attitudes and beliefs towards early ART amongst MSM 
with EHI attending a central London HIV clinic. This was followed by a multi-site cross-   
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Figure 3.1 PhD study design 
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sectional survey (phase B) to obtain an estimate of the prevalence of the views identified in 
the qualitative component amongst a wider population of MSM recruited across the UK, 
and identify factors associated with uptake of early ART, as well as high HIV transmission-
risk behaviours. The first and second workstreams ran concurrently, and phases A and B of 
workstream 2 ran sequentially.  
The rationale for taking this sequential approach to workstream 2 was that by conducting 
the exploratory qualitative work first, it was possible to identify themes in the men’s 
attitudes and beliefs to early ART, which I may not have identified myself. At the time of 
starting this study, there were no data published on attitudes, beliefs and acceptability of 
ART amongst men with EHI. I wanted to avoid a dictatorial “top-down” method of designing 
a questionnaire without consultation with the men who would complete it, which would 
have led to a survey which established the level of agreement with my attitudes and 
beliefs. Conducting the qualitative work first allowed me to develop the questionnaire 
based on the attitudes, beliefs and themes derived from the seroconverters themselves, 
from the “bottom up”. A full overview of the two work streams now follows.  
 Workstream 1: Analysis of data from the UK Register of HIV Seroconverters  3.3.3
This part of the PhD was quantitative in nature and used data from the UK Register of HIV 
Seroconverters to epidemiologically characterise the time from seroconversion to ART 
initiation and viral load at first clinic presentation. I examined temporal trends in time from 
seroconversion to, and CD4 count at, ART initiation to investigate whether patterns of ART 
uptake had changed over time amongst individuals diagnosed in EHI. I also examined viral 
load at first clinic presentation amongst MSM with EHI, to understand how early an 
intervention with ART would be required to maximise its impact on HIV transmission. The 
specific research questions this workstream sought to answer were: 
 Has time from seroconversion to ART initiation changed over time amongst 
people with EHI? 
 When do MSM with EHI first present to HIV clinic and what is their viral 
load at first presentation? 
 Has viral load at first clinic presentation changed over time? 
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 Workstream 2: Exploring and quantifying attitudes, beliefs and acceptability 3.3.4
towards early ART and changes in sexual behaviour after HIV diagnosis  
3.3.4.1 Workstream 2 phase A: Qualitative component  
This qualitative phase comprised of two parts. The first was an in-depth interview study 
with 14 MSM with EHI presenting to a central London HIV clinic. I conducted the interviews 
with the aim of exploring the attitudes, beliefs, and acceptability of early ART amongst this 
population.  The specific research questions this phase aimed to address were:  
 How does being diagnosed with recent HIV infection affect men’s lives? 
 How do MSM with EHI feel about early ART? 
In the second part of phase A, I drew on the themes identified during the in-depth 
interviews to develop new survey items measuring the newly identified attitudes and 
beliefs towards HIV treatment. In an iterative process I piloted and refined the resulting 
questionnaire using cognitive interviewing techniques amongst MSM with EHI recruited 
from the same London HIV clinic.  
3.3.4.2 Workstream 2 phase B: Cross-sectional survey of MSM seroconverters 
This phase was quantitative and involved conducting a cross-sectional pen and paper 
survey in 16 HIV clinics across the UK to quantify the sexual behaviour, attitudes, beliefs 
and acceptability of early ART amongst MSM with EHI. I undertook this phase as a sub-
study of the existing multi-site MRC-funded UK Register of HIV Seroconverters. This phase 
aimed to answer the following research questions: 
 How widely held are the attitudes and beliefs identified in workstream 2 
phase A amongst MSM with EHI in the UK? 
 What proportion of MSM with EHI regarded early ART as acceptable? 
 What proportion of MSM initiated early ART, and what factors are 
associated with this? 
 Amongst MSM who initiated early ART, what were the predominant 
reasons for initiation? 
 What proportion of MSM engaged in high-risk sex after HIV diagnosis, and 
what factors are associated with this? 
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 Conceptual framework of the thesis 3.3.5
Figure 3.2 outlines my conceptual framework for the thesis, which I developed based on my 
background reading and the findings from my scoping review of the literature presented in 
chapter 2. It illustrates how the research questions addressed in workstream 1, and in 
phase A and B of workstream 2, relate to one another and assist in examining the specific 
aspects of the overarching research question. 
Boerma and Weir’s proximate-determinants framework of HIV transmission is influenced 
by the three biological parameters adapted from May and Anderson’s simple model of 
transmission: per contact risk of transmission (β),  exposure of susceptible to infected 
individuals (c) and the duration of infectiousness (D) 61,65. In order to reduce secondary 
transmission of HIV, early ART would have to influence the proximal determinants of these 
three parameters as outlined in section 1.5. Assessment of the extent to which this is 
currently possible amongst MSM with EHI comprises the utility element to the research 
question.  
Workstream 1 aims to elucidate whether MSM with EHI present to clinic early enough that 
initiating ART immediately could mediate elevated viraemia observed in early infection and 
reduce the per contact risk of transmission. Focussing on another biological determinant of 
transmission as proposed by Boerma and Weir, exposure of susceptible to infected 
individuals 65, phase B of workstream 2 aims to assess the proportion of MSM who engage 
in sex which carries a high risk of HIV-transmission after receiving their HIV diagnosis. By 
investigating the factors associated with engagement in high-risk sex after diagnosis it may 
be possible to identify men most at risk of transmitting HIV after HIV diagnosis.  
Workstream 1 also aims to provide an estimate of ART uptake by describing trends in ART 
initiation over time amongst HIV seroconverters. A further estimate of early ART uptake, 
specifically amongst MSM with EHI will be provided by phase B of workstream 2, which will 
also identify demographic, clinical, attitudinal and behavioural factors independently 
associated with early ART initiation in this group.  
As mentioned previously, uptake of ART is partially dictated by the acceptability amongst 
those who would use it, and estimates of this will be provided by the cross-sectional survey 
data (phase B of workstream 2). Underlying the acceptability of early ART are men’s 
attitudes and beliefs towards it, which will be explored in detail the in-depth interview 
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study (phase A of workstream 2), as well as empirically described in the cross-sectional 
survey (phase B of workstream 2). Importantly, men’s attitudes and beliefs towards ART are 
a product of men’s experiences over their life, and perhaps most acutely, in their 
experience of being diagnosed with HIV and the aftermath. The in-depth interview study 
(phase A of workstream 2) aims to elucidate men’s experiences over this time, and how 
these may relate to their attitudes and beliefs around early ART.  
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Figure 3.2 Conceptual framework of the interrelationship of factors influencing the acceptability and utility of early ART to reduce HIV transmission 
amongst MSM with EHI in the UK 
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 Workstream 1 methods: Analysis of data from the UK Register of 3.4
HIV Seroconverters 
Risk of HIV transmission is known to increase with blood plasma HIV viral load 66, with the 
high viraemia observed around the time of seroconversion likely resulting in increased 
transmission risk 105–110, and both mathematical modelling and phylogenetic studies 
suggesting individuals with EHI contribute disproportionately to the HIV  
epidemic 72,110,112,113,116,118,121,122. The timing of presentation to clinic services and the 
corresponding viral load amongst individuals with EHI may provide some insight as to 
whether initiation of ART could be useful in preventing secondary transmission form this 
population. In addition to this elevated viraemia during EHI, there are also conflicting 
reports from Europe and the US on changes in initial viral load and set point over time, a 
proxy of HIV virulence194,195. At the time of initiating this thesis, there were no published 
data characterising viral load at first clinic presentation, and examining temporal trends 
amongst ART-naïve seroconverters in the UK. Secondly, it is important to contextualise the 
rest of the PhD by describing the temporal trends in ART initiation amongst UK 
seroconverters.  
I therefore undertook analyses using data from the UK Register of HIV Seroconverters with 
the aim of characterising viral load at first clinic presentation. I also examined temporal 
trends in time from HIV seroconversion to initiation of ART amongst the same cohort.  
The specific objectives were: 
 To examine temporal trends in time from seroconversion to, and CD4 count 
at, ART initiation amongst people diagnosed in EHI 
 To establish when MSM with EHI first present to HIV clinic and their viral 
load at first clinic presentation 
 To examine temporal trends in viral load at first clinic presentation amongst 
MSM with EHI. 
 Overview of the UK Register of HIV Seroconverters 3.4.1
The UK Register of HIV Seroconverters is a cohort of individuals whose time of HIV 
seroconversion can be reliably estimated. The study was started in 1994 with the primary 
aim of estimating the time from HIV seroconversion to AIDS and death and to examine 
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related factors. Full details of the methodology of the study can be found elsewhere 196–198, 
so a brief overview is presented here.  
Individuals are eligible to join the UK Register if they meet at least one of the following 
criteria for having confirmed laboratory evidence of HIV seroconversion: 
1. An HIV antibody negative test followed by an HIV antibody positive test within 12 
months (prior to 2004 the maximum window between negative and positive tests 
was 3 years and those recruited using this definition continue to be followed up in 
the UK Register)  
2. Test “incident” at low level using a RITA assay 
3. HIV antibody negative with positive reverse transcription polymerase chain 
reaction (RT-PCR) 
4. Equivocal HIV antibody test supported by a repeat test within a 2 week period 
showing a rising optical density.  
5. Have clinical manifestations of symptomatic HIV seroconversion illness supported 
by antigen positivity and <4 bands on Western Blot.  
In addition, individuals infected through mother-to-child transmission are eligible when 
they are 16 years of age. All patients provide written informed consent to enrol in the 
study.  
Recruitment of individuals to the UK Register can be prospective and retrospective. 
Individuals enrolling to the study provide consent for all their HIV clinical data, both 
historical and future, to be extracted and collated by the UK Register study team. Once an 
individual is enrolled in the study, a case registration form, see appendix 8, is completed by 
the clinic staff. This collects the following information: initials, soundex, date of birth, sex, 
ethnicity, probable route of HIV acquisition, country of infection, dates of the laboratory 
evidence of seroconversion, dates and values for previous CD4 counts, dates and values of 
previous viral loads including the assay type and cut-off, ART status (including previous 
treatment, pre- and post-exposure prophylaxis [PrEP and PEP]), dates and details of AIDS 
defining conditions, other serious medical conditions, Hepatitis B and C testing history, date 
and causes of death, and date last seen in clinic.  A 10ml EDTA blood sample is requested as 
close to first positive test as possible, and thereafter annual bloods are requested. It is 
possible to enrol to the UK Register and consent to making clinical data available without 
providing a blood sample.  
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Annual follow up data are provided by the study clinics through the UK Register follow-up 
proforma, although some of the larger clinics provide viral load, CD4 and ART data as 
electronic downloads. Data on date last seen at clinic, CD4 and viral load measures 
performed since last follow-up, date of last follow-up blood sample, ART status changes, 
pneumocystis pneumonia (PCP) prophylaxis status, any AIDS diagnosis, other life 
threatening events, Hepatitis B and C testing since last follow-up are collected via a patient 
specific follow-up proforma generated through the UK Register database and sent out to 
clinics annually. 
HIV infections are reported on a voluntary basis to national surveillance centres: PHE, Public 
Health Wales and Health Protection Scotland (HPS). Through collaboration with these 
organisations and cross-checking of databases, the UK Register study team endeavours to 
identify all seroconverters in the UK for enrolment to the study. Cross-checking the UK 
Register database with HIV/AIDS databases held at PHE and HPS also enables tracing of 
individuals who have been lost to follow-up. In addition to these surveillance centres, the 
UK Register team cross-check information on those who become lost to follow-up with the 
Office of National Statistics (ONS) in England, Wales and Northern Ireland and the General 
Registrar Office (GRO) in Scotland to check for deaths. In addition, HIV subtypes are 
identified through FASTA files obtained from clinics and by cross-checking patients enrolled 
on the UK Register with the MRC hosted UK HIV Resistance Database. Matching records 
with the above mentioned organisations and databases is always performed using initials, 
date of birth, sex and soundex code. 
The UK Register has ethics approval from South Birmingham Research Ethics Committee, 
REC reference number: 04/Q2707/155 (see appendix 9).  
 Analysis of temporal trends in ART initiation  3.4.2
3.4.2.1 Study population 
The data used in the ART initiation analysis were downloaded from the UK Register 
database on 2nd January 2014.  Data were restricted to individuals aged 16 or more 
seroconverting on or after 1st January 1998, when ART first became routinely available in 
UK clinics, to 31st December 2011, to allow adequate follow-up time. Only individuals who 
acquired HIV sexually or through injecting drugs were included in the analysis. 
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3.4.2.2 Variable definitions 
Date of HIV diagnosis was defined as the earlier of either first antibody positive or first 
detectable viral load. Date of HIV seroconversion was estimated as the midpoint between 
HIV antibody negative and positive tests in those meeting UK Register inclusion criteria 1, 
(see section 3.4.1). In individuals who present with evidence of AHI (inclusion criteria 3-5) 
or a RITA incident test (inclusion criteria 2) the date first HIV-positive was used as the date 
of HIV seroconversion. HIV test interval is defined as the time interval between HIV 
antibody positive and negative antibody test dates for individuals meeting inclusion criteria 
1. For individuals who present to clinic with evidence of AHI, or who are RITA incident (UK 
Register seroconversion eligibility criteria 2-5), the HIV test interval was coded as 0. 
ART start date was defined as the earliest date any ART drug was initiated, providing it was 
after, or in the 7 days prior to, the date of HIV diagnosis. Where ART was both commenced 
and ended prior to date of HIV diagnosis it was deemed to be PEP or PrEP. For patients 
identified as having taken PrEP or PEP, their date of ART start was the first date of ART after 
HIV diagnosis.  
CD4 count at ART initiation was calculated as the mean of the last two measurements taken 
in the 6 months prior to ART initiation, where only one measure was available this was used 
(18.8% of sample). 
Diagnosis in PHI was defined as having an HIV test window <180 days, and initiation of ART 
in PHI was defined as having an ART start date within 180 of estimated date of 
seroconversion.  Interruption of ART amongst those initiating in PHI was defined as 
terminating ART for 2 weeks or longer. 
3.4.2.3 Statistical analysis 
I used time to event analyses to examine the effect of calendar year of seroconversion on 
time from HIV seroconversion to ART initiation. Follow-up was censored at date last 
assessed or date of death. Kaplan-Meier plots were produced to visually describe time from 
seroconversion to ART initiation by the independent variable of interest year of HIV 
seroconversion (modelled as seven categories: pre-2000, 2000-1, 2002-3, 2004-5, 2006-7, 
2008-9, 2010-11).  
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Cox proportional hazards models were used to assess changes over calendar time, adjusting 
for age at seroconversion (continuous, in 10 year increments), sex (male, female), HIV 
exposure category (sex between men, sex between men and women, injecting drug user) 
and HIV test interval (<30 days, ≥30 days). HIV test interval was regarded as an a-priori 
confounder; shorter HIV test intervals have been shown to be associated with both 
presence and severity of seroconversion symptoms, faster disease progression and shorter 
time to AIDS199,200. Data on ethnicity were available but not included in the models due to 
the large proportion of white ethnicity individuals (87.1%) and the limited prognostic value 
of combining non-white ethnicities.  
Temporal trends in CD4 count at ART initiation were assessed using ordinary least squares 
regression, modelling square root transformed CD4 count, year of seroconversion as a 
continuous variable (per 10 years) and  adjusting for the above mentioned covariates.  
Logistic regression was used to assess temporal trends in the proportion of individuals 
diagnosed in PHI (defined as having an HIV test interval of less than 180 days), who initiated 
ART within 6 months of seroconversion. Amongst individuals who initiated ART in PHI, I 
used time to event analysis to determine time from ART initiation to interruption, censoring 
at date of death or date last assessed.  
All data management and statistical analyses were performed using STATA 13 201. 
3.4.2.4 Sensitivity analyses 
Three separate sensitivity analyses were conducted: 
1. To account for the fact that some clinicians’ prescribe short-course ART in PHI, I 
performed a sensitivity analysis excluding individuals diagnosed in PHI from the 
main time to ART initiation analysis;  
2. For the same reason I also excluded those known to have started ART within PHI in 
a sensitivity analysis of CD4 count at ART initiation; 
3. Finally, I excluded individuals known to be recruited to SPARTAC trial from the 
analyses of ART in PHI.  
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 Analysis of viral load at first clinic presentation  3.4.3
3.4.3.1 Study population 
Data used in the following analyses were downloaded on the 15th August 2013 from the UK 
Register of HIV Seroconverters database.  Data were restricted to individuals who reported 
their likely route of HIV infection as through sex between men as the main focus of this 
thesis is MSM with EHI, and as differences in viral load between males and females, 
amongst different exposure groups and ethnicities have been previously  
documented 79,202,203.  Data were restricted to individuals diagnosed with HIV on or after 1st 
January 1997, when viral load testing became routine in UK clinical practice. 
3.4.3.2 Variable definitions 
Date of HIV diagnosis, HIV seroconversion, HIV test interval and ART start date were 
defined as in the time to ART initiation analysis as outlined above (see section 3.4.2.2). AHI 
was defined as presentation with an HIV test interval of <30 days.  
Viral load at first clinic presentation was defined as the first viral load measure taken for 
each patient. Men were excluded from the analysis if they started ART prior to their first 
viral load measure being taken. Where two or more viral load measures were taken on the 
same date, the mean of available measurements was used. The midpoint of the lower limit 
of detectability was used for viral load measures that were undetectable, e.g. 20 copies/mL 
if the lower limit was 40 copies/mL. For viral load beyond the upper detection limit of the 
assay, the upper limit of detection was used as an estimate of viral load. Viral load was log10 
transformed to normalise the distribution. Log transformed viral load was grouped into the 
five categories according to risk of transmission established by Quinn et al 66: undetectable 
(<2.7 log10 copies/mL), 2.7-3.9 log10 copies/mL, 4.0-4.69 log10 copies/mL, 4.7-4.99 log10 
copies/mL and >5.0 log10 copies/mL. 
CD4 count at diagnosis was estimated as the mean of the first two CD4 counts following HIV 
diagnosis (measured within 6 months of diagnosis) where two or more were taken, or else 
the first measure was used. Likewise, CD4 at ART commencement was defined as the mean 
of the last two CD4 counts measured within the 6 months prior to ART start date (up to 2 
weeks after ART initiation) where two counts were available, or else the single measure was 
used.   
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The following variables were re-categorised into binary variables due to the small number 
in the dataset: ethnicity (white/non-white), and HIV subtype (B and non-B).  Time from 
seroconversion to first viral load measure was grouped into the following 6 categories: 0-7 
days, >7 days-30 days, >30 days-90 days, >90 days-180 days, >180 days-365 days, >365 
days. Year of seroconversion was grouped into the following year groups: 1997-99, 2000-1, 
2002-3, 2004-5, 2006-7, 2008-9 and 2010-12.  
Over the years there have been a variety of different assays used to measure plasma HIV 
viral load in UK clinics. To adjust for viral load assay type in sensitivity analyses these were 
grouped into 3 main types of assay: branch DNA (bDNA), polymerase chain reaction (PCR) 
and nucleic acid sequence-based amplification (NASBA).  Individual assays recorded on the 
UK Register were classified into assay type by a clinical virologist (Dr Eleni Nastouli) at UCLH 
Virology laboratory.  I used the data from the UK Register of HIV Seroconverters database 
to create a variable categorising assays according to their upper limit of detection 
>100,000, >500,000, >750,000 and >10,000,000 copies/mL. Table 3.1 outlines the assays 
used in the UK Register of HIV Seroconverters and lists assay type and upper detection limit 
allocated to each assay.  
3.4.3.3 Statistical analysis 
Median viral load at presentation was calculated with interquartile range (IQR). The 
proportion of individuals within each viral load category was calculated according to the 
time from seroconversion to first viral load measure. 
To examine changes in initial viral load by time since seroconversion, data were restricted 
to individuals with a viral load measure within one year of seroconversion. Log transformed 
continuous viral load measures were plotted against time from seroconversion to initial 
viral load (modelled as a continuous variable in days) in a scatterplot, with ordinary least 
squares (OLS) simple linear regression model used to check for evidence of any temporal 
trend.  This model was compared to a model fitting time from seroconversion to first viral 
load as a 5 group categorical variable, and a likelihood ratio test was used to assess for 
evidence of departure from linearity.  
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Table 3.1 Coding table for HIV-1 RNA assays 
Assay name 
Assay 
type 
Upper range of detection 
(copies/mL) 
Abbott U-S PCR >10,000,000 
Chiron/Bayer 2.0 bDNA >500,000 
Chiron/Bayer 3.0 bDNA >500,000 
Chiron/Bayer unspecified bDNA >500,000 
Cobas 1.5 (<400) PCR >750,000 
Cobas 1.5 U-S (<50) PCR >100,000 
Cobas Taq Man PCR >10,000,000 
Cobas Unspecified PCR >750,000 
NASBA (<1000/<400) NASBA >6,000,000 
NASBA U-S (<50/<150) NASBA >100,000 
NASBA Unspecified NASBA >6,000,000 
Nuclisens Easy Q NASBA >10,000,000 
Nuclisens US (<50) NASBA >100,000 
Nuclisens Unspecified NASBA >6,000,000 
Other Unknown >100,000 
Roche 1.0 (<400) PCR >750,000 
Roche 1.5 (<400) PCR >750,000 
Roche 1.5 US (<50) PCR >100,000 
Roche Taq Man PCR >10,000,000 
Roche Unspecified (<400) PCR >750,000 
Roche(<40) PCR >10,000,000 
PCR=polymerase chain reaction; bDNA=branched DNA; NASBA=nucleic acid sequence based amplification 
 
To examine trends in initial viral load over calendar time the log transformed continuous 
viral load measures were plotted by date of seroconversion in a scatterplot. Viral load at 
first presentation was modelled with year group of diagnosis fitted as a continuous variable 
using ordinary least squares (OLS) simple linear regression model to check for evidence of 
any temporal trend.  This model was compared to a model fitting calendar year of 
seroconversion as a 7 group categorical variable, and a likelihood ratio test was used to 
assess for evidence of departure from linearity. 
Trends in viral load at first presentation by both time since seroconversion and over 
calendar time were assessed using the same multivariate model. The following 
independent variables were considered as potential confounders: ethnicity, age at 
seroconversion, HIV subtype, HIV test interval, evidence of acute infection, time from 
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diagnosis to first viral load measurement, viral load assay type and viral load assay upper 
range of detection. Associations between these variable and viral load at first presentation 
were tested first by modelling each independent variable in an OLS simple regression 
models and using a likelihood ratio test to assess goodness of fit. Variables found to be 
associated at the p<0.10 level were put forward for multivariate analyses.  
Multiple regression OLS models were then built using independent variables found to be 
associated in the univariate regression models to the p<0.10 level. A forward stepwise 
approach to model building was used with independent variables added one by one and 
likelihood ratio test used to assess goodness of fit. The variables found to be most strongly 
associated with viral load at presentation were added first to the model. A p-value of <0.10 
meant that the variable remained in the model and the next was added. Independent 
variables were checked for possible interactions with one another by fitting interaction 
terms and using the likelihood ratio test to assess goodness of fit. 
Collinearity and multicollinearity were checked by examining the variance inflation factor 
(VIF) for each independent variable in the final multiple regression models using the “collin” 
command in STATA 12 204, using a VIF cut off of 10. 
HIV subtype, viral load assay type and viral load assay cut-off all had a substantial amount 
of missing data but were found to be associated with initial viral load in simple OLS 
regression model. I elected to exclude them from the full model to maximise power and 
instead assessed their influence on the observed associations in sensitivity analyses.  
Restricted cubic spline (RCS) functions of seroconversion date were introduced to the 
univariate and final multivariate model to examine the evidence of non-linearity in the 
relationship between viral load at first presentation and time from seroconversion to ART 
initiation. Using RCS to split a continuous independent variable into splines by defining 
knots in the data, either by the predetermined values as proposed by Harrell 205 or at values 
of choice, allows for an almost limitless graphical representation of the shape of the 
association between x and y 206. Knots for the RCS were created at 5, 25, 50, 75 and 95th 
percentiles in this analyses, though I also conducted sensitivity analyses modelling 
seroconversion date using 3 and 7 knot splines, and comparing the 3 or 7 spline model to 
the 5 spline model using likelihood ratio tests.  
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Predicted initial viral load was graphed by time from HIV seroconversion to initial viral load, 
with 95% confidence intervals for both the unadjusted and adjusted models, fitting time as 
a RCS function with 5 splines.  Restricted cubic spline functions of seroconversion date were 
introduced to the final univariate and multivariate models to examine the evidence of non-
linearity in the relationship between viral load at first presentation and calendar time. 
Predicted initial viral load was graphed by year of seroconversion with 95% confidence 
intervals for both the unadjusted and adjusted models, fitting time as a RCS function with 5 
splines.  The final OLS models were checked for evidence of violation of the assumptions 
underlying linear regression. 
All data management and statistical analyses were carried out using STATA 12 204. 
3.4.3.4 Sensitivity analyses  
The following sensitivity analyses were planned for the final OLS multiple regression model 
assessing temporal trends in viral load at first clinic presentation: 
 Data were restricted to MSM with an HIV test interval of ≤180 days 
 Data were restricted to a more homogenous sample of white ethnicity MSM  
 Viral load at presentation was right truncated at 5.0 log10 copies/mL  
 HIV subtype was added in the multiple regression model. 
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 Workstream 2 phase A methods: In-depth interview study 3.5
This phase of workstream 2 involved in-depth interviews with MSM diagnosed in EHI 
attending a central London HIV clinic, with the aim of exploring the range of attitudes and 
beliefs towards early ART and understanding the experiences of men diagnosed with recent 
HIV infection.  
This phase of workstream 2 aimed to answer the following research questions:  
 How does being diagnosed with recent HIV infection affect men’s lives? 
 How do MSM with EHI feel about early ART? 
The standalone qualitative findings to answer the research questions above are presented 
in full in chapter 5. In addition, the themes identified in these interviews were used to 
develop questionnaire items for the cross-sectional survey (workstream 2 phase B). These 
were piloted using cognitive interviewing and the process is outlined in section 3.6.  
Ethics approval was granted for the qualitative study and cognitive interview piloting by 
Camden and Islington Research Ethics Committee (ref. 09/H0722/92), see appendix 10. 
 Data collection 3.5.1
The target population for this qualitative study were men aged ≥16 years of age, attending 
a central London HIV Clinic with laboratory evidence of HIV seroconversion in the past 12 
months, and whose reported route of HIV transmission was through sex with men.   The 
initial timeline allocated for me to recruit the men was six months, based on an average of 
25-30 new HIV diagnoses a month at the clinic. PHE estimates that 20% of newly diagnosed 
infections are incident 9 meaning a total of 5-6 new diagnoses a month would be eligible for 
the study. Assuming the response rate would be 50-65%, six months was calculated to be 
sufficient to recruit the desired number of individuals. 
 Sampling strategy 3.5.2
Using purposive sampling to fulfil an age-based quota, I aimed to recruit 3 men from each 
of the following age categories (16-25 years, 26-30, 31-35, 36-40, 41+). This quota was 
chosen to try to ensure the range of opinions reflected the views of men over a wide age 
distribution. There were many other factors likely to be associated with attitudes and 
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acceptability towards early ART, for example ethnicity, educational level, historical risk 
behaviour and geographic area, however due to the limited target size of the IDI study, the 
fact that recruitment was from a single clinic in London and the challenges in recruiting 
men with early HIV infection, I elected to purposively sample based only on age.  
 Eligibility criteria 3.5.3
Individuals were eligible for the study if they met all of the following criteria:  
 Primary route of exposure to HIV was through sex with men 
 Were eligible for the UK Register of HIV Seroconverters (as outlined in section 
3.4.1)  
Individuals were not eligible for the study if they meet any the following criteria: 
 Inability to provide full informed consent for their participation 
 Experience of a severe psychological reaction to their HIV diagnosis 
 Inability to speak and read English 
Initially men had to be interviewed within 6 months of their HIV diagnosis, however due to 
slow recruitment within the first 3 months of the study a pragmatic decision was made to 
increase this to 12 months after diagnosis.  
As the eligibility criteria for this study matched that of the UK Register of HIV 
Seroconverters, for which the central London HIV clinic was a participating site, the 
invitation for this qualitative study piggybacked the invitation to participate in the UK 
Register. As I was not a member of the patient clinical care team I was not permitted to 
make contact with the patient without an introduction from clinic staff.   
 Data collection 3.5.4
A topic guide (see appendix 11) was developed in conjunction with the research team: 
Professor Graham Hart, Professor Kholoud Porter and Dr Richard Gilson. As the IDI study 
was intended to be exploratory in nature, no pre-existing social or psychological theory was 
used to underpin its development. Whilst there was no patient and public involvement 
(PPI) group created for this study, I did meet with the HIV clinic patient representatives to 
seek and include their opinions on the study design and the topic guide and built in 
suggestions where possible. In addition, Simon Collins from HIV-iBase, an HIV treatment 
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activist group, was involved throughout the PhD as a member of the UK Register of HIV 
Seroconverters Steering Committee.  
Prior to initiation of the study, I conducted a practice face-to-face in-depth interview with a 
colleague highly experienced with qualitative research methods in order to practise using 
the topic guide and receive feedback on my interviewing style. As the study population was 
very small, I made the pragmatic decision not to pilot the topic guide within the population, 
but to start recruitment with a view to amending the topic guide as the study progressed.  
Prior to commencing the interview all patients were given the patient information sheet to 
read (appendix 12), had the study aims and any risks of participation discussed, and written 
informed consent was obtained (appendix 13).  Interviews were digitally audio recorded 
unless the patient declined when asked prior to the interview commencing. I took notes on 
the topic guide during each the interview to assist with probing and immediately after the 
interview I wrote up a summary of my experience of the interview, the key themes that 
emerged from memory and any thoughts relating to the interview or topic guide.  
When all the interviews had been conducted, the audio recordings were transcribed 
verbatim by an external agency experienced in transcribing sensitive data for similar 
studies. The agency had been recommended by other members of the Department and 
held a full confidentiality agreement with UCL. 
 Development of the topic guide 3.5.5
The topic guide underwent several revisions after the interviews commenced, as was 
originally planned.  One of the first changes to make to the topic guide was to add in two 
statements to gather respondents’ views on whether HIV transmission was possible whilst 
virologically suppressed on ART and whether it was necessary to disclose HIV status if 
somebody was virologically suppressed on ART.  I initially found discussions around ART, 
transmission and disclosure challenging as individuals had differing levels of knowledge 
about treatment and I felt I was in danger of leading those who had less knowledge by 
asking specific questions about transmission.  To make the process less open to this 
problem, I added two statements to the interview process and asked individuals their 
opinions on the statements, whether they agreed or disagreed with them, and why they 
felt that way.  
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I also included a question about previous experiences of PEP. This topic came up during the 
second interview and it became obvious that any attitudes to ART may well be coloured by 
previous experience with PEP, whether good or bad. Since then, respondents were asked 
about their knowledge and experiences with PEP. In addition to this, I asked about their 
experiences in taking other medications for long periods of time or for other chronic 
conditions as this may have had some bearings on beliefs and attitudes towards long term 
commitment to ART. 
 Data analysis 3.5.6
I carried out thematic analysis of the data using the Framework approach as developed by 
the National Centre for Social Research. Framework analysis is a systematic technique 
which uses matrices to chart the cases, themes and sub-themes that emerge in your 
dataset 190.  
Verbatim transcripts were checked through by me in Microsoft Word to remove any 
identifiable information. I then read through each transcript whilst listening to the audio 
recording of the interview to mark the transcripts where any strong emotions were present 
as well as checking the transcripts were verbatim.  Whilst reviewing the transcripts I kept a 
log of all of the themes and sub-themes that emerged from the data.  
In consultation with the CI, Professor Graham Hart, I constructed a thematic framework 
(see table 3.2) based on the study topic guide and the list of themes that had emerged from 
reviewing the transcripts. 
At this point I imported the transcripts into NVivo 207, and applied the thematic framework 
to three interviews at random to test and refine it, indexing the transcripts on each 
occurrence of a sub-theme.  NVivo was then used to automatically generate framework 
matrices for each of the themes, plotting the cases (participants) along the rows and the 
sub-themes in columns.  NVivo automatically populated each matrix cell with quotations 
coded with the case specific sub themes. I then reviewed the content of each cell, 
condensing the information whilst retaining the context and language used by the 
participant as much as possible (see appendix 14 for an example). NVivo maintains links in 
each of the matrix cells to the original quotes in the transcripts which facilitated the 
analysis process.  
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From the summarised frameworks, I then identified overarching phenomenon acting across 
themes and sub-themes and pertaining to the research questions. The data were then 
examined for linkages between the phenomenon and possible explanations. 
 
  
 
1
1
2
 
Table 3.2 Thematic framework for qualitative study 
Theme Subthemes 
Life experiences Alcohol and drug use Housing Socialising Other 
 Coming out Looks and attractiveness Stresses  
 Family Sexual relationships Work and study  
HIV Diagnosis Co-infections & complications Feelings Previous testing experience Stigma 
 Disclosure GP or hospital Reasons for testing Other 
 Effect on life Illness or symptoms Receipt of diagnosis  
Sexual Behaviour Discussing HIV status  Meeting partners Relationships Type of sex 
 Feelings about sex Post-diagnosis Risk perception  
 HIV transmission Pre-diagnosis Risk reduction  
HIV Treatment Concerns about treatment When to start treatment Role of clinician Trials and evidence 
 Early treatment Health Short-course Other 
 Effects of treatment PEP Treatment and transmission  
 Expectations Reasons for starting Treatment knowledge  
Other issues Abandoning responsibilities Health Mental health Visibility of HIV 
 Exercise Health service related Personal struggles  
 Guilt Homophobia Pornography  
 HCV co-infection Law and prosecution THT  
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 Workstream 2 phase B methods: Cross-sectional survey  3.6
This section describes in detail the methods used in the development of sexual behaviour 
and attitudes to early ART survey sub-study of the UK Register. Here I outline the overall 
survey design, the development of the questionnaire tool, the methods of data collection 
and data analysis used. The survey sought to describe and quantify the prevalence of the 
attitudes and beliefs towards early ART uncovered in the in-depth interview study. It also 
aimed to identify factors associated with uptake of early ART and with engaging in high-risk 
(defined as behaviours which are most likely to lead to onward transmission of HIV) sexual 
behaviour after HIV diagnosis.  
Specifically, the research questions workstream 2 phase B aimed to address were:  
 How widely held are the attitudes and beliefs identified in workstream 2 phase 
A amongst MSM with EHI in the UK? 
 What proportion of MSM with EHI regarded early ART as acceptable? 
 What proportion of men initiated early ART, and what factors are associated 
with this? 
 Amongst MSM who initiated early ART, what were the predominant reasons for 
initiation? 
 What proportion of MSM present a heightened HIV transmission-risk after HIV 
diagnosis and what factors are associated with this? 
 Survey and questionnaire design  3.6.1
For logistical and financial reasons a cross-sectional pen and paper survey design was 
selected. Computer-aided self-interview methods were considered but dismissed as being 
prohibitively expensive and difficult to implement across multiple sites. During the study 
design phase the members of the UK Register Steering Committee were consulted, with 
their feedback incorporated into the final survey design.  
From the outset, I intended to keep the questionnaire as short as possible whilst capturing 
as much information as possible. The questionnaire was divided into separate sections to 
capture data on respondent demographics, socio-economic status, HIV testing history and 
seroconversion experience, sexual behaviour including substance use in the six months 
prior to HIV diagnosis, sexual behaviour in the time since diagnosis including substance use 
 114 
 
and status disclosure, ART experience (including PEP), and acceptability, barriers and 
attitudes towards early ART.  
Nesting the survey in the UK Register allowed for a shorter questionnaire as much of the 
key demographic and clinical data were collected through the UK Register already.  It also 
increased the accuracy of clinical measures which would otherwise have been captured 
using self-report methods.   
The questions used in the final questionnaire are a combination of questions developed 
from the in-depth interview study (phase A of workstream 2), and questions which have 
been previously used in other cross-sectional surveys including: the Gay Men’s Sexual 
Health Survey (GMSHS), the ASTRA (Antiretrovirals, Sexual Transmission Risk and Attitudes) 
study and the SHARPN (Sex, Health, Antiretrovirals and Partner Notification) studies, all 
undertaken at UCL Research Department of Infection and Population Health. I decided to 
utilise questions and attitude statements from these questionnaires where possible as they 
all had been previously used within the population of interest (HIV-positive MSM recruited 
in sexual health clinics or, in the case of GMSHS, in the community) and undergone 
previous validity checks. The sexual behaviour questions were adapted from those used in 
the UCL and PHE run Gay Men’s Sexual Health Survey. This survey ran annually, from 1997 
to 2006, then repeated in 2008, 2011 and 2013 in gay community venues and has so been 
validated in a similar population as the target population in this study 208,209. One strength 
of the sexual behaviour question format from this study is that they require numeric 
answers and can be combined to assess the number of serodiscordant/status unknown UAI 
partners, which is a key outcome of interest as the behaviour most-likely to lead to onward 
transmission of HIV. Several attitude and belief statements were taken from the ASTRA 
study, which allows the possibility of cross-comparison of attitudes to ART between ASTRA 
respondents with chronic HIV and our survey respondents with recent HIV infection. In 
addition, the questions on substance use before and during sex were taken from the 
SHARPN study.  
 Development of new survey questions 3.6.2
One advantage of adopting a sequential mixed methods approach to workstream 2 was 
that it permitted the development of new questions based on the themes which emerged 
from the in-depth interview study in phase A. Though the original plan to conduct all the in-
depth interviews prior to designing the survey was not possible due to slow recruitment 
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and time constraints, data were available from the eight interviews conducted before 
questionnaire piloting began. Several themes emerged from the in-depth interview study, 
which had not been considered previously, and which were subsequently included in the 
survey questionnaire.  
In the qualitative study it became apparent that some men expected HIV treatment to be 
given in the same manner as other diseases, and so expect ART to be prescribed 
immediately upon diagnosis. Also many of the men interviewed believed there were health 
benefits to starting ART early, despite a lack of randomised trial evidence indicating this. 
Men also appeared to delineate between the altruistic ideal of starting treatment to 
protect your HIV negative partner and starting treatment to reduce anxiety of transmission. 
Interestingly one man went on to suggest that being on ART made it easier to disclose his 
HIV status to sexual partners.  Specific attitude and belief statements were designed by me 
to assess the prevalence of these viewpoints in the wider population of MSM recruited to 
the UK Register. For simplicity and due to lack of time to fully pilot the questionnaire, the 
attitudes and belief statements were written as individual standalone statements, and not 
as constructs made up of multiple items.  
 Questionnaire piloting and validation 3.6.3
I conducted piloting of the questionnaire by using cognitive interview techniques with 4 
MSM attending a central London HIV clinic. By using cognitive interviewing it was possible 
to identify questions that were difficult for respondents to understand and answer. Most 
importantly, it permitted identification of the elements that make them difficult to answer 
and allowed respondents to suggest possible solutions. 
The cognitive interview questions are designed to establish the methods employed by the 
respondents to: 
 Understand and interpret the questionnaire questions 
 Recall information needed to answer questionnaire questions 
 Judge what information is relevant in answering questionnaire questions. 
Men were invited to participate in the cognitive interviews as per the qualitative interview 
eligibility criteria and recruitment methods, the information sheet and consent form can be 
found in appendix 15 and 16.  I conducted one-to-one face-to-face interviews in a private 
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room at the study site.  The men were given the pilot questionnaire and asked to complete 
it one section at a time. At the end of every questionnaire section, I asked them to talk me 
through how they went about answering the questions.  Particular focus was given to 
understanding, interpretation and recall of information for all newly developed questions, 
the calculation and ability to recall the number of partners for the sexual behaviour study.  
In addition, the overall appearance, ordering, routing and flow of the questionnaire were 
also assessed in these interviews.  During the interviews I took comprehensive paper notes 
which I subsequently assessed after each interview.  I also timed how long it took 
participants to complete each section of the questionnaire which enabled me to calculate a 
guide time for completion. The aim was to keep the questionnaire short enough to 
complete in 15 minutes, and all of the men took 15-20 minutes to complete it during the 
cognitive interviews. 
I found the cognitive interview process to be highly insightful and useful; not only were the 
issues highlighted in real time by the men as they completed the questionnaire but many 
men went on to provide assistance in finding a solution to problems.  From this perspective, 
piloting became a two way process whereby a problem was raised by the respondent, for 
example the wording of a question, I could then seek immediate feedback from them on 
potential alternative wordings, with the men themselves sometimes suggesting more 
appropriate wording. 
As a result of the pilot study, many changes were made to the questionnaire from the 
original to the final version (see appendix 17 for a log of the changes).  One example of a 
major change following piloting using cognitive interviews, was the way the respondents 
conceptualised “early ART”. It became evident that men had different expectations as to 
when treatment would normally be started; what then constituted “early”, and whether it 
was a CD4 based definition or a time based decision. To alleviate this issue and remove the 
confusion of the CD4 guided definition of early, I reworded the attitude and belief 
statements to use the term “now” as opposed to “early”; i.e. “I would start ART now if 
there was a proven health benefit to me”.   This made it conceptually clearer and by 
definition, as all respondents were only eligible for the survey within the first year of 
diagnosis and were seroconverters, the majority of respondents would have a CD4 count 
>350 at the time of completion. 
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The final version of the questionnaire was designed by me using MS Word and 500 were 
professionally printed as stapled booklets for distribution across participating HIV centres. 
A PDF version can be found in appendix 18.    
 Sample size and power estimation 3.6.4
The plan for this survey was to recruit 120 individuals in the 12 month recruitment period 
allocated to the sub-study.  This number was based on the following calculation: 247 
seroconverters were recruited to the UK Register in 2012-2013 overall, of these 220 met 
eligibility criteria for this sub-study (were MSM recruited to the UK Register within 12 
months of their HIV diagnosis and aged ≥16 years at seroconversion). Assuming a 55% 
response rate for the survey resulted in a likely number of 120 men recruited over a 12 
month period.  
Assuming a 40% uptake of early ART, a sample size of 120 gives 80% power to detect this 
prevalence to within 13%, at the 5% significance level. Given this assumption, a sample size 
of 120 would provide 80% power to detect as significant at the 5% significance level an 
association between early ART uptake and a given risk factor that increases the prevalence 
by 1.5 times (e.g. from 31% to 49%).   
 Selection of study centres 3.6.5
I emailed all UK Register principal investigators at the HIV centres who actively recruited to 
the UK Register in 2012-13 enquiring whether they would be interested in recruiting to the 
survey sub-study and giving a brief 1 page outline of the proposed research.  All responses 
of interest were followed up by a further email upon receipt of ethics approval and the 
process of seeking R&D approval was initiated for these centres.  Once R&D approval was 
granted for a clinic the survey questionnaires and envelopes were sent out to the research 
team and recruitment could begin.  
 Ethics 3.6.6
Ethics permission was sought for this section of the PhD by means of a substantial 
amendment to the UK Register of HIV Seroconverters protocol adding the survey as a sub-
study. Permission was granted by the National Research Ethics Service Committee West 
Midlands, South Birmingham on the 7th May 2013, REC ref. 04/Q2707/155 amendment ref: 
Protocol v3.1 (appendix 19).   
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R&D approval for the sub-study was obtained at each of the HIV centres participating in the 
survey prior to commencement of survey recruitment. This involved the UK Register study 
manager, Louise Walker-Nthenda, and I liaising with the study PIs at each centre to notify 
the relevant R&D Departments of the substantial amendment to use the new protocol. Due 
to the number of research studies conducted at St Mary’s Hospital and Chelsea and 
Westminster Hospital, a request was made for me to present the study to a panel of 
clinicians for internal study approval prior to the R&D application. I did so and on both 
occasions the study was approved both by the internal review committee and by the R&D 
departments.    
 Data protection and patient anonymity 3.6.7
I designed the questionnaire to be anonymous and contain no uniquely identifiable 
information if intercepted in transit.  Questionnaires were linked to their corresponding UK 
Register database record by a combination of the HIV clinic recruiting the patient, the last 4 
digits of the patient’s clinic number, date of birth and, if necessary, date first HIV positive; a 
combination of variables I successfully piloted within the UK Register database to be able to 
generate a one-to-one match.  
Once questionnaires were received at the MRC CTU, they were stored in a locked cupboard 
in a secure area. The sub-study database was encrypted and stored on the MRC secure 
network and was password protected for extra security.  
 Eligibility and recruitment 3.6.8
Men were eligible for the survey if they were aged 16 years or over at HIV diagnosis, their 
likely route of HIV exposure was sex with another man, and they were recruited to the UK 
Register of HIV Seroconverters prior to or at the same time as recruitment to this survey.  
The survey questionnaire had to be completed by the patient within one year of their date 
of HIV diagnosis. Men who were considered by their clinical care team to be experiencing 
psychological difficulties in coming to terms with their diagnosis were not eligible for the 
sub-study. It was the responsibility of research staff at each clinic to assess and enforce all 
eligibility criteria. Men who were recruited and completed the questionnaire outside of the 
one year eligibility period were identified and excluded by me from the final study 
population. 
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Eligible men were given a participant information sheet (appendix 20) and informed that 
participation in the survey sub-study was optional and they were permitted to enrol in the 
UK Register without participating in the survey. For those agreeing to participate in the 
survey, written informed consent was required for both the UK Register and the survey 
(appendix 21). This was taken by clinic staff with separate consent forms and information 
sheets for the UK Register and survey sub-study.  
Prior to the commencement of survey recruitment in each clinic, I provided a list of patients 
recruited to the UK Register in the past 12 months, as these patients were eligible for the 
survey up until one year after their diagnosis.  The idea was that clinic staff could recruit 
these eligible patients if they happened to attend before a year after their HIV diagnosis 
(so-called retrospective recruitment). The majority of clinics operated their own system for 
identifying seroconverters eligible for the survey, however, and retrospective recruitment 
was not implemented by the majority of the clinics. Instead, they favoured a process of 
prospective recruitment where newly identified eligible seroconverters were recruited to 
both the UK Register and the Survey at the same time.  
Once the participant had consented to the survey, the nurse or researcher completed the 
questionnaire front cover and handed it to the participant with a pen and an envelope. 
Men were instructed to complete the questionnaire in the clinic, place it into the envelope 
provided, seal it for confidentiality and give it back to the research staff.  The research staff 
then returned the questionnaire to MRC CTU data manager in the sealed envelope.  
 Study period 3.6.9
Ethics permission for this study was granted in May 2013 however the long process of 
obtaining R&D permission from each participating site resulted in a lengthy delay in some 
cases between ethics approval and recruitment commencement. All centres operated a 
continuous recruitment period, with the exception of Brighton and Guy’s and St Thomas’ 
hospital who conducted recruitment in two phases. Recruitment to this study continued 
until December 2014. 
 Data entry  3.6.10
I entered the questionnaire data into a Microsoft Access database designed and built by me 
for this study. Upon completion of data entry I randomly selected 30 questionnaires and 
double checked the database entry with the questionnaire booklet to ensure data 
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consistency. The data were exported from Access using .csv files and imported into STATA 
where they were merged with the corresponding UK Register record using the last 4 digits 
of the respondent clinic numbers and the name of the HIV centre the patient was recruited 
from.  After using this method of matching there were a number of questionnaires which 
remained unmatched.  For these I manually matched the records using HIV centre, patient 
date of birth and/or date first HIV positive allowing for typographic errors in the above. If, 
after manual matching, a questionnaire remained unmatched the relevant clinic was 
informed, as this was usually indicative that the clinic had not returned the corresponding 
UK Register case report form for that patient. In all but a few cases the clinic then 
forwarded the patient’s UK Register form for entry to the database and a match could then 
be made. 
 Data analyses 3.6.11
3.6.11.1 Data management 
The distributions of ordinal and continuous variables were checked for normality, with 
relevant transformations applied to them in the presence of notable skewness and/or 
kurtosis. For this reason viral load at diagnosis was log transformed, and CD4 at diagnosis 
was square root transformed for logistic regression models.  
The attitude and belief statements were originally measured using a 5-point likert scale. For 
the purposes of calculating a binary outcome for each attitude and belief statement the 5-
point scales were recoded into binary outcomes in the following way: respondents who 
answered “Agree” or “Strongly agree” to each statement were recoded as “Agree”; all 
those answering “Strongly disagree”, “Disagree”, “Neither agree or disagree” or “Don’t 
know” were coded as “Did not agree”. 
As both descriptive and risk factor analyses were planned using the survey data I have split 
the statistical methods into descriptive and analytic sections.  
3.6.11.2 Variable definitions 
The majority of variables included in the final analyses were derived directly from individual 
survey questions and presented as continuous data, binary or categorical variables. Several 
of the sexual behaviour variables were however derived from the responses to two or more 
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questions, and involved various assumptions. The definitions of these variables are given 
below.  
Unprotected anal intercourse (UAI) 
Reporting insertive or receptive anal sex, with one or more partners and without a condom 
in the recall period.  
Serodiscordant UAI status partners before HIV diagnosis 
Reporting insertive or receptive anal sex, with one or more partners without a condom in 
the recall period, where the partner’s HIV status was not known to be HIV negative.  
This variable was derived from the answers to the following two questions: 
“C8a In the 6 months prior receiving your HIV diagnosis, with how many 
men have you had anal intercourse (active or passive) without a 
condom?” 
and  
“D9a: Since receiving your HIV diagnosis, how many of the men have you 
had anal intercourse (active or passive) without a condom did you know 
were HIV positive?”. 
 
Serodiscordant UAI after HIV diagnosis 
This was defined as reporting insertive or receptive anal sex with one or more partners 
without a condom in the recall period, where the partner’s HIV status was not known to be 
HIV-positive. 
This variable was derived from the answers to the following two questions: 
“D8a Since receiving your HIV diagnosis, with how many men have you 
had anal intercourse (active or passive) without a condom? 
D8b Of these, how many were once only partners?” 
and  
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“D9a: Since receiving your HIV diagnosis, how many of the men have you 
had anal intercourse (active or passive) without a condom did you know 
were HIV positive? 
D9b Of these, how many were once only partners?” 
The total number of serodiscordant (HIV negative or status unknown) UAI partners after 
diagnosis was calculated as the number of reported UAI partners post-diagnosis (answered 
in D8a) minus the number of HIV-positive UAI partners post-diagnosis (answered in D9a). 
The binary variable engagement in serodiscordant UAI post-diagnosis was calculated from 
the number of serodiscordant UAI partners and coded as follows: 0, if no serodiscordant 
partners were reported; and 1, if >0 partners were reported. 
The same methods were used to derive the number of casual serodiscordant UAI partners 
but using the answers to questions D8b and D9b. 
Exclusive condom use since HIV diagnosis 
This was defined as reporting AI with one or more partners since receiving HIV diagnosis, 
when the number of reported UAI partners was 0. 
Exclusive serosorting since HIV diagnosis 
This was defined as reporting UAI with 1 or more partners since diagnosis but the number 
of reported serodiscordant UAI partners was 0.   
ChemSex (before or after diagnosis) 
ChemSex (measured in the time before and since diagnosis) was defined as reporting the 
use of any of the following drugs before or during sex: liquid ecstasy (GHB/GBL), 
methedrone, methamphetamine, piperazines or ketamine. The substances included in the 
definition were decided in November 2014 in consultation with the following members of 
the UK Register of HIV Seroconverters Steering Committee; Prof Kholoud Porter, Prof 
Andrew Phillips, Dr Sarah Fidler, Dr Richard Gilson, Dr Julie Fox and Simon Collins. Notably 
the inclusion of piperazines and ketamine in the definition above means that the chemsex 
definition used in this thesis, differs from the now “standard” chemsex definition 
developed by 56 Dean Street and ReShape, and published on the iBase website in 
December 2014 210. According to this official definition, chemsex is defined as the use of 
three “chems” (GHB/GBL, methedrone and/or methamphetamine) in a sexual context.  
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3.6.11.3 Descriptive analyses  
The descriptive research questions under study were:  
 How acceptable is ART at diagnosis to MSM seroconverters? 
 What proportion of ART-naïve MSM would start early ART for TasP in the 
absence of clinical benefit? 
 What are the main barriers to early ART initiation amongst ART-naïve MSM? 
 What are the main reasons for early ART initiation amongst MSM on ART? 
 What proportion of MSM reported sexual behaviour that could lead to HIV 
transmission after HIV diagnosis? 
Descriptive statistics were calculated for all explanatory and outcome variables with 
proportions calculated for binary and categorical outcomes.  Ordinal and continuous data 
were described using medians and interquartile ranges (IQR) or means and standard 
deviations (SD).   
3.6.11.4 Exploratory risk factor analyses 
Two risk factor analyses were conducted using the survey data. These were designed to 
answer the following research questions:  
 What factors are associated with initiation of early ART? 
 What factors are associated with engaging in high-risk sexual behaviour which 
could lead to onward transmission after HIV diagnosis? 
“Early ART” was defined as having self-reported taking ART since receipt of their HIV 
diagnosis. By definition of survey eligibility, this had to have been within 1 year of HIV 
diagnosis. The denominator was all men responding to the question “Have you taken ART 
since receiving your HIV diagnosis?”.   
“High-risk” sex post-diagnosis was a composite outcome and was defined as reporting 
either of the following behaviours: 
 UAI with one or more HIV-negative or status unknown partners since HIV 
diagnosis  
 ChemSex and AI with one or more partners since HIV diagnosis.  
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The denominator was all men who answered whether they had had oral or anal sex since 
HIV diagnosis.  
3.6.11.5 Univariate risk factor analyses  
Descriptive statistics were calculated for all explanatory and outcome variables. Ordinal and 
continuous data were described using medians and interquartile ranges (IQR), and 
categorical variables were described using proportions. 
Chi squared tests were first used to test for associations between binary/categorical and 
binary outcomes and t-tests were used to compare independent means. Time from HIV 
diagnosis to questionnaire completion was considered an a-priori confounder and was 
adjusted for in all regression models. This is because it is known to be associated with the 
outcomes of interest, ART uptake and high-risk sex, and likely to be associated with many of 
the explanatory variables too. The relationship between time from diagnosis to 
questionnaire completion and the outcomes of interest were modelled as a continuous and 
categorical, with likelihood ratio test used to compare models and assess for departure 
from linearity. Each explanatory variable was modelled with the outcome early ART uptake, 
controlling for time from HIV diagnosis to questionnaire completion as a continuous 
variable.  
All continuous explanatory variables were modelled first as linear terms, and secondly as 
categorical variables with likelihood ratio test used to assess departure from linearity. In 
the event of evidence of departure from linearity (at the p<0.05 level), continuous variables 
were modelled as categorical terms, otherwise they remained in the model as continuous 
terms.  
3.6.11.6 Multivariate analysis of factors associated with early ART 
All explanatory variables found to be associated with the outcome at the p<0.2 level in 
univariate analysis, after adjusting for time from diagnosis to survey completion, were put 
forward for inclusion in the multivariate models. The dataset for analysis was small with 
data from 117 men available for analysis, and the low number of men with the event of 
interest (n=55) limited the number of variables it was possible to adjust for in multivariate 
analysis. I made the pragmatic decision to use a conceptual framework approach to 
multivariate modelling, in order to restrict the number of variables included in the model at 
any one time and maximise power.  
 125 
 
A multi-level conceptual framework was developed (see table 3.3). The base level included 
factors that were known a-priori to be associated with the outcome of interest (early ART 
initiation). Each subsequent level contained first socio-demographic, then clinical, next 
attitudinal and finally behavioural variables.  
First, all variables in the base level that were found to be associated at the p<0.2 level in 
univariate analysis, were added to the multiple logistic regression model adjusting for time 
from diagnosis to survey completion. Variables found not to be associated at the p<0.1 
level in the multivariate model were then dropped from the model individually (starting 
with factors with the highest p-values), with a likelihood ratio test performed to ascertain 
goodness of fit. This created a final “base model” which featured time to survey completion 
as well as all variables from level 1 of the framework which were associated in multivariate 
logistic regression at the p<0.1 level. The more severe cut-off of p<0.1 was used for 
selecting the variables for the final base model due to the small dataset size and number of 
men initiating ART. This translated to a lack of power to adjust for many factors at any one 
time in multivariate analysis. 
For each of the subsequent levels of the conceptual framework, all variables within the 
level under study were first examined individually in the univariate time-adjusted analysis. 
In multivariate analysis all factors within the level found to be significant at p<0.2 level in 
time-adjusted analysis were added to the final base model. Backward elimination was then 
used to drop factors within that framework level which were not associated at the p<0.1 
level after adjusting for all the other variables in the level and the final base model.  This 
process was repeated for each of the hierarchical levels outlined in table 3.4.  
Finally, a composite model including all variables from all levels of the conceptual 
framework which were found to be associated with early ART at the p<0.1 level after 
adjusting for variables in the final base model and within each level.  
Collinearity and multicollinearity were checked by examining the variance inflation factor 
(VIF) for each independent variable in the final multiple regression models using the “collin” 
command in STATA 13 201, using a VIF cut off of 10. 
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Table 3.3 Hierarchical conceptual framework of variables under study for multivariate analysis of factors associated with early ART initiation 
Conceptual framework level Variable(s) of interest   
A-priori confounders Time from diagnosis to survey completion 
1. Base model  
(factors known to be associated 
with starting early ART) 
Year first HIV positive 
HIV test interval – months  
 
Age at HIV seroconversion 
Square root CD4 count at diagnosis 
 
Recruited from an HIV centre with PHI interests 
Dr advised starting ART 
2. Socio-demographic  factors Ethnicity 
Years full time education after 16 years of age 
Currently employed  
Home owner 
Current living arrangements 
Sexual orientation 
 
Current regular male partner 
Recruited from London HIV centre 
3. Clinical/seroconversion factors Diagnosed in acute infection (seroconversion  
interval <30 days)  
Log10 viral load at diagnosis 
Seroconversion symptoms self-reported 
Individual seroconversion symptoms: 
rash/ headache/sore throat/fever/body 
aches/vomiting or diarrhoea/ night sweats 
Seroconversion symptoms affected daily routine 
STI co-infection at HIV diagnosis 
Ever taken PEP 
4. Attitudes to ART Surprised at HIV-positive result 
Expected to start ART within 1 month of HIV 
diagnosis 
Would have accepted ART at diagnosis if 
offered 
“Being on ART and having an undetectable vial 
load means that HIV is unlikely to be passed to a 
sexual partner even through anal intercourse 
without a condom” 
“It is  not necessary to disclose your HIV status to a 
sexual partner if you are on ART and have an 
undetectable viral load” 
“Better HIV treatment means that people are 
less worried about catching HIV” 
“It is better for my health to start ART earlier 
rather than later” 
5. Behavioural factors Had AI in 6 months before HIV diagnosis 
Had casual AI in 6 months before HIV diagnosis 
Had UAI in 6 months before HIV diagnosis 
Had casual UAI in 6 months before HIV 
diagnosis 
Had non-concordant UAI in 6 months before 
HIV diagnosis 
Had casual non-concordant UAI in 6 months 
before HIV diagnosis 
Met partners in sex on premises venue in 6 months 
before diagnosis 
Had ChemSex in 6 months before diagnosis 
Had AI since diagnosis  
Had casual AI since diagnosis  
Had UAI since diagnosis 
Had casual UAI since diagnosis  
 
Had non-concordant UAI since HIV diagnosis 
Had casual non-concordant UAI since HIV 
diagnosis 
Had ChemSex since diagnosis 
Disclosed status to: 
Nobody/GP/HIV-positive friend/HIV-negative 
friend/family/regular partner/work 
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3.6.11.1 Multivariate analysis of factors associated with high-risk sex after HIV diagnosis 
Due to the high levels of collinearity between the sexual behaviour risk factors, I felt it was 
inappropriate to conduct multivariate analyses for this outcome. Instead, only the time 
from HIV diagnosis to questionnaire completion adjusted data are presented.   
All data management and statistical analyses were carried out using STATA 13 201. 
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4 Workstream 1 results: trends in ART initiation and viral 
load at first clinic presentation  
In this chapter I present the results from workstream 1; the secondary analysis of data from 
the UK Register of HIV Seroconverters, the methods of which can be found in chapter 3, 
section 3.4.  This workstream aimed to use data from the UK Register of HIV seroconverters 
to examine temporal trends in the uptake of ART amongst individuals with EHI and to 
describe viral load at first clinic presentation amongst MSM with EHI.  
Specifically, it aimed to answer the following research questions: 
1 When do individuals with EHI initiate ART in the UK, and has this changed over 
time? 
2 How high is viral load when MSM with EHI first present to clinic in the UK?  
3 Has initial viral load changed over time amongst MSM with EHI in the UK? 
 
 Temporal trends in ART initiation amongst HIV seroconverters 4.1
The analyses presented in this section (4.1) were presented at BHIVA Spring conference in 
2014, and were therefore conducted amongst seroconverters whose route of exposure was 
through heterosexual sex and IDU, in addition to MSM.   
 Eligibility and cohort characteristics 4.1.1
Of the 3619 individuals enrolled in the UK Register as of 1st January 2014 and aged ≥16 
years at the time of seroconversion, 1885 were excluded from the analysis for the following 
reasons: 1834 seroconverted before 1st January 1998 and after 31st December 2011, 22 
initiated ART before their HIV diagnosis, and 22 had an unknown route of transmission (see 
figure 4.1). Of the 1734 remaining, the median year of seroconversion was 2005 (IQR 2001, 
2009) and the cohort was largely male (94%), exposed to HIV through sex between men 
(90%), of white ethnicity (87%) and of median (IQR) age 32.8 years (27.2, 40.3), see table 
4.1. These demographic variables remained stable over time.  
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Figure 4.1 Eligibility flowchart for analyses assessing time to, and CD4 count at, ART 
initiation amongst a UK cohort of HIV seroconverters 
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Table 4.1 Demographics and clinical characteristics of UK seroconverters eligible for time to ART initiation analysis, by calendar year of seroconversion 
   
Calendar year of seroconversion 
    Overall  1998-1999 2000-01 2002-03 2004-05 2006-07 2008-09 2010-11 
N   1,734 194 244 246 254 224 225 347 
Median (IQR) age at seroconversion – 
years 
32.8  
(27.2, 40.3) 
31.9  
(28.1, 37.4) 
32.5  
(27.6, 38.1) 
33.3  
(27.6, 39.4) 
34.0  
(27.3, 41.1) 
33.4  
(25.8, 40.8) 
31.8  
(27.0, 41.6) 
32.7  
(26.6, 41.3) 
Sex (%) Male 94.1 94.9 93.4 89.8 94.1 97.8 92.9 95.7 
Exposure (%) MSM 89.9 92.3 88.9 85.4 87.0 94.6 90.2 91.1 
 
IDU 0.5 2.1 0.4 0.8 0.4 0.0 0.0 0.0 
  MSW 9.7 5.7 10.7 13.8 12.6 5.4 9.8 8.9 
HIV test interval
a
 (%) <30 days 23.1 12.4 17.6 16.3 32.3 23.7 22.7 30.8 
Ethnicity (%) White 87.1 88.1 83.2 88.2 86.6 90.2 84.4 88.5 
 
Non-white 7.2 6.2 8.2 9.4 9.5 4.0 7.6 5.5 
  Missing 5.8 5.7 8.6 2.4 3.9 5.8 8.0 6.1 
IQR=interquartile range; MSM=sex between men; MSW=sex between men and women; IDU=injecting drug use; a=interval between HIV antibody negative and positive tests. a=HIV test interval is the interval 
between HIV antibody negative and positive tests.
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 Temporal trends in time from seroconversion to ART initiation  4.1.2
Of the 1734 individuals, contributing 4634 years of follow-up, 1337 (77.1%) started ART. 
The Kaplan Meier graph in figure 4.2, illustrates the time to ART initiation by calendar year 
of seroconversion split into 7 year groups. Whilst there is little difference in ART uptake 
within the first year of infection by year of seroconversion, ART initiation in the first 6 
months was most rapid in 2000-03. There was a decrease over time in the median time 
from seroconversion to ART initiation from 3.7 (95%CI 3.2, 4.9) years pre-2000 to 2.8 (2.2, 
3.5), 2.9 (2.3, 4.0), 2.6 (2.2, 3.0), 2.3 (1.8, 2.7), 2.2 (1.8, 2.7) and 1.4 (1.3, 1.7) years in 2000-
1, 2002-3, 2004-5, 2006-7, 2008-9 and 2010-11, respectively (p-trend <0.001).  There was 
strong evidence of a linear decrease in time to ART initiation over calendar time which 
remained after adjusting for covariates, with the risk of ART initiation increasing by 6% 
every calendar year (95% CI 4-7%; p<0.001), see table 4.2. Older age at seroconversion and 
shorter HIV test interval were also associated with ART initiation in the adjusted model.  
ART can be prescribed by clinicians in short-course form during primary infection, defined 
as the first 6 months following seroconversion. To avoid the influence of trends in short-
course ART in PHI on overall ART temporal trends I performed a sensitivity analysis 
excluding those diagnosed in PHI (HIV test interval <180 days). The upwards trend in risk of 
ART initiation over calendar time remained highly significant and increased to 9% per 
calendar year (95% CI 7-12%; p<0.001) in the fully-adjusted model (data presented in 
appendix 22). Controlling for CD4 count at HIV diagnosis in the Cox model also produced 
limited change to the risk of ART initiation (data presented in appendix 23).  
 Temporal trends in CD4 count at ART initiation in UK seroconverters 4.1.3
Of the 1734 individuals eligible for the analysis, 1259 had at least one CD4 count available 
at ART initiation. There was strong evidence of an upward linear increase in CD4 at 
initiation over calendar time from median 284 cells/mm3 (IQR 190, 378) pre-2000 to 280 
(221, 410), 297 (227, 380), 314 (241, 450), 330 (272, 412), 337 (282, 437), 375 (296, 511) in 
2000-1, 2002-3, 2004-5, 2006-7, 2008-9, 2010-11, respectively (p-trend<0.001), see figure 
4.3. After adjusting for sex, age at seroconversion, exposure category and HIV test interval 
the temporal increase in CD4 count at ART initiation remained significant (p<0.001), see 
table 4.3. This upward trend in CD4 at initiation over time remained in the sensitivity 
analysis excluding individuals who started ART in PHI, with an increase seen from median 
275 cells/mm3 (IQR 187, 352)  pre-2000 to 375 (301, 500) in 2010-11 (p-trend<0.001).
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Figure 4.2 Kaplan Meier plot of time from seroconversion to ART initiation amongst UK 
seroconverters, by calendar year of seroconversion 
 
 
 
 
 
 
 
 
 
 
 
Number at risk      
Pre-2000 194 153 128 109 85 70 
2000-1 244 167 134 106 87 70 
2002-3 246 181 142 110 94 67 
2004-5 254 179 144 105 64 43 
2006-7 224 162 116 81 49 31 
2008-9 225 162 107 73 24 4 
2010-11 347 202 70 7 0 0 
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Table 4.2 Factors associated with risk of ART initiation amongst HIV seroconverters in the UK  
  Unadjusted HR 95% CI p Adjusted HR
a
 95% CI p 
Calendar year of seroconversion (per year increase) 1.06 (1.04, 1.08) <0.001 1.06 (1.04, 1.07)  <0.001 
Age at seroconversion (per 10 year increase) 1.14 (1.08, 1.21) <0.001 1.13 (1.07, 1.19) <0.001 
HIV test interval
b
       
30 days or more 1 - <0.001 1 - <0.001 
<30 days 1.59 (1.40, 1.80) 1.42 (1.24, 1.62) 
Sex         
Male 1 - 0.357 1 - 0.682 
Female 1.11 (0.89, 1.40) 1.08 (0.76, 1.52) 
HIV exposure category       
MSM 1 - 0.291 1 - 0.940 
MSW 1.16 (0.97, 1.40) 1.02 (0.77, 1.34) 
IDU 0.97 (0.46, 2.03) 1.15 (0.53, 2.51) 
Analyses based on 1743 individuals, contributing 4633 person years at risk, of whom 1337 initiated ART. HR= Hazard ratio; CI=confidence interval; MSM=sex between men; MSW=sex between men and women; 
IDU=injecting drug use. a=adjusted for all other variables in the table; b=interval between HIV antibody negative and positive tests 
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Figure 4.3 Temporal trend in median CD4 count at ART initiation 
 
Note: Error bars denote interquartile range 
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Table 4.3 Factors associated with CD4 count (square root transformed cells/mm3) at ART initiation 
  
Unadjusted 
coefficient 95% CI p-value 
Adjusted
a
 
coefficient 95% CI p-value 
Calendar year of seroconversion 
(per 10 year increase) 
2.05 1.43, 2.67 <0.001 1.98 1.36, 2.61 <0.001 
Age at seroconversion  
(per 10 year increase) 
-0.04 -0.30, 0.21 0.735 -0.07 -0.32, 0.19 0.619 
HIV test interval
b
       
30 days or more 0.00 - 0.012 0.00 -  
<30 days 0.76 0.17, 1.35  0.68 0.09, 1.27 0.024 
Sex       
Male 0.00 - 0.192 0.00 - 0.002 
Female 0.71 -0.36, 1.79 2.57 0.93, 4.21 
Exposure group             
MSM 0.00 - 0.596 0.00 - 0.012 
MSW -0.23 -1.10, 0.66 -1.93 -3.25, -0.61 
IDU -1.66 -5.29, 1.98 -2.71 -6.44, 1.01 
Analyses based on 1259 individuals with one or two CD4 counts within the 6 months prior to ART initiation.  CI=confidence interval; MSM=sex between men; MSW=sex between men and women; IDU=injecting drug 
use.  a=Adjusted for all other variables in the table; b=interval between HIV antibody negative and positive tests. 
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 Temporal trends in ART initiation in PHI 4.1.4
Of the 1734 seroconverters, 967 presented in PHI (with a HIV test interval of ≤6 months) 
and, of these, 251 (26%) initiated ART within 6 months of seroconversion. The proportion 
starting ART in PHI fluctuated over calendar time; increasing from 27.9% pre-2000 to a peak 
of 50.0% in 2000-1, and decreasing to the lowest values in more recent years to 12.9% in 
2008-9 and 19.8% in 2010-11, see table 4.4.  Those starting ART in PHI, were most likely to 
initiate with a non-nucleoside reverse transcriptase inhibitor (NNRTI) based combination, or 
a protease inhibitor (PI) based combination, though between 2004 and 2007 PI-based 
combinations were substantially more popular than NNRTI with around 83% starting them 
as opposed to 13%. 
The 251 individuals initiating ART in PHI contributed 478 person-years of follow-up, during 
which time 168 (66.9%) stopped therapy. There was strong evidence of temporal variation 
in time from PHI ART initiation to stopping, with individuals seroconverting from 2008 
onwards far less likely to stop therapy within the first year, after adjusting for prognostic 
factors, (p<0.001), see table 4.4.   
After conducting sensitivity analyses excluding individuals known to be enrolled on the 
SPARTAC trial (a trial of short-course ART initiated in PHI which ran from 2003-2007), there 
remained strong evidence of heterogeneity in the proportion starting ART in PHI over 
calendar year of seroconversion in adjusted models (p<0.001), with a notable decrease in 
uptake observed after 2004 (see appendix 24). The temporal effect on time from ART 
initiation in PHI to stopping after excluding SPARTAC patients remained highly significant 
(p<0.001) with the proportion stopping within 12 months decreasing substantially after 
2008 (see appendix 24). 
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Table 4.4 Temporal trends in ART initiation, starting combinations and time to stopping ART in patients with primary HIV infection 
 
  
Calendar year of seroconversion
a
 
  
  1998-99 2000-01 2002-03 2004-05 2006-07 2008-09 2010-11 p-value 
N 61 98 114 175 148 139 232   
% (95% CI) initiating ART in PHI 
27.9 
(18.0, 40.4) 
50.0 
(40.2, 59.8) 
35.1 
(26.9, 44.3) 
29.1 
(22.9, 36.3) 
20.3 
(14.5, 27.6) 
12.9 
(8.3, 19.7) 
19.8 
(15.2,25.5) 
p<0.001
b
 
% (95% CI)  ART starting classes                 
NRTI+NNRTI 29.4 75.5 57.5 15.7 16.7 44.4 47.8  
(12.4,55.1) (61.4,85.7) (41.7,71.9) (8.0,28.6) (7.0,34.8) (23.4,67.7) (33.7,62.3)  
NRTI+PI 64.7 16.3 42.5 84.3 83.3 38.9 47.8  
(39.6,83.7) (8.3,29.6) (28.1,58.3) (71.4,92.0) (65.2,93.0) (19.3,62.9) (33.7,62.3)  
NRTI only 5.9 8.2 0 0 0 11.1 4.3  
(0.8,33.6) (3.1,20.1) (0,0) (0,0) (0,0) (2.7,36.4) (1.1,16.1)  
Other 0 0 0 5.6 0 0 0  
(0,0) (0,0) (0,0) (0.7,32.1) (0,0) (0,0) (0,0)  
% (95% CI) of those starting ART in PHI who 
stop within 12 months
c
  
52.9 
(32.0, 77.0) 
62.9 
(49.4, 76.4) 
72.5 
(58.3, 85.1) 
82.4 
(70.8, 91.3) 
86.7 
(72.2, 95.8) 
11.1 
(2.9, 37.6) 
11.3 
(4.9, 25.1) 
P<0.001
d
 
ART= antiretroviral therapy; PHI=primary HIV infection; CI=confidence interval; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; PI=protease inhibitor. 
a=Calendar year of seroconversion modelled as categorical year groups; b=p-value for heterogeneity from logistic regression model of effect of year group of seroconversion (categorical) adjusting for sex, exposure 
group (MSM, MSW, IDU), age at seroconversion (continuous, per 10 years) and HIV test interval (30 days or more, < 30 days); c=time to event analysis assessing time from ART initiation in PHI to stopping ART; 
based on 251 individuals starting ART in PHI, contributing 478 person-years at risk, of whom 168 stopped therapy; d p-value for heterogeneity in Cox proportional hazards model, modelling year group of 
seroconversion (categorical) and adjusting for sex, exposure group (MSM, MSW, IDU), age at seroconversion (continuous, per 10 years) and HIV test interval (30 days or more, < 30 days) 
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 Viral load at first clinic presentation amongst MSM with early HIV 4.2
infection in the UK 
As a reminder this part of workstream 1 sought to establish viral load at first clinic 
presentation amongst MSM with EHI enrolled in the UK Register, and to examine temporal 
trends in viral load at first clinic presentation.  The methods for this analysis can be found in 
section 3.4.3.  
 Eligibility and data availability 4.2.1
As of 1st January 2013, 3,552 individuals were enrolled in the UK Register, with the median 
year of seroconversion 1999 (IQR 1992, 2006). The predominant route of exposure was sex 
between men (83.6%), with heterosexual contact, IDU and vertical transmission accounting 
for 9.1%, 5.9% and 0.1%, respectively. As expected, with a high prevalence of MSM, the 
majority of the cohort is male at 92%. The median age at seroconversion is 30.7 years (IQR 
25.5, 37.4). The majority were eligible for the study because they had a previous negative 
test in the last 3 years 88.5%; and for these the median HIV test interval 198 days (IQR 79, 
383). 7.5% presented with laboratory evidence of acute HIV infection.   
A total of 84,534 viral load measurements were taken between 1988 and 2013 with a 
clearly visible increase in the annual number of tests from 526 in 1996 to 2,342 in 1997.. 
This coincides with reports from the clinic laboratories of when viral load testing became 
routine. Due to the sparse viral load data before 1997 I limited inclusion criteria to those 
first testing positive with HIV from 1997 onwards.  
Of the 3,552 people enrolled to the UK Register, 2,102 were diagnosed with HIV on or after 
1st January 1997. As my thesis focusses specifically on MSM with primary HIV infection, data 
for this analysis were restricted to men who reported their likely route of HIV infection to 
be through sex with other men (n=1,845). Of these, 1,543 had an HIV test interval 1 year or 
less and 1,500 had one or more ART-naïve viral load measure available. 
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 Cohort characteristics 4.2.2
The characteristics of the 1,500 MSM enrolled to the UK Register with one or more viral 
load measure available for analysis are outlined in table 4.5. In summary, the median year 
of seroconversion was 2006 (IQR 2003, 2010) and median HIV test interval was 3.8 months, 
(IQR 0.7, 7.4). 18.1% of the men were diagnosed during acute infection. Both the HIV test 
interval and the proportion presenting during acute infection fluctuated over the years but 
no systematic pattern was observed overall.   
Men were a median of 32.7 years old at the time of seroconversion (IQR 27.1, 40.0), this 
varied slightly over the study years between 30.7 years in 1997-9 to 34.3 in 2002-5 but 
there was no clear trend over time. The vast majority of the men in the cohort were of 
white ethnicity (91%). The proportion of non-white ethnicity MSM fluctuated over calendar 
time and was highest in 2008-9 at 13% and lowest in 2002-3 at 4.8%. HIV subtype data 
were not available for the majority of the cohort; only 37.3% had a subtype available 
overall and in 2010-12 only 1.9% had been sub-typed. Overall, 75% of men had their first 
viral load within 2 weeks of the date of HIV diagnosis, at a median of 6 days after. This 
interval was longest in 1997-9 at 12 days, but was stable at between 5 and 9 days 
otherwise. 
Over 95% of the cohort had information available on the type of the viral load assay used to 
measure first viral load. Overall the most common assay type was PCR-based accounting for 
over 78% of measures. Unsurprisingly, there was a shift in the use of assays over time, with 
the popularity of bDNA-based assays waning in favour of PCR assays over time, from 40% in 
1997-99 to 1.3% in 2010-12. NASBA assays were used infrequently across all years at 4.9% 
overall; their use peaked in 2002-3 and again in 2008-09 when they accounted for 11.5% of 
first viral load measures. 
 Characterising viral load at first presentation amongst UK MSM with early HIV 4.2.3
infection 
Overall, the median (IQR) viral load at first presentation was 5.0 (4.4, 5.7) log10 copies/mL, 
taken a median of 75 (20, 132) days after seroconversion. There was strong evidence 
(p<0.001) of a linear trend with viral load at first presentation decreasing by 0.09 log10 
copies/mL (95% CI -0.11, -0.07) for every month between seroconversion to first viral load 
 140 
 
measure, see figure 4.4 and table 4.6. There was significant evidence of departure from 
linearity (p<0.001) in the association between time from seroconversion to viral load, so it 
was modelled as a 5 group categorical variable (<1 week, ≥1 week and <1 month, ≥1 month 
and <3 months, ≥3 and <6 months and ≥6 months). In the unadjusted model including time 
from seroconversion to viral load as a categorical variable, there was significant evidence of 
differences in viral load at first presentation over time (p<0.001). A small increase in viral 
load of 0.06 log10 copies/mL was seen between <1 week and 1 week-1 month categories, 
then from 1 month after seroconversion a decrease in viral load becomes apparent, which 
slows from 6 months onwards. 
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Table 4.5 Demographic and clinical characteristics of MSM HIV seroconverters eligible for viral load analysis, by calendar year of seroconversion 
  Calendar year of seroconversion 
 Total 1997-99 2000-01 2002-03 2004-05 2006-07 2008-09 2010-12 
N 1500 143 133 166 205 204 192 457 
Median (IQR) age at 
seroconversion - years 
32.7 
(27.1, 
40.0) 
30.7 
(26.9, 
35.0) 
32.3 
(27.4, 
36.3) 
34.3 
(27.5, 
41.1) 
34.3 
(27.2, 
41.6) 
33.8 
(27.2, 41.6) 
31.7 
(26.8, 
41.0) 
32.4 
(26.3, 
40.2) 
Median (IQR) HIV test interval - 
months  
3.8 
(0.7, 7.4) 
5.6 
(2.2, 8.7) 
3.5 
(0.7, 8.1) 
5.0 
(2.4, 8.9) 
3.3 
(0.2,6.1) 
3.7 
(1.0, 7.0) 
4.1 
(1.3, 7.2) 
3.2 
(0, 6.9) 
Median (IQR) time from 
seroconversion to first VL 
measure - days 
70.5  
(20, 132) 
94 
(57, 167) 
67 
(19, 134) 
100.5 
(42, 147) 
70 
(14, 113) 
74 
(27, 135) 
75 
(22, 122) 
53 
(7, 117) 
Median (IQR) time from 
diagnosis to first VL measure - 
days 
6 
(1, 15) 
12 
(2, 27) 
7 
(0, 14) 
9 
(1, 18) 
7 
(1, 15) 
7 
(2, 19) 
5 
(1, 13) 
5 
(0, 11) 
Evidence of acute infection (%)         
No 81.9 81.1 75.2 83.1 77.6 86.3 83.3 82.9 
Yes 18.1 18.9 24.8 16.9 22.4 13.7 16.7 17.1 
Ethnicity (%)         
White 90.9 89.5 90.2 94.6 92.2 92.7 87.0 90.6 
Non-white 7.6 5.6 6.0 4.8 7.3 5.9 13.0 8.3 
Missing 1.5 4.9 3.8 0.6 0.5 1.5 0.0 1.1 
IQR=interquartile range; HIV test interval= interval between HIV antibody negative and positive tests; VL=viral load; PCR=polymerase chain reaction; bDNA=branched DNA; NASBA=nucleic acid sequence based 
amplification 
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Table 4.5 (continued) 
 Year of seroconversion 
 Total 1997-99 2000-01 2002-03 2004-05 2006-07 2008-09 2010-12 
HIV Subtype (%)         
B 34.9 48.3 51.9 57.2 51.7 47.1 42.2 1.7 
Non-B 2.3 0.0 4.5 3.6 3.9 2.5 4.7 0.2 
Missing 62.7 51.8 43.6 39.2 44.4 50.5 53.1 98.0 
Viral load assay type (%)         
PCR 77.9 49.7 66.9 54.2 75.6 87.3 81.3 93.9 
bDNA 12.6 39.9 30.1 28.9 13.2 4.9 0.5 1.3 
NASBA 4.9 4.9 0.8 11.5 2.4 5.9 11.5 1.5 
Unknown 4.7 5.6 2.3 5.4 8.8 2.0 6.8 3.3 
Assay cut off in copies/mL (%)           
>100,000 11.2 10.5 13.5 19.9 32.2 6.9 5.7 2.4 
>500,000 12.6 39.9 30.1 28.9 13.2 4.9 0.5 1.3 
>750,000 25.6 39.2 52.6 32.5 35.1 32.8 21.9 5.0 
>6,000,000 3.6 4.9 0.8 8.4 1.5 5.4 7.8 0.7 
>10,000,000 42.3 0.0 0.8 4.8 9.3 48.0 57.3 87.3 
Missing 4.7 5.6 2.3 5.4 8.8 2.0 6.8 3.3 
IQR=interquartile range; HIV test interval= interval between HIV antibody negative and positive tests; VL=viral load; PCR=polymerase chain reaction; bDNA=branched DNA; NASBA=nucleic acid sequence based 
amplification 
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There was also evidence of an association between calendar time and initial viral load, with 
an increase in initial viral load of 0.18 log10 copies/mL per decade. There was evidence of 
departure from linearity however (p=0.027), and so calendar year of seroconversion was 
included in the adjusted model as a 7 group categorical to improve model fit. Initial viral 
load was also found to be higher by 0.07 log10 copies/mL with every 10 year increase in age 
at seroconversion (p=0.023), lower by -0.44 log10 copies/mL for non-white MSM (p<0.001) 
and higher by 0.71 log10 copies/mL for those presenting with laboratory evidence of acute 
infection (p<0.001). HIV test interval was inversely associated with first viral load, with a -
0.06 log10 copies/mL decrease in viral load measure observed per 1 month increase in HIV 
test interval (95% CI -0.07, -0.04; p<0.001). Similarly, first viral load measure decreased as 
time from diagnosis to first viral load measure increased by -0.02 log10
 copies/mL per month 
(95% CI -0.03, -0.01, p<0.001).    
The association between time to initial viral load from seroconversion with first viral load 
measure remained strong in the fully-adjusted model (p<0.001), after controlling for 
ethnicity, age at seroconversion, presentation during acute infection, and calendar year of 
seroconversion.   
Figures 4.5a and b illustrate the unadjusted and fully-adjusted ordinary least squares 
regression prediction of viral load at first presentation by time from seroconversion 
modelled as a 5 knot restricted cubic splines (RCS) anchored at the 5th, 25th, 50th 75th and 
95th percentiles. Figure 4.5a clearly illustrates the much higher viral load in those presenting 
to clinic within the first 30 days of seroconversion at around 5.3 log10 copies/mL and the 
rapid decline seen thereafter until the plateau is reached at around 100 days post 
seroconversion at about 4.7 log10 copies/mL. 
In the model adjusting for ethnicity, age at seroconversion, evidence of acute infection and 
calendar year of seroconversion, the peak viral load seen at first presentation and the value 
at which viral load plateaued was similar at around 5.2 log10 copies/mL and 4.8 log10 
copies/mL, respectively (see figure 4.5b).  
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Figure 4.4 Scatterplot of HIV viral load at presentation by time since seoroconversion 
amongst MSM seroconverters in the UK, with OLS line of best fit  
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Table 4.6 Factors associated with HIV viral load at first clinic presentation (log10 copies/mL) amongst MSM with early HIV infection in the UK 
    
Unadjusted 
coefficient 95% CI 
p-
value 
Adjusted 
coefficient
d
 95% CI 
p-
value 
Time from seroconversion to first VL (per month increase)
a
 -0.09 -0.11, -0.07 <0.001 - - - 
Time from seroconversion  <7 days 0 - <0.001 0 - <0.001 
to first VL 1 week- 1 month 0.06 -0.14, 0.27 
 
0.07 -0.13, 0.27 
 
 
>1 month - 3 months -0.33 -0.48, -0.17 
 
-0.02 -0.20, 0.16 
 
 
>3 months-6 months -0.61 -0.76, -0.46 
 
-0.28 -0.46, -0.10 
 
 
>6 months -0.75 -0.98, -0.53   -0.37 -0.62, -0.13   
Year of seroconversion (per 10 year increase) 
b
 0.18 0.06, 0.30 0.004 - - - 
Year of seroconversion 1997-99 0 - 0.002 0 - 0.020 
 
2000-01 0.28 0.03, 0.54 
 
0.20 -0.04, 0.45 
 
 
2002-03 0.21 -0.02, 0.45 
 
0.19 -0.04, 0.42 
 
 
2004-05 0.3 0.08, 0.53 
 
0.22 0.00, 0.45 
 
 
2006-07 0.21 -0.02, 0.44 
 
0.19 -0.03, 0.42 
 
 
2008-09 0.1 -0.13, 0.33 
 
0.09 -0.14, 0.32 
 
 2010-12 0.39 0.19, 0.59   0.33 0.13, 0.53   
Age at seroconversion (per 10 year increase) 0.07 0.01, 0.12 0.023 0.03 -0.02, 0.09 0.278 
Ethnicity  White 0 -   0 -    
  Non-white -0.44 -0.65, -0.24 <0.001 -0.44 -0.64, -0.24 <0.001 
CI=confidence interval; VL=viral load. a= likelihood ratio test showed evidence departure from linearity (p<0.001) time since seroconversion modelled as categorical variable in adjusted model. b=likelihood ratio 
test showed evidence departure from linearity (p=0.027) so year of seroconversion modelled as categorical variable in adjusted model. c=HIV test interval and time from diagnosis to first VL measure excluded from 
multivariate model due to collinearity with time from seroconversion to first VL measure. d=Adjusted for year of seroconversion (categorical), evidence of acute infection, age at seroconversion (per 10 year 
increase) and ethnicity. 
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Table 4.6 (continued) 
 
    
Unadjusted 
coefficient 95% CI p-value 
Adjusted 
coefficientd 95% CI p-value 
Laboratory evidence of acute infection  No 0 - <0.001 0 - <0.001 
  Yes 0.71 0.58, 0.85   0.56 0.38, 0.74   
HIV test interval (per month increase)
c
 -0.06 -0.07, -0.05 <0.001 - - - 
Time from diagnosis to 1st VL (per month increase)
c
 -0.19 -0.03, -0.01 <0.001 - - - 
CI=confidence interval; VL=viral load. a= likelihood ratio test showed evidence departure from linearity (p<0.001) time since seroconversion modelled as categorical variable in adjusted model. b=likelihood ratio 
test showed evidence departure from linearity (p=0.027) so year of seroconversion modelled as categorical variable in adjusted model. c=HIV test interval and time from diagnosis to first VL measure excluded from 
multivariate model due to collinearity with time from seroconversion to first VL measure. d=Adjusted for year of seroconversion (categorical), evidence of acute infection, age at seroconversion (per 10 year 
increase) and ethnicity. 
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Figure 4.5 Estimated mean HIV viral load at first clinic presentation amongst MSM with 
recent HIV infection by time since seroconversion, modelled using restricted cubic splines 
 
 
a) Simple linear regression model; b) Multiple regression model adjusting for calendar year 
of seroconversion, age at seroconversion, ethnicity, laboratory evidence of acute infection. 
Note: Black line denotes mean and blue shaded area denotes 95% confidence interval. Time from seroconversion to first viral 
load measure modelled using restricted cubic splines anchored at the 5th, 25th, 50th, 75th and 95th percentiles. 
 
a) 
b) 
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 Temporal trends in viral load at first clinic presentation 4.2.4
Median viral load at initial presentation increased from the lowest value 4.75 log10 
copies/mL in 1997-99 to the highest value of 5.11 in 2000-01, then remained relatively 
stable at around 5.00 until 2006-7 before decreasing to 4.86 in 2008-09 and increasing 
again to 5.07 in 2010-12.  A scatterplot of the raw data fitted with an OLS line of best fit, 
showed no notable linear increase in initial viral load over time (see figure 4.6).  
Figure 4.6 Scatterplot of HIV viral load at first clinic presentation amongst MSM 
seroconverters in the UK by date of seroconversion, with OLS line of best fit 
 
As presented in table 4.6, there was a positive correlation between seroconversion year 
and initial viral load, with an increase of 0.18 log10 copies/mL per 10 year increase in 
seroconversion year (95% CI 0.06, 0.30; p=0.004). When seroconversion year was modelled 
as a 7 group categorical variable there was evidence of heterogeneity in the effect of year 
of seroconversion on initial viral load (p=0.002) with fluctuations in viral load over time 
peaking twice: in 2004-2005, at 0.30 log10 copies/mL above the reference year 1997-99; and 
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again in 2010-12, at 0.39 above the reference year.  A likelihood ratio test confirmed 
departure from linearity (p=0.027) so seroconversion year was modelled in adjusted models 
as a categorical variable.  Ethnicity, age at seroconversion, acute infection, HIV test interval, 
time from diagnosis to first viral load and time from seroconversion to first viral load were 
all found to be associated with first viral load in unadjusted analysis. These variables were 
therefore included in the multivariate analysis as they were potential confounders of the 
association between calendar year of seroconversion and initial viral load. After adjusting 
for all the potential confounding variables , the temporal association between year of 
seroconversion and initial viral load weakened slightly but remained significant (p=0.020). 
The pattern of fluctuations in viral load over time remained unchanged, though their 
magnitude decreased slightly. Initial viral load in the most recent year group 2010-12 
remained the highest out of all the other years at 0.33 log10 copies/mL higher than the 
reference group 1997-99.  
Graphical depictions of the unadjusted and adjusted temporal trends in initial viral load are 
shown in figures 4.7a and b, allowing non-linearity by modelling date of seroconversion as 
RCS with knots at 5, 25, 50, 75 and 95th percentiles. An increase in viral load at first 
presentation is observed from around 4.6 log10 copies/mL those seroconverting in 1997 to 
over 4.9 in 2003. It then plateaued at around this level until 2009, after which initial viral 
load increased to 5.2 log10 copies/mL.  The shape of the curve remained after adjusting for 
ethnicity, age at seroconversion, acute infection and time from seroconversion to initial 
viral load, though the magnitude of initial viral load across all years was slightly lower, the 
plateau was flatter, and the peak initial viral load in 2012 was lower at just under 5.1 log10 
copies/mL (see figure 4.7b).  
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Figure 4.7 Predicted temporal trend in mean viral load at first presentation amongst MSM 
in the UK 
 
Figure a) Unadjusted simple linear regression estimates; figure b) Multiple regression 
estimates, adjusting for time from seroconversion to first viral load, age at seroconversion, 
ethnicity and acute infection. 
Note: Black line denotes mean and blue shaded area denotes 95% confidence interval. Time from seroconversion to first viral 
load measure modelled using restricted cubic splines anchored at the 5th, 25th, 50th, 75th and 95th percentiles. 
a) 
b) 
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 Sensitivity analyses  4.2.5
I conducted several sensitivity analyses to ascertain the robustness of the temporal 
variation in initial viral load, most of which are displayed in table 4.7 and figures 4.8a-d. To 
reduce the uncertainty around date of seroconversion, I restricted the analysis to MSM 
with a shorter HIV test window of ≤180 days. Interestingly this resulted in a stronger 
association (p=0.010) and an increase in all the year group effects as compared to the 
reference category. Figure 4.8b illustrates the resulting graph, which follows the same 
pattern of variation as the final adjusted model as shown in figure 4.8a, with slightly lower 
estimated viral load in both 1997 and 2012. Initial viral load in 2012 remains the highest of 
all years.   
After restricting the dataset to white MSM (N=1364), there remained weak evidence of an 
association between year of seroconversion and initial viral load (p=0.065), though the 
coefficients and shape of the curve remain relatively unchanged and initial viral load 
remains highest in most recent years (figure 4.8c).  
Finally, after right truncating viral load at 5.0 log10 copies/mL (the lowest upper limit of 
detection used across the assays), the temporal pattern remained as did the association 
(p=0.030) (figure 4.8d).  
Additional sensitivity analysis was planned to be performed on the final multivariate model 
by adjusting for HIV subtype, however the high proportion of missing subtype data overall 
(62.7%), and in particular the near total lack of sub-type data in those seroconverting in 
2010-12 (98.0%), rendered this unfeasible. 
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Table 4.7 Sensitivity analyses of calendar trends in viral load at first clinic presentation amongst MSM with EHI 
 
 
Model a)Final adjusted multivariate 
model (N=1478) 
Model b) MSM with HIV test interval 
≤180 days (N=976) 
Model c) white MSM only 
 (N=1364) 
Model d) Right truncating VL at 5.0 log10 
copies/mL (N=1478) 
  Coefficient 95% CI p-value Coefficient 95% CI p-value Coefficient 95% CI p-value Coefficient 95% CI p-value 
1997-99 0 - 0.020 0.00 - 0.010 0.00 - 0.065 0.00 - 0.030 
2000-01 0.20 -0.04, 0.45 0.35 0.03, 0.68 0.19 -0.07, 0.44 0.11 -0.06, 0.28 
2002-03 0.19 -0.04, 0.42 0.35 0.04, 0.66 0.21 -0.03, 0.45 0.12 -0.04, 0.28 
2004-05 0.22 0.00, 0.45 0.34 0.06, 0.63 0.25 0.02, 0.45 0.13 -0.03, 0.28 
2006-07 0.19 -0.03, 0.42 0.36 0.06, 0.65 0.21 -0.02, 0.44 0.04 -0.11, 0.20 
2008-09 0.09 -0.14, 0.32 0.21 -0.09, 0.51 0.18 -0.06, 0.41 -0.06 -0.21, 0.10 
2010-12 0.33 0.13, 0.53 0.49 0.23, 0.76 0.34 0.13, 0.54 0.14 0.00, 0.28 
VL=viral load; MSM=men who have sex with men. a=Final model adjusting for time from seroconversion to first VL, age at seroconversion, ethnicity and acute infection. b=Model a but restricting to MSM with HIV 
test interval of ≤180 days. c=Model a but restricting to white ethnicity MSM. d=Model a but right truncating viral load at 5.0 log10 copies/mL.  
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Figure 4.8 Sensitivity analyses of temporal trends in HIV viral load at first presentation amongst MSM with EHI 
 
Figure a) Final adjusted model 
(n=1,478). 
Figure b) restricts to MSM 
ethnicity with an HIV test interval 
<=180 days (n=976).  
Figure c) restricting to white MSM 
(n=1,364).  
Figure d) right truncating viral 
load at presentation at 5.0 log10 
copies/mL (n=1,478). 
Note: Black line denotes mean and blue 
shaded area denotes 95% confidence 
interval. Time from seroconversion to 
first viral load measure modelled using 
restricted cubic splines anchored at the 
5
th
, 25
th
, 50
th
, 75
th
 and 95
th
 percentiles.
a) b) 
c) d) 
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 Summary discussion 4.3
These data from a UK cohort of recent HIV seroconverters show that time from 
seroconversion to initiation of ART has decreased over time, from a median of 3.7 years in 
1998-99 to 1.4 years in 2010-11. This has been accompanied by an increase in CD4 count at 
ART initiation; over a quarter of individuals who seroconverted in 2010-11 and started 
therapy, did so with a CD4 count greater than 500 cells/mm3. As time to ART initiation has 
crept nearer to seroconversion overall, there has been an apparent decrease in the 
proportion initiating ART in PHI in more recent years. Whilst these findings may appear to 
contrast, it is possible for both to co-exist, through a shift away from specific short-course 
treatment of primary infection and an overall decrease in the time to initiation of ‘lifelong’ 
ART. From 2008 onwards, notably more of the individuals who started ART in PHI appeared 
to remain on treatment as opposed to using the short-course approach. These results 
appear to indicate a general movement towards earlier initiation of ‘lifelong’ ART in the UK 
amongst those identified in EHI, independent of the strategy of treating PHI with short-
course ART.  
The viral load data presented in this chapter indicate that the peak viraemia in EHI is 
observed in MSM presenting to clinic at around 30 days post seroconversion, though it 
remains elevated in men presenting at up to 100 days after seroconversion. In order for 
TasP to have the maximal effect of reducing transmission potential in MSM with PHI it 
would need to be started within one month of seroconversion, though there may still be 
some added benefit from early ART in reducing the observed elevated viraemia up until 100 
days post seroconversion. Currently only 24% of MSM enrolled in the UK Register cohort 
presented to clinic within 30 days of seroconversion. In order to increase the proportion of 
men diagnosed before peak viraemia, men would have to test more frequently than the 
current PHE recommendation of every three-months 211, perhaps a regularly as monthly or 
every 6 weeks.  
The relationship between ethnicity and viral load is highlighted in these findings also, with 
non-white MSM having consistently lower initial viral loads than their white counterparts. 
Conversely, older age was associated with higher initial viral load in univariate analysis, 
however the relationship did not persist in multivariate models. Whether the observed 
lower plasma viral load amongst non-white ethnicity, and to a lesser extent younger MSM, 
corresponds to a reduced transmission risk warrants further investigation.  
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These data also indicate evidence of a possible increase in viral load at first presentation 
over time amongst MSM seroconverters. The increase in initial viral load from 4.68 log10 
copies/mL in 1997 to 5.12 log10 copies/mL in 2012 as predicted by the adjusted RCS model 
equates to an increase on the linear scale from 47,863 to 131,826 copies/mL; an increase of 
83,963 copies/mL over the 15 year period. It is highly possible that these estimates are 
overly inflated, due to the increased use of more sensitive viral load assays in recent years 
with higher upper limits of detection, but even when right truncating viral load measures at 
5.0 log10 copies/mL in sensitivity analyses, a significant increase in initial viral load over time 
persisted, albeit at a lower threshold.  
 Strengths and limitations 4.3.1
By using data from a seroconverter cohort, it was possible to characterise ART initiation and 
initial viral load amongst individuals identified at the earliest point in infection without the 
bias of late presentation to services. The use of laboratory confirmation of seroconversion 
date in the UK Register adds strength to this data, as dates are estimated with a strong 
degree of confidence.  It also allowed us to examine trends in treatment during primary HIV 
infection, which, in the UK, has separate initiation guidelines.  
There are drawbacks to using a seroconverter cohort however. By definition of eligibility, 
seroconverters may display more health seeking traits than those presenting later 212; most 
are regular testers and perhaps recognise their HIV risk or know the symptoms of 
seroconversion. It may also be that disease progression in those experiencing symptomatic 
acute infection is accelerated compared to those asymptomatic in early infection, resulting 
in presentation because of ill health due to rapid progression 213. The results arising from 
this study population may therefore not be representative to recent seroconverters who do 
not present to clinic for diagnosis during in EHI.  
4.3.1.1 Time to ART initiation analysis 
More rapid disease progression and CD4 decline in those seroconverting in more recent 
years has been reported 79 and could also cause the apparent temporal trend to initiate 
closer to seroconversion. The upward trend observed in CD4 at ART initiation hints that this 
is unlikely in this population, however, and including CD4 at seroconversion in sensitivity 
analysis in the adjusted Cox model examining temporal trends in ART initiation did not 
affect the estimate.  However, the analysis of CD4 count at initiation is based only upon 
individuals who have already started ART, and it is impossible to predict the CD4 count that 
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others will start at in the future. Whilst median CD4 count at initiation is likely to decrease 
as individuals initiate therapy later in infection, the high proportion of seroconverters in the 
most recent years who had started therapy within the follow-up period means that this is 
likely to affect the estimate less.  
Prescribing patterns in UK clinics can vary; certain centres may have a reputation to be 
more proactive in treating early, or hold research interests in ART in PHI. I was unable to 
control for recruitment centre as there are numerous small centres across the UK who 
provide only a few patients to the UK Register of HIV Seroconverters, so I can only 
acknowledge this as a limitation. The other potential source of bias comes from trials of 
treatment in PHI; the SPARTAC trial is one such example and recruited from August 2003-
July 2007, likely increasing the proportion of MSM initiating ART in PHI over this time 
period. Whilst I was able to run sensitivity analysis excluding individuals enrolled in 
SPARTAC, by virtue of a link between the UK Register and SPARTAC databases, there may 
have been other locally managed trials which I was unaware of. In the UK, treatment in PHI 
is recommended for individuals with persistently low CD4 count (for 3 or more months), 
neurological involvement or AIDS defining illness 132. I assumed it unlikely that the 
prevalence of these conditions would change over time, and so did not adjust for these 
factors in our model.   
4.3.1.2 Viral load at first clinic presentation analysis 
Viral load assay technologies have developed considerably since their introduction leading 
to an exponential increase in the linear range of the assays, from <500 to 500,000 
copies/mL pre-2006, to between <50 and 10,000,000 in those most commonly used from 
2006 onwards.  As use of different assay type is strongly associated with time, significant 
collinearity exists between assay type, upper limit of detection and calendar time, making it 
difficult to control for assay type in multiple regression models assessing temporal trends.  
To attempt to account for changes in the upper linear range of detection I performed 
sensitivity analyses by right truncating viral load data at 5.0 log10 copies/mL (500,000 
copies/mL) and rerunning the multiple regression models. 
The finding that the initial viral load was highest amongst those presenting in most recent 
years could be due to a possible selection bias. It is possible that symptomatic people are 
more likely to be recruited to the UK Register earlier compared to those who are 
asymptomatic. Compared to asymptomatic seroconverters, those who are symptomatic are 
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likely to have higher viral loads during early infection129. This may lead to greater 
engagement with their HIV clinic during the first few months of HIV infection due to ill 
health, thus providing more opportunity for recruitment to the study. Conversely, 
asymptomatic seroconverters may be more likely to disengage with an HIV clinic 
temporarily until later in their infection, and hence may have less chance of being invited 
and recruited to the UK Register until later on in the course of infection when they re-
engage with care. For seroconverters recruited in earlier year groups, this bias is less of a 
problem as these “asymptomatic seroconverters” are likely to be recruited retrospectively 
a few years after their seroconversion date. For more recent years however, less time has 
elapsed in which to retrospectively recruit these seroconverters.  Currently the date of 
recruitment to the UK Register is not captured in the study database so there is no way of 
systematically assessing the extent of this bias, or adjusting for it. It is however important 
to acknowledge that if found to be problematic, it could cause an overestimation in viral 
load at first presentation in the most recent year groups.  
 Chapter summary 4.4
The key results of this chapter are highlighted in blue in the thesis schematic presented 
overleaf (figure 4.9). In this chapter I provided evidence of more rapid uptake of ART over 
time amongst HIV seroconverters in the UK; half of those most recently diagnosed started 
ART within 1.4 years of seroconversion. In line with these findings, there was also an 
increase in the CD4 count at which seroconverters initiated ART; over 25% did so with a 
CD4>500 in the most recent years. The reasons for this tendency to initiate earlier in 
infection in more recent years are unclear. Possible reasons may include the influence of 
international guidelines recommending initiation at CD4>500 or test and treat approach, a 
greater acceptability of treatment amongst patients or increased use of TasP. The next 
section of the PhD aims to investigate the acceptability of early ART amongst MSM 
seroconverters using mixed methods approach.  
The data presented in this chapter indicate that to maximize the impact of TasP on peak 
viraemia amongst MSM seroconverters in the UK, it would need to be initiated within 30 
days of seroconversion. Currently, only one in four of the MSM seroconverters who enrol in 
the UK Register present this early in their infection, and would have the opportunity to 
initiate this early. After the first 30 days of infection, viraemia amongst those presenting 
appears to decrease reaching a plateau at around 100 days post seroconversion. From a 
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public health perspective if considering risk of HIV transmission for a single sexual act, these 
results indicate that the benefit of immediate TasP in UK MSM presenting from 30 days 
post seroconversion wanes over time, and by 100 days post seroconversion, becomes no 
more than it would be for those presenting in chronic infection. There may still be a benefit 
to ART initiation after the initial 100 days if cumulative transmission risk is considered, 
however, as the earlier ART is successfully initiated, the shorter the duration of 
infectiousness is, and so more potential transmission occurrences could potentially be 
averted.  This is particularly the case for those individuals who present with very high 
viraemia after 100 days post-seroconversion; around 1 in 3 seroconverters who presented 
to clinic 3-12 months after seroconversion had an initial viral load >5.0 log10 copies/mL, 
corresponding with a very high transmission risk and so would benefit from TasP. 
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Figure 4.9 Conceptual framework of the thesis including results from workstream 1 
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5 Workstream 2 phase A results: How do MSM with recently 
acquired HIV infection feel about early ART? 
In the previous chapter I presented data from the first workstream of my PhD. Using data from 
the UK Register I demonstrated that there had been a shift towards earlier initiation of ART 
over time amongst recent seroconverters in the UK. In this chapter I present the findings of 
phase A of workstream 2, the qualitative in-depth interview study, the methods of which can 
be found in chapter 3, section 3.5. The aims of this workstream were to understand the 
attitudes and beliefs of MSM with EHI towards early ART, and how early ART may sit in the 
context of recent diagnosis of EHI.  
Specifically, the workstream aimed to answer two research questions:  
 How does being diagnosed with recent HIV infection affect men’s lives? 
 How do MSM with early HIV infection feel about early ART? 
In this chapter I first present an overview of the demographic makeup of the respondents. I 
then describe the men’s experience of being diagnosed with HIV, its effect on their lives and 
how they adjusted to the diagnosis. Next the men’s knowledge and expectations around ART 
are described along with the themes that emerged from the data whilst focusing on the 
research question “How do MSM with early HIV infection feel about early ART?”. 
 Respondent demographics 5.1
Fourteen MSM attending one inner-London HIV clinic were interviewed over the course of this 
study which ran from 2010-2013 (see table 5.1). All MSM had laboratory confirmed evidence of 
seroconversion and most were interviewed within 6 months of their date of HIV diagnosis. The 
majority of men were ART-naïve at the time of interview, 3 were on ART and one man had 
picked up his prescription on the day of the interview but had not yet started, so was 
subsequently classed as not on ART. Notably, all of the men who were on ART, as well as the 
man who had just collected his first dose of ART, were interviewed in late 2012 and 2013.  
The majority of respondents were aged between 31-35 years of age, and of white British 
ethnicity, though there a range of ethnicities were represented. Men were well-educated on 
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the whole, and all were employed, except the current student. Five of the 14 men were in a 
relationship at the time of HIV diagnosis, three with a HIV-negative partner, one with a known 
positive partner, and, one with a partner who was diagnosed HIV positive at the same time as 
the respondent. At the time of interview, only two men remained in their relationship (one 
with an HIV negative partner, and one with a positive one).  
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Table 5.1 Characteristics of in-depth interview respondents (n=14) 
  
n 
Year of interview 2010 5 
 
2011 3 
 
2012 2 
 
2013 4 
Age at diagnosis (years) <25 2 
 
26-30 2 
 
31-35 6 
 
36-40 2 
41+ 2 
Seroconversion identification method Ab- then + within 12 months 10 
 
Ab- and PCR + 2 
 
RITA incident 2 
Experienced seroconversion symptoms No 4 
 
Yes 9 
 
Don't know 1 
Time form HIV diagnosis to interview <3 months 5 
 
3-6 months 7 
 
>6 months 2 
On ART at time of interview No 11 
 
Yes 3 
PEP ever No  11 
 
Yes 2 
 
Don't know 1 
HCV co-infection No 13 
 
Yes 1 
Ethnicity/nationality White British 8 
 
White African 2 
 
White European 1 
 
White North American 1 
 
Black Latin American 1 
 
White Latin American 1 
Ab-=HIV antibody negative; Ab+=HIV antibody positive; PCR+=viral load detectable on polymerase chain reaction; RITA=recent 
infection testing algorithm; PEP=post-exposure prophylaxis; HIV+=HIV antibody positive; HIV-=HIV antibody negative. 
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Table 5.1 (continued): Characteristics of in-depth interview respondents (n=14) 
  
n 
Partnership status at diagnosis Single 9 
 
In relationship with HIV+ partner 2 
 
In relationship with HIV- partner 3 
Partnership status at interview Single 12 
 
In relationship with HIV+ partner 1 
 
In relationship with HIV- partner 1 
Education status University level 12 
 
Below university level 2 
Employment status Employed 12 
 
Self-employed 1 
 
Student 1 
Housing status Home owner 3 
 
Rented accommodation  10 
 
Unknown 1 
Ab-=HIV antibody negative; Ab+=HIV antibody positive; PCR+=viral load detectable on polymerase chain reaction; RITA=recent 
infection testing algorithm; PEP=post-exposure prophylaxis; HIV+=HIV antibody positive; HIV-=HIV antibody negative. 
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 The impact of HIV diagnosis 5.2
To understand how men felt about early HIV treatment it was important to first understand 
how they felt about their HIV diagnosis, and how it had impacted their lives.  
The men interviewed received their HIV diagnoses either in a primary care setting or after 
presenting for HIV testing at the sexual health clinic. The men who reported experiencing ill 
health in the lead up to their HIV diagnosis all presented to their GP at the time they were ill, 
one respondent even registered with a GP for the first time in 10 years as he felt so sick. Of the 
men who presented to the GP, most reported flu-like symptoms, swollen glands, rash and fever 
and in two cases extreme diarrhoea and weight-loss. All but one of these men were sent home 
without an HIV test. The others were told they likely had a virus, and should “take some 
paracetamol”, or were diagnosed with a range of conditions by their GP, including impetigo, 
pharyngitis, glandular fever, vertigo, bacterial stomach-bug and an ear infection and given 
antibiotics or other forms of treatment. The one respondent who was HIV tested by his GP at 
the first visit was diagnosed in Spain and the doctor did not inform him he was being tested for 
HIV.  It therefore came as a huge shock when he returned for the test results to be told by 
another doctor he was HIV-positive. Men presented several times to their GP before an HIV 
test was offered or recommended, if it was at all. One patient who suffered with a rash, flu-like 
symptoms and chronic diarrhoea also presented to A&E whilst experiencing these symptoms 
after fainting several times at work but was not offered an HIV test. Men who were diagnosed 
with HIV by UK GPs were all referred to the HIV clinic for further care, with the respondent 
based in Spain self-referring himself and travelling home to the UK for appointments.  
Of the men who tested HIV-positive through the sexual health clinic, two went to be tested 
because of a specific sexual incident which was causing them worry. The others went either 
because it was time for their routine six monthly or annual test, or because they had other STI 
symptoms. For the men who had a blood test for HIV they said they knew then that they were 
going to be told they had HIV when they received a phone call from the health advisors at the 
clinic asking to come into the clinic to discuss the results. One man even asked to be told over 
the phone then and there to avoid lengthening the experience. This was largely due to previous 
experience of receiving text messages for other STI results, and hearing friends’ stories of 
receiving a call from the clinic which led to a positive HIV diagnosis.  
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Whilst all of the men had very different backgrounds and lifestyles, it was striking how similar 
their reaction to HIV diagnosis was. Men generally appeared to report two phases in the 
process of coming to terms with their HIV diagnosis, though the duration of these phases 
varied by individual. The two phases could be divided into the immediate aftermath of being 
diagnosed which was characterised by shock, numbness and intense negative feelings which 
commonly lasted days or weeks. In the interviews men notably did not reflect on what was 
discussed with the clinic staff at the diagnosis appointment, or the level of support they had 
been offered. Upon reflecting on this initial period, the men universally described the raw 
intrinsic emotions experienced at this time instead. This was followed by a longer phase of re-
adjustment in which extrinsic forces came into play through talking to others, seeking further 
information and rationalising the situation. This two-phase period of coming to terms with HIV 
is very neatly conceptualized by the two respondents below.   
 
“I did think three days afterwards, I remember sat [at work].  I remember 
sitting there and thinking will I ever think of anything else? Because at … on 
that day I was doing my job and then went and sat for 20 minutes and that 
was all I was thinking about. And I walked to say I don’t know, for example, 
Marks & Spencers to get a sandwich. And that was all I was thinking about.  
And I did the … and that was all.  It was literally 24/7. That was all I was 
thinking about. But I have to say, a week later. It had changed. And I wasn’t 
thinking about it so much. Um, I think because as I said the [stutter] sexual 
partner had he said well, I had it for seven years. I was like, wow, okay.  Um, 
and I’d known him for about 3 or 4 years and he’d never mentioned it. And 
whatever. So I thought oh, okay perhaps life’s not completely over at this 
point. And it [stutter] took about three or four days to it not to become the 
most important thing in my head.” 
White British man, age 31-35, single, >6 months since diagnosis, not on 
ART 
 
“I mean, the first couple of weeks was, yeah, it was just, like, a surviving 
situation. And then after that, I suppose, I don't know, I was gradually 
starting to kind of think about the implications of it and find out about them. 
Because you assume, initially, that, you know, kind of, “That’s it. My life’s 
over.” Certainly as it was before I knew about this. But then, I don't know, I 
think in a way, like, some of the changes – although, I’m not saying it’s a 
good thing, or anything like that – but some of the changes that have 
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happened or that mentally that I've felt differently, some of it has been 
good.” 
White British, age 26-30, in relationship, 3-6 months since diagnosis, not 
on ART 
In the following sections, I describe how men felt upon receipt of their HIV diagnosis, their 
methods of adjusting to life with HIV, and the impact it had on their life and relationship, which 
provides the context for the thematic analysis of the research question “How do MSM with 
recent HIV infection feel about early ART?”. 
 The immediate reaction: shock and a maelstrom of negative feelings  5.2.1
The reporting of one or more of negative emotional reactions upon receipt of diagnosis was 
universal, as was shock. Negative feelings of disappointment, anger, blame, sadness, 
hopelessness, panic and feeling “dirty” were reported by the men upon receiving their 
diagnosis. These feelings were most acute in the hours and days immediately following 
diagnosis, and then gradually ebbed with time. In the two men with a self-reported 
predisposition to depression however, these feelings remained at an overwhelming level for 
months, and were still felt to some extent at the time of the interview.  
“I cried for months and months and I used to say to myself, I’m screaming 
and dragging at home on my own saying I’m so disappointed, disappointed, 
this was still hammers in my mind I was so disappointed“ 
Black South American, age 36-40, single, 3-6 months since diagnosis, not 
on ART 
Negative emotions could be directed internally and/or externally. The feelings of anger and 
disappointment were commonly directed both internally and externally. Men reported feeling 
very angry and disappointed with the sexual partner that gave them HIV, but also at 
themselves for putting themselves at risk of acquiring HIV.   
Feelings of panic were reported by the men and appeared to have three sources: fear of having 
transmitted to a partner; fear of being ill, or being in pain; and fear that others will find out 
about the diagnosis. Panic was most acute in men who worried they had transmitted HIV to 
somebody else, especially in the men who had an HIV negative regular partner at the time of 
 167 
 
diagnosis. This feeling was exacerbated and mingled with paranoia and guilt where HIV had 
been acquired outside of the agreed parameters of the relationship.  
Reflecting on the moments following his HIV diagnosis, having suspecting he contracted HIV in 
a sauna whilst “cheating” on his partner, the respondent below described himself as feeling like 
“scum of the earth” and “horrible” that he could have passed it to “the person you love”. In this 
circumstance, the negative feelings experienced at the time of diagnosis were centred around 
the effect of his cheating on his relationship and the chance his partner may now have HIV, 
rather than any personal implications of having HIV himself.  
“it wasn’t so much being positive that I was worried about I was so focussed 
on the relationship I was so focussed on that and that was what was causing 
the hurt, yes, there was the HIV as well. But again I have friends who are HIV 
positive and who have and lead very fruitful lives, a bit of a cliché but, so 
there was a worry there but I was more worried how this was going to affect 
my relationship with my partner and then about 10 days after my diagnosis I 
felt really down, I almost, I suppose it’s as close to suicidal as I have ever 
been and I don’t have it in me, and I don’t think there was ever any real 
danger of doing it and I got in touch with a woman who is a life coach and I 
dropped her an email and said this is what has happened can you help me, 
and I’ve been seeing her since, and talking to her a lot.. I got a lot of value in 
terms of trying to give some meaning as to why I caught it, how I caught it, 
the types of behaviour that led me to it and how I can change it and how I 
can break it and how I have broken it since then.”   
White European, age 31-35, single, 3-6 months since diagnosis, on ART 
 Adjustment to the diagnosis 5.2.2
Men found different ways to get them through this initial bleak period, amongst the coping 
mechanisms mentioned were meditating, appointing a life-coach and exercising. However, the 
most recurrent theme was that of distracting oneself during this time. Men talked about the 
importance of having something to focus on other than HIV; most commonly a relationship, 
work, a job interview or just being with people. Idleness or lack of preoccupation might result 
in the return of negative thoughts about HIV. For the respondent below, being with his friends 
was crucial over that time period to stop him tormenting himself and to help him deal with his 
biggest fear of being lonely. 
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“The week from when I found out, that whole week, every night, I was going 
to friends’ houses because I couldn’t bear to be on my own. If I was on my 
own my head, my thoughts would start to spiral and I would think more 
about it and I would kind of torment myself in terms of, “Oh my God,” you 
know, and feeling scared and lonely. That was, my biggest thing was being 
lonely. And so I had to be around friends. And when I was around them, I 
wasn’t around them so much even really talking about it, we were just 
having time together, eating dinner, watching TV and stuff. But just to be 
with somebody, it took my mind off of it. And that really helped, having 
those friends around me. And that was really the only way that I dealt with 
it, just to tell a few people close to me and talk to them about …” 
White British, age 26-30, single, <3 months since diagnosis, not on ART 
HIV diagnosis appeared to have less of an effect on men’s life if they had experienced other 
traumatic life events. Men who found themselves in this situation tended to have a more 
pragmatic view of life in which HIV was perceived as not such a big deal.  
“Erm, it's not had an enormous effect.  Erm, in a sense that, you know, I still 
go out and see friends, still you know, go to work and same old job, still 
looking to buy a flat and do all those other things the same … same old, 
same old. Erm, I still, you know, do … take my exercise, all the rest of it, I'm, 
you know, exactly the same. Erm, so I don’t think it's had a major erm, 
effect.  I mean I've, I've been through a couple of erm, fairly major things 
before where I had a erm, a to… completely unprovoked erm, erm, 
homophobic attack in 2004, I was stabbed five times. So that was, yeah, so 
that was just, you know, a random nutter basically. So, I've been … you 
know, I've already sort of come through a few things, I'm a bit more sort of 
philosophical about these kind of knocks that come along because actually, 
you know, what … I'm still here. Still, still the same as I was yesterday more 
or less. So erm, so yeah I don’t, I don’t have too much of a problem there.” 
White British, age 36-40, single, <3 months since diagnosis, not on ART  
Men sometimes attempted to put their HIV into context by comparing their situation to others 
they perceived as worse off, for example somebody who was “dying of cancer” or had no 
money to buy food. This comparison appeared to be a way to maintain perspective on the 
situation, to refocus on the positives and remind them that they are relatively fortunate. HIV 
diagnosis could be easier to deal with if it was followed by an event perceived to be 
comparably worse. One respondent was diagnosed with Hepatitis C very shortly after his HIV 
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diagnosis, which in his opinion made his HIV diagnosis almost inconsequential, as he explains 
below.  
“Erm, no, no in some ways, it’s kind of almost reinforced, it’s almost 
reinforced in my head how the HIV seems like not a problem at all. Whereas 
the Hep it seems like the major problem at the moment and that’s probably 
a bit, because like when I told my brother, I told him about, I was doing it in 
chronological order, there’s something I should have told you before but I 
didn’t want to, I’m HIV, and he was like wow and sat down and goes oh, and 
then you know it was obviously the second one, and I told him about the Hep 
C, and similarly when I told my boss, she said well Hep C, that’s not too bad 
and it’s like well actually I think it’s a hell of a lot worse than the HIV 
personally yeah, but maybe that’s again how I am thinking now but yeah, 
the majority of people I know say that you know you see so many people 
living normal lives, people just saying I take a pill a day it’s fine, and you hear 
some people say oh god I had this treatment and I couldn’t sleep and it’s like 
yeah but you’ve got some choices here, whereas at the moment in the Hep C 
there isn’t really any choice and that’s what you’ve got to get and people say 
it’s awful and they have to have time off work and all the rest of it so that’s 
really in my mind at the moment.” 
White British, age 31-35, single, 3-6 months since diagnosis, not on ART 
For some, the process of re-adjustment involved the men educating themselves about HIV 
often through internet research and sometimes by making contact with other HIV-positive 
people. Sharing experiences with other positive men was perceived as a great way for men to 
educate themselves about HIV from people who had been through the same feelings as 
themselves and helped the men face their fears and worries. However, self-guided research 
and learning about HIV was avoided by some men who were keen to avoid scare stories and 
untrustworthy sources of information. 
 Diagnosis as an impetus for self-reflection and self-improvement 5.2.3
Whilst already having a positive or pragmatic worldview before HIV diagnosis appeared to 
make it easier to accept an HIV diagnosis, some men adopted a more positive outlook on life 
after being diagnosed with HIV. In these men the time following diagnosis was used to self-
reflect and create a plan for self-improvement in all aspects of life, be it work, fitness or sexual 
behaviour. This process could be self-conducted or, in the case of two of the men, facilitated by 
a therapist or a life coach.  
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“It hasn’t affected my life but it has affected it. So it’s hard. I feel … it 
certainly makes you assess your life, and I've done a lot of self-assessment 
recently. And that can sometimes be a good thing and sometimes a bad 
thing. And I've talked to my friends about this and they say, “You can go 
through a time when you beat yourself up,” not just because of HIV but I've 
started, you know, “What am I doing with my life? Where am I going with 
my life?” you know. “Who am I? What am I trying to be? Why am I not 
achieving the goals that I set myself when I was younger?” And you, all of 
that stuff. And I think that that, for me, I’d be worried about getting into 
depression and things like that if I let myself go down that route.  So I try not 
to. But it does make you assess your life a lot, and about who you are as a 
person and where you want to be. And some of my friends, that’s been a 
really positive thing, it’s made them want to go to the gym more, it’s made 
them want to look after themselves more and be healthy and fit, and not go 
out partying all the time, you know. So it can have a good effect on your life 
as well.”  
White British, age 26-30, single, <3 months since diagnosis, not on ART  
 
One man, who reported experiencing a severe bout of depression following his diagnosis, 
related the moment he decided he had to take some action. For him, setting a strict gym 
routine allowed him to feel better about himself and combat the depression. It put him in a 
better mental place to turn his life around and start his own business.  
 
 
“I was so depressed and I was crying every single day, how sad is it, since 
September every single day I was crying, I wasn’t even talking, the sound of 
my voice was irritating me.  If you get to this point, I tell you what, you have 
only one way or you get up and do something or you barricade yourself 
because of, what is the point to be like ... I wasn’t even a vegetable, I was 
like rotting, so and I then looked at the cigarette and said I’m going to finish 
you and you’re going to be the last cigarette I smoke. So I throw the 
cigarette, I throw the weed, on the sanitary and I flush it, because I knew 
that if I would put it in the bin, after I had a few sweets and probably some 
snacks from the fridge I would definitely searched for the weed in the bin, for 
the weed. And then I put the alarm on, I put my two alarms, my two mobile 
phones I put the alarm on, I woke up at 6.30, by 7.30 I was at the gym and 
then I started to go the gym since early February for 5, it varied between 3-6 
days a week. Then later on in the morning before I go to work, and that’s 
how I, you know made me like ... I think probably the ... it also makes you 
feel healthy, it makes you feel part of that group that you would like to be 
and you work hard and then you go to the mirror before you get changed 
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and then you take your wet shirt off and you look at your tummy and your 
chest and you feel good, you go to work with a different attitude. ” 
Black South American, age 36-40, single, 3-6 months since diagnosis, not 
on ART 
 Effect on relationships 5.2.4
Men described how their HIV diagnosis put strain on relationships with family, friends and at 
work, as well as their sexual relationships. The urge to talk about the HIV diagnosis straight 
after receiving it was strong in many of the men. Of the men interviewed all but one had 
disclosed their status to someone outside of the clinic, be it friends, family or work. The one 
man who had not disclosed felt it was unnecessary as he did not want people to “treat him 
differently” or “feel sorry” for him. He did, however, disclose his status to casual sexual 
partners he met online. In his mind there was a clear distinction from people he had sex with, 
and would not see again, to the people he cared about and had meaningful relationship with.  
5.2.4.1 Friends and family 
There was a need to be selective about who could be told about the diagnosis. Most men told 
one or two of their closest friends shortly after diagnosis, and only ever the people they could 
totally trust. Pragmatic decisions had to be made as telling the wrong people could result in a 
loss of control over who knew, or a change in the relationship dynamic because they felt pity 
towards them. In the worst case scenario men feared rejection from their friends. One man 
had a particularly bad experience with his best friend who shut off contact after he disclosed 
his HIV status, resulting in deepening feelings of despair and isolation at a time of already 
heightened stress.  
Telling another HIV-positive friend brought the benefit of having a shared experience and being 
able to relate to each other, without the pity. Men who disclosed to HIV-positive friends talked 
of being able to “talk science” together, of their shared understanding of the situation and the 
ability to support each other in confidence without the risk of judgement. In many cases this 
resulted in a closer friendship.   
“My first instinct was I need to tell someone, I need to share this with 
someone because I felt it was so hard to just be myself, and so I, I told a 
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good friend of mine who is also HIV and I knew that he was HIV and we were 
open, and in a way it was good because it makes our friendship really strong, 
so we can support each other.” 
White South American, age 41+, single, <3 months since diagnosis, not on 
ART 
“RES:  “I've subsequently met one person through the internet who is also 
positive … who I kind of knew from the gym about six years ago. And 
having him has been really helpful, because he’s been kind of a 
stranger but a friend, do you know, I’ve only just met him… through 
finding out, and that’s, to talk to him has been really helpful. He’s 
been very kind. 
INT: And is he at a similar kind of phase? 
RES: No, he’s been positive for four years. He’s on medication now. He’s 
kind of, I think he’s dealt with it a lot. But he had no-one, when he 
found out he didn’t tell anyone. He didn’t know anyone else that was 
in the same situation, so it was quite lonely for him, and I think that 
he’s met me and he wants to kind of be the person that he didn’t 
have. Which is really sweet of him. 
And he’s been really supportive, phoning me a lot, coming round to 
see me, talking to me about his situation, I've been talking to him 
about mine and the problems that I've had. And that’s been a huge 
help. I think me talking to other people that are HIV-positive is the 
biggest help. Talking to people that are not HIV-positive doesn’t really 
help, to be honest, because they don't understand what, they don't 
really understand what it’s like. They can feel sorry for you and talk to 
you about it but it’s a big help to have someone who you can say, 
“What's your CD4? What's your viral load? How did you feel? Who did 
you tell? Did you get sick? Did you not get sick? Do you know who it 
was?” All of those questions, to have something in common with 
someone helps massively.” 
White British, age 26-30, single, <3 months since diagnosis, not on ART  
 
A common theme amongst the men was the unwillingness to disclose their HIV status to their 
family. Oftentimes men explained that their parents just would not understand and that they 
“did not cope” or “struggled to come to terms” with them being gay so telling their parents 
they were HIV positive was out of the question.  
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“RES:  I absolutely can’t tell my family, they’re bananas so ... my mother’s 
quite mentally ill, she’s bipolar so she’s not going to deal with it. And 
my sister won’t keep her mouth shut and so if I’m not telling them, I’m 
just not going to tell any of them, they don’t need to know. 
INT: So do they know that you’re gay? 
RES: Yeah, they do and they’re sort of fine with all of that, in their sort of 
Daily Mail reading way. You know they’re fine with it as long as I’ve 
got some nice clean cut guy and I’m going steady with him and 
they’re not fine if they think anything vaguely progressive is 
happening. You know, parents ... as long as I don’t get my ear pierced 
they’d be very understanding, because that’s what they think being 
gay is, you know and that’s what they’ll think HIV is, they’ll think it’s 
all grubbing around in seedy nightclubs they just won’t understand 
anything.” 
White British, age 31-35, <3 months since diagnosis, not on ART 
Other times, non-disclosure was a way of protecting their family from extra stress when it 
wasn’t necessary. Disclosure to family tended to occur with siblings rather than parents as they 
were often perceived to be more worldly. Some of the negative feelings experienced at 
diagnosis centred on the idea of “letting people down” by catching HIV; two men explicitly 
mentioned that their parents had told them not to catch HIV when they first came out as being 
gay. Other men “felt bad” for not telling their friends and family but hoped they would 
understand the reasons why, if or when they did choose to disclose in the future. 
5.2.4.2 At work  
The men interviewed came from a broad range of occupations and whilst many men notified 
work because of the time they would need off for appointments, for a few men, being 
diagnosed with HIV created a crisis over whether they would be able to continue in their 
current job or career. One respondent was in the medical profession and knew that he had to 
notify occupational health immediately, but was unsure how it would influence his career. 
Another man was a teacher who was worried about the “inbuilt ignorance” amongst parents 
towards HIV-positive gay men working with children. For him, being diagnosed with HIV meant 
he wanted to take a job in a university and get away from the risk of encountering stigma at 
work. 
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5.2.4.3 Long term partners 
For the men who had an HIV negative partner at the time of HIV diagnosis, the period 
immediately following diagnosis was regarded as particularly stressful. This was due to the 
added worry that they may have transmitted HIV to their partner. Men related their tales of 
calling their partners to the clinic to be tested and the anxious wait for the result.  
 “I can talk about it now because I’ve done a lot of work around this, but it 
wasn’t and then the horrible thing was I did have unprotected sex with my 
boyfriend was the fear that I had infected him and that horrible window 
period between you know and me obviously feeling like I’m the scum of the 
earth so yeah ... it was horrible, I mean he was in complete shock but oddly 
enough we still couldn’t keep our hands off each other if you see what I 
mean, like literally days later it was really. It was really awkward and 
horrible because I then went to, the day I got diagnosed, he came over, he 
got tested straightaway and that was negative, he then came with me to the 
other clinic just next door and then I had a chat with the nurse or doctor I 
can’t even remember and then we sort of parted ways, and it was like erm 
okay I’m completely on my own now, so a) I had to deal with the fact that I 
was HIV positive and I lost my boyfriend, in the space of 2 hours and then 
erm there was still contact going in him sending messages and me sending 
messages and then we met again a couple of days later  and it was really a 
very intense conversation and somehow we ended up in a hotel in Kings 
Cross having a drink and then ended up booking a room there and sleeping 
with each other because it was just like so, we couldn’t let go of each other 
and it was so much to. And that continued for weeks on end, he disappeared 
for a while then we sort of got back together I suppose erm and you know 
gradually I think he sort of accepted it, about 6 weeks later he had his final 
result back saying that he was negative so that helped and erm throughout 
we were still seeing each other.” 
White European, age 31-35, single, 3-6 months since diagnosis, on ART 
Maintaining a serodiscordant partnership was testing when barebacking was a feature of the 
relationship prior to HIV diagnosis. Men could be put under pressure by their negative partner 
to continue to bareback despite the risk of transmission and refusal to do so invariably led to 
stress on the relationship. Interestingly, one man perceived his HIV negative partner’s 
insistence to abandon condoms as a loving gesture, as their partner still wanted the same level 
of intimacy despite the risks involved.  
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“Yeah, well obviously I got back with my ex that night and that was, yeah, 
yeah it was weird, it was very weird to start with, erm I kind of wore a 
condom and whatever, but I was kind of nervous about kissing him too much 
and things like that, erm ... and then but then he piped up with the idea of 
let’s not use condoms which I was really unhappy about and I said why?  And 
I refused point blank then for at least a month, but then at the same time, 
every time I insisted on using a condom he was like looking at me like it was, 
he was really annoyed and so in the end we started, you know, so, it’s your 
choice and in some ways that’s really sweet if that’s the case” 
White British, age 31-35, single, 3-6 months since diagnosis, not on ART 
Men reported experiencing very intense emotional feelings of desire and love for their partners 
after receiving their HIV diagnosis, and it even appeared to reignite one relationship. These 
feelings could be short lived, however with the practicalities of navigating through the 
emotional upheaval of receiving an HIV diagnosis and the stress and worry of transmission. For 
two respondents, being diagnosed resulted in a closening of the relationship with their long 
term partners: one whose partner was, and remained HIV negative; and one whose partner 
was diagnosed HIV positive at the same time. Common to both of these couples was the 
concept that HIV was a collective journey that both members of the partnership took together, 
from educating oneself about HIV to attending appointments together, even in the case of the 
serodiscordant couple.   
 Finding a new sexual identity 5.2.5
Sexual behaviour could change significantly following HIV diagnosis, for a variety of reasons. 
Amongst men who did not have long term partner at the time of diagnosis, conscious 
abstinence was adopted by some, this was called different things by different men from acting 
like a “nun”, a “virgin” or a “priest” to taking a “year of cleansing”. Men reported a range of 
reasons underlying the decision to remain abstinent. Some experienced a total lack of interest 
in sex, linked in some cases to a depression following HIV diagnosis or the feeling of being 
“dirty” or “infected”. This was usually acknowledged as a temporary state, that these feelings 
will probably change given time. 
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“INT:  So, would you say that the diagnosis has had an effect on your sex 
life? 
RES: Well I mean it’s just completely obliterated any notion of it.  You 
know I’m not really part of that big sexual gay scene anyway. You 
know secretly I’m quite middle class and I just want a Labrador and a 
husband, I don’t really, I’ve never really been part of that scene and 
I’m, I’ve no interest in the grubbiness of it, you know. I think, but I do 
feel quite dirty, I’m told I’m ill, it’s odd, you know I might buy shares in 
hibbiscrub or something, I’m sure it will pass but you know, but 
effectively one ought to be less infectious if there’s any way to do it.” 
White British, age 31-35, <3 months since diagnosis, not on ART 
For other men, a feeling of sexual desire was still present but the actual practicalities of having 
sex were off-putting. Sex minus all the social and emotional factors was perceived as just a 
mechanical act.   
 “I’ve been a virgin…it’s just I find it really, really hard at the moment to 
come to someone and say look I’m HIV positive would you like to have sex 
with me [laughs]… It is not a very easy thing to do , and I need to tell people 
and obviously they have to know and so they can take all the 
preparations[sic]…It’s not that I don’t feel horny or anything like that, I do, 
it’s just that it’s not the same… For the time being, I know it will come back, I 
know things will probably change but it’s just like having sex for the sake of 
having sex…Maybe I should become a priest or something,” 
White South American, age >40, <3 months since diagnosis, not on ART 
Men described a huge fear of rejection from sexual partners. Experiencing stigma in the most 
intimate part of their life at a time where confidence and self-esteem were already low was too 
much for some men to cope with. In these cases, abstinence became a mechanism to protect 
from further negative feelings and emotions such as worry and anger.   
 “I think the fear of rejection is quite strong, even though when you think 
about it actually if people knew 20% of London and gay men are HIV positive 
a lot of them are not on medication, the amount of people I must have slept 
with who had HIV that I didn’t know, and didn’t tell me, didn’t even know 
themselves, so somebody telling you that they have it but they’re on 
medication should actually reassure them to some extent but it’s a really 
tricky one and I don’t know, and that’s part of the reason why actually I 
don’t want to worry about it at the moment, that’s why I want this cleansing 
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I don’t want to have to tell people and deal with the rejection because I get 
very angry.” 
White European, age 31-35, single, 3-6 months since diagnosis, on ART 
Serosorting for positive partners was another strategy which was adopted by men keen to 
avoid experiencing stigma after diagnosis. Men who had met HIV-positive casual partners 
before they were diagnosed, often contacted these partners after diagnosis as it was perceived 
as “safer” and a way to avoid “getting hurt” by rejection. 
“I was, at first, terrified of having sex. And I have had sex since I found out. 
I've had sex mostly with other people that are HIV-positive that I have known 
about or known of, or whatever. As I said, I've always been quite open, I’m 
not, when I was negative I wasn’t the sort of person that would not have sex 
with someone that was positive. So I had met people that I’d known over the 
years who had, perhaps, been casual sexual partners that I knew were HIV-
positive. So I kind of contacted them, and spoke to them, a) someone to talk 
to and, b) because I knew that they were in the same position as me and I 
could have sex with them without, with the guarantee of not having that 
question of, “Are you positive?” and then you have to say, “Yes,” and they're 
not. And I’m not ready for that stress right now of someone freaking out that 
I’m positive and they're negative.  So for me, it’s a safer option to have 
sex with someone that’s positive right now.” 
White British, age 26-30, single, <3 months since diagnosis, not on ART 
The internet was another method used to meet positive partners. By updating their Gaydar or 
Grindr profile to include a reference to their HIV-positive status, men felt that their partners 
would know what they were getting into before they even make contact. This was not a fool 
proof strategy however, as one of the respondents pointed out he often met guys online who 
didn’t bother to read the profile and only looked at the pictures. Men who used the internet to 
source partners before tended to report less of an impact of diagnosis on sexual behaviour.  
“It's not really changed much to be honest. Just, erm I'm just meeting more 
people that are also positive or on treatment.  I don't know ... we can ... you 
know we don't need to, erm pass that hurdle of telling each other.  It's not so 
much of a shock.” 
White African, age 31-35, single, 3-6 months since diagnosis, on ART 
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Being diagnosed with HIV could bring with it a sexual liberation, and could result in a more lax 
attitude to using condoms. However this did not necessarily reflect a carefree attitude to sex as 
there was a notable degree of coquettishness or even shame in the narratives of the men, who 
often described their barebacking as a “bad” thing or something to be regretted.  
“I think my attitude to unprotected sex has actually got worse since the 
diagnosis.  It's also worse at times but I also switch between moods very 
easily, I've got it, doesn't matter now, other times, like I said, don't be 
ridiculous, so I don't know.  That's bad because I consider myself quite 
educated on the subject but I considered myself educated on the subject 
before.  And if I'm thinking these sort of things then people who don't know 
as much about it and aren’t as aware, are really going to get screwed over.“ 
White British, age <25, single, <3 months since diagnosis, on ART 
Men who had actively sought HIV-positive partners since receiving their diagnosis, either on 
the internet or out and about in bars, clubs or saunas, reported an external social pressure to 
bareback now they were HIV positive. This could be hard to resist in different situations, 
especially where recreational drugs such as crystal methamphetamine were involved and 
senses were dampened.  
“It goes back to the whole bare backing thing that I’m still now, I’m now 
really struggling to get to terms with because when you’re negative and you 
say no I’m negative I only play safe people understand. But now that I’m 
positive, kind of people look at you weirdly if you say I only play safe. And it’s 
like well you’re positive, so yeah in the last few months I started playing not 
quite safe and look where it’s got me so [a Hep C infection]” 
White British, age 31-35, single, 3-6 months since diagnosis, not on ART 
Amongst the men not so involved in the London gay scene, serosorting for HIV-positive 
partners was described as a very strange process. Having spent their adult lives avoiding HIV 
they would not have considered a positive partner prior to diagnosis because of the potential 
risk of contracting HIV. To go against these lifelong practices took some getting used to and 
also resulted in some guilt now the shoe was on the other foot.  
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“INT: I was going to ask has it changed your sex life since having the 
diagnosis? 
RES: Oh yes, yeah definitely.   
INT: Have you had any sexual partners since ... ? 
RES: I have but that was, but that ... I knew they were HIV positive which 
was kind of ... which was a bit strange.  But, yeah.  
INT: Just out of interest, how did you meet them? 
RES: So when I was at university I was, erm, I kind of did some training to 
kind of be in a, kind of like ... not a counsellor, that's the wrong word, 
but some kind of training to support other people that were in the 
college that I was in.  And there were some people there that I have 
picked up, I was kind of like friends with who they'd ... we were kind of 
sort of advertised at the college for the people to come to talk to you 
if they had issues they needed to.  And one of the things that 
somebody came to talk to me about was they had been diagnosed 
with HIV.  So that was the first ... that same person was the first 
person that I spoke to on the day of the diagnosis and it was through 
him that I met other people that he knew and then ...  Yeah.  
INT: And so, you said it was weird, can you kind of expand on that a little 
bit? 
RES: Well weird just because, err, erm, it's odd because it's not something 
that I would have done if I'd have been HIV negative…  
 Well because I would have made every precaution to avoid it.  Like 
when I went to Ethiopia, I got all my own needles in case I ever need 
any operation.  I did everything to avoid the risks of it, so I wouldn’t 
have had sex with somebody who's HIV positive knowingly 
beforehand.  Erm, knowing so much more about it now ... I did ... I 
was fairly informed six months ago but I know a lot more now 
because the amount of reading I have done.  And kind of now 
understanding that the risks involved from somebody who is on 
medication and who does have undetectable viral loads and all the 
rest of it, I probably would have had a relationship with somebody 
who was. But, not have ... it's kind of a lot of education that I've had 
to have to be able ... to have thought that in hindsight.” 
White British, age <25, single, 3-6 months since diagnosis, not on ART 
Men engaging in casual sex often strove to select seroconcordant partners and use condoms, 
but this was not always achievable. Serosorting was often acknowledged as particularly difficult 
 180 
 
when recreational drugs were being used and in group sex scenarios. Two respondents who 
regularly engaged in group sex using crystal methamphetamine acknowledged the lack of 
control they experienced whilst high, and how they often could not remember what had 
happened after the event. The respondent below relates the importance of crystal meth to his 
enjoyment of group sex and in particular fisting, along with the hazards of not being totally in 
control. This incident occurred at a party after his HIV diagnosis and just prior to his diagnosis 
with Hepatitis C.  
“I’m fully aware that they probably do make you take risks that you wouldn’t 
normally take, you know, any risks that I took were, again, well yes, making 
you less aware of what’s happening around you, so yeah like the time 
before, I remember just someone had been inside someone else and then he 
put his hand straight in me, and it was like oh, oh well, it’s happened now I 
can’t, there’s no point in ... but kind of said make sure you wash your hands 
next time, but yeah it kind of it sort of dampens things down but it kind of 
maybe ... yeah it takes a few hours to get ready for fisting and then if you 
haven’t got any drugs it kind of, it seems you spend more time getting ready 
than actually enjoying yourself which kind of then seems a bit wrong so the 
drugs are maybe drag the thing out and it’s quite sociable and chatting and 
whatever” 
White British, age 31-35, single, 3-6 months since diagnosis, not on ART 
 ART knowledge and expectations of when to start 5.3
Knowledge about ART was varied amongst the respondents but in general, men were relatively 
well informed about HIV and treatment. The most commonly cited sources of information 
about HIV and ART were their HIV clinicians, HIV-positive friends and partners/ex-partners, the 
internet and previous GUM clinic visits. After receiving their HIV diagnosis, a few men attended 
a newly diagnosed course which ran at the clinic and recommended the experience highly.  
The internet was used prolifically for information gathering after diagnosis with Terrence 
Higgins Trust (THT) and NAM, in addition to HIV-positive and gay forums, being accessed to 
understand more about the course of HIV and people’s experiences with ART. For some men 
though, seeking information on the internet was seen as a hazardous activity as it was difficult 
to avoid opinion pieces and sift out the “scare stories” from the real facts. HIV forums in 
particular divided the men, with some men using them profusely, and others just not being 
able to “identify” with the men who post on the forums.  
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When asking men to recall their expectations about starting ART when they were first 
diagnosed, a few respondents demonstrated a very low level of knowledge about HIV and the 
typical course of infection. Amongst these men, the delay to starting treatment after their HIV 
diagnosis was a big surprise. HIV was such a big deal to them that they could not fathom the 
idea that somebody diagnosed with HIV would do nothing after diagnosis for potentially a 
number of years. They assumed that they would be starting straight after diagnosis. As one 
man elaborated:  
“I’m coming from a point of absolute ignorance, all I know about AIDS is how 
not to get it, I don’t know anything about what happens now. I just assumed 
that the second you got diagnosed there would be this flurry of medical 
activity and you would end up on lots of tablets and I’d feel like shit for a few 
weeks and then things would go back to normal… But I didn’t really, it didn’t 
register, it never occurred to me that you wouldn’t be starting treatment 
instantly anyway.”  
White British man, age 31-35, single, interview <3 months of diagnosis 
At the opposite end of the spectrum, I interviewed men who were incredibly knowledgeable 
about HIV treatment and knew about some of the key clinical trials and research studies, for 
example SMART, START and VISCONTI (Virological and Immunological Studies in Controllers 
after Treatment Interruption), a cohort study of 14 seroconverters who maintained virological 
control for at least 24 months after stopping treatment initiated in PHI 214. This knowledge was 
usually, though not always acquired after HIV diagnosis, through the leaflets that were given to 
the men upon diagnosis, websites such as NAM, the THT, and through discussions with their 
HIV clinician as well as other HIV-positive men. Men who were more knowledgeable on ART 
appeared to be more likely to be aware of the difference in national treatment guidelines 
between the US and UK. 
An interesting finding from the interviews, was that a strong expectation to start ART shortly 
after diagnosis was observed in those who were at polar opposites on the treatment 
knowledge spectrum. Men who had very limited knowledge of HIV were as likely to report the 
expectation or desire to start immediately as those who demonstrated the fullest 
understanding of the potential benefits of early ART and differing treatment guidelines 
worldwide. Those less knowledgeable appeared to be willing to try it, so long as there were no 
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huge health risks, and those more knowledgeable tended to believe that there were health 
benefits associated with early ART initiation and this neutralised any risks of starting earlier. 
 How do MSM with recent HIV infection feel about early ART? 5.4
As outlined in section 5.2 and 5.3, HIV diagnosis can be a highly emotional time for men with 
recent HIV infection, with their reaction to the diagnosis dependent on many personal and 
social factors. The experience of HIV diagnosis and the social and personal context it occurs in 
may partially dictate men’s feelings towards ART.  Thematic analysis of the transcripts to 
answer the research question “How do MSM with recent HIV infection feel about early ART?” 
revealed four overarching themes:  
 Treatment as a responsibility  
 Treatment as a source of fear and uncertainty 
 Treatment as an empowering force 
 Trust before treatment. 
These four themes encapsulate the men’s underlying attitudes, beliefs, assumptions and 
knowledge about HIV and treatment.  Figure 5.1 is a diagrammatic representation of how 
men’s feelings towards early ART sit within the broader landscape of their personal reaction to 
HIV diagnosis. A multitude of personal, social and environmental factors influenced men’s 
reaction and adjustment to their HIV diagnosis and are presented in the outer circle of figure 
5.1. These factors in turn also held influence over how men felt about early ART, as explained in 
the identified in the next section.  
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Figure 5.1 Conceptual diagram of MSM’s feelings towards early ART in the context of factors which influence their personal reaction to being 
diagnosed with recent HV infection 
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 ART as a responsibility 5.4.1
The decision to start ART was perceived by men to come with a great deal of responsibility. 
This responsibility could be further categorised into both internal responsibility (a personal 
responsibility to themselves and their own health) and external responsibility (a 
responsibility to partners).  
5.4.1.1 The internal responsibility to protect one’s health 
Health was often presented by the men as a holistic concept, with going to the gym, 
exercising, giving up smoking, eating healthily, sleeping more, not “partying” too hard and 
not taking so many recreational drugs were all mentioned as things that should be done to 
improve individual health alongside HIV treatment. Men spoke of a responsibility to look 
after their own health, with starting HIV treatment at the right time an integral part of this 
concept. 
Respondents could be generally categorized into those who believed treatment was to be 
initiated when CD4 count dropped to 350 or when the doctor tells them that they need to 
start, and those men who saw starting treatment as their own decision to make. Early 
treatment did not necessarily feature in a health context as a positive thing. Some men 
mentioned their concerns about the side effects of treatment and worries about resistance 
in the long term having a potentially negative impact on their health. In these cases, men 
leaned towards putting off treatment until such time as they felt they needed it or, were 
told they needed to start by their doctor.   
Amongst the men, there was a feeling of responsibility to maintain good mental health as 
well as physical health. The avoidance of the additional stress and worry of transmitting to 
sexual partners, if undetectable on treatment, was perceived as a big advantage to starting 
treatment early. However, starting treatment very soon after diagnosis could add another 
source of stress whilst men were already not in a very good mental position whilst still 
assimilating the HIV-positive diagnosis. 
“But I think, with HIV, there’s two big hurdles: there’s finding out that 
you’ve got it and then there’s going on some tablets for the rest of your 
life. A big hurdle. And that’s something I don’t feel I’m ready for just yet… 
It would be too much of a – a head fuck, sorry… I couldn’t think of a 
better word for it. I’m only one month diagnosed. I need to absorb that, 
become happy with that, before I can then, in my mind do the next 
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hurdle which is medication. But if I had to, because of my health was 
terrible, I would do it right now.” 
White British, age 26-30, single, <3 months since diagnosis, not on ART 
This reaction appeared to most affect men who had strong beliefs that side effects were 
inevitable, and seemed linked to their fears about ART.  
“What a lot of people know about the treatment is what it was like 
maybe ten years ago. I mean, it was very sort of, you know, toxic, and 
that’s what I imagined anyway. So I think that that would have been in 
my mind, that, “Oh God, that’s it then.” It would have brought it home 
much quicker and much … and also, the fact of having to take a tablet 
every day and kind of having those side-effects early on, when you're not 
in a very good mental position, I think wouldn’t necessarily be positive if 
it’s not absolutely necessary.”  
White British man, age 26-30, in relationship, 3-6months since 
diagnosis, not on ART 
Taking personal responsibility for the decision of when to start ART was not universally 
embraced; some men perceived the decision when to start as their clinician’s job and they 
would do whatever is recommended by them. Amongst the men interviewed, this total 
deference to medical expertise appeared to have two underlying explanations. Firstly, the 
clinicians were seen by some men to be the ultimate experts with many years training and 
expertise in HIV. This perceived wealth of knowledge and understanding held by the 
clinician was enough for men to accept the clinician’s advice, sometimes with little input 
from themselves. Secondly, a total deferral to medical opinion could also reflect a personal 
indecisiveness about whether early ART was a good or bad idea. The men below recount 
their desires to avoid uncertainty and to be told by the clinician when to start, instead of 
being asked their opinion.   
“I would have followed medical advice, so in a way I wouldn’t have 
wanted to be asked if I want to, it's more we recommend that you do or 
we recommend that you wait until then, so yeah.  I don't want the 
uncertainty in a way, there is that grey area that's not understood yet…  
But in a way I don't want to have to make that decision myself, I want to 
be told what's the best thing to do and I don't ... well that's the thing the 
science doesn't know exactly, erm.  So that, that's ... basically I want to 
do the best thing but the science isn't sure, and some of the tests have 
been misleading because of the cross sections they've used to come up 
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with the results.  So it's hard for me to make my mind up if I want to start 
or not or if it matters when I start.” 
White British, aged 21-25, single, 3-6 months since diagnosis 
Maintaining quality of life was mentioned by most men as the ideal end goal in the decision 
as to when to start treatment. This was commonly framed as a compromise between 
starting treatment sooner rather than later to give their health the best chance, and 
avoiding the medication as long as possible to avoid the possible side effects. Men placed 
great emphasis on being able to enjoy life to the full now, with what will happen in the 20-
40 years’ time something very “abstract” to them.   
“I don't really think long-term so I'm not sure.  Erm, I just think about 
now so I want a better life now. I'm not too bothered about living until 
I'm 70, so.  You know, I don't even know if I want to but, erm I just don't 
... I want to have a good life in the now, not ... you know.  And I still want 
to be healthy, I want to be healthy.” 
White African, age 31-35, single, 3-6 months since diagnosis, on ART 
Taking tablets every day for the rest of their life could be a huge responsibility in itself, and 
put some men off starting early. Age seemed to be an important factor here, with younger 
men in particular struggling with the responsibility of committing to something so long 
term. The older men, on the other hand, appeared more able to deal with this, possibly 
because were likely to be on other medication by this point in their lives. As one man put it, 
he was already taking daily tablet for blood pressure so it is not such a problem to take one 
for HIV at the same time.   
5.4.1.2 External responsibility 
There was much discussion around the responsibility to protect sexual partners from the 
virus and how early HIV treatment could be used to this end. Protecting partners, like 
health, was largely presented as a holistic theme, with TasP was just one of many strategies 
discussed by the men. Men largely understood and believed the reduction of transmission 
risk afforded by TasP, however, a diverse range of opinions were offered over the personal 
responsibility to protect partners.  
Two motivations for using ART to reduce transmission risk appeared in the data. The first 
was based on the concept of altruism. Men reported situations in which they might feel a 
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“sense of duty” to protect their partners from HIV, though this was mainly framed in the 
context of long term HIV negative partners.  For these men, the potential personal health 
sacrifices of starting early could be offset by the desire to protect their long term partner 
from all the stress, worry and lifestyle changes that they were experiencing. 
“I knew that once you’re undetectable it’s very, well I don’t know this, 
but I have been told that it’s very unlikely that you’ll pass it on, and still 
seeing [name of HIV negative long term partner] I thought that was the 
least I could do, to reduce the risk for him.”  
White European, aged 31-35, single, 3-6 months since diagnosis, on 
ART 
“I know a friend that started because he was seeing someone who was 
negative and he did that, and I suppose that would be a point on an 
altruistic but on a very visible scale because that’s the person you love 
and you’re with”  
White British, aged 31-35, single, 3-6 months since diagnosis, not on 
ART 
But using treatment to reduce transmission to others was not always presented as an 
entirely altruistic ideal. One individual neatly expressed two intrinsic benefits to starting 
ART to reduce transmission: namely avoiding the guilt of transmission, and increasing 
sexual confidence. 
“I don't think it is entirely an altruistic reason. I mean, it’s like, you do 
want to protect the person that you're with, and whatever. And also, 
like, if I were to pass it on to someone else I would feel guilty and, you 
know, that would be … And also, just knowing that the chances of, even 
if there was, you know, an accident, or whatever, that it wouldn’t, that 
the chances would still be very low of you passing it on. I think that 
would just, like, make me feel more kind of confident about having sex, 
and things like that. And, you know, reassuring other people as well… 
that there's, you know, not much risk” 
White British, aged 26-30, in relationship, 3-6 months since diagnosis, 
not on ART 
The responsibility to protect sexual partners was not universally felt, particularly in men 
who were still angry about contracting HIV. These men tended to feel that “it takes two to 
tango” and that HIV negative partners should take equal responsibility to protect 
themselves from HIV. When asked whether he would consider starting treatment early 
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purely to reduce the chances of transmission, if there were no proven health benefits to 
himself, one respondent answered:  
“It’s hard, it’s a very ... God you could have a debate about and ... 
Because I would say well no one did it for me and you know whatever at 
the time same point I was trying to play safe and so I managed to get it 
and so yeah I suppose catch me on the right day”  
White British, aged 31-35, single, 3-6 months since diagnosis, not on 
ART 
When discussing TasP use in the wider MSM population, many men held strong beliefs that 
reducing the population viral load could create a “healthier society” and was as a good 
idea.  
“I know that they offer the treatment once you get to a certain point on 
your CD4 count which is 350 below ... erm and they are thinking about to 
do from 500 below because of the fact that if the people get an 
undetectable virus then obviously there’s less chance for them to pass to 
other people, so if everybody gets undetected virus on their body, so ... it 
would much, much, it would be a way it’s putting the virus to other 
people and it would be a much healthier society actually which I think is 
quite a good idea, because if everybody is undetectable so why erm if 
you keep on having sex because I’ve seen loads of people having 
unprotected sex, they don’t care.”  
Latin American, aged >41, single, <3 months since diagnosis, not on 
ART 
However, whilst public health benefits of TasP were acknowledged, the perceived personal 
sacrifice of experiencing side effects and long term toxicities could put men off until such a 
time as it was needed for their own personal health.  
“I know there some talk of moving up to 500 which in my opinion then 
makes me wonder whether it’s actually treating the population rather 
than necessarily treating the individual because obviously then that’s 
good to stop infecting other people which I can understand, but from a 
purely selfish point of view, the side effects, there will always be some 
side effects and I think they’re getting better all the time and they’re 
saying the cardiovascular side effects, so from a selfish point of view I 
would rather stay off treatment as long as I can, but then I’m not scared 
of, you know when I need it, I obviously need it.”  
White British, aged 31-35, single, 3-6 months since diagnosis, not on 
ART 
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Whilst TasP was seen as a great option, it was not always perceived as a reason to give up 
having protected sex. For some men, any risk of transmitting, no matter how small, placed 
too much worry or stress on them so men talked of the necessity of continued condom use 
in conjunction with TasP.  
 “I know of stories about people that have had unprotected sex, you 
know, a negative person having unprotected sex with a positive person 
who’s undetectable, and thinking that that’s okay. I do know that the 
chances are much more reduced. I think that that is true. I wouldn’t 
personally want to do that because… I've said to my friend, “I would hate 
for someone to say that I've given this to them.” I don't ever want to be 
that person. Because I know, as a, although I don't hate the person that 
I’m pretty sure gave it to me, he will always be in my head, I will always 
remember him. And I don't want to be that person in someone else’s 
mind. I’m quite a genuine, honest person and I don't, I couldn’t cope with 
that myself.” 
White British, age 26-30, single, <3 months since diagnosis, not on ART 
Interestingly a few men felt a responsibility to help others who find themselves in their 
situation in the future by engaging in HIV treatment research, be it interviews like this or 
clinical trials. The feeling that they were benefitting from those who had engaged in the 
past made men feel like part of a community, and it was their duty to do the same for the 
next generation.  
“I understand that the only way that so much is known now about it is 
because people have gone through trials of different kinds, and stuff like 
that. So, I think, I do feel like I’m part of, I don't know, a community I 
suppose and, like, whatever. So I think, in order to increase knowledge 
about it as well.”  
White British, aged 26-30, in relationship, 3-6 months since diagnosis, 
not on ART 
“I’ve told myself, as soon as I found out about this, that I want to help as 
much as I can. Hence, why I’m here now.  I will take an hour out of my 
week, every week, to do something like this if someone wants me to, 
because it really is important to me, you know. I want to help people and 
I want to get as much understanding of this as possible. So I understand 
the value of research.”  
White British, aged 26-30, single, <3months since diagnosis, not on ART 
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 ART as a source of fear and uncertainty 5.4.2
Receiving an HIV diagnosis was a very stressful time for the men interviewed, with many 
emotions to deal with and uncertainties to face as outlined in section 5.3.  These newly 
diagnosed men experienced many worries over the unknown entities in the weeks 
following diagnosis, with a multitude of questions arising about what to expect in the future 
and how HIV would affect their quality of life. The prospect of starting ART brought with it 
an additional set of unknowns and uncertainties in the form of fear of side effects and 
toxicities, drug resistance, treatment duration, uncertainty of scientific evidence and ART as 
a marker for attracting HIV stigma.  
5.4.2.1 Fear of side effects 
Concerns over the potential side effects of ART were universally mentioned by participants 
as a source of worry and potential barrier to initiation. Side effects – as described by the 
respondents - fell into those experienced in the short term when they start taking therapy 
(for example diarrhoea, vomiting, night sweats, dizziness) and long term side effects 
(cardiovascular, liver related, neurological) commonly referred to in medical literature as 
toxicities. Interestingly, long term side effects brought with them their own set of 
uncertainties as they were perceived to be less well researched, so more of an unknown 
entity. 
“Yeah. I mean, I still, one thing that I still don't feel I is fully been 
answered but, is sort of what the long-term effects of the treatment are. 
And I mean, I don't know if that’s because it’s not completely known, 
because these treatments haven't been, you know, used for that long, I 
mean, relatively. So I think I’d want to know a bit more about that before 
I decided. Because obviously, once I start, that’s it then, you have to keep 
taking them. So yeah, I’d want to know a bit more about that, effects on 
my liver and so on, and whatever.”  
White British, aged 26-30, in relationship, 3-6 months since diagnosis, 
not on ART 
Whilst most men appreciated that they were in no way guaranteed to experience side 
effects, this did not detract from the fear of them. For some men the fear of side effects 
was based on previous experiences with PEP, for others it came from the experiences of 
HIV-positive friends or partners. Interestingly, the men’s views of ART were often 
acknowledged by themselves as being “old fashioned” or based on outdated information, 
but despite this acknowledgement the fear remained. 
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“My view on treatment was a little bit old-fashioned, I think, because of 
my experience ten years ago. My ex used to take, I would guess at 
around 20 big tablets a day, that he used to take twice a day, and they 
used to make him ill and give him diarrhoea and no appetite. And they 
used to make you lose weight and kind of you have that stereotypical 
image of, you know, looking really gaunt. And it was … so that was, I was 
a bit scared about treatment. Even my ex I had five years ago, the 
treatment he was on was better, but still he had to take a few tablets 
and it’d make him a bit ill, sometimes.” 
White British, aged 26-30, single, <3months since diagnosis, not on ART 
Though side effects featured heavily in the discourse around barriers to starting ART, it was 
not always the acute illness brought on by side effects that were the source of the fear. 
Some of the lesser side effects like drowsiness and inability to concentrate particularly 
concerned individuals, especially from a work perspective. This was very apparent in jobs 
where the safety and security of members of the public were at risk from symptoms of 
drowsiness.  
Whilst side effects were universally talked about, some men held a very pragmatic opinion 
of when to start ART. The benefit of ART on quality of life could be worth the risk of side 
effects, if the time was right to start. Though it came down to personal opinion as to 
whether that time was right so soon after diagnosis. 
5.4.2.2 Drug resistance 
Another fear that emerged from the interviews was drug resistance, though notably fewer 
men mentioned it. Uncertainty arose around whether choosing to start ART earlier would 
restrict drug choices in the future. The idea of drug resistance was acknowledged by 
respondents as complex and somewhat confusing, however. It was interesting to hear the 
way one man understood the balance between resistance and time on ART, as he explains 
below.   
 “I don’t know to a certain extent there are advantages of taking the 
medicine very early but I think there are certain things because then your 
body gets used to it and then you have to take another medicine and 
then your body gets used to it again and then it takes another one and 
then how long will you keep taking different medicine, so perhaps the 
longer you leave then you take it, the longer your expectancy for your life 
and things go on, because there is medicines available, I don’t know.” 
Latin American, aged 41+, single, <3months since diagnosis, not on ART 
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The short-course treatment approach to PHI appeared to cause some confusion amongst 
several of the men as they were under the impression that treatment was for life. Stopping 
ART after a short-course of a year or so of treatment was perceived to increase the risk of 
drug resistance and these men could not understand why anyone would want to do that.   
5.4.2.3 Permanence of treatment 
The permanence of treatment could be a scary prospect, for younger men in particular, 
with the thought of having to do something for the rest of their life deemed “abstract”. One 
man, who picked up his first tablets on the day of the interview, likened his feelings 
towards starting ART for life to the horror he felt when he had dermatitis as a child.  
“I remember as a kid I had eczema and um, uh, sorry not eczema, 
dermatitis in my hair. And I was given this solution to put in and I 
remember like at the age of 12 going to bed and thinking.  Oh my god 
am I going to be putting this solution in my hair when I’m 65.  Oh my 
god.  Uh, within a few months it had gone and I stopped the treatment.  
Um, so yeah, I imagine when I take that tablet tonight, I’m going to be 
like, okay this is every day now for … the … for the rest of my life.” 
White British, aged 31-35, single, >6 months since diagnosis, not on 
ART 
Amongst the men aged over 35, this appeared to be less of a problem as it was likely that 
they would be put on some other permanent medication for something else at some point 
soon anyway. 
 “I said to, to my ex, when he started taking treatment, I said, ‘Well okay, 
erm, most … not most people, an awful lot of people when you get to 
forty or beyond are having some sort of tablet for something’. Blood 
pressure or, you know, they’ve got inhaler or they're got this, that and 
the rest of it, so, you know, picking up a pill off the table in the morning 
is, is not that drastic is it really, you know, everybody does it really at 
some stage or another so erm, as long as … as long as the result of that 
is that you're fit and well then I don’t see any point in dwelling on what 
the pill’s actually there for too much”  
White British, aged 36-40, single, <3 months since diagnosis, not on 
ART 
Short-course treatment was perceived by some men as a more acceptable way to start ART, 
as the tangible end date, whether 3 or 12 months in the future, was easier to get to grips 
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with than the unknown entity of life-long treatment.  One man even thought that he would 
most likely stay on ART if he started short-course therapy.  
5.4.2.4 Treatment as a marker of HIV positivity 
As discussed in section 5.3, men commonly felt stigmatised for being HIV positive and were 
very selective about who they disclosed their status to in order to avoid unwanted social 
situations.  Face to face disclosure of positive status was typically undertaken by men on a 
case-by-case basis, in a pragmatic and controlled way. One negative aspect of starting ART, 
was that men would have to carry it with them and that this would physically mark them 
out as being different, possibly resulting in attention and unwanted questions. It was 
particularly notable amongst men who travelled with work or who worked unusual hours.  
“Well it was funny actually because um, today, I picked up. I’ve picked up 
the tablets. And when she handed them to me I was like oh, okay.  
They’re in that sort … they’re in that little container. I don’t know what I 
was expecting.  I don’t know because it was 4 weeks I was being given. I 
didn’t know whether I was expecting a big box. Because I was going 
okay, oh god, you know. Um, you know in a few weekends’ time, I’m 
going to Poland for three days. And funny enough that was in the back of 
my head and also I want to go to New York. For a … for a week, I’ve got a 
friend that lives there.  And now being on treatment. It’s like okay so if 
I’m going through security. Would the security guard sort of like say 
okay, you know, what’s this. And if my … if a work colleague is next to 
me, am I going to have to justify what it is.” 
White British, aged 31-35, single, >6 months since diagnosis, not on 
ART 
“I was thinking how am I going to do if I have to take my medication 
now, how am I going to do in terms of taking that medication if it, would 
I ... especially with the time difference at work and I know that, and 
would I take in front of the people, would I go to toilet quickly and take 
the medication, because I don’t want people to ask questions”  
Latin American, aged 41+, single, <3months since diagnosis, not on ART 
This was not just a problem for travelling but also could be influences by living 
arrangements, as one man explained that he was so grateful he owned his own house so 
that if he started he would not have to hide medication from housemates.  
“I’m so blessed and I thank to God and touch wood that I have a property 
and I wouldn’t have a problem with medication in there instead of being 
sharing with someone who doesn’t know my background and I think I 
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have to keep hiding medications and doctors prescriptions and you 
know, because very unfortunately we still live in this world that people 
do sort of have a discrimination but yes, I don’t have any problem.”  
Latin American, aged 36-40, single, 3-6 months post diagnosis, not on 
ART 
5.4.2.5 Uncertainty in scientific evidence 
The uncertainty in the scientific and medical community around whether there were 
individual health benefits in starting ART earlier was a source of consternation for some 
men trying to decide whether early treatment was for them. The evidence base supporting 
early treatment was often described as “unclear” or as a “grey area”. On one hand, this was 
an important factor for some men, who reported a need for good evidence that starting 
early was better for their health to override the recommendation to delay starting until 
CD4≤350 cells/mm3.  
“When I know I need it because my CD4 is plummeting and I’m becoming 
ill or whatever, like that then yes I’ll happily start, then prior to that I 
would have to be shown some very convincing argument to make me” 
White British, age 31-35, single, 3-6 months since diagnosis, not on ART 
“So if the doctor tells me I need to, or if there was good evidence of 
starting early was better, then I would.” 
White British, aged 26-30, single, <3months since diagnosis, not on ART 
For other men scientific uncertainty surrounding health benefits of early treatment was not 
such a big problem, with the evidence from cohort studies and the hope of a cure and being 
able to stop the drugs in the future enough to consider early ART.  
“Erm, I suppose I just do have a hope that there would be something 
within my lifetime that would mean that I would be able to stop at some 
point and there would be possibly a cure.” 
White British, aged 21-25, single, 3-6 months since diagnosis, not on 
ART 
Near the end of the in-depth interview study, the VISCONTI (Virological and Immunological 
Studies in CONtrollers after Treatment Interruption) study reported findings of post-
treatment control amongst 14 seroconverters in France who initiated ART soon after 
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infection for an average of 3 years. These results were widely reported by the national 
media, and appeared to influence men’s decision to start early in two cases.  
 “Mainly because this Visconti trial [sic] was, a huge thing, erm, so 14 
patients out of 70 odd, I'd say you know to maintain viral expression 
[sic].  Erm, there was a tiny little bit of time pressure there because you 
had to start within ... if I was going to start it needed to be in those few 
weeks, otherwise, you know there was no evidence in  starting after that.  
Erm that was mainly it and the hope that in a few years I'd be able to 
come off them, or try to coming off them and see what happened.” 
White British, aged 21-25, single, <3 months since diagnosis, on ART 
 ART as a source of empowerment  5.4.3
HIV treatment was perceived as an empowering force by some respondents, which was an 
important olive branch at a time which was characterized by a loss of control over their life. 
Treatment was a way of regaining control of their body after losing control to the virus, 
improving sexual confidence, a chance to live their old life and a way to futureproof 
themselves.  
5.4.3.1 Regaining control of one’s body 
Men talked about a period of feeling out of control of their body when they first found out 
they are HIV positive. Some men even visualised the virus invading their cells whilst another 
referred to HIV as being like “gremlins”. Early treatment was a way of restoring some 
control on the situation by “fighting” this tangible image of HIV. 
“And also I’m from [European country] originally, when you’re ill you get 
a pill, you take antibiotics for everything, I still have that mindset, it was 
like a control thing, I wanted to control it straight away I did not want to 
wait for two years to 5 years and hopefully it would go down and need to 
be told at some point you need to start taking it.  I wanted to get the 
virus down straightaway I wanted to attack it, I had this fear that the 
longer I waited the more my cells would be penetrated, I know it’s 
probably not how it happens it but that’s how I visualised it.”  
White European, aged 31-35, single, 3-6 months since diagnosis, on 
ART 
Early treatment was also perceived as a way of being pro-active by not letting the virus 
dominate them and make them more ill. This pro-activity helped men feel more in control 
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and contributed to a more positive mental state. Men believed ART would prevent further 
illness and help them regain control of their own body again.   
As described in section 5.3 above, feelings of powerlessness, self-blame and loss of self-
esteem were commonly felt at diagnosis. Sitting back and doing nothing for potentially 
years was seen by some men as compounding these feelings. The ability to control the 
situation using treatment assisted with combatting feelings of helplessness and was 
perceived as a conscious step towards restricting the damage to their immune system, 
keeping options open and “future proofing” themselves by keeping the virus in check form 
a very early time point.  
5.4.3.2 Increasing sexual confidence 
Starting treatment was, for some, a way of increasing sexual confidence lost after diagnosis 
as outlined in section 5.3. Being “infectious” was associated with feelings of “grubbiness” 
and being “dirty”, but treatment was a possible way to help reduce this stigma.  The label 
of being “infectious” could be downgraded or removed totally if they were on treatment 
with undetectable viral load which reduced the worry of transmission to partners and the 
risk of criminal prosecution.  Men also mentioned the idea that being undetectable on 
treatment could facilitate status disclosure with sexual partners as they could say they were 
highly unlikely to transmit the virus even if something went wrong.  
“And so glad I have now because as I say, the conversation you can have 
about it now, you're undetectable with risk of transmission and the 
chances of you transmitting are very, very low.”  
White British, aged 21-25, single, <3 months since diagnosis, on ART 
Though not all men agreed that it was necessary to disclose HIV status to sexual partners 
and TasP could be perceived as a reason not to disclose to partners. Being undetectable on 
ART made them effectively uninfectious, which meant their risk of transmission was so 
negligible that it was not worth discussing. In this case, not disclosing was a potential way 
to reduce the chance of rejection by sexual partners based on HIV status, and avoid 
subjecting themselves to stigma.  
“If the risks are miniscule… the one kind of part of my reading which did 
kind of help me a bit was knowing that if you have sex with somebody 
who has an undetectable viral load, there’s less chance of you getting 
HIV, than somebody who believes they’re negative… so knowing that the 
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chances of me passing it on is less than just somebody who thinks they’re 
negative. That makes it justifiable not to have to disclose it straight 
away…” 
White British, aged 21-25, single, 3-6 months post diagnosis, not on 
ART 
5.4.3.3 A chance to live their old life 
Interestingly, there was a perception that HIV treatment could give them a lease of life that 
was lost after contracting HIV. Some men mentioned that they felt they could not live their 
desired lifestyle working and/or socialising as they used to and felt really drained. Going on 
treatment was a potential way to extend their energy and allow them to live the lifestyle 
they lived before contracting HIV. The respondent below describes his dwindling energy 
levels and an assumption that it was HIV that was doing this to his body. 
 “It was becoming really hard because I was just always tired, just 
exhausted the whole time and, erm I go to the gym every second day and 
you can sort of tell, you've just got no motivation to do it.  You're forcing 
yourself and you're like ... you're doing weights that are like much lighter 
than before and you're doing less because you just don't have the 
energy. Erm, and I didn't ... I thought it must be the HIV doing that so I 
wanted to get rid of that to be honest. I'm feeling a lot healthier so. You 
know, I've got more energy in the evenings. So it's good that I'm on 
treatment I think.”  
White African, aged 31-35, single, 3-6 months since diagnosis, on ART 
 “Yeah, yeah he’d [respondents’ HIV-positive partner] a really bad week, 
the week before last um, we’d actually … actually had a party … party at 
our house.  Um and it was a dinner party and we ended up taking some 
drugs and then we kind of stayed up until uh, this was on Saturday night, 
stayed up until Sunday night. Just carrying on. But that week he really 
struggled and he was like oh, do you want … because … if he was going 
to feel like this then he wants to take … start taking the drugs[ART]… like 
sooner.” 
White African, aged 31-35, in relationship, 3-6 months since diagnosis, 
not on ART 
5.4.3.4 Improving future treatment options 
Early ART was also perceived as giving men more control of their future treatment options, 
at a time where much research was being conducted. This feeling was particularly evident 
in those who were hopeful of a future cure, be it functional (where HIV remains in the body 
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but is rendered uninfectious and does no damage) or sterilising (a complete eradication of 
HIV). Notably this sub-theme featured more heavily in the more recent interviews, and was 
perhaps related to media coverage of the VISCONTI study and talk of a functional cure at 
the time. 
 “I've got to remain hopeful and the idea of starting treatment early was 
that, erm I would be protecting myself and there's always research 
coming out saying if you start earlier, your chances are better, you know.  
And there was one that came out the other day, I think saying that if 
you've started early that they're the people who will be most likely to 
benefit from a functional cure.”  
White British, aged 21-25, single, <3 months since diagnosis, on ART 
5.4.3.5 Loss of control 
The prospect of starting ART led to a perception of a loss of control in some individuals, 
which provided a stark contrast to the proactive views outlined above. Common amongst 
those reporting feelings of disempowerment associated with ART initiation, were two sub-
themes both very much linked to the fear/uncertainty theme described above in section 
5.5.2.  The first was the belief that by starting ART men would be handing over control of 
their body to the drugs themselves, with no knowledge as to what side effects, if any at all, 
would be experienced and how long they would last. The second was the concept that the 
physical presence of the tablets themselves, whether in a cupboard at home, or when men 
carried them on their person, was a visual indicator of being HIV positive, there for anybody 
to see. These men felt they currently had a fair amount of control over who knew about 
their status or not; they had disclosed only to select people, or in some cases, nobody at all. 
The decision to start ART required careful consideration of what would be the sacrifice of 
control over who knew about their status, as there was always a risk somebody (not 
necessarily a partner, but a family member or housemate) would see the tablets and find 
out they are HIV positive. As mentioned in the fear/uncertainty theme, the underlying 
factor common to fear of some side-effects and fear of people knowing men’s HIV status 
was stigma.  
 Trust and ART 5.4.4
The theme of trust emerged many times over the course of the interviews, though was 
seldom mentioned explicitly. Starting ART involved placing trust in not just the clinical care 
providers, but in the economy and government and in science and research.  
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5.4.4.1 Trust in medical opinion 
Respondents demonstrated an implicit trust in their HIV clinician’s medical opinion as to 
the best time to start ART. This trust was often unequivocal, given that often the men had 
met the doctor only one or two times. It appeared that trust in the clinician could be 
granted by default through previous positive experiences with the GUM clinic in the same 
building.  
“INT:  If you were kind of asked at your first appointment, not when you 
were diagnosed, but your first [HIV clinic name] appointment, erm, how 
would you have felt about taking HIV treatment?  What would your 
response have been? 
RES: … so after the diagnosis? 
INT: Yes, after the diagnosis 
RES: If they'd said to me, ‘Do … we’d like you to start treatment now’ 
how would I have felt about that? 
INT: Yeah.   
RES: I would’ve felt fine about that.  Erm, because erm, like I say, I've 
been going there for quite a few years, erm, so I'm reasonably familiar 
with them and I absolutely trust their advice so if that was their advice 
then I would take it” 
White British, age 36-40, single, <3 months since diagnosis, not on ART  
Men talked about consulting with their doctors about whether they need to start ART and 
in some cases totally deferred the decision making to their clinician, who was perceived to 
be the “expert”. Whilst some men displayed an implicit expectation that HIV clinicians 
would present all treatment options to their patients, it became apparent that not all of the 
respondents had received a discussion about the possibility of early treatment. From this 
perspective, the clinician was the “gatekeeper” of early treatment and, in some cases, their 
attitudes and beliefs precluded the discussion or offer or early treatment to patients. 
Not all respondents followed medical advice without question, however. There were 
scenarios where the men’s viewpoints differed from those of the healthcare provider team 
as to when to start ART, and this could lead to suspicions that providers were saying things 
to make men feel better about their diagnosis. 
 200 
 
“I think it’s interesting that when you get diagnosed and you come and 
see the health advisor they go oh it’s the ... I don’t know if they say it’s 
the average or something is about 7 or 8 years and then virtually 
everyone I know seems to start within 2 or 3, so I wonder if that is what, 
you know maybe it’s the 19 year old outliers that jack that average up 
and what is that, is that the mean, the median or the mode, who knows 
or ... you know but I wonder if they also do that just to lessen the blow of 
your diagnosis and make you think that it’s going to be a while so you 
don’t need to worry about it yet and life is going to be normal for now.”  
White British, aged 31-35, single, 3-6 months since diagnosis, not on 
ART 
Two of the respondents made a personal decision very early after infection, and without 
consulting their clinician, that they would like to start early treatment. Both were very well 
informed about UK and international treatment guidelines and current research. It was 
clear they both expected some resistance to their request for early treatment, as they 
perceived it to be against the BHIVA guidelines [although it was not] and that the clinician 
would adhere to the guidelines. Their expectations manifested in different ways, resulting 
in very different feelings going into their first consultations.  One assumed he would have to 
fight to be allowed to start, but would not have taken no for an answer.  
“And I thought I was going to be up for a battle I thought they wouldn’t 
let me but then the doctor was actually quite, well if that’s what you 
wanted, you can do, but she didn’t actively advise me to do it… I was 
100% confident that I was going to start straight away, if the doctors 
here wouldn’t have let me I would have found one who would have.”  
White European, aged 31-35, single, 3-6 months since diagnosis, on 
ART 
The other man professed to feeling very “awkward” about asking for treatment early. This 
was not helped in the consultation itself by the doctor apparently being quite dismissive of 
it.  
 
“Okay, so ... but then I'd spoken to [doctor’s name] and he was, not 
negative about the idea of starting treatment but he was quite like 
dismissive of it.  He's trained in Epidemiology as well.  So the numbers 
aren’t good enough to show, not either way, it's just like START [sic] trial, 
that didn't really show anything unless you were on it for 96 weeks and 
then only a small reduction in the reservoir and better HIV immune 
response.  And he was just like, erm, I'm not sure, it's a big decision to go 
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on treatment, I've got guys who ... the last thing they want to do is be on 
treatment, they beg not to be on treatment.”  
White British, aged 21-25, single, <3 months since diagnosis, on ART 
In this second scenario, the patient ended up rethinking after this initial consultation and 
deciding against early treatment, only to be advised by the same doctor on his next 
appointment that he now believed the patient should start early and recommended him to 
do so.  This case demonstrated how instrumental the clinician’s underlying attitude to early 
treatment can be in decision to start, particularly in patients who may be nervous about 
asking for treatment as they think it is an out of the ordinary request.  
5.4.4.2 Trust in the government and economy 
Questions were raised by some participants over the long term free provision of ART in 
such an economically and politically uncertain environment. A lack of trust in the current 
government led to feelings that NHS budget cuts may extend to ART in the future and a fear 
of not being able to personally afford treatment costs. 
“I read somewhere about the different points at which people in 
different countries start treatment. And that in America it’s kind of, it’s 
recently changed to 500, in Britain it’s 350. So I mean, it seems like … and 
then I just think, you know, “Well, why is that?” you know, “Is it for sort 
of, is it because of money constraints, like it’s expensive to start 
treatment early?” In which case, it’s, I don't know, like, feeling a slight 
feeling of suspicion towards the motives of, like, you know, the 
Government or the NHS, or whatever.”  
White British, aged 26-30, in relationship, 3-6 months since diagnosis, 
not on ART 
 
Interestingly, one man considered starting ART sooner for this reason, as he would then be 
on it for life and thought the NHS could not then cut his supply as this would be damaging 
to his health.  
 
“You know, but that’s the other thing that I’ve been a bit concerned 
about, because the government is getting worse, because the 
government cuts, the UK cuts, who knows that in a few years’ time, 
they’re going to say that okay all the people who are on the treatment 
now, they can carry on having treatment, but the people who have not 
 202 
 
been treated so far, they have to pay for the medication and you can’t 
afford to do that.”  
Latin American, aged 41+, single, <3months since diagnosis, not on ART 
5.4.4.3 Trust in scientific research and medicine 
Trust in science and medicine was an important underlying factor in the decision to start 
early. On the whole men held a lot of faith in medical research, and were excited about 
future treatment developments. Research reported in the mainstream media was very 
influential, with many men relaying evidence for a future cure for HIV from newspaper 
articles they had read or documentaries aired on television.  
Conflicting evidence from different research studies focusing on early treatment published 
over the interview period provided some consternation in men who were heavily engaged 
with treatment literature. In particular, the stark differences between the US “test and 
treat” approach and BHIVA treatment guidelines caused confusion and suspicion. The idea 
that two panels of experts could review the same evidence base and come up with 
different conclusions was troubling, possibly because of the tendency to believe medicine is 
based on hard facts and not opinion. Some men also reported a lack of trust in the safety of 
clinical trials for early treatment, as they had seen trials go wrong on the news, or heard 
about misreporting of results.  
 Summary discussion 5.5
 Key findings 5.5.1
Using qualitative data from my in-depth interview study I have demonstrated that MSM 
with EHI view the decision to start ART early as a balancing act involving a trade-off 
between the perceived benefits of starting ART early and managing the fears and 
uncertainties surrounding its initiation (see figure 5.2).  The potentially empowering effects 
of early treatment such as the reduction of infectiousness and its associated stigma, as well 
as perceptions of improved physical and mental health were pitted against the fears 
surrounding side effects, toxicity, drug resistance, increased visibility of HIV leading to 
stigma and economic and scientific uncertainty. The conundrum of early treatment is 
further complicated as it is posed within the emotionally charged backdrop of a recent HIV 
diagnosis, which for many of the men involved facing a great deal of uncertainty and a 
period of adjustment (see figure 5.1). 
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The decision to start early ART was perceived by men as part of a responsibility to maintain 
their own health and that of their partners. Seeking clinical advice from the doctor as well 
as gathering knowledge from several other sources, namely NAM, THT, mainstream media, 
newly diagnosed courses, patient representatives, HIV-positive forums and friends, was 
crucial to the decision making process for proactive men. Trust in the patient-doctor 
relationship was also crucial, and differences in opinion over the value of early ART could 
undermine this relationship.  Men who totally deferred the decision to start to the clinician 
tended to do so as they were undecided on the merits of early treatment, or felt they could 
never match the knowledge levels and clinical expertise of their HIV physician.  
Figure 5.2 Benefits and barriers to initiation of ART amongst MSM with early HIV 
infection attending an HIV clinic in central London 
 
Some respondents entered a period of celibacy following their HIV diagnosis, reported to 
last from weeks to a planned “year of cleansing”. Whilst initiation of ART exclusively to 
prevent transmission would be rendered useless amongst these individuals, an argument 
remains to initiate early to achieve undetectable viraemia and lessen the stigma of being 
“infectious” and associated feelings of “dirtiness”. Men reported both felt and enacted 
stigma associated with being HIV positive in the interviews. Having an undetectable viral 
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load, could lessen the emotional burden of being infectious even if sex is not actively being 
sought at the time. Good sexual relationships are an integral part of a healthy lifestyle, and 
many of the men interviewed led very active sex lives prior to diagnosis. Achieving 
undetectability through TasP was perceived as a way to normalise meeting sexual partners 
again face-to-face, with less fear of rejection anticipated in this scenario.  Notably, TasP was 
not trusted entirely to prevent transmission and was often talked about as a risk-reduction 
strategy in combination with continued condom use and serosorting for HIV-positive 
partners.  
Early treatment could be an empowering force which could help immensely with the 
process of adjusting to life as an HIV-positive MSM by eliminating the stigma and worry of 
being infectious. For those who believed in a future cure, largely stoked by regular news 
reports in the mainstream media, the hope this would come in their lifetime, made it more 
appealing to start early. For these men ART was unlikely to be for life. In some cases 
starting ART soon after seroconversion was seen by men as a way to put themselves in the 
best position to benefit from a functional cure.  
At the time of HIV diagnosis worry and uncertainty were rife amongst the men interviewed. 
Some men struggled to come to terms with HIV diagnosis, and were overwhelmed by the 
idea of initiating treatment straight away due to the myriad of other uncertainties it would 
bring. For these men, losing their quality of life through looking and feeling ill or not being 
able to perform at work were often regarded as unavoidable side effects of treatment and 
the reason to delay starting as long as possible. Subscribing to lifelong treatment was also a 
very difficult concept to deal with for younger men in particular. Short-course treatment 
could make early ART more appealing because of the tangible end date, with the option of 
then staying on ART if the much anticipated side effects were not experienced. However 
short-course treatment was believed to be hazardous by some men as they had read that 
starting ART after stopping is bad for your health.  
 Strengths and limitations 5.5.2
This study is the first to examine how MSM with EHI in the UK feel about early initiation of 
ART. Previous studies have assessed attitudes and beliefs in people living with HIV but not 
recent seroconverters. Whilst recent seroconverters currently only form a small 
subpopulation of HIV diagnoses a year, the current push for more regular testing, along 
with the routine application of RITA, will likely result increasing proportion of newly 
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diagnosed men being identified during EHI. The fact that seroconverters do not necessarily 
have the same “clinical need” for starting ART as those diagnosed later in infection may 
alter their way of thinking about ART so findings from interviews with men with chronic 
infection may not translate to seroconverters. 
Using in-depth interviews allowed the men to describe, in their own words, their 
experiences and feelings about diagnosis and early ART in a neutral setting without 
judgement. The two-way process of the interviews allowed me to probe respondents 
further and develop explanations of some of the mechanisms underlying the observations.  
The purpose of the in-depth interviews are not to measure the number of men who hold a 
particular view, but to explore the depth and complexity of men’s views on early treatment. 
From this perspective, this dataset was rich and varied covering a range of ethnicities and 
backgrounds.  
5.5.2.1 Selection bias 
There were however, some limitations to the study. As only one clinic was used to recruit 
patients, there was a risk of selection bias in the participants. Some HIV clinics have 
different ART policies, or may hold research interests in early treatment. The clinic used for 
this study did not hold research interest in early treatment, but men may select their HIV 
clinic by whether they are likely to have early treatment prescribed or not. If I had 
conducted the study at a pro-early treatment clinic I may well have recruited men with very 
different perspectives of early treatment, and this should be considered when interpreting 
the findings.  
I experienced ongoing recruitment problems to this study, which were caused both by clinic 
logistics hampering the meeting of patients, and a reluctance to enrol in the study once 
men were invited to take part. The small study population, lack of engagement in the study 
from the clinic staff, complex eligibility criteria and the absence of a research nurse 
dedicated to the UK Register for a substantial proportion of the study period hampered my 
initial introduction to patients. Interestingly, a few of the health advisors thought it was 
inappropriate to invite any individuals who had been recently diagnosed to engage in 
research and refused to refer to the study based on their moral preference. To negate 
these problems, I met several times with the HIV nursing team and the health advisor team 
to discuss the study and to field any questions or concerns individuals had. However, even 
after contact had been made with an eligible patient to explain the study and I had invited 
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them to participate, the qualitative nature of the study deterred some men from 
participating.  In contrast, of the men who agreed to be interviewed many professed it was 
an enjoyable experience and some even said they found it quite therapeutic talking about 
lots of things they felt they couldn’t talk to anyone else about.  Any differences between 
respondents and non-respondents in terms of social demographic factors, knowledge and 
or sexual behaviour will have led to bias in the views represented in these findings, and this 
should be considered as a study weakness. 
To add to this, the result of the slow and erratic recruitment to this study was the failure to 
meet the age quota for this study. Whilst this means data from a narrower age range is 
represented here, I feel that the results are likely representative of the majority of MSM 
diagnosed with recent infection in the UK, whose median age is 33 years (IQR 27-40), as 
reported in section 4.2. I had also hoped to be able to develop typologies of seroconverters 
dependent on their attitudes to early treatment, but slow recruitment led to me curtailing 
the study to focus on other parts of the PhD and I did not have a sufficient number of 
interviews to fulfil this objective.   
5.5.2.2 Information bias 
As with any study researching sensitive subject matter, there is always a risk of respondents 
giving socially desirable answers. This study is no exception, and the effects of social 
desirability may well be exacerbated in the in-depth interview scenario as it involves talking 
face-to-face with the interviewer. On the whole I felt that there was good rapport between 
myself and the respondents. Nevertheless, there were moments of inconsistency in two of 
the men’s narratives, which may reflect a censoring of information; however, the majority 
of men appeared happy to talk about their sexual behaviour in depth and provided 
consistent accounts. 
Recall bias may also have been introduced by the study design. Men were asked to recount 
their feelings at the time of diagnosis, which may have been influenced by factors arising 
since diagnosis. In an ideal situation, a baseline interview would have been conducted at 
diagnosis followed by a follow-up interview 3-6 months later, however time and financial 
constraints made this approach impractical. The result was a large range in the time from 
diagnosis to interview, from 2 weeks after diagnosis up to 9 months post-diagnosis, and 
whilst this resulted in a wide range of perspectives, it also made direct comparisons 
between respondents difficult and enhanced the possibility of recall bias.  
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The crucial role of healthcare providers in the process of deciding to start treatment must 
also be acknowledged, with the HIV clinician the gatekeeper to accessing early ART in many 
cases. Their underlying attitudes and beliefs towards early ART are an implicit step in the 
decision making process as they dictate when, or whether, the patient is first offered early 
ART, and their personal opinion is often sought as to whether early therapy is a good idea. 
One limitation of this study is the one-sided nature of assessing the role of the clinician in 
the decision to start. A future qualitative study should be conducted to better understand 
clinician’s perspectives on treatment in early infection, and the factors involved in the 
decision to offer or recommend early ART.   
5.5.2.3 Representativeness 
The slow and erratic recruitment to this study resulted in a long study period (2010-2013), 
which likely introduced issues with the representativeness of findings due to changes in the 
study context over time.  HIV clinicians in the UK tend to use the BHIVA treatment 
guidelines to inform clinical practice which, over the study period, recommended ART on 
clinical grounds for patients who presented with a CD4 count ≤350cells/mm3, an AIDS 
defining illness, or with evidence of primary HIV infection and neurological involvement. 
However, the degree to which clinicians’ maintain an up-to-date knowledge of recent 
research findings published after the last set of guidelines varies, and a number of key 
studies focusing on early ART as TasP 215 or in primary infection 214,216 were published over 
the study period. Although the BHIVA guidelines recommending initiation at CD4≤350 
cells/mm3 remained unchanged over the study period, a position statement in response to 
the HPTN-052 was released by BHIVA in January 2013 217. This stated that there should be 
discussion between healthcare providers and all HIV-positive adults about the effect of ART 
on transmission, and that the possibility of starting ART to reduce transmission should be 
discussed with ART-naïve individuals who wish to start to reduce transmission.  
The results from these studies and the subsequent guideline changes may have impacted 
on attitudes and beliefs towards early ART amongst clinicians, as well as patients. Certainly 
it was notable that prior to late 2012 none of the men interviewed had started ART, 
whereas in 2013 three out of the four men interviewed had started. A full discussion of how 
these studies and subsequent guideline changes affected attitudes towards ART can be 
found in the discussion, in chapter 7.  Whilst I cannot be certain that the greater proportion 
of the men on ART interviewed in more recent years was directly due to these study results, 
it is a very plausible explanation. It would also serve to highlight the transient nature of 
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people’s attitudes and beliefs, highlighting how they may change over time and with shifts 
in evidence.  
5.5.2.4 Interviewer bias 
Throughout the interview process I was aware of the fact that as a female, I was very 
different from the men being interviewed, and that this may have a bearing on the results 
of the qualitative study. In addition, there was a possible power imbalance as men 
recruited to the study were all known by me to be HIV positive and MSM, whereas as the 
researcher my HIV status and my sexuality was unknown to the participant.  Whilst it is 
impossible to judge the effect of these factors on the data generated from the interviews, 
these personal characteristics at least were stable throughout the interview process, so 
were a constant potential source of bias.  
More of an issue was the fact that five of the in-depth interviews were conducted whilst I 
was pregnant; three of which when I could no longer hide this fact.  This was of particular 
concern to me as it was a very visible change to my personal characteristics which carried 
with it a host of social expectations. In the interviews I conducted before and after I was 
pregnant, some men discussed difficult encounters with their parents around coming out 
and disclosure of HIV status. I was concerned that during the interviews conducted when I 
was visibly pregnant, men may not be so honest about these situations or may be more 
concerned about upsetting or shocking me given my impending motherhood. It is difficult 
to know the exact effect of my pregnancy on the relationship between the respondents and 
myself in the interviews and impossible to account for It, but I feel it is important to 
acknowledge it. 
Only one patient declined to have their interview audio recorded; he was in the legal 
profession and for reasons of confidentiality did not want to be on record talking about his 
sexual behaviour and his HIV status. For this individual I resorted to taking notes with pen 
and paper during the interview but I found this experience very difficult and felt that the 
extra concentration required to note-take detracted from that required to follow the topic 
guide and probe efficiently. As a result the interview felt stilted, shallow and did not flow as 
well as the other interviews.  
Whilst I had no experience of conducting qualitative research prior to this study, I did 
attend  several courses: namely “Conducting in-depth interviews”, by the Social Research 
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Association; “Analysing Qualitative Data” and “Using Framework Analysis”, both run by the 
National Centre for Social Research (NatCen); and an NVivo course, run by UCL. On 
designing and conducting the study and analysis I liaised closely with my secondary 
supervisor and the study CI, Professor Graham Hart, who has many years of experience in 
conducting qualitative research and advised me throughout the research process.  Despite 
this however, there was inevitably a period of learning on the job for me. My confidence as 
an interviewer, my ability to actively listen and to probe effectively developed markedly 
over the course of this qualitative study, and as a result the later interviews were 
significantly longer and contained much richer data.  
Finally, the transcripts were only coded by me as there was no funding to employ 
somebody to double code. Whilst I employed the Framework approach in the qualitative 
analysis, which has been noted to be systematic and reproducible 190, it is possible that 
other individuals may have interpreted the men’s words and sentiments in a different 
manner to me. Whilst I strove for objectivity in all aspects of the research process, by 
documenting the themes and subthemes, and discussing the frameworks in detail with 
Prof. Hart, the lack of external validation of my transcript coding inevitably leaves the 
results open to any unintended subjectivity in my opinions. 
 Chapter summary 5.6
A summary of the findings of this chapter are presented in the conceptual framework in 
figure 5.3. In this chapter I have demonstrated that the decision to start early ART is highly 
personal and depends on a myriad of social and personal factors. It involves a complicated 
balancing act of assessing benefits and risks, presented at a highly emotional time in men’s 
lives in the aftermath of HIV diagnosis. The perceived benefits and barriers to treatment 
differ between individuals, depending on many social and personal factors which also 
influence how men cope with the HIV diagnosis itself.  
Whilst the decision to start early ART can be perceived as a further burden at a time of 
already heightened stress, for some men the initiation of early treatment may assist with 
the coming to terms with HIV positivity through the removal or reduction of the 
stigmatizing label of being “infectious”. The mental relief of achieving undetectable viral 
load through early treatment, with the subsequent reduction/removal of the stigma of 
being “infectious”, was apparent in these men but has been largely overlooked in the 
literature as a reason to start early therapy.  Early treatment can be perceived as a 
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normalising influence, allowing men to live life like they did before their HIV diagnosis, to 
meet partners as they used to and to increase sexual confidence at a time when self-
esteem and self-confidence would normally be low.  
Early treatment to prevent transmission was regarded as a welcome addition to the 
armoury of risk reduction strategies currently used by the men, which included abstinence, 
serosorting, and using condoms. Whilst TasP was seen as a great idea for public health, it 
was not regarded as a  panacea; on a personal level not all men had enough confidence in 
TasP to abandon condom use altogether. In addition, many of the men interviewed 
reported a period of sexual abstinence following HIV diagnosis and depending on the 
prevalence and duration of this abstinence, early ART to prevent transmission may have 
less of an impact on onward transmission than predicted. However, amongst men who 
engaged in high-risk sexual activities after diagnosis, for example group sex, fisting and 
recreational drug use, there is a strong rationale to initiate early ART for TasP reasons due 
to the reported lack of control when engaging in these sexual practices.  
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Figure 5.3 Conceptual framework of the thesis including results from workstream 1, and phase A of workstream 2 
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6 Workstream 2 phase B results: Survey of sexual 
behaviour, attitudes, beliefs and acceptability to early ART 
amongst MSM with early HIV infection 
In this chapter I present the results of the survey of sexual behaviour, attitudes, beliefs and 
acceptability to early ART, which was nested in the UK Register of HIV Seroconverters. The 
aim of this workstream was to estimate the prevalence of acceptability towards early ART 
as well as some of the attitudes and beliefs which arose from these in-depth interviews. 
The survey also sought to describe sexual behaviour over EHI, and assess risk factors for 
engaging in HIV transmission risk-behaviours after HIV diagnosis. The specific objectives 
were to: 
 Describe the prevalence of the attitudes and beliefs to early ART identified in the 
in-depth interview study 
 Estimate the proportion of MSM with EHI who regarded early ART as acceptable 
 Examine the predominant reasons for early ART initiation amongst MSM who 
started ART in EHI  
 Estimate proportion of MSM who initiated early ART, and examine what factors 
were associated with this 
 Estimate the proportion of MSM who present a heightened HIV transmission-risk 
after HIV diagnosis and examine what factors are associated with this. 
The full methods can be found in chapter 3, section 3.6, but as a brief reminder MSM were 
eligible for the survey if they were recruited to the UK Register (i.e. had laboratory evidence 
of recent seroconversion) and were aged ≥16 years. Participation involved one-off self-
completion of a pen-and-paper questionnaire within 12 months of HIV diagnosis.  
 Eligibility, survey completion and non-response 6.1
This survey ran from July 2013 to December 2014 in 16 UK Register centres. Overall, 141 
questionnaires were returned, of which 134 were successfully matched to a corresponding 
record in the UK Register database. Of these, 17 were ineligible: 2 had never had sex with 
another man and 15 completed the questionnaire >12 months after date of HIV diagnosis. 
Data from 117 respondents were included in this analysis. It was not possible to calculate a 
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survey response rate as despite staff recruiting at the centres being asked to keep count of 
the number of men refusing to participate, none actually did so. Instead it was possible to 
calculate the proportion of survey-eligible men recruited to the UK Register who were also 
recruited to the survey at participating centres. Table 6.1 illustrates the number of survey 
participants recruited from each centre, and the number of survey-eligible UK Register 
participants enrolled over the survey study period.  The majority of men were recruited 
from 3 London HIV centres: 29.1% from St Mary’s Hospital, 12.8% from Guy’s and St 
Thomas’, and 10.3% from Mortimer Market Centre. Overall, the proportion of all survey 
eligible men recruited to the UK Register who were recruited to the survey was 45.7%, 
though this varied substantially between centres. It is important to note however that this 
is likely to be a conservative estimate due to the way the survey was carried out in each 
centre; some men classified as “non-responders” in the above calculations may not have 
actually been invited to participate in the survey.  
Comparisons were made between survey participants and those enrolled to the UK Register 
during the survey period but not participating in the survey. Overall, there were no 
observed differences in key demographic and clinical characteristics, see table 6.2. 
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Table 6.1 Proportion of UK Register recruits who were eligible and recruited to the survey 
sub-study by HIV centre: July 2013-December 2014 
HIV Centre 
No. of survey 
eligible MSM 
recruited to UK 
Register 
No. of 
eligible MSM  
recruited to 
the survey 
% UK 
register 
recruits 
completing 
the survey 
% of 
survey 
recruits from 
each centre 
London, Guy’s & St. 
Thomas' Hospital 74 15 20.3 12.8 
London, St. Mary's Hospital 70 34 48.6 29.1 
Brighton, Brighton General 
Hospital 16 11 68.8 9.4 
Liverpool, Royal Liverpool 
University Hospital 14 10 71.4 8.5 
Manchester, Withington 
Hospital 14 5 35.7 4.3 
London, Mortimer Market 
Centre 13 12 92.3 10.3 
London, 56 Dean Street - 
Sexual Health Clinic 10 8 80.0 6.8 
Birmingham, Selly Oak 
Hospital 10 6 60.0 5.1 
London, Charing Cross 
Hospital 10 3 30.0 2.6 
Bradford, St. Luke’s Hospital 6 2 33.3 1.7 
London, Homerton Hospital 5 5 100.0 4.3 
Bristol, Southmead Hospital 5 2 40.0 1.7 
London, Chelsea & 
Westminster Hospital 3 1 33.3 0.9 
Sutton-in-Ashfield, King's 
Mill Centre 3 1 33.3 0.9 
London, Kings College 
Hospital 2 1 50.0 0.9 
Leeds, St. James University 
Hospital 1 1 100.0 0.9 
Total 256 117 45.7 100 
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Table 6.2 Comparison of characteristics of survey respondents and MSM enrolled in the UK Register but not recruited to the survey 
  
Not recruited to survey Survey respondent 
 
Variable   n 
Median 
(IQR) or % n 
Median 
(IQR) or % p-value
a
 
Age at seroconversion (years)      
 Median (IQR) 165 33 (28, 41) 117 33 (28, 39) 0.206 
HIV test interval (months)
b
      
 Median (IQR) 165 2.1 (0, 5.0) 117 2.7 (0, 5.5) 0.606 
CD4 at seroconversion (cells/mm
3
)       
 
Median (IQR) 158 555 (428, 696) 112 518 (403, 667) 0.408
c
 
Viral load at seroconversion (log10 copies/mL)      
 Median (IQR) 154 5.2 (4.6, 6.0) 112 4.8 (4.3, 5.8) 0.235 
Ethnicity       
 White 134 81.2 98 83.8 0.581 
Non-white 31 18.8 19 16.2   
Seroconversion identification method      
 HIV Ab- then HIV Ab+ ≤12 months 103 62.4 82 70.1 0.540 
HIV Ab- and PCR+ 34 20.6 17 14.5 
 RITA 26 15.8 17 14.5 
 Equivocal Ab then  Ab+ 2 1.2 1 0.9  
Cross-sectional survey study recruitment period July 2013-December 2014. IQR=interquartile range; Ab-=antibody negative; Ab+=antibody positive; PCR=polymerase chain reaction; RITA=recent infection testing 
algorithm.  a=p-value obtained using t–test for continuous variables and chi2 for categorical variables; b=interval between HIV Ab negative and positive tests; c= t-test performed on square root CD4 to normalise 
distribution 
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 Demographic and clinical characteristics of the respondents 6.2
Table 6.3 outlines the demographic and clinical characteristics of the 117 eligible survey 
respondents. They were mostly of white ethnicity (83.8%) with a median (IQR) age at 
seroconversion of 33 years (28, 39).  The median year of seroconversion was 2013 (2013, 
2014), the HIV test interval (the time between negative and positive antibody tests) was 81 
days (0, 168) and 35.9% (42/117) had a HIV test interval of less than 30 days. The median 
time from diagnosis to questionnaire completion was 76 days (29, 191). Median CD4 count 
and log HIV viral load at seroconversion was 518 (403, 671) cells/mm3 and 4.8 (4.3, 5.8) 
log10 copies/mL, respectively. Most were recruited from London HIV centres (67.5%; 
79/117) and around half (51.3%; 60/117) were recruited from three UK centres known to 
have a research interest in primary HIV infection, namely: Brighton and Sussex University 
Hospital in Brighton, St Mary’s Hospital and Guy’s and St Thomas’ Hospital, both in London. 
Most respondents were in current employment (82.1%; 96/117), had three or more years 
of full-time education after the age of 16 (84.6%; 99/117), and nearly a third (32.5%; 
38/117) were home owners. Most men self-identified as gay/homosexual 89.7% (105/117), 
though 9.4% (11/117) identified as bisexual and one man as heterosexual with an interest 
in transgender men.  52 men (44.8%) had a regular male partner at the time of 
questionnaire completion, and of these over half (51.9%; 30/52) reported their partner’s 
HIV status as positive, 42.3% (22/52) as negative and 5.8% (3/52) did not know their 
partner’s status.  
The most common reasons given for seeking the last HIV test were that it was a routine test 
(41.0%; 48/117) or because they felt unwell (35.0%; 41/117). Over two thirds (68.4%; 
80/117) of men reported being surprised by their HIV positive result, though 21.4% 
(25/117) were not. A notable proportion, 23.3% (27/116) of men reported previously taking 
PEP, with the median number of times 1 (IQR 1, 2; max 6). 
Nearly two thirds of men (65.5%; 76/116) reported feeling unwell in the run up to their HIV 
diagnosis, with 38.8% (45/116) reporting that these symptoms affected their daily routine. 
The median (IQR) duration of symptoms was 14 days (7, 21), with the median duration of 
routine disruption being of 7 days (5, 14).  The most commonly reported symptoms were 
fever (53.4%; 62/116), night sweats (50.0%; 58/116), body aches (40.5%; 47/116) and sore 
throat (36.2%; 42/116), see figure 6.1.  
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Table 6.3 Demographic and clinical characteristics of MSM seroconverters recruited to the 
survey 
Variable Level n 
Median 
(IQR) or % 
Time from diagnosis to questionnaire 
completion (days) Median(IQR)  117 76 (29, 191) 
Year of seroconversion Median(IQR)  117 
2013 (2013, 
2014) 
Age at seroconversion (years) Median(IQR)  117 33 (28, 39) 
Ethnicity White 98 83.8 
 
Non-white 19 16.2 
HIV test interval (days)  Median(IQR)  117 81 (0, 168) 
CD4 at seroconversion (cells/mm
3)
 Median(IQR)  112 518 (403, 667) 
HIV viral load at seroconversion (log10 
copies/mL) Median(IQR)  112 4.8 (4.3, 5.8) 
Years of full time education >16 years of age <3 years 18 15.4 
 ≥3 years 99 84.6 
Currently employed No 21 17.9 
 
Yes 96 82.1 
Own or rent accommodation Own outright 38 32.5 
 
Rent - private landlord 64 54.7 
 
Rent - council/HA/other 15 12.8 
Current living arrangements Alone 30 25.6 
 
Partner 31 26.5 
 
Friends/tenants/lodgers 43 36.8 
 
Family/guardians 13 11.1 
Sexual orientation Gay/homosexual 105 89.7 
 
Bisexual 11 9.4 
 
Other 1 0.9 
Regular male partner No 64 55.2 
 
Yes 52 44.8 
HIV status of regular male partner Negative 27 51.9 
 
Positive 22 42.3 
 
Don't know 3 5.8 
Recruited from HIV centre with PHI interests No 57 48.7 
 
Yes 60 51.3 
Evidence of acute HIV infection No 75 64.1 
 
Yes 42 35.9 
Recruited from a London HIV centre No 38 32.5 
 
Yes 79 67.5 
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Table 6.3 (continued) 
Variable Level n 
Median (IQR) 
or % 
Reason for last HIV test Routine test 48 41.0 
 
Condom failed 6 5.1 
 
UAI with HIV+ partner 7 6.0 
 
UAI with HIV unknown 
status partner 19 16.2 
 
UAI with HIV- partner 20 17.1 
Felt unwell 41 35.0 
 GP/hospital recommend 10 8.5 
Seroconversion symptoms experienced No 40 34.5 
 
Yes 76 65.5 
Number of days symptoms lasted Median(IQR)  76 14 (7, 21) 
Symptoms affected daily routine No 26 33.8 
 
Yes 45 58.4 
 
Don't know 6 7.8 
Number of days daily routine was disrupted Median(IQR)  48 7 (5, 14) 
Surprised at HIV positive result No 25 21.4 
 
Yes 80 68.4 
 
Don't know 12 10.3 
STI diagnosed at HIV diagnosis No 64 55.7 
 
Yes 51 44.3 
IQR=interquartile range; HIV test interval=time interval between HIV Ab negative and positive tests; HA=Housing 
Association; PHI=primary HIV infection; UAI=unprotected anal intercourse; STI=sexually transmitted infection 
 
 
Of the 115 men who responded to the question, 44.3% (n=51) reported being diagnosed 
with an STI at the time of HIV diagnosis. Figure 6.2 illustrates the STIs diagnosed at the time 
of HIV diagnosis. The most prevalent STI was gonorrhoea which was reported by 28.7% of 
men (33/115), the second most common STI was chlamydia reported by 15.7% (18/115) 
men with the other STI’s prevalence all under 10%.  
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Figure 6.1 Prevalence of reported HIV seroconversion symptoms  
 
Figure 6.2 Prevalence of STI co-infections at time of HIV diagnosis 
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 Acceptability, attitudes and uptake of ART 6.3
Early ART appeared to be acceptable to men at the point of diagnosis; when asked to think 
back to their HIV diagnosis, nearly half the men (47.8%; 55/115) reported that they had 
expected to start ART within 1 month of their HIV diagnosis, see figure 6.3.  Furthermore, 
two thirds of men (66.7%; 76/114) stated they would have accepted ART at diagnosis if they 
had been offered it, with 24.6% (28/114) reporting they may have, and 8.8% (10/114) 
saying that they would not have accepted.  Overall, 58.9% (63/107) of men reported their 
doctor had advised them to start ART and 47.4% (55/116) had initiated ART at the time of 
questionnaire completion.  
 
Figure 6.3 When asked to think back to their HIV diagnosis, how soon after HIV diagnosis 
did MSM expect to start ART? (n=115) 
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 Amongst ART-naïve MSM 6.3.1
Of the men who had not taken ART since their diagnosis, 74.6% (44/59) said they had 
considered starting ART since their HIV diagnosis and 46.7% (28/60) expected to start ART 
within the next month, see figure 6.4.   
Figure 6.4 How long in the future, from the date of questionnaire completion, did ART-
naïve MSM expect to start ART? (n=60) 
 
 
Figure 6.5 illustrates ART-naïve men’s attitudes and beliefs towards ART. Overall, 61.0% 
(36/61) of ART-naïve men agreed with the statement “I am ready to start ART now”, and 
10.2% (6/59) disagreeing.  82.5% (47/57) agreed they “would start ART now if there was a 
proven health benefit to me”, however there appeared to be some doubt about whether 
evidence of health benefit existed as 59.6% (34/57) agreed with the statement “It is better 
for my health to start ART earlier rather than later”.  Whilst the majority of men (73.7%; 
42/57) did not agree with the statement “I would prefer to delay starting ART for as long as 
possible, even if this meant a small increased risk of getting a serious illness”, 8.8% (5/57) 
did agree with the statement. Also of note were the 22.8% (13/57) who agreed with the 
statement “There was no point in starting ART when I feel well”. 
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Figure 6.5 Attitudes and beliefs of ART-naïve MSM towards early ART (numbers denote percentages) 
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81.0% (47/58) of men agreed with the statement “I would start ART now if it reduced the 
chance of passing HIV to sexual partners, even if there were no proven health benefits to 
me”. However fewer ART-naïve men (60.5%; 26/43) agreed with the statement “Being on 
ART and having an undetectable viral load means that HIV is unlikely to be passed to a 
sexual partner even through sex without a condom”.  Ultimately, many men appeared to be 
guided by their doctors’ advice on whether to start, with 62.5% (35/56) agreeing they 
would “start ART when the doctor tells me I should start” and 12.5%  (7/56) disagreeing 
with the statement. 
Side effects were a concern for many ART-naïve men with 69.6% (39/56) agreeing with the 
statement “I am concerned about the possible side effects of ART”. Fewer men perceived 
drug resistance to be a problem, with 7% (4/57) agreeing with the statement “Starting ART 
now could reduce my future treatment options”, though nearly half the men (47.4%, 27/57) 
neither agreed or disagreed, or did not know the answer to this statement.  The 
permanence of treatment appeared to put a fifth of ART-naïve men off the idea of starting 
ART now; 20.7% (12/58) agreed with the statement “I would not start ART now because I 
would have to be on it for the rest of my life”, and 10.7% (6/56) of men agreed with the 
statement “Starting ART now would not fit in with my lifestyle”.  Short-course ART did not 
seem appealing to respondents, with 36.8% (21/57) of men agreeing with the statement “I 
would start ART now if I only had to take it for a year”.  
 Amongst men on ART 6.3.2
Of the 55 men who had started ART since their diagnosis, 94.5% (52/55) were still on ART at 
the time of questionnaire completion, see table 6.4. Whilst respondents were asked why 
they stopped ART, the 3 respondents not currently on ART did not give a reason for 
stopping. Most men (69.1%, 38/55) started ART within 1 month of their diagnosis and 
94.5% (52/55) within 6 months. The majority (75.6%; 41/55) also self-reported starting 
when their CD4 count was >350 cells/mL: 29.1% (16/55) at CD4 351-500, and 45.5% (25/55) 
at CD4>500. The self-reported last viral load of men on ART was mostly “detectable” at >50 
copies/mL (55.6% 30/54), whilst 31.5% (17/54) had an undetectable viral load and the rest 
were unsure.  
Figure 6.6 illustrates the attitudes, beliefs and reasons for starting ART amongst men who 
had started early ART. The most common reasons to start ART appeared to be health-
related: 96.3% (52/54) said they started “to control the spread of HIV in my body”, and 
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96.3% (52/54) “to reduce the damage HIV was doing to my body”. In addition, 85.2% 
(46/54) started to “improve my quality of life” and “to increase my life expectancy”. 
Overall, 90.7% (49/54) of the men on ART agreed “It is better for my health to start ART 
earlier rather than later”.  
Protecting partners from HIV was also important though, with 88.9% (48/54) agreeing they 
“started ART to reduce the risk of passing HIV to my sexual partner(s)”, though this may not 
have been wholly altruistic as 84.9% agreed with the statement “I started ART to reduce my 
anxiety about transmitting HIV to my sexual partner(s)”. 60.4% (32/53) of men agreed 
“Being on ART makes it easier to disclose my HIV status to sexual partners”. Around 1 in 10 
men (9.8%; 5/51) agreed with the statement “I started ART because my partner wanted me 
to”.  
Just over half (50.9%, 27/53) started as their doctor advised them to, and a similar 
proportion (51.9%, 27/52) agreed with the statement “When I am ill I take medication 
straight away to fight the illness”. 26.4% (14/53) of the men started ART early as part of a 
clinical trial. Treatment interruption was seen negatively by most men; 79.6% (43/54) 
agreed with the statement “Stopping or having a break in ART will be bad for my health”.  
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Table 6.4 Attitudes to early ART and reasons for starting amongst MSM initiating ART in 
early HIV infection 
Variable Level N Percentage 
How soon after diagnosis did you start 
ART? <1 month 38 69.1 
 
≥1 & <6 months 14 25.5 
 
≥ 6months 3 5.5 
Are you still on ART? No 3 5.5 
 
Yes 52 94.5 
What was your main reason for 
starting? Only for own health 8 14.5 
 
Mostly own health, a little to 
prevent transmission 13 23.6 
 
Equal mix of both 29 52.7 
 
Mostly to reduce transmission, 
but little for own health 2 3.6 
 
Only to reduce transmission 2 3.6 
 
Don't know 1 1.8 
Last CD4 before starting - self-
reported ≤200 1 1.8 
 
201-350 6 10.9 
 
351-500 16 29.1 
 
>500 25 45.5 
 
Can't remember/don't know 7 12.7 
Last viral load measure - self-reported <50 copies/mL 17 31.5 
 
≥50 copies/mL 30 55.6 
 
Can't remember/don't know 7 13 
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Figure 6.6 Attitudes towards early ART and reasons for starting early amongst MSM who started early ART (numbers denote percentages) 
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 Factors associated with early ART initiation in MSM with early 6.4
HIV infection 
 Time-adjusted analysis 6.4.1
Time from HIV diagnosis to questionnaire completion was considered to be an a-priori 
confounder and all models were adjusted for this. In addition, year of HIV diagnosis, HIV 
test interval, age at HIV seroconversion, CD4 count at diagnosis, recruitment from a centre 
with PHI interests and doctor advising the patient to start were all identified as factors 
likely to be associated with early ART initiation based on results of the qualitative study and 
the literature, and so comprised the “base model”.   
Table 6.5 highlights that after adjusting for time from diagnosis to questionnaire 
completion, only the doctor advising initiation of ART was significantly associated with early 
ART uptake (OR 7.34; 95% CI 2.76, 19.50; p<0.001). There was also a tendency that men on 
ART had a lower CD4 count at HIV diagnosis, median 520 (IQR 411, 718) in those not on ART 
compared to 491 (390, 629) in those on ART, though this was not significant at the p<0.05 
level in the regression model. 
Table 6.6 illustrates the association between various clinical factors and early ART initiation 
after adjusting for time from HIV diagnosis to questionnaire completion. Though there was 
no significant difference in the reporting of one or more seroconversion symptoms 
between those who had and hard not started early ART, men who reported a rash in the 
months preceding HIV diagnosis were more likely to have started ART to those who had not 
experienced a rash (OR 2.49; 1.06, 6.02; p=0.043). Men who had taken PEP in the past had 
3.15 times the odds of having started ART (95% CI 1.22, 8.09, p=0.017) compared to those 
who had not.  Men who were diagnosed with another STI at the time of HIV diagnosis were 
less likely to have started ART (OR 0.28; 95% CI 0.13, 0.63; p=0.002); though when 
examining individual STIs only gonorrhoea co-infection was associated at the p<0.05 level 
(OR 0.29; 0.12, 0.71; p=0.007, data not shown).  
The associations between sexual behaviours, both before and after HIV diagnosis, and early 
ART initiation (after adjusting for time from HIV diagnosis to questionnaire completion) are 
presented in table 6.7. None of the sexual behaviour risk factors were found to be 
associated with initiation of early ART, though there was a tendency that men on ART were 
less likely to report engaging in casual serodiscordant UAI before HIV diagnosis (OR 0.49; 
95% CI 0.22, 1.11; p=0.086).  
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Table 6.5 Base model and demographic factors associated with early ART initiation, adjusting for time from diagnosis to questionnaire completion 
  
ART naïve  On ART     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % N OR
a
 95% CI 
p-
value 
Time from diagnosis to 
survey completion 
Per month 61 1.4 (0.7, 5.5)  55 3.7 (1.6, 8.0) 116 1.14 1.02, 1.27 0.019 
Year first HIV positive Per year  61 2013 (2013, 2014)  55 2013 (2013, 2014) 116 1.55      0.85,  2.83 0.156 
HIV test interval
b
 Per month  61 2.8 (0, 5.9)  55 2.5 (0, 5.5) 116 0.95      0.83,  1.07 0.396 
Age at HIV seroconversion Per year 61 32.5 (27.3, 38.2)  55 33.4 (27.9, 41.3) 116 1.01      0.97,  1.06 0.55 
CD4 count at diagnosis
c
  Cells/mm
3
  58 520 (411, 718)  53 491 (390, 629) 111 0.92      0.84,  1.02 0.103 
Recruited from an HIV 
centre with PHI interests 
No  31 50.8  25 45.5 116 1 -  0.188 
Yes 30 49.2  30 54.5   1.71      0.77, 3.81   
Doctor advised starting 
ART 
No 32 58.2  12 23.1 107 1 -  <0.001 
Yes 23 41.8  40 76.9   7.34      2.76, 19.50   
Ethnicity  White 49 80.3  48 87.3 116 1 -  0.331 
 Non-white 12 19.7  7 12.7   0.6      0.21, 1.69   
Years full time education 
>16 years of age 
<3 years 7 11.5  10 18.2 116 1 -  0.383 
3 years or more 54 88.5  45 81.8   0.62      0.21, 1.81   
IQR=interquartile range; OR=odds ratio; CI=confidence interval; HIV test interval=time between HIV antibody negative and positive tests. 
a=OR adjusting for time from HIV diagnosis to survey completion modelled as a continuous term; b=interval between HIV antibody negative and positive tests; c=modelled as square root transformed cells/mm3 
 
  
  
 
2
2
9
 
Table 6.5 (continued)   
  
ART naïve  On ART     
Factor of interest Level n 
Median (IQR) 
or % 
 
n 
Median 
(IQR) or % N OR
a
 95% CI 
p-
value 
Currently employed  No 8 13.1  13 23.6 116 1 -  0.176 
  Yes 53 86.9  42 76.4   0.5      0.19, 1.36   
Own or rent accommodation 
Own  21 34.4  17 30.9 116 1 -  0.651 
Rent - private landlord 34 55.7  29 52.7   1.01      0.44, 2.31   
  Rent - other 6 9.8  9 16.4   1.71      0.50, 5.91   
Current living arrangements 
  
  
  
Alone 18 29.5  11 20 116 1 -  0.562 
Partner 17 27.9  14 25.5   1.03      0.35, 3.03   
Friends/tenants/lodgers 20 32.8  23 41.8   1.69      0.63, 4.52   
Family/guardians 6 9.8  7 12.7   1.97      0.51, 7.59   
Sexual orientation 
  
  
Gay/homosexual 54 88.5  50 90.9 115 1  - 0.842 
Bisexual 6 9.8  5 9.1   1.14      0.31, 4.14   
Other 1 1.6  0 0   1.14      1.02, 1.27   
Current regular male partner 
  
No  31 51.7  32 58.2 115 1 -  0.364 
Yes, HIV+  14 23.3  8 14.5   0.48      0.17, 1.36   
Yes, HIV-/unknown status  15 25  15 27.3   0.99      0.40, 2.41   
Recruited from London HIV centre 
No 16 26.2  21 38.2 116 1 -  0.453 
Yes 45 73.8  34 61.8   0.73      0.32, 1.67   
IQR=interquartile range; OR=odds ratio; CI=confidence interval 
a=OR adjusting for time from HIV diagnosis to survey completion modelled as a continuous term; b=interval between HIV antibody negative and positive tests; c=modelled as square root transformed cells/mm3 
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Table 6.6 Association between clinical factors and early ART initiation, after adjusting for time from diagnosis to questionnaire completion 
  
ART naïve  On ART     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % N OR
a
 95% CI 
p-
value 
Diagnosed in acute infection No 37 60.7  37 67.3 116 1 - 0.840 
Yes 24 39.3  18 32.7  0.92 0.42, 2.04  
HIV viral load at diagnosis Log10 copies per mL 57 4.85 (4.26, 5.83)  54 4.82 (4.30, 5.79) 111 1.12 0.81, 1.53 0.495 
Experienced seroconversion 
symptoms 
No 20 33.3  20 36.4 115 1 - 0.877 
Yes 40 66.7  35 63.6  0.94 0.43, 2.07  
Experienced rash at 
seroconversion 
No 49 81.7  36 65.4 115 1 - 0.043 
Yes 11 18.3  19 34.6  2.49 1.06, 6.02  
Experienced headache at 
seroconversion 
No 44 73.3  36 65.5 115 1 - 0.160 
Yes 16 26.7  19 34.6  1.83 0.79, 4.24  
Experienced sore throat at 
seroconversion 
No 39 65.0  34 61.8 115 1 - 0.584 
Yes 21 35.0  21 38.2  1.24 0.57, 2.72  
Experienced fever at 
seroconversion 
No 30 50.0  24 43.6 115 1 - 0.350 
Yes 30 50.0  31 56.4  1.44 0.67, 3.08  
Experienced body aches at 
seroconversion 
No 39 65.0  30 54.5 115 1 - 0.197 
Yes 21 35.0  25 45.5  1.66 0.77, 3.60  
IQR=interquartile range; OR=odds ratio; CI=confidence interval 
a=OR adjusting for time from HIV diagnosis to survey completion modelled as a continuous term 
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Table 6.6 (continued)   
  
ART naïve  On ART     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % N OR
a
 95% CI 
p-
value 
Experienced vomiting & diarrhoea at 
seroconversion 
No 43 71.7  42 76.4 115 1 - 0.704 
Yes 17 28.3  13 23.6  0.85 0.36, 1.99  
Experienced night sweats at seroconversion No 31 51.7  27 49.1 115 1 - 0.662 
Yes 29 48.3  28 50.9  1.18 0.56, 2.51  
Seroconversion symptoms affected daily 
routine 
No 38 63.3  32 58.2 115 1 - 0.484 
Yes 22 36.7  23 41.8  1.32 0.61, 2.85  
STI co-infection at diagnosis No 25 41.7  38 70.4 114 1 - 0.002 
Yes 35 58.3  16 29.6  0.28 0.13, 0.63  
Ever taken PEP No 52 86.7  36 65.5  1 - 0.017 
 Yes 8 13.3  19 34.5 115 3.15 1.22, 8.09  
IQR=interquartile range; OR=odds ratio; CI=confidence interval; STI=sexually transmitted infection; PEP=post exposure prophylaxis 
a=OR adjusting for time from HIV diagnosis to survey completion modelled as a continuous term 
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Table 6.7 Association between behavioural and attitudinal factors and early ART initiation, adjusting for time from diagnosis to questionnaire completion 
  ART naïve  On ART     
Factor of interest Level n Median 
(IQR) or % 
 n Median 
(IQR) or % 
N OR
a
 95% CI p-
value 
Had AI pre-diagnosis No 2 3.3  1 1.8 116 1 - 0.668 
Yes 59 96.7  54 98.2  1.73 0.14, 21.33  
Had casual AI pre-diagnosis No 10 16.4  10 18.2 116 1 - 0.867 
Yes 51 83.6  45 81.8  0.92 0.34, 2.47  
Had UAI pre-diagnosis No 9 15.0  9 16.7 114 1 - 0.514 
Yes 51 85.0  45 83.3  0.63 0.29, 1.35  
Had casual UAI pre-diagnosis No 23 38.3  26 49.1 113 1 - 0.235 
Yes 37 61.7  27 50.9  0.63 0.28, 1.42  
Had SD UAI pre-diagnosis No 18 31.0  21 38.9 112 1 - 0.268 
Yes 40 69.0  33 61.1  0.63 0.28, 1.42  
Had casual serodiscordant UAI pre-
diagnosis 
No 30 53.6  36 67.9 109 1 - 0.086 
Yes 26 46.4  17 32.1  0.49 0.22, 1.11  
ChemSex pre-diagnosis No 31 53.5  27 50.9 111 1 - 0.824 
Yes 27 46.6  26 49.1  1.09 0.51, 2.34  
Met partners in a sex on premises 
venue pre-diagnosis 
No 42 68.9  30 54.5 116 1 - 0.657 
Yes 19 31.1  25 45.5  1.19 0.56, 2.52  
Had AI post-diagnosis No 26 42.6  15 27.3 116 1 - 0.545 
 Yes 35 57.4  40 72.7  1.32 0.54, 3.26  
IQR=interquartile range; OR=odds ratio; CI=confidence interval; AI=anal intercourse; UAI=condomless anal intercourse; SD=serodiscordant 
a=OR adjusting for time from HIV diagnosis to survey completion modelled as a continuous term 
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Table 6.7 (continued) 
  ART naïve  On ART     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % 
N OR
a
 95% CI p-value 
Had casual AI post-diagnosis No 37 61.7 30 54.6 115 1 - 0.802 
Yes 23 38.3 25 45.5  0.90 0.39, 2.10  
Had UAI post-diagnosis No 46 75.4  33 60.0 116 1 - 0.296 
 
Yes 15 24.6  22 40.0 
 
1.53 0.67, 3.66 
 
Had casual UAI post-diagnosis No 49 80.3  45 81.8 116 1 - 0.309 
Yes 12 19.7  10 18.2  0.60 0.22, 1.66  
Had serodiscordant UAI post-diagnosis No 56 91.8  49 89.1 116 1 - 0.739 
Yes 5 8.2  6 10.9  0.80 0.20, 3.11  
Had casual serodiscordant UAI post-
diagnosis 
No 57 93.4  51 92.7 116 1 - 0.617 
Yes 4 6.6  4 7.3  0.68 0.14, 3.16  
ChemSex post diagnosis No 41 70.7  32 61.5 110 1 - 0.645 
Yes 17 29.3  20 38.5  1.22 0.53, 2.80  
Expected to start ART within a month of 
diagnosis 
No 33 55.0  26 48.2 114 1 - 0.210 
Yes 27 45.0  28 51.8  1.66 0.75, 3.64  
Would have taken ART at diagnosis if offered No/unsure 31 51.7  6 11.3 113 1 - <0.001 
Yes 29 48.3  47 88.7  15.6 4.61, 52.85  
IQR=interquartile range; OR=odds ratio; CI=confidence interval; AI=anal intercourse; UAI=condomless anal intercourse; SD=serodiscordant; a=OR adjusting for time from HIV diagnosis to survey completion modelled 
as a continuous term 
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Table 6.7 (continued) 
  ART naïve  On ART     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % 
N OR
a
 95% CI p-value 
“Being on ART and having an 
undetectable viral load means that 
HIV is unlikely to be passed to a 
sexual partner even through anal 
intercourse without a condom” 
Don’t agree 17 39.5  21 38.9 97 1 - 0.849 
Agree 26 60.5  33 61.1  1.08 0.47, 2.51  
“It is not necessary to disclose your 
HIV status if you are on ART and 
have an undetectable viral load” 
Don’t agree 36 83.7  43 81.1 96 1 - 0.821 
Agree 7 16.3  10 18.9  1.13 0.38, 3.38  
“Better treatment means people 
are less worried about HIV” 
Don’t agree 22 51.2  22 40.7  1 - 0.135 
Agree 21 48.8  32 59.3 97 1.93 0.82, 4.56  
“It is better for my health to start 
ART earlier rather than later” 
Don’t agree 22 39.3  5 9.3  1 - <0.001 
Agree 34 60.7  49 90.7 110 13.10 3.60, 47.3  
Disclosed HIV status to nobody No 52 86.7  54 98.2  1 - 0.079 
 Yes 8 13.3  1 1.8 115 0.15 0.02, 1.25  
Disclosed HIV status to GP No 44 73.3  28 50.9  1 - 0.030 
Yes 16 26.7  27 49.1 115 2.41 1.09, 5.34  
Disclosed HIV status to a HIV 
positive friend 
No 45 75.0  28 50.9   - 0.012 
Yes 15 25.0  27 49.1 115 2.81 1.26, 6.28  
IQR=interquartile range; OR=odds ratio; CI=confidence interval; a=OR adjusting for time from HIV diagnosis to survey completion modelled as a continuous term 
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Table 6.7 (continued) 
  ART naïve  On ART     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % 
N OR
a
 95% CI p-value 
Disclosed HIV status to a HIV 
negative friend 
No 38 63.3  15 27.3   - <0.001 
Yes 22 36.7  40 72.7 115 4.48 2.00, 10.06  
Disclosed HIV status to family No 45 75.0  34 61.8   - 0.275 
 Yes 15 25.0  21 38.2 115 1.58 0.69, 3.61  
Disclosed HIV status to work No 52 86.7  44 80.0   - 0.391 
Yes 8 13.3  11 20.0 115 1.56 0.56, 4.31  
IQR=interquartile range; OR=odds ratio; CI=confidence interval; a=OR adjusting for time from HIV diagnosis to survey completion modelled as a continuous term 
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There was a tendency that men who had disclosed their positive status to a friend were 
more likely to have initiated early ART (OR 2.18; 95% CI 1.26, 6.28; p=0.066); be it an HIV-
positive friend (OR 2.81; 95% CI 1.26, 6.28; p=0.012) or an HIV negative friend (OR 4.48; 
95% CI 2.00, 10.06; p<0.001).  They were also more likely to disclose their HIV positive 
status to their GP (OR 2.41; 95% CI 1.09, 5.34; p=0.03).  
Men who stated they would have accepted ART at diagnosis if they had been offered were 
much more likely to have started early ART (OR 7.57; 95% CI 1.49, 38.40; p<0.001) than 
those that would not have or were unsure.  Of the attitude statements, starting ART early 
was associated with agreement with the statement “It is better for my health to start ART 
earlier rather than later”; those who agreed were more likely to have started ART (OR 
13.05; 95% CI 3.60, 47.27; p<0.001).  
 Multivariate analysis 6.4.2
Factors found to be associated with initiation of early ART in the time from diagnosis to 
survey completion adjusted model at p<0.20 were considered for multivariate analysis and 
grouped into a hierarchical conceptual framework outlined in table 6.8. Time from 
diagnosis to questionnaire completion was considered an a-priori confounder and adjusted 
for in all analyses.  Year of HIV diagnosis, CD4 at seroconversion, the patient’s doctor 
advising to start ART and being recruited from a centre with PHI interests have all been 
noted to be associated with uptake of early ART in previous research so comprised the base 
model.  All other factors were grouped into clinical/seroconversion factors, attitudes and 
beliefs, and behavioural factors and modelled in the next stage within their respective 
groups.  
Table 6.9 indicates that after adjusting for all of the base model variables, time from 
diagnosis to questionnaire completion was highly associated with early ART initiation with a 
1.4 increase in the odds of starting early per 1 month increase in time elapse since HIV 
diagnosis. Men whose doctors had advised early ART were more likely to have initiated 
ART, with the odds of starting early nearly 6 times higher than those whose doctors did not 
(aOR 5.98; 95% CI 2.14, 16.68; p=0.001). There was no evidence of any interactions 
between any of the base model variables.  
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Table 6.8 Conceptual hierarchical framework for multivariate modelling of factors 
associated with early ART 
Model level Variables included 
A-priori confounders Time from diagnosis to survey completion  
Base model  Year first HIV positive 
CD4 count at diagnosis
a
 
Recruited from an HIV centre with PHI interests 
Dr advised starting ART 
Socio-demographic  factors Currently employed  
Clinical/seroconversion factors Seroconversion symptoms – rash 
Seroconversion symptoms – headache 
Seroconversion symptoms – body aches 
STI co-infection at HIV diagnosis 
Ever taken PEP 
Attitudes and beliefs Would have accepted ART at diagnosis if offered 
“It is better for my health to start ART earlier rather than later” 
 “Better HIV treatment means that people are less worried about 
catching HIV” 
Behavioural factors Had casual serodiscordant UAI in 6 months before HIV diagnosis 
Disclosed status to nobody
b
 
Disclosed status to GP 
Disclosed status to HIV+ friend 
Disclosed status to HIV- friend 
Note: all factors included in the table were associated at the p<0.2 level in univariate time-adjusted analysis 
a=square-root transformed cells/mm3 
b=whilst this independent variable was associated in the time from HIV diagnosis to questionnaire completion adjusted 
analysis, small numbers meant it was not possible to include it in multivariate analysis 
 
Table 6.9 Association between base model variables and early ART initiation, after 
adjusting for all other variables in the table (N=103) 
Variable Level aOR
a
 95% CI p-value 
Time from HIV diagnosis to survey 
completion  
Per 1 month increase 1.40 1.16, 1.70 <0.001 
Year diagnosed HIV positive  Per 1  year increase 2.07 0.93, 4.59 0.074 
CD4 count at seroconversion  (square root 
cells/mm
3
) 
Per 1 unit increase 0.91 0.81, 1.02 0.102 
Recruited from a PHI centre No 1 - 0.123 
 Yes 2.25 0.80, 6.36  
Doctor advised starting ART No 1 - 0.001 
 Yes 5.98 2.14, 16.68  
aOR=adjusted OR; CI=confidence interval; PHI=primary HIV infection 
a=OR adjusted for all of the other variables present in the table 
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Table 6.10 shows the association between the demographic and clinical factors found to be 
associated with initiation of early ART at p<0.2 in the time-adjusted analysis. Model 1 
shows the association of each independent variable after adjusting for the base model 
variables time from HIV diagnosis to questionnaire completion, year of HIV diagnosis and 
doctor advised starting ART. After adjusting for these, men diagnosed with an STI at HIV 
diagnosis were less likely to have initiated early ART (aOR 0.28; 95% CI 0.11, 0.72; p=0.009) 
compared to those who did not have an STI. Men who had reported previous PEP use were 
more likely to have started early (aOR 3.71; 95%CI 1.22, 11.60; p=0.021), as were those who 
reported experiencing a rash at seroconversion (aOR 3.01; 95% CI 1.00, 9.08; p=0.051).   
Table  6.10 Association between demographic and clinical variables and early ART 
initiation, adjusted for base model and other covariates 
 
Model 2 in table 6.10 shows the association of those variables associated with early ART 
initiation in model 1 at the p<0.10 level, after adjusting for associated base model variables, 
as well as all other independent variables in the table associated at p<0.1 in model 1.  The 
odds ratios remained largely unchanged for all three of these associated variables, after 
   Model 1    Model 2  
Variable Level aOR  95% CI p-value 
 
aOR 
95% 
CI p-value 
Currently employed No 1 - 0.149   N/A  
Yes 0.40 0.12, 1.39   
Self-reported rash No 1 - 0.051  1 - 0.050 
Yes 3.01 1.00, 9.08   3.22 1.00, 
10.37 
 
Self-reported 
headaches 
No 1 - 0.225   N/A  
Yes 1.87 0.68, 5.15   
Self-reported  body 
aches 
No 1 - 0.264   N/A  
Yes 1.70 0.67, 4.32   
STI coinfection at 
HIV 
No 1 - 0.009  1 - 0.023 
Yes 0.28 0.11, 0.72   0.31 0.12, 0.85  
Previous PEP No 1 - 0.021  1 - 0.021 
 
Yes 3.76 1.22, 11.60   4.14 1.24, 
13.81 
 
aOR=adjusted odds ratio; CI=confidence interval; STI=sexually transmitted infection; PEP=post exposure prophylaxis 
Model 1= adjusted for time from HIV diagnosis to questionnaire completion, year of HIV diagnosis, doctor advised starting 
ART;  
Model 2= adjusted for time from HIV diagnosis to questionnaire completion, year of HIV diagnosis, doctor advised starting 
ART, experienced rash at seroconversion, STI coinfection  
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adjusting for the other variables in the table associated at p<0.1, as well as associated base 
level variables.  
Table 6.11 outlines the association between early ART initiation and the attitudes and 
behavioural variables which were found to be associated at p<0.2 in the time-adjusted 
analysis. Model 1 shows that, after adjusting for the base model variables, there was very 
strong evidence that men were more likely to have initiated early ART if they reported they 
would have accepted ART at diagnosis (aOR 21.87; 95% CI 4.50, 106.26; p<0.001) and if 
they agreed with the statement “It is better for my health to start ART earlier rather than 
later” (aOR 50.88; 95% CI 6.49, 399.07; p<0.001).  Men who had initiated ART in EHI were 
more likely to have disclosed their HIV status to their friends, be it HIV-positive friends (aOR 
3.41; 95% CI 1.29, 9.07; p=0.013) or HIV negative friends (aOR 3.69; 95% CI 1.42, 9.58; 
p=0.007). After adjusting for all the other associated variables at p<0.10 in model 1 as well 
as base model variables, disclosure to a HIV-positive friend was no longer associated with 
early ART initiation. The odds ratio dramatically dropped for agreement with the statement 
“It is better for my health to start ART earlier rather than later” (aOR 28.06; 95% CI 2.05, 
383.71; p=0.012) though it remained significant.  The other associated variables changed 
very little.  
Table 6.12 shows the final model of factors associated with initiation of early ART, adjusted 
for all over variables in the model. After adjusting for all of the other variables associated at 
the p<0.10 level at each level of the conceptual framework, time from HIV diagnosis to 
survey completion was still strongly associated with early ART initiation, with the odds of 
starting ART increasing by 1.53 per month elapsed between HIV diagnosis and 
questionnaire completion (95% CI 1.14, 2.05; p=0.004). Men who reported that they would 
have accepted ART at diagnosis if offered were also significantly more likely to have started 
early ART after adjusting for all other variables (aOR 15.50; 95% CI 2.66, 90.27; p=0.002) as 
were men who held positive health beliefs around early ART by agreeing with the 
statement “It is better for my health to start ART earlier rather than later” (aOR 17.36; 95% 
CI 1.57, 192.18; p=0.020). Independently of all other factors, those men whose clinician had 
recommended starting ART had 5.03 times the odds of having initiated early ART (95% CI 
1.15, 22.03; p=0.015).  There was also evidence that men who had disclosed their HIV 
status to an HIV negative friend were more likely to have initiated early ART (aOR 6.96; 95% 
CI 1.44, 33.75; p=0.016). None of the other factors remained significant in the fully-adjusted 
model. 
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Table 6.11 Association between attitudes and behavioural variables and early ART initiation, adjusting for base model and other covariates 
 
  Model 1  Model 2 
Variable Level aOR 95% CI p-value  aOR 95% CI p-value 
Would have accepted ART at diagnosis if offered No 1 - <0.001  1 - 0.001 
Yes 21.87 4.50, 106.26   20.61 3.40, 124.90  
“Better HIV treatment means that people are less worried about catching HIV” No 1 - 0.171   N/A  
Yes 2.02 0.74, 5.56      
“It is better for my health to start ART earlier rather than later” No 1 - <0.001  1 - 0.012 
Yes 50.88 6.49, 399.07   28.06 2.05, 383.71  
Reported casual SD UAI in 6 months before HIV diagnosis No 1 - 0.282   N/A  
Yes 0.57 0.20, 1.59      
Disclosed HIV status to GP 
 
No 1 - 0.117   N/A  
Yes 2.16 0.82, 5.66      
Disclosed HIV status to  HIV-positive  friend No 1 - 0.013  1 - 0.131 
Yes 3.41 1.29, 9.07   3.20 0.71, 14.48  
Disclosed HIV status to HIV negative friend No 1 - 0.007  1 - 0.048 
 Yes 3.69 1.42, 9.58   4.49 1.01, 19.96  
aOR=adjusted odds ratio; CI=confidence interval; SD=serodiscordant/status unknown; UAI=condomless anal intercourse. 
Model 1= adjusted for time from HIV diagnosis to questionnaire completion, year of HIV diagnosis, doctor advised starting ART;  
Model 2=adjusted for time from HIV diagnosis to questionnaire completion, year of HIV diagnosis, doctor advised starting ART and all variables associated at p<0.01 in model 1. 
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Table 6.12 Final adjusted model of factors associated with initiation of early ART (N=94) 
 
Level aOR
a
 95% CI  p-
value 
Time from HIV diagnosis to survey completion  Continuous per 
month increase 
1.53 1.14, 2.05 0.004 
Year diagnosed HIV positive  Continuous per  
year increase 
2.38 0.62, 9.15 0.207 
Square root CD4 at seroconversion (cells/mm
3
) Continuous per 1 
unit increase 
0.94 0.79, 1.13 0.524 
Clinician recommended starting ART No 1 - 0.015 
 Yes 5.03 1.15, 22.03  
Experienced a rash at seroconversion No 1 - 0.861 
 Yes 0.87 0.19, 4.09  
STI co-infection at HIV diagnosis No 1 - 0.312 
 Yes 0.51 0.14, 1.88  
Previously taken PEP No 1 - 0.372 
 Yes 2.13 0.41, 11.13  
Would have accepted ART at diagnosis if 
offered 
No 1 - 0.002 
 Yes 15.5
0 
2.66, 90.27  
“It is better for my health to start ART earlier 
rather than later” 
No 1 - 0.020 
Yes 17.3
6 
1.57, 
192.18 
 
Disclosed HIV status to HIV negative friend No 1 - 0.016 
 Yes 6.96 1.44, 33.75  
aOR=adjusted odds ratio; CI=confidence interval; STI=sexually transmitted infection; PEP=post exposure prophylaxis. 
a=model adjusted for all other variables in the table 
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  Sexual behaviour amongst MSM recent seroconverters  6.5
 Sexual behaviour in the six months prior to, and time since, HIV diagnosis 6.5.1
Table 6.13 shows the prevalence of various sexual behaviours reported by the men in the 
survey during the 6 months before HIV diagnosis, and the time between HIV diagnosis and 
questionnaire completion. All men reported having any type of sex (either anal or oral) with 
another man in the six months prior to diagnosis, and nearly all men (97.4%, 114/117) reported 
having any AI during that time, the median number of partners being 6 (3, 15).  82.9% (97/117) 
reported AI with a casual (once only) male partner over this time, median number of casual 
partners 4 (1, 9).  Condomless AI (UAI) was reported by 84.3% (97/115) and condomless UAI 
with a casual partner by 58.1% (65/114), median overall and casual UAI partner numbers were 
2 (1, 5) and 1 (0, 3). UAI with serodiscordant/unknown status men in (serodiscordant UAI) the 
six months prior to HIV diagnosis was reported by 65.5% (74/113), and with casual partners by 
40.0% (44/110). The median number of overall serodiscordant UAI partners was 1 (0, 3) and 
casual serodiscordant UAI partners was 0 (0, 2).  
Of note, 21.1% (16/76) of the 76 men who reported experiencing seroconversion symptoms 
also reported having UAI whilst experiencing these symptoms. Men experiencing 
seroconversion-like symptoms reported UAI with more regular partners over the symptomatic 
period median (IQR) of 1 (1, 2.5) compared to 0 (0, 2) casual partners. 
As expected, there was a decrease in the proportion of men reporting any sexual activity after 
diagnosis with 31.6% (37/117) of men reporting having had no sex (either OI or AI) since their 
HIV diagnosis. Though it is important to note that the recall period post-diagnosis varied 
between individuals and was much less than the 6 month recall period pre-diagnosis (median 
76 days; IQR 29-191). The proportion of men reporting any AI since diagnosis was 64.1% 
(75/117), with reported median partner numbers of 1 (0, 3). 41.4% (48/116) reported AI with a 
casual partner, median partner number 0 (0, 2).  Less than a third of men (31.6%, 37/117) 
reported UAI and 18.8% (22/117) casual UAI.  Around 1 in 10 of the men (9.6%, 11/117) 
reported having UAI with serodiscordant/status unknown partners since their diagnosis. 6.8% 
(8/117) reported serodiscordant UAI with casual partners.  
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Table 6.13 Prevalence of reported sexual behaviours before and after HIV diagnosis amongst 
MSM seroconverters attending UK clinics 
  
In 6 months 
before HIV diagnosis 
 
In time interval 
since HIV diagnosis 
Variable 
 
n 
Median 
(IQR) or %   n 
Median 
(IQR) or % 
Had any sex (AI or OI) No 0 0 
 
37 31.6 
Yes 117 100 
 
80 68.4 
Any AI No 3 2.6 
 
42 35.9 
Yes 114 97.4 
 
75 64.1 
No. of AI partners 
 
117 6 (3, 15) 
 
117 1 (0, 3) 
Any casual AI No 20 17.1 
 
68 58.6 
Yes 97 82.9 
 
48 41.4 
No. of casual AI partners 
 
117 4 (1, 9) 
 
116 0 (0,2) 
Any UAI No 18 15.7 
 
80 68.4 
Yes 97 84.3 
 
37 31.6 
No. of UAI  partners 
 
115 2 (1, 5) 
 
117 0 (0,1) 
Any casual UAI  No 49 43 
 
95 81.2 
Yes 65 57 
 
22 18.8 
No. of casual UAI partners 
 
114 1 (0, 3) 
 
117 0 (0, 0) 
Any SD UAI  No 39 34.5 
 
106 90.6 
Yes 74 65.5 
 
11 9.4 
No. of SD UAI partners 
 
113 1 (0, 3) 
 
117 0 (0, 0) 
Any casual SD UAI  No 66 60 
 
109 93.2 
Yes 44 40 
 
8 6.8 
No. of casual SD UAI partners 
 
110 0 (0, 2) 
 
117 0 (0, 0) 
Illegal drug use before or during sex No 54 48.2 
 
69 62.7 
Yes 58 51.8 
 
41 37.3 
Injected drugs before or during sex No 110 94.8 
 
106 93.8 
Yes 6 5.2 
 
7 6.2 
Engaged in "ChemSex" No 59 52.7 
 
74 66.7 
Yes 53 47.3 
 
37 33.3 
Engaged in high-risk sex  
(either SD UAI or ChemSex and AI) 
No 29 24.8 76 65.0 
Yes  88  75.2   41 35.0 
IQR=interquartile range; AI=anal intercourse; OI=oral intercourse; UAI=condomless anal intercourse; SD UAI=serodiscordant/status 
unknown condomless anal intercourse. 
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 Recreational drug use before and during sex 6.5.2
Table 6.13 shows that there were high levels of recreational drug use amongst respondents; in 
the six months prior to diagnosis, 51.8%, (58/112) of men reported using illegal drugs 
immediately before or during sex but this proportion dropped markedly after diagnosis to  
37.3% (41/110), though fewer men had resumed sexual activity after diagnosis.  The proportion 
of men reporting injecting drugs before or during sex was low though at 5.2% (6/116) prior to 
diagnosis and 6.2% (7/113) after diagnosis. 47.3% of men (53/112) had participated in 
“ChemSex” (defined as the use of any of any the following drugs before or during sex: 
GHB/GBL, methedrone, methamphetamine, piperazines or ketamine) in the 6 months prior to 
diagnosis, compared to 33.3% (37/111) in the time since diagnosis. 
Figure 6.7 shows that in the six months prior to HIV diagnosis, the most commonly-used 
stimulants before and during sex were alcohol and poppers with 72.3% (81/112) and 65.2% 
(73/112) of men, respectively reporting their use. These remained the most commonly used 
stimulants in the period after HIV diagnosis, though the proportion of men who reported using 
them decreased markedly to 40.9% (45/110) for alcohol and 39.1% (43/110) for poppers.  The 
most popular illegal drugs used before and during sex were the same both before and after HIV 
diagnosis, though the proportion using them decreased after diagnosis in all cases.  
 Meeting sexual partners  6.5.3
Figure 6.8 shows the most commonly reported methods of meeting sexual partners in the six 
months prior to diagnosis was through smartphone apps (66.7%, 78/117), the  internet (60.7%, 
71/117), in bars/clubs (48.7%, 57/117) and in saunas (29.3%, 34/117) with men using a 
median(IQR) of 3 (2, 4) methods to meet partners. After diagnosis, the four most common 
methods for meeting partners remained the same, though the popularity of their use amongst 
those men who were sexually active was lower. Meeting partners on the internet and in bars 
and clubs were notably less popular after HIV diagnosis. Men reported using a fewer number of 
methods of meeting new partners after diagnosis of median 2 (1, 3).  
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Figure 6.7 Reported alcohol and drug use during sex amongst MSM before and after HIV 
diagnosis  
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Of note, in the six months prior to diagnosis, the proportion of sexually active men who met 
new partners at a sex-on-premises (SOP) venue (sauna/backroom or sex club/cruising ground 
or cottage) was 38.5% (45/117), and this remained similar at 31.0% (22/71) after diagnosis. Of 
the men who met new partners in a SOP venue after their HIV diagnosis, all but one (95.5% 
21/22) had met partners in an SOP venue before their diagnosis. 
Figure 6.8 Reported methods of meeting new sexual partners reported by sexually active 
MSM seroconverters before and after their HIV diagnosis  
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 Factors associated with engagement in high-risk sex after HIV diagnosis 6.5.4
Figure 6.9 outlines sexual behaviour by transmission risk. It is clear that 57% of survey 
respondents engaged only in behaviour which carried very little risk of transmitting HIV to 
sexual partners either by having not engaging in AI since diagnosis (36%) or exclusively using 
condoms for AI (21%). A further 8% of men did engage in UAI but reduced their risk of 
transmitting HIV by exclusively serosorting for HIV-positive partners. The highest risk of onward 
transmission comes from the 10% who engaged in UAI with serodiscordant or status unknown 
partners and the 26% who reported having AI since HIV diagnosis and engaging in ChemSex, 
due to the lack of control over safe sex practices under the influence of ChemSex drugs.   
Figure 6.9 Prevalence of sexual behaviours amongst MSM after receiving HIV diagnosis 
(n=117) 
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since receiving your HIV diagnosis?”. Overall, 35.0% (41/117) of men had engaged in sex that 
could have led to onward transmission of HIV: 30 had engaged in ChemSex and AI since 
diagnosis, 5 had engaged in serodiscordant UAI, and 6 had engaged in both serodiscordant UAI 
and ChemSex.  
Table 6.14, illustrates the association between demographic factors and engagement in high-
risk sex, post diagnosis. As expected, time from HIV diagnosis to questionnaire completion was 
strongly associated the odds of engaging in high-risk sex after HIV diagnosis; the odds 
increasing by 1.21 for every month since diagnosis (95% CI 1.08, 1.35; p=0.001). All associations 
between independent variables are adjusted for time from HIV diagnosis to questionnaire 
completion. Of note, a larger proportion of men who engaged in high-risk sex after HIV 
diagnosis did not have a regular male partner, compared to men not engaging in high-risk sex, 
65.9% and 49.3%, respectively, however there was only very weak evidence of an association 
after adjusting for time from diagnosis to questionnaire completion (p=0.093). None of the 
other demographic factors were associated with engaging in high-risk sex after HIV diagnosis 
after adjusting for time from HIV diagnosis to questionnaire completion. 
Table 6.15 shows the association between clinical factors and engagement in high-risk sex after 
HIV diagnosis. After adjusting for time from HIV diagnosis to questionnaire completion, there 
was weak evidence that men recruited from centres with a PHI research interest were more 
likely to have engaged in risky sex since their HIV diagnosis (OR 2.32; 95% CI 0.95, 5.63; 
p=0.064). There was also weak evidence that men who reported experiencing seroconversion 
like symptoms were less likely to have engaged in high-risk sex since diagnosis (OR 0.34; 95% CI 
0.20, 1.05; p=0.066). Specifically, men who reported a rash were significantly less likely to 
report high-risk sex after diagnosis (OR 0.34; 95% CI 0.12, 0.97; p=0.043), as were those who 
reported having a sore throat (OR 0.37; 95% CI 0.15, 0.91; p=0.031) or body aches (OR 0.24; 
95% CI 0.10, 0.62; p=0.003). The odds of engaging in high-risk sex after HIV diagnosis were 4.73 
times higher for men who reported previously taking PEP, compared to those who had never 
taken PEP (95% CI 1.81, 12.33; p=0.001). Although more of the men who had engaged in high-
risk sex had initiated ART than men who did not (58.5% vs 41.3%), there was no significant 
association after adjusting for time from HIV diagnosis to questionnaire completion. 
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Table 6.14 Demographic and social factors associated with engagement in high-risk sex after HIV diagnosis, adjusting for time from HIV 
diagnosis to questionnaire completion 
  
Has not engaged in 
high-risk sex since HIV 
diagnosis 
 
Engaged in high-risk sex 
since HIV diagnosis     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % N OR
a
 95% CI 
p-
value 
Time from diagnosis to 
survey completion
b
 
Per month increase 
(continuous) 
76 1.5 (0.7, 4.8)  41 5.0 (2.1, 8.0) 117 1.21 1.08, 1.35 0.001 
Year of HIV diagnosis Per year increase 
(continuous) 
76 2014 (2013, 
2014) 
 41 2013 (2013, 2014) 117 0.68 0.35, 1.33 0.259 
Age at HIV seroconversion Per year increase 
(continuous) 76 
32.6 (27.4, 
40.2) 
 
41 32.8 (28.4, 37.4) 117 0.97 0.92, 1.02 0.232 
Ethnicity  White 61 80.3  37 90.2 117 1 - 0.169 
 Non-white 15 19.7  4 9.8  0.42 0.12, 1.45  
Recruited from London 
HIV centre 
No 24 34.6  14 34.1 117 1 - 0.463 
Yes 52 68.4  27 65.9  1.38 0.57, 3.41  
Years full time education 
after 16 years of age 
<3 years 11 14.5  7 17.1 117 1 - 0.994 
3 years or more 65 85.5  34 82.9  1.00 0.33, 2.99 
 Currently employed  No 16 21.1  5 12.2 117 1 - 0.162
  Yes 60 79.0  36 87.8  2.28 0.72, 7.22  
Own or rent 
accommodation 
Own  25 32.8  13 31.7 117 1 - 0.955 
Rent - private landlord 41 54.0  23 56.1  0.98 0.40, 2.37  
  Rent - other 10 13.2  5 12.2  0.82 0.22, 3.09  
IQR=interquartile range; OR=odds ratio (adjusted for time from HIV diagnosis to questionnaire completion); CI= confidence interval 
a=odds ratio adjusting for time from HIV diagnosis to questionnaire completion; b=likelihood ratio test for departure from linearity modelling time from diagnosis to questionnaire completion as a 
linear versus a 4 group categorical variable p=0.588. 
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Table 6.14 (continued) 
  
Has not engaged in 
high-risk sex since HIV 
diagnosis 
 
Engaged in high-risk sex 
since HIV diagnosis     
Factor of interest Level n 
Median 
(IQR) or % 
 n
n 
Median 
(IQR) or % N OR
a
 95% CI 
p-
value 
Current living 
arrangements 
Alone 20 26.3  10 24.4 117 1 - 0.244 
Partner 21 27.6  10 24.4  0.66 0.21, 2.10  
Friends/tenants/lodgers 24 31.6  19 46.3  1.44 0.52, 4.00  
Family/guardians 11 14.5  2 4.9  0.37 0.06, 2.11  
Sexual orientation 
  
Gay/homosexual 66 86.8  39 95.1 117 1 - 0.350 
Bisexual/Other 10 13.2  2 4.9  0.46 0.09, 2.35  
Current regular male 
partner (RMP) 
  
No RMP 37 49.3  27 65.9 116 1 - 0.093 
HIV+ RMP 14 18.7  8 19.5  0.68 0.23, 1.96  
HIV-/unknown RMP 24 32.0  6 14.6  0.32 0.11, 0.94  
IQR=interquartile range; OR=odds ratio; CI= confidence interval 
a=odds ratio adjusting for time from HIV diagnosis to questionnaire completion 
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Table 6.15 Clinical factors associated with engagement in high-risk sex after HIV diagnosis, adjusting for time from HIV diagnosis to 
questionnaire completion 
  
Has not engaged in high-
risk sex since HIV 
diagnosis 
 
Engaged in high-risk sex 
since HIV diagnosis     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % N OR
a
 95% CI p-value 
HIV test interval  Per month increase 
(continuous) 
76 3.0 (0.0, 5.4)  41 2.5 (0.2, 5.9) 117 0.91 0.80, 1.05 0.185 
Diagnosed in acute 
infection 
No 60 79.0  32 78.1 117 1 - 0.324 
Yes 16 21.0  9 21.9  1.66 0.61, 4.56  
CD4 count at diagnosis (square 
root transformed cells/mm3) 
 Per unit increase 
(continuous) 
72 458.3  
(398.3, 672.5) 
 40 579.8  
(418.0, 648.3) 
112 1.03 0.93, 1.13 0.592 
HIV viral load at 
seroconversion 
Per log10 increase 
(continuous) 
73 4.9 (4.4, 5.8)  39 4.5 (4.1, 5.6) 112 0.93 0.66, 1.31 0.671 
Recruited from an HIV 
centre with PHI 
interests 
No  39 51.3  18 43.9  1 - 0.064 
Yes 37 48.7  23 56.1 117 2.32 0.95, 5.63  
Doctor advised starting 
ART 
No 29 42.0  15 39.5  1 - 0.652 
Yes 40 57.0  23 60.5 107 1.59 0.65, 3.87  
Experienced 
seroconversion symptoms  
No 21 28.0  19 46.3  1 - 0.066 
Yes 54 72.0  22 53.7 116 0.46 0.20, 1.05  
Experienced rash at 
seroconversion 
No 51 68.0  35 85.4  1 - 0.043 
Yes 24 32.0  6 14.6 116 0.34 0.12, 0.97  
IQR=interquartile range; OR=odds ratio; CI=confidence interval; STI=sexually transmitted infection; HIV test interval=time between HIV Ab negative and positive tests 
a=odds ratio adjusting for time from HIV diagnosis to questionnaire completion 
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Table 6.15 (continued) 
  
Not engaged in high-risk 
sex since HIV diagnosis 
 Engaged in high-risk 
sex since HIV 
diagnosis     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % N OR
a
 95% CI p-value 
Experienced headache at 
seroconversion 
No 48 64.0  33 80.5 116 1 - 0.197 
Yes 27 36.0  8 19.5  0.54 0.21, 1.38  
Experienced sore throat at 
seroconversion 
No 42 56.0  32 78.1 116 1 - 0.031 
Yes 33 44.0  9 21.9  0.37 0.15, 0.91  
Experienced fever at 
seroconversion 
No 32 42.7  22 53.7 116 1 - 0.358 
Yes 43 57.3  19 46.3  0.69 0.31, 1.53  
Experienced body aches at 
seroconversion  
No 37 49.3  32 78.1 116 1 - 0.003 
Yes 38 50.7  9 21.9  0.24 0.10, 0.62  
Experienced vomiting & diarrhoea at 
seroconversion 
No 56 74.7  30 73.2 116 1 - 0.579 
Yes 19 25.3  11 26.8  1.29 0.52, 3.21  
Experienced night sweats at seroconversion No 34 45.3  24 58.5 116 1 - 0.206 
Yes 41 54.7  17 41.5  0.59 0.26, 1.33  
Seroconversion symptoms affected daily 
routine 
No 42 56.0  29 70.7 116 1 - 0.159 
Yes 33 44.0  12 29.3  0.54 0.23, 1.27  
STI co-infection at diagnosis No 43 56.6  21 53.9 115 1 - 0.720 
Yes 33 43.4  18 46.1  1.16 0.51, 2.64  
IQR=interquartile range; OR=odds ratio; CI=confidence interval; STI=sexually transmitted infection 
a=odds ratio adjusting for time from HIV diagnosis to questionnaire completion 
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Table 6.15 (continued) 
  
Not engaged in high-risk 
sex since HIV diagnosis 
 Engaged in high-risk sex 
since HIV diagnosis     
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % N OR
a
 95% CI p-value 
Ever taken PEP No 66 86.8  23 57.5 116 1 - 0.001 
 Yes 10 13.2  17 42.5  4.73 1.81, 12.33  
Currently taking ART No 44 58.7  17 41.5 116 1 - 0.287 
 Yes 31 41.3  24 58.5  1.56 0.69, 3.56  
IQR=interquartile range; OR=odds ratio; CI= confidence interval; PEP=post exposure prophylaxis; ART=antiretroviral therapy 
a=odds ratio adjusting for time from HIV diagnosis to questionnaire completion 
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Table 6.16 shows the association between sexual behaviour in the six months prior to diagnosis 
and engagement in high risk sex since HIV diagnosis, after adjusting for time from HIV diagnosis 
to questionnaire completion. The odds of engaging in risky sex post-diagnosis were higher for 
men who reported casual AI prior to HIV diagnosis (OR 4.37; 95% CI 1.13, 16.93; p=0.033) and 
casual condomless AI prior to diagnosis (OR 3.41; 95% CI 1.39, 8.42; p=0.008). There was very 
strong evidence that engagement in ChemSex prior to diagnosis was a risk factor for 
engagement in high-risk sex after HIV diagnosis (OR 26.95; 95% CI 7.39, 98.30; p<0.001). In 
addition, men who engaged in high-risk sex after diagnosis were more likely to have met 
partners in a sex on premises venue prior to diagnosis (OR 3.17; 95% CI 1.38, 7.29; p=0.007). 
As is illustrated in table 6.16, men who reported having high-risk sex after HIV diagnosis also 
reported significantly higher numbers of regular and casual AI partners compared to those who 
did not.  This was true also of regular and casual UAI partners, and serodiscordant UAI partners. 
As the distribution for sexual partner count variables were skewed, I conducted sensitivity 
analyses where observations in the tail (>99th percentile) were removed to check for leverage. 
The odds ratios and confidence intervals remained unchanged for all partner count variables. 
Table 6.17 shows the association between various sexual behaviours after diagnosis and 
engaging in high-risk sex, after adjusting for time from HIV diagnosis to questionnaire 
completion. Men who had engaged in high-risk sex were significantly more likely to have had 
higher AI partner numbers since diagnosis, both regular (OR 1.41; 95% CI 1.16, 1.71; p=0.001) 
and casual partners (OR 1.69; 95% CI 1.24, 2.29; p=0.001). They were also much more likely to 
report having condomless AI (OR 10.40; 95% CI 4.01, 26.80; p<0.001) and condomless AI with 
one or more casual partners (OR 16.90; 95% CI 4.47, 63.82; p<0.001). Serodiscordant UAI and 
ChemSex after HIV diagnosis were not included as risk-factors in the model as they comprised 
the definition of the outcome under study, high-risk sex.
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Table 6.16 Association between pre-diagnosis sexual behaviours and engagement in high-risk sex HIV after diagnosis, adjusting for time from 
HIV diagnosis to questionnaire completion 
  Has not engaged in high-
risk sex since HIV 
diagnosis 
 
Engaged in high-risk 
sex since HIV diagnosis 
    
Factor of interest Level n 
Median 
(IQR) or %  n 
Median 
(IQR) or % N OR
a
 95% CI p-value 
Any AI pre-diagnosis No 3 3.9  0 0.0     
Yes 73 96.1  41 100.0 117 N/A N/A N/A  
Median number of AI 
partners pre-diagnosis 
Per 1 partner 
increase (continuous) 
76 4(2, 8.5) 
 
41 12 (6, 20) 117 1.09 1.04, 1.14 0.001 
Any casual AI pre-diagnosis No 17 22.4  3 7.3  1 - 0.033 
Yes 59 77.6  38 92.7 117 4.37 1.13, 16.93  
Median number of casual 
AI partners pre-diagnosis 
Per 1 partner 
increase (continuous) 
76 2(1, 5.5) 
 
41 8 (3, 15) 117 1.09 1.03, 1.15 0.003 
Any UAI pre-diagnosis No 16 21.3  2 5.0  1 - 0.070 
Yes 59 78.7  38 95.0 115 4.25 0.89, 20.31  
Median number of UAI 
partners pre-diagnosis 
Per 1 partner 
increase (continuous) 
75 2 (1, 3) 
 
40 3.5 (2, 12) 115 1.18 1.06, 1.31 0.002 
Any casual UAI pre-
diagnosis 
No 39 52.0  10 25.6  1 - 0.008 
Yes 36 48.0  29 74.4 114 3.41 1.39, 8.42  
Median number of casual 
UAI partners pre-diagnosis 
Per 1 partner 
increase (continuous) 
75 0 (0, 2) 
 
39 2 (0, 8) 114 1.22 1.06, 1.36 0.004 
IQR=interquartile range; OR=odds ratio; CI=confidence interval; AI=anal intercourse; UAI= condomless anal intercourse; N/A=conducting a logistic regression was not possible due to lack of 
observations or collinearity.  
a=adjusted for time from HIV diagnosis to questionnaire completion modelled as a linear term 
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Table 6.16 (continued) 
  Has not engaged in high-
risk sex since HIV 
diagnosis 
 
Engaged in high-risk sex 
since HIV diagnosis 
    
Factor of interest Level n 
Median 
(IQR) or %  n 
Median 
(IQR) or % N OR
a
 95% CI p-value 
Any SD UAI pre-
diagnosis 
No 29 39.2  10 25.6 113 1 - 0.238 
Yes 45 60.8  29 74.4  1.72 0.70, 4.24  
Median number of SD 
UAI partners pre-
diagnosis 
Per 1 partner increase 
(continuous) 
74 1 (0, 2)  39 1 (0, 6) 113 N/A 
Any casual SD UAI pre-
diagnosis 
No 48 66.7  18 47.4 110 1 - 0.084 
Yes 24 33.3  20 52.6  2.10 0.91, 4.89  
Median number of 
casual SD UAI partners 
pre-diagnosis 
Per 1 partner increase 
(continuous) 
72 0 (0, 1.5)  38 1 (0, 3) 110 N/A 
ChemSex pre-diagnosis No 52 73.2  7 17.1 112 1 - <0.001 
Yes 19 26.8  34 82.9  26.95 7.39, 98.30  
Met partners in a sex 
on premises venue pre-
diagnosis 
No 55 72.4  17 41.5 117 1 - 0.007 
Yes 21 27.6  24 58.5  3.17 1.38, 7.29  
IQR=interquartile range; OR=odds ratio; CI=confidence interval; AI=anal intercourse; UAI= condomless anal intercourse; SD=serodiscordant/status unknown 
 a=adjusted for time from HIV diagnosis to questionnaire completion modelled as a linear term 
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Table 6.17 Association between sexual behaviours after diagnosis and engagement in high-risk sex HIV after diagnosis, adjusting from time 
from HIV diagnosis to questionnaire completion 
  Has not engaged in 
high-risk sex since HIV 
diagnosis 
Engaged in high-risk 
sex since HIV 
diagnosis 
    
Factor of interest Level n 
Median 
(IQR) or % 
n 
Median 
(IQR) or % 
N OR
a
 95% CI p-value 
Any AI post-diagnosis No 42 55.3 0 0.0 117 N/A 
 Yes 34 44.7 41 100.0     
Number of AI partners 
post-diagnosis 
Per 1 partner 
increase (continuous) 
76 0 (0, 1) 41 5 (2, 15) 117 N/A 
Any casual AI post-
diagnosis 
No 60 78.9 8 20.0 116 1 - <0.001 
Yes 16 21.1 32 80.0  12.2 4.58, 32.64  
Number of casual AI 
partners post-diagnosis 
Per 1 partner 
increase (continuous) 
76 0 (0, 0) 40 2 (1, 7.5) 116 N/A 
Any UAI post-diagnosis No 66 86.8 14 34.2 117 1 - <0.001 
 
Yes 10 13.2 27 65.8  10.40 4.01, 26.80  
Number of UAI partners 
post-diagnosis 
Per 1 partner 
increase (continuous) 
76 0 (0, 0) 41 1 (0, 5) 117 N/A 
Any casual UAI post-
diagnosis 
No 73 96.1 22 53.7 117 1 - <0.001 
Yes 3 3.9 19 46.3  16.90 4.47, 63.82  
Number of casual UAI 
partners post-diagnosis 
Per 1 partner 
increase (continuous) 
76 0 (0, 0) 41 0 (0, 4) 117 N/A 
OR=odds ratio; CI=confidence interval; AI=anal intercourse; UAI= condomless anal intercourse; N/A=conducting a logistic regression was not possible due to lack of observations or 
collinearity. a=adjusted for time from HIV diagnosis to questionnaire completion modelled as a linear term 
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Table 6.17 (continued)  
  Has not engaged in high-
risk sex since HIV diagnosis 
 Engaged in high-risk sex 
since HIV diagnosis 
    
Factor of interest Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % 
N OR
a
 95% CI 
p-
value 
Any SD UAI post-diagnosis No 76 100.0  30 73.2 117  N/A  
Yes 0 0.0  11 26.8     
Median number of SD UAI 
partners post-diagnosis 
Per 1 partner increase 
(continuous) 
76 0 (0, 0)  41 0 (0, 1) 117  N/A  
Any casual SD UAI post-diagnosis No 76 100.00  33 80.5 117  N/A  
Yes 0 0.0  8 19.5     
Median number of casual SD UAI 
partners post-diagnosis 
Per 1 partner increase 
(continuous) 
76 0 (0, 0)  41 0 (0, 0) 117  N/A  
ChemSex post-diagnosis No 69 98.6  5 12.2 111  N/A  
Yes 1* 1.4  36 87.8     
OR=odds ratio; CI=confidence interval; AI=anal intercourse; UAI= condomless anal intercourse; SD=serodiscordant/status unknown; N/A=conducting a logistic regression was not possible due to lack of 
observations or collinearity.  
a=adjusted for time from HIV diagnosis to questionnaire completion modelled as a linear term; *individual reported engaging in ChemSex but no AI. 
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The association between four attitudes and engagement in high-risk sex after HIV diagnosis are 
presented in table 6.18. After adjusting for time from diagnosis to questionnaire completion, 
there was evidence that men who agreed with the statement “Being on ART and having an 
undetectable viral load means that HIV is unlikely to be passed to a sexual partner even 
through anal intercourse without a condom” were more likely to have engaged in high-risk sex 
compared to those who did not (OR 2.72; 95% CI 1.03, 7.21; p=0.044). In addition, men who 
agreed with the statement “Better treatment means people are less worried about HIV” were 
more likely to have engaged in high-risk sex after diagnosis than those who did not agree (OR 
2.71; 95% CI 1.01, 7.31; p=0.049).  
Due to the multi-collinearity of the sexual behaviour variables, and the very small number of 
other variables found to be associated with the outcome after adjusting for time from diagnosis 
to questionnaire completion, there was little benefit from fitting a multivariate model. 
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Table 6.18 Association between attitudes towards ART and engagement in high-risk sex after HIV diagnosis, adjusting from time from HIV 
diagnosis to questionnaire completion 
  Has not engaged in 
high-risk sex since 
HIV diagnosis 
 Engaged in high-risk 
sex since HIV 
diagnosis 
    
Variable Level n 
Median 
(IQR) or % 
 
n 
Median 
(IQR) or % 
N OR
a
 95% CI p-value 
“Being on ART and having an undetectable 
viral load means that HIV is unlikely to be 
passed to a sexual partner even through 
anal intercourse without a condom” 
Don’t agree 29 45.3  9 26.5 98 1 - 0.044 
Agree 35 54.7  25 73.5  2.72 1.03, 7.21  
“It is not necessary to disclose your HIV 
status if you are on ART and have an 
undetectable viral load” 
Don’t agree 54 85.7  26 76.5 97 1 - 0.294 
Agree 9 14.3  8 23.5  1.82 0.59, 5.61  
“Better treatment means people are less 
worried about HIV” 
Don’t agree 32 50.0  13 38.2 98 1 - 0.049 
Agree 32 50.0  21 61.8  2.71 1.01, 7.31  
“It is better for my health to start ART 
earlier rather than later” 
Don’t agree 19 26.4  9 23.1 111 1 - 0.203 
Agree 53 73.6  30 76.9  1.94 0.70, 5.38  
IQR=interquartile range; OR=odds ratio; CI=confidence interval 
a=odds ratio adjusting for time from HIV diagnosis to questionnaire completion. 
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 Summary discussion 6.6
Early ART, offered at the point of diagnosis was acceptable to the majority of MSM with EHI 
recruited to this study. Two thirds (95% CI 58.1-73.4%) would have accepted ART at diagnosis if 
they were offered it and a further 25% (95% CI 16.7-32.5%) would have considered it. Not only 
was it acceptable but it appeared to be expected; nearly half of the respondents had expected 
to start ART within a month of diagnosis, and 47% (95% CI 38.3-56.5%) of respondents had 
already started ART by the time of questionnaire completion. Of the men who had not yet 
started ART, 61% (95% CI 48.8-73.2%) agreed with the statement “I am ready to start ART 
now”.  
Most respondents who had initiated ART by the time of questionnaire completion believed in 
the health benefits of early treatment: 97% (95% CI 91.3-100.0%) reported starting to reduce 
the damage HIV was causing and to control the spread of HIV and 90% (95% CI 83.0-98.5%) 
agreed with the statement “It is better for my health to start ART earlier rather than later”.  In 
fact, nearly 40% of men who were on ART at the time of completing the questionnaire said 
they had started ART mostly, or only, for health reasons. Protecting partners from HIV was also 
important though, with 89% (95% CI 80.5-97.3%) starting to reduce the risk transmission, 
though this may not have been wholly altruistic as 85% (95% CI 75.5-94.5%) reported starting 
to reduce the anxiety of transmission. 60% (95% CI 47.2-73.6%) of men believed that being on 
ART made it easier to disclose their HIV status to sexual partners.  
Whilst the majority of men surveyed had not engaged in sex which carries a high-risk of HIV 
transmission since their HIV diagnosis, nearly 1 in 10 men reported engaging in UAI with a 
serodiscordant/unknown status partner since receiving their diagnosis. In addition, a quarter of 
MSM surveyed had reported engaging in ChemSex and having AI since receiving their diagnosis. 
Given the documented loss of control under the influence of ChemSex drugs, it is likely that 
there is an increased risk of transmitting HIV in this setting. Engagement in these two high-risk 
sex practices after diagnosis was associated with higher partner numbers prior to diagnosis, 
engaging in ChemSex prior to diagnosis and having ever taken PEP. There was also evidence 
men were more likely to agree with a variation of the Swiss Statement if they had engaged in 
high-risk sex since diagnosis and were more likely to display treatment optimism beliefs by 
agreeing with the statement “Better treatment means people are less worried about HIV”. 
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Whilst the proportion of men engaging in high risk sex was higher amongst those on ART, this 
was not found to be statistically significant at the p<0.05 level, though it is not possible to rule 
out that this finding may have been due to a lack of power to detect small differences.  
 Strengths and limitations 6.7
 Selection bias 6.7.1
The proportion of UK Register recruits who completed this survey was not particularly high, at 
45% of eligible MSM. It is important to note though that this is likely to be a conservative 
estimate as clinics did not have the resources to record invitations and refusals, although asked 
to do so. The result was that some of the men classed as non-respondents in this thesis were 
likely not invited to participate by the clinic.  Importantly, the number of men who were invited 
and refused to participate in the UK Register itself was not available and no data exist which 
compare UK Register respondents to seroconverters not enrolled in the UK Register, so we are 
unable to assess whether any selection bias exists. It is conceivable that men who are more 
health-conscious maybe more likely to know about possible benefits of early treatment and be 
more interested in taking part in medical research, at which point this study may over-
emphasise the acceptability of early ART. In some circumstances, it is possible to weight survey 
data by key characteristics to account for differences between the population and the study 
sample. However, no suitable population-based parameters exist for recent seroconverters in 
the UK on which to base such a weighting scheme.  
Whilst it is impossible to assess whether there was selection bias to the UK Register as a whole, 
it is important to acknowledge that HIV centres differ in their clinical or research focus and, 
crucially for this study, some clinics or doctors become known amongst patients as ”specialists” 
in PHI. Therefore, it is plausible that differences in ART acceptability exist amongst men 
recruited from different HIV centres. The fact that those centres with an interest in PHI tend to 
recruit more seroconverters to the UK Register, and over half of the patients surveyed were 
recruited from the three centres with PHI interests, may also have led to selection bias.  Whilst 
it was not possible to adjust for the individual HIV centre of recruitment due to the small study 
numbers and the fact that many HIV centres contributed very small numbers of patients, I did 
examine the effect of recruitment from centres known to have PHI interests. Interestingly, 
whilst there was a tendency of MSM recruited from PHI centres to have started ART early, this 
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was not statistically significant after adjusting for other factors. One plausible explanation is 
that any effect of attending a PHI centre on early ART initiation, was most likely enacted 
through the doctors at the centre being more likely to advise the patient to start early ART; a 
factor which was strongly independently associated with early ART initiation with men 5 times 
more likely to start if they have been recommended to by their clinician.   
Such bias could have been minimised through use of a sampling strategy to select participating 
UK centres, stratified by geographic area and perhaps by the probability of ART initiation in EHI, 
however financial and logistical issues prohibited this. The necessity to maximise survey 
response amongst a relatively small population over the course of a short time period of 1 year, 
meant that any clinic willing to recruit to the study was permitted to do so. Even with this 
approach, we did not recruit the required sample size and found recruitment rates to be 
generally low amongst participating centres. Overall recruitment to the study was slow and 
sometimes erratic. The main reason for this was the lack of funding for the survey sub-study 
meant that no extra financial incentive could be offered to clinics to recruit to this study, over 
and above what is already paid for recruitment to the UK Register. Research teams at the larger 
centres in particular reported being stretched by the number of ongoing research projects, and 
understandably had to prioritise recruitment according to financial incentives.  
 Information bias 6.7.2
A strength of this study was that the survey questions were validated through use of cognitive 
interview techniques. This enabled me to refine the language, make the questions more 
understandable to the respondents, and provided a level of confidence that questions were 
measuring the construct we intended to measure. Unfortunately due to lack of time and the 
small study population, it was not possible to pilot the questionnaire in a representative 
population large enough to assess the reliability of the questions using test-retest methods, or 
to conduct principle component analysis to refine and collate the attitude statements.  
Item response was generally good with the exception of three attitude questions at the end of 
the questionnaire which nearly 15% of the men did not answer. This item non-response was 
most likely a by-product of the questionnaire booklet design with a notable number of men 
who were ART-naïve not following the questionnaire routing to the end of the booklet. This 
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meant that, compared to men who had started early ART, a larger proportion of ART-naïve men 
had missing data for the statements assessing agreement with a version of the “Swiss 
statement”, whether disclosure of HIV status was necessary if undetectable or ART and the 
statement assessing treatment optimism (questions H1, H2 and H3 in appendix 18). Whilst it is 
an unlikely scenario, any systematic difference in the attitudes or beliefs of the men who 
overlooked these questions to those who responded may have impacted on the final findings 
of the factors associated with early ART initiation, especially given the small numbers involved 
in the analyses.   
Whilst every effort was made to recruit as many men as possible, the target sample size was 
not reached. Though recruitment was extended for 6 months, the lack of time and funding 
available made it unfeasible to run the survey for longer, or in more HIV centres. As a 
consequence, the small number of respondents resulted in low power to detect associations, 
and a subsequent increased chance of type II error. This was particularly problematic in the 
multivariate risk factor analyses, where there were only enough numbers to assess for 4 or 5 
independent variables in models and it was necessary to construct a conceptual framework for 
multivariate analysis for this reason. Independent variables found to have very strong 
associations with outcomes of interest (i.e. had very high odds ratios) were unlikely to be 
greatly affected by low power, however some of the more subtle associations may not be 
apparent in the data due to the low number of respondents.  It is important to therefore 
acknowledge that a lack of association at the p<0.05 level may mean there truly is no 
association in the population, or may mean that there is but it was unlikely to be detected with 
this small sample size. In addition to high risk of type II error, the high number of independent 
variables modelled in the risk factor analyses may have resulted in type I error, whereby the 
null hypothesis is incorrectly rejected due to chance. The statistical cut off of p<0.05 was used 
in this study resulting in a 1 in 20 chance of incorrectly rejecting the null hypothesis for any 
given test. The multiple testing involved in the risk factor analyses (for ART initiation and high 
risk sex), and in-particular through use of the stepwise model building and conceptual 
framework has likely resulted in an increased probability of type I error in these results.  
One major limitation of a cross-sectional design, is the inability to establish the temporal 
sequence of the independent factors of interest and the outcomes under study, for example 
whether the positive attitudes to ART preceded early ART initiation or whether they were part 
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of a post-hoc rationalisation after starting ART early. It is, therefore, important to acknowledge, 
as with any cross-sectional study, that the findings of this study show only associations and not 
necessarily causation.  
Serodiscordant UAI pre-diagnosis was defined as condomless sex with somebody known to be 
HIV-positive or with unknown HIV-status in the 6 months before diagnosis. This may have 
introduced misclassification error in the reporting of serodiscordant UAI pre-diagnosis, as it 
was not possible to ascertain whether the respondent was HIV-positive or negative when 
serodiscordant UAI partners were reported in the 6 months pre-diagnosis. It is conceivable that 
some of the serodiscordant partners reported pre-diagnosis were actually concordant. 
Similarly, the limitations of using serodiscordant UAI as a proxy for transmission risk should be 
acknowledged. Serodiscordant UAI has many variations, and can be undertaken in combination 
with other risk-reduction methods which were not ascertained in this survey; such as strategic 
positioning (where the HIV-positive partner assumes the receptive role) and withdrawal (where 
the HIV-positive partner withdraws before ejaculation), along with undetectable viral load 218.  
Indeed, amongst the men who engaged in high-risk sex and were on ART, it was not possible to 
determine whether risky sexual behaviour was undertaken whilst undetectable on ART as there 
was no temporal sequence data for sexual behaviour in relation to ART initiation.  The median 
time to achieve undetectability has been estimated at 12 weeks 219 and the BHIVA TasP Position 
Statement specifies that viral load should sustained at <50 copies/mL for 6 months prior to 
being classed as uninfectious 217. Given these stipulations, it is likely that many of the men on 
ART in this study did not meet BHIVA criteria for being classed as “uninfectious”. Whilst it 
would have been possible to extend the questionnaire length and enquire in more depth about 
resumption of sexual behaviour and timing of sex especially in relation to initiation of ART, 
keeping the survey as short as possible was crucial to maximise participation. In addition, a 
cross-sectional design is a sub-optimal approach to understanding resumption of sexual 
behaviour as it is subject to recall bias, and it was not possible to ascertain exactly when sexual 
behaviour resumed. An observational cohort approach, including repeat surveys at regular 
follow-up intervals alongside clinical measures of viraemia would be the best approach for 
understanding resumption of sexual behaviour following diagnosis in EHI. 
This survey included questions which may be regarded as sensitive by some people and may 
not be answered truthfully. Providing-socially desirable responses to questions, especially for 
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sexual behaviours known to be high risk is a known problem and, whilst there is no way to 
prevent it, steps were taken to minimize its occurrence. To minimise the influence of 
interviewer bias, the questionnaire was designed to be self-completed and all study 
documentation assured anonymity of the data. Clinic staff were asked to reassure participants 
of the anonymous nature of the study and respondents were provided with a sealable 
envelope to put the questionnaire into after completion. Nonetheless, survey completion in the 
clinic setting may have resulted in reports of lower partner numbers and fewer high-risk 
behaviours, which would underestimate the prevalence of high-risk behaviours linked to 
secondary transmission of HIV.  
The possibility of recall bias is also introduced with this study design. Men were asked to recall 
numbers of sexual partners in the six months prior to HIV diagnosis and in the time between 
HIV diagnosis and questionnaire completion. Recall of events is likely to be easier for those who 
are less sexually active, and over shorter durations. During the questionnaire piloting men were 
asked to use the “walk through” method to describe how they were answering the partner 
number questions. It was commonplace for men with larger partner numbers to use logical 
estimation methods for example, “I averaged two sex partners a week over that period and 
there are 4 weeks in a month, so that’s 8 a month multiplied by 6 months”.  Some even went so 
far to include holidays in the estimation, and increase partner numbers accordingly. As the 
focus on the analyses here was less on partner numbers and more on overall prevalence of 
sexual behaviour, it is unlikely that recall bias where partner numbers were over or 
underestimated by a small amount would have affected the overall associations.  
Another limitation with the survey design is that men had different recall periods for the sexual 
behaviour after HIV diagnosis, depending on time elapsed between HIV diagnosis and 
completing the questionnaire. Unsurprisingly, men were more likely to have resumed having 
sex the longer the time interval between questionnaire completion and diagnosis. Whilst I 
adjusted for this interval in all regression analyses, it is likely that a number of the men 
interviewed within a month of diagnosis may have resumed sexual behaviour if they had been 
interviewed 2 or 3 months after diagnosis. Once again, this problem could not have been 
avoided given the financial and logistic constraints of the study, however warrants 
acknowledgement. 
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In an ideal world, I would have undertaken a follow-up study with men asked to complete the 
survey at diagnosis, and then again 3, 6 and 12 months after diagnosis. This approach would 
have enabled us to establish more of a temporal sequence between independent variables and 
the outcomes of interest, whilst also standardising recall periods. However, it would have also 
brought with it another set of challenges. Many clinics were reticent to approach patients for 
research at the point of diagnosis due to the heightened emotions at this time, and the 
potential for disengagement from care following diagnosis may have hampered follow-up. Such 
a study design is also very labour-intensive and would have required selection of a smaller 
number of large HIV clinics in which to run the study. Given the small population under study 
and the necessity for 12 months follow-up, this would have to result in a much longer study 
period. Instigation of a simple cross-sectional design in this case allowed us to achieve a greater 
geographical spread, with over a third of the respondents recruited from 8 centres outside of 
London, and is a strength of the study. 
One other important caveat of the study findings is that agreement with statements in a survey 
is not necessarily the same as acting on them. Acceptability and intention does not necessarily 
translate to behaviour but as evidenced here, the uptake of ART amongst these MSM was high 
with nearly half of men already on ART by the time they completed the questionnaire. 
Invariably with surveys, there are topics it would have been interesting to include in the final 
questionnaire. With retrospect, including a measure of HIV related stigma and mental health 
would have been useful in this study, as well as including questions to ascertain ART 
knowledge, previous PrEP use and sex work. In addition, it would have been useful to use 
principal component analysis (PCA) to understand the underlying components of the attitudes 
and beliefs identified in workstream 2 phase A. Unfortunately as attitudes and beliefs around 
early ART were different according to ART status in the survey, the number of observations 
were relatively small (n=55 on ART and n=61 ART-naïve), and the number of variables (p) to 
include in the PCA models were relatively large (p=14 for MSM on ART and p=12 for ART-naïve 
MSM). The subsequent observation to variable ratios for both MSM on ART and ART-naïve 
were too small to be able to use PCA reliably 220.  
Use of PCA could have also been beneficial in overcoming the observed multicollinearity by 
reducing the number of covariates in the multivariate sexual behaviour model, however the 
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observation to variable ratios were even smaller in this analysis than in the factors associated 
with cART analysis, thus rendering the approach inappropriate in this study context. The only 
other way of dealing with collinearity is by the removal of variables with evidence of high 
correlation. This approach was deemed unfeasible due to the very high correlation amongst 
almost all of the associated covariates; all sexual behaviour covariates, ever taken PEP, and 
chemsex pre-diagnosis. The removal of all of these collinear measures would have amounted to 
little more than the univariate models presented. 
 Chapter summary 6.8
The findings presented in this chapter are highlighted in blue overleaf on the theoretical 
framework (figure 6.10). In this chapter I have shown that offering ART at the point of diagnosis 
is acceptable to the majority of the MSM with EHI who were surveyed; most would have 
accepted ART at diagnosis if they had been offered it by their clinician. Almost half of the men 
surveyed had initiated early ART and, of those who had not, around half expected to start ART 
in the next month. Men reported starting ART for health reasons in addition to preventing 
transmission of HIV, an interesting finding due to the lack of randomised clinical trial evidence 
indicating clinical benefit of earlier treatment at the time of the survey.  
Believing that earlier ART is beneficial to health, and being willing to start ART at diagnosis if it 
had been offered, were most strongly associated with early ART initiation.  The role of the 
clinician was also important, and men were more likely to have initiated early ART if they had 
been advised to do so by their doctor. It also appeared that men who had initiated ART were 
more likely to have disclosed their status to HIV negative friends, perhaps reflecting a tighter 
social network amongst men who were on ART. 
From a TasP perspective, I have shown that over a third of men reported engaging in high risk 
sex that could have led to secondary HIV transmission since receiving their diagnosis. Nearly 1 
in 10 of the men surveyed reported having one or more serodiscordant/status unknown UAI 
partners since their HIV diagnosis, and over a quarter of men surveyed had engaged in 
ChemSex and AI since their diagnosis. Given the lack of control and loss of inhibitions 
commonly reported during ChemSex, there is an elevated risk that secondary HIV transmissions 
may have occurred from these men since HIV diagnosis. 
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 Figure 6.10 Conceptual framework of the thesis including results from workstream 1 and both phases of workstream 2 
 
 270 
 
7 Discussion 
In this chapter I present a synthesis of the findings from the two workstreams of this PhD to 
answer the overarching research question. The key findings from each of the three results 
chapters, covering the statistical analysis of UK Register data (chapter 4), the qualitative in-
depth interview study (chapter 5) and the cross-sectional survey (chapter 6), are presented 
in the context of work which was published from 2010 onwards, after my literature reviews 
were completed. Where possible, I triangulate the findings from all three chapters 
discussing how they contrast and complement each other to deepen our understanding of 
the mechanisms and reasons behind some of the observations. I then discuss the 
implications of the thesis findings on clinical practice and policy, and my recommendations 
for future research.  
 Main thesis findings  7.1
This multi-disciplinary, mixed-methods PhD sought to answer the following overriding 
research question:  
“Is early antiretroviral therapy acceptable to MSM with early HIV 
infection attending UK HIV clinics, and could it be used in this population 
to reduce HIV transmission risk?” 
The research question is composed of two components: the acceptability of early ART and 
the potential utility of early ART in the context of the current HIV epidemic amongst MSM 
in the UK. The main thesis findings are summarised in the conceptual framework in figure 
7.1, and a synthesised overview of the key findings now follows.  
 Early ART is highly acceptable to MSM with early HIV infection 7.1.1
Data from the cross-sectional survey indicated early ART was highly acceptable at the point 
of HIV diagnosis; 2 in 3 of the men surveyed would have accepted early ART if it had been 
offered to them, with 24% stating they may have and only 9% stating they would not have. 
Nearly 50% of respondents expected that they would start ART within a month of diagnosis, 
and of those men who were still ART-naïve at questionnaire completion, 61% stated they 
were ready to start ART now.  
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Figure 7.1 Conceptual framework of the acceptability and utility of early ART to reduce HIV transmission amongst MSM with early HIV infection in the UK 
 
 272 
 
At the time of writing, no studies investigating acceptability of early ART amongst MSM 
with EHI in the UK had been published with which to directly compare these results. A 
review of the literature published up until December 2012 investigating acceptability 
towards TasP identified only three studies in which acceptability towards TasP was 
measured 221. Of these studies none were directly applicable to the population under study 
here: two were conducted amongst of PLWH with chronic infection recruited form HIV 
clinics in the US 222,223,  and one online survey of HIV-positive (11.7% of respondents) and 
negative MSM in Australia 224.  The article by Kalichman et al, examined the association 
between belief that undetectable viral load decreases transmission risk and STI infection 
amongst MSW and MSM using a cross-sectional design, finding that the proportion of 
respondents with an STI held greater belief in that undetectable meant uninfectious 223.  
Dombrowski et al reported that 56% of a random sample of 136 ART-naïve PLWH (MSM 
and MSW) attending a Seattle clinic expressed interest in initiating ART solely to reduce 
transmission, and that 61% of them believed that doctors should offer TasP to patients 222.  
Holt et al conducted a cross sectional online survey amongst 1,283 MSM in Australia 
comparing attitudes to PrEP and TasP between HIV-positive and negative MSM 225. The 
authors reported similar attitudes to PrEP amongst positive and negative men, though 
compared to HIV-positive men, HIV-negative men were less likely to believe in there were 
health benefits to ART, and that undetectable viral load means an individual is uninfectious. 
In addition to the above studies, a qualitative study was also conducted involving semi-
structured interviews with recently diagnosed Australian MSM to elicit their opinions on 
ART 226. In this study, conducted between 2011 and 2012, 53 men who were diagnosed with 
HIV within the last two years were recruited across all Australian states and territories 
except the Northern Territory, with half of the respondents having started ART.  The 
themes identified in this study were similar to those emerging from the qualitative work 
presented in this thesis, with the men demonstrating a range of knowledge of ART and TasP 
and notably seeing ART as a personal balancing act between the benefits and risks of ART.  
Perhaps the most appropriate study investigating acceptability of early ART in the UK with 
which to compare these thesis results is the ASTRA study which was published after the 
aforementioned review. ASTRA examined the attitudes of 281 ART-naïve PLWH with 
CD4≥350 recruited from 8 HIV outpatient clinics in the UK, 85% of whom were MSM 227. 
ASTRA reported that 63% of respondents stated they would start ART “now” to reduce risk 
of serious illness, or to make themselves less infectious to a sexual partner. A comparison 
between findings from this thesis and the ASTRA study is possible in relation to the 
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statement “I would want to start treatment now if this would make me less infectious to a 
sexual partner, even if there was no benefit to my own health”, as the same statement was 
used in both studies. A much higher proportion of ART-naïve MSM with EHI in this thesis 
(81%) agreed with this statement compared to the ASTRA respondents (45%). Also of note, 
the proportion undecided over the statement was far lower in this study at 17%, compared 
to 30% in ASTRA. This difference could be due to the new evidence and extra publicity TasP 
had received by the time I conducted my survey in July 2013-December 2014, compared to 
ASTRA which was February 2011-December 2012.  
When I embarked on this PhD, only observational evidence existed indicating ART could 
prevent sexual transmission of HIV, and that initiating earlier ART, whether during PHI or at 
CD4>350, may be beneficial compared to delaying it. Since then, the evidence base on both 
TasP and early ART for clinical benefit has grown dramatically with several key studies 
reporting findings which have resulted in shifts in attitudes towards early ART. Specifically 
from a TasP perspective, observational evidence from the Partners in Prevention study 
showed a 92% decrease in risk of transmission amongst heterosexual serodiscordant 
couples where the HIV-positive partner had started ART 228. This was corroborated in 2011, 
with the publication of findings from the landmark HPTN-052 trial which provided 
randomised evidence of a 96% (95% CI 73%-99%) reduction in transmission amongst 
serodiscordant couples where the HIV-positive partner received immediate ART treatment, 
compared to deferring it 215. In total, 39 transmission events were observed across both 
treatment arms, four of which occurred in the early therapy group. However comparison of 
the HIV viral genotype between partners where a transmission event was observed 
revealed that only one of the four observed transmission events was acquired from the 
HIV-1 infected partner, indicating that the other three events had occurred outside of the 
study partnership. Moreover, the single transmission event which remained attributable to 
the index partner in the early treatment arm occurred within the first three month follow-
up period following ART initiation when viral load is unlikely to be totally suppressed. One 
of the main limitations of this study was that it was conducted in predominantly 
heterosexual couples in Africa and Asia, and questions remained regarding the 
generalisability of the results to MSM.  
Following publication of HPTN-052, BHIVA guidelines were updated to include TasP 
guidelines, recommending the evidence that ART lowers transmission is discussed with all 
patients including an assessment of current risk of transmission to others, and that after 
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this, if a patient wishes to commence ART with a CD4>350 the decision is respected 229. In 
January 2013, after recruitment to ASTRA closed but before my survey began, BHIVA and 
EAGA released a joint TasP position statement, outlining in detail the specific conditions 
that should be in place to achieve a low risk of transmission on ART 217. These conditions 
were that viral load must be sustained at ≤50 copies/mL for a minimum of 6 months, that 
both partners be free of other STIs (as verified by STI screens for both partners, and after 
every occurrence of sex outside the partnership), and that viral load monitoring occurs 
every 3-4 months.  
Also during the course of my survey, in March 2014, the interim analysis from the PARTNER 
study (a large observational cohort of serodiscordant couples) corroborated the HPTN-052 
findings by reporting that the best estimate of risk of sexual transmission of HIV whilst on 
ART was zero 230. Crucially, the PARTNER study findings included a substantial proportion of 
MSM as well as MSW; over half the couples enrolled were MSM with 21,000 of the 44,500 
condomless sex events being anal sex. Whilst the rates of transmission for both anal sex 
(men and women combined) and anal sex with ejaculation were estimated at 0 per 100 
couple-years follow-up, the upper 95% confidence intervals for these estimates were 0.96 
and 1.97 per 100 couple years, respectively. Phase 1 of the PARTNER study has since been 
published showing no linked transmission events to have occurred in the study, hence the 
best estimate of risk of transmission on ART remained zero 231. This was accompanied by a 
reduction of the upper confidence interval for the risk of transmission for anal sex (men and 
women combined) to 0.71 per 100 couple-years of follow-up. Unlike in a clinical trial setting 
where research conditions are optimised, the observational design of PARTNER means the 
findings are representative of the real world setting, as is reflected in the reports of 
inconsistent or total absence of condom use in partnerships.  
Further evidence of the effectiveness of TasP amongst MSM serodiscordant couples has 
also been provided by the Opposites Attract study, a cohort of serodiscordant MSM couples 
currently under follow-up in Australia, Thailand and Brazil 232. Though Opposites Attract is 
not powered to give as precise estimates as PARTNER, the interim findings indicated there 
were no transmission events in the 90.8 couple years follow up encompassing a total of 
5,905 acts of condomless AI across 88 couples. The estimated incidence rate for 
condomless sex was 0 (95% CI 0-4.06) per 100 couple years follow-up. Given the 
randomised evidence supporting TasP, and now observational evidence suggesting a low 
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risk of transmission between serodiscordant MSM, it is unsurprising that acceptability to 
ART is high amongst the men in this survey.  
 Uptake of ART in early HIV infection was high 7.1.2
In line with the very high acceptability of early ART found in this thesis, the uptake of early 
ART was also high amongst MSM in the cross-sectional survey with 47% of MSM having 
started by the time of questionnaire completion at a median of 76 days (IQR 23, 191) post-
diagnosis. To some extent, this corroborated the findings of workstream 1, the analysis of 
data from the UK Register of HIV Seroconverters, which showed a more rapid rate of 
uptake of ART over calendar time in 2010-11, resulting in a decrease in median time from 
seroconversion to ART initiation from 3.7 years pre-2000 to 1.4 years in 2010-2011. These 
findings of initiation sooner after seroconversion in more recent years  and at higher CD4 
counts are broadly in line with those previously reported amongst PLWH in the UK 47,233. 
However, analysis of UK Register data also revealed a tapering in the proportion of 
seroconverters initiating ART in PHI from 2004 onwards, with only around 1 in 5 
seroconverters presenting in PHI starting ART in PHI in 2010-11. So, whilst the overall time 
to initiation has decreased, this does not appear to be driven by targeted treatment of PHI. 
Using time to event analysis of the UK Register is the optimal way to examine trends in ART 
uptake as it accounts for loss to follow-up, but it also necessitates a long follow-up period 
and so I could only include data up until 2010-11 in the analyses. The findings from the 
cross-sectional survey which ran from 2013-14 suggested that time to initiation may have 
decreased further after 2011, as 47% of MSM respondents had initiated within 1 year of 
their diagnosis, and, of those who had, 69% had done so within a month of their HIV 
diagnosis. Whilst a further decrease in the time to ART initiation is likely due to the 
mounting evidence for TasP and ART for health benefits, the comparison between the 
cross-sectional and time to event analysis has some caveats. Firstly, it assumes that the 
cross-sectional survey sub-population is representative of the wider UK Register population 
and whilst there were no differences between the respondents and non-respondents in 
terms of clinical and demographic characteristics, it was not possible to compare their 
attitudes and beliefs towards early ART. Equally, it may be that the UK Register centres who 
recruited to the survey had more of an interest in early ART and therefore were more likely 
to discuss, and/or recommend early ART, than the centres who did not recruit to the 
survey.  Both of these situations could have resulted in a selection bias towards survey 
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respondents who were more amenable to early ART, and resulted in an overestimation of 
the proportion of MSM with EHI who start ART early in the UK.  
 Attitudes and beliefs towards early ART 7.1.3
One of the strengths of using mixed methods research design is that it permits triangulation 
of qualitative and quantitative findings to facilitate a deeper understanding of mechanisms 
underlying the observed high acceptability and uptake. In workstream 2 I explored the 
context of EHI diagnosis through in-depth interviews by asking men about their experiences 
over this time, along with the way men felt about ART in EHI. I then estimated the 
prevalence of selected themes identified from the qualitative study in the multi-site cross-
sectional survey. The information from this mixed-methods thesis results in both an 
estimate of the prevalence of attitudes and beliefs towards early ART, along with the depth 
of understanding of the mechanisms behind the findings.  
7.1.3.1 Early ART to prevent transmission: altruism or self-protection? 
Nearly 90% of men who started ART in the survey agreed with the statement “I started ART 
to reduce the risk of transmission to my sexual partner(s)”, however, 85% agreed with the 
statement “I started ART to reduce my anxiety about transmitting HIV to my sexual 
partners”. The in-depth interview study revealed a strong desire and a felt responsibility to 
protect sexual partners from HIV infection, with TasP regarded as one way to achieve this. 
These feelings of responsibility to protect partners, both long term and casual, were also 
widely reported by Down et al, in their semi-structured interviews with recently diagnosed 
MSM in Australia 226. In line with previous work by Nimmons et al on prevention altruism 
178, this desire to protect partners could at least partially be ascribed to selfless motivations 
to protect others from experiencing the emotional turmoil of an HIV diagnosis that they 
were themselves experiencing. However, personal motivations were also present amongst 
the men interviewed. An extreme anxiety over transmitting HIV to sexual partners was 
linked to worries around potential prosecution for intentional transmission, dissolution of 
relationships and the overwhelming feelings of guilt that would accompany a transmission 
event. The alleviation of stress and anxiety of HIV transmission afforded by TasP, at this 
time of intense emotional upheaval, was regarded as a major advantage of early ART 
amongst the men in this thesis.  
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7.1.3.2 TasP was not the panacea of HIV prevention, but another arrow in the risk 
reduction quiver 
One concern with the widespread rollout of TasP is “risk compensation”, the idea that 
people will come to depend solely on ART to prevent transmission, resulting in reduced use 
of condoms along with other risk-reduction methods. My survey revealed that 61% of men 
agreed with the statement “Being on ART and having an undetectable viral load means that 
HIV is unlikely to be passed to a sexual partner even through anal intercourse without a 
condom”, and 85% of the men who started ART appeared to do so to reduce transmission. 
But the in-depth interview study indicated that whilst men might believe that ART reduced 
transmission, this would not automatically result in the abandonment of other risk 
reduction strategies, predominantly using condoms and serosorting. In fact, despite 
evidence for the efficacy of TasP, total trust in it to prevent transmission was notably 
lacking; any risk of transmission was perceived by some as a risk too many. This was 
especially true of MSM interviewed who were in long term serodiscordant partnerships, 
where the strong emotional element present in the partnership exacerbated the perceived 
responsibility to protect their partner form HIV.  Even amongst MSM who were not in a 
serodiscordant relationship, ART was referred to as an additional method of risk reduction 
to add to their armoury of condom use, serosorting and strategic positioning. This finding 
amongst HIV-positive MSM, that TasP tends to be viewed as an additional risk reduction 
methods to complement existing ones, is in line with findings from the qualitative research 
amongst HIV-negative MSM who use PrEP to reduce transmission 234–236.  
One finding of note from the in-depth interview study was that TasP may enable risk 
reduction via an additional pathway than by solely reducing the probability of transmission 
due to undetectable viral load. TasP was perceived by the men interviewed to facilitate HIV 
disclosure, and this was confirmed in the survey data; 60% of men on ART agreed that 
“Being on ART makes it easier to disclose my HIV status to sexual partners”.  Discussing HIV 
status with sex partners is a key component of successful implementation of sero-adaptive 
risk-reduction behaviours such as strategic positioning and serosorting. This finding appears 
to reflect the adoption of viral undetectability into safer-sex negotiations, as has been 
reported amongst MSM in the Netherlands, where 63% of the 120 HIV-positive men who 
reported UAI since diagnosis had factored undetectable viral load into the decision to 
engage in UAI with a partner; 44% with HIV-positive partners (to avoid super-infection) and 
38% with presumed HIV-negative partners (to prevent transmission) 237. 
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Findings from the in-depth interviews may shed light on the reasons why ART is perceived 
to facilitate status disclosure. Despite the medical advances which have made HIV a 
manageable disease, and no longer a death sentence, the stigma surrounding HIV infection 
remains, even amongst high prevalence populations like MSM in the UK 238–240. Stigma can 
manifest as enacted stigma, defined by Scambler as an episode of discrimination against 
someone with HIV, and also as felt stigma, which is comprised of two elements: a personal 
feeling of shame associated with being HIV positive, in addition to the fear of enacted 
stigma2.  A systematic review of the literature on social support, stigma and HIV disclosure 
noted the existence of an inverse relationship between felt stigma and HIV status  
disclosure 241. Discussion of HIV status is commonly regarded amongst UK MSM as a  
“unilateral responsibility” attributed to either the person with HIV (to disclose their positive 
status voluntarily), or the HIV negative partner (to ask about HIV status), with very few men 
regarding it as a “shared responsibility” 238.  
There was a strong perception of responsibility to disclose HIV status amongst the men 
interviewed, and this created an anxiety about forming new sexual partnerships. Disclosing 
their HIV status was perceived to put them at risk of experiencing enacted stigma through 
sexual rejection by potential partners based on HIV positivity, irrespective of whether this 
outcome was likely or not. Felt stigma was very evident amongst the men interviewed and 
when reflecting on their feelings about being HIV positive, men commonly struggled with 
the concept of being “infectious”, describing themselves as “dirty” or “grubby”. For the 
men in my study, this felt stigma caused both by the fear of enacted stigma and the shame 
of being infectious, and in some cases experience of enacted stigma itself, resulted in 
problems with forming relationships and sexual abstinence. ART was regarded as a way to 
reduce this label of being infectious by decreasing the amount of virus in the body, and thus 
alleviating some of the associated felt stigma. Improved self-efficacy and agency afforded 
by felt stigma reduction can facilitate negotiation of sexual encounters using the reduction 
in infectiousness as a way to mediate the risk of encountering enacted stigma.  
Despite the positive effect TasP may have in reducing transmission anxiety and facilitating 
disclosure, it should be noted that the preventive element of ART can be perceived as an 
additional burden to some individuals. Young et al highlighted that the availability of TasP 
might result in an external expectation on HIV-positive individuals to take TasP due to the 
public health benefits which could in turn result in constrained treatment choices and poor 
mental health 242. They argue that these feelings may add to the “burden of prevention” 
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that HIV-positive individuals already carry, due to the addition of ART adherence to the 
existing social expectations to disclose HIV status and negotiate safer sex.    
Ultimately, the ideal scenario is one where the responsibility to negotiate safer sex falls 
with both HIV negative and positive parties, yet the most recent Gay Men’s Sex Survey 
indicated that 67% of men in England had not discussed HIV status with their last casual sex 
partner 239. As the evidence base supporting TasP expands and uptake increases, it is likely 
that the knowledge about TasP in the MSM community will also improve. Whether an 
improved knowledge of TasP in the wider MSM community brings with it a reduction in the 
likelihood of experiencing enacted stigma in the form of sexual rejection based on HIV 
serostatus, remains to be demonstrated. Recently published data from a cross-sectional 
internet survey conducted in Australia in 2012, indicated that 1 in 5 HIV-negative and 
positive MSM reported being willing to have UAI with a serodiscordant partner if the HIV-
positive partner was on ART, however this willingness was independently more likely to be 
reported by HIV-positive MSM 243. It is likely knowledge and attitudes to TasP amongst 
MSM have changed since the data were collected in 2012 however, due to recent results 
from the PARTNER and Opposites Attract studies 230,232,244. The high efficacy and 
effectiveness of PrEP in preventing HIV acquisition amongst high-risk MSM 245,246 will also go 
some way towards achieving a balance in the responsibility to prevent HIV transmission 
between HIV-positive and negative MSM, by providing a biomedical tool with which HIV 
negative men can protect themselves from HIV, so long as it becomes widely available in 
the UK, which at the time of writing is not the case.   
7.1.3.3 Men believed there were health benefits to starting ART early 
Nearly all of the survey respondents (96%) who had initiated early ART reported that they 
started “to control the spread of HIV in my body” and “to reduce the damage HIV was doing 
to my body”.  In addition, 38% percent of the men who initiated ART by the time of survey 
completion had chosen to do so solely, or predominantly, for their own health. In 
multivariate analysis of factors associated with early initiation, men who agreed with the 
statement “It is better for my health to start ART earlier rather than later” were 17 times 
more likely to have initiated early ART than those who did not agree.  The strong health 
beliefs in early ART demonstrated by the survey respondents was of particular interest, 
given the absence of randomised clinical evidence of any health benefit to ART over the 
study period (2010-2014).   
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Whilst during the study period the HPTN-052 study provided RCT evidence of the efficacy of 
TasP 215, no equivalent RCT was published to tip the equipoise regarding clinical benefit of 
early ART initiation. This remained the case until the findings of the START trial were 
published in 2015, showing that earlier initiation of ART at CD4>500 improved health 
outcomes when compared to deferring to CD4≤350 247.  Several observational studies were 
however published over the PhD study period to indicate a potential clinical benefit of 
initiation of ART in chronic infection at higher CD4 counts 215,248–253. In addition, data from 
the HTPN-052 trial revealed the early ART arm, who initiated at CD4 350-550 cells/mm3, 
experienced 41% (HR 0.59; 95% CI 0.40-0.88; p=0.01) fewer clinical events (serious HIV-1 
related clinical events or death) than the deferred treatment arm (who initiated at 200-250 
cells/mm3) 215. Of the 105 events observed, 99% occurred in Africa and Asia, and most were 
tuberculosis-related but there were no differences between the arms in overall mortality. 
The findings from these studies, along with the increased evidence on the efficacy of TasP, 
led to several national and international bodies changing their treatment recommendations 
over the study period, with IAS-US 254 and France 255 updating their treatment guidelines to 
recommend universal test and treat approach. The US-DHHS 256 and WHO 257 switched to 
recommending treatment initiation for asymptomatic PLWH at CD4≤500 cells/mm3 and 
EACS  recommended clinicians to “consider” treatment in asymptomatic HIV infection 258, 
though they maintained the recommended threshold at ≤CD4 350 cells/mm3. Over this 
same period BHIVA maintained their recommendation to initiation ART at CD4 ≤350 
cells/mm3 in those with chronic asymptomatic infection 229.   
The release of the START trial results in May 2015, after recruitment to the UK Register 
survey sub-study had ended, resulted in a global change to HIV guidelines with a universal 
recommendation of immediate ART initiation after HIV diagnosis. START randomised 4685 
individuals with CD4>500 from 35 countries to  receive immediate ART (n=2326), or to the 
deferred treatment arm to receive treatment when CD4 count fell to 350, or the patient 
developed an AIDS-related event 247.  Patients were followed up for a median of 2.8 years 
(IQR 2.1-3.9 years), over which time 138 primary end-point events (a composite of serious 
AIDS-related events, serious non-AIDS events or death) were reported. Despite the rate of 
AIDS and non-AIDS events being lower than expected, the trial was stopped early as the 
rate of the primary end point was 57% lower in the early treatment arm, compared to the 
deferred arm (hazard ratio [HR] 0.43; 95% CI 0.30-0.62; p<0.001). These findings were 
consistent across age, sex, race, geographic region, baseline CD4, baseline viral load, 
smoking status and Framingham 10 year coronary heart disease risk. The most commonly 
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experienced primary end-point events were cardiovascular disease, non-AIDS defining 
cancers and tuberculosis, with 62% of the tuberculosis events observed in Africa. Aside 
from the rate of bacterial infections, which was 48% lower in immediate treatment arm, no 
evidence of differences between the arms in the secondary outcome of symptomatic  
grade 4 events (potentially life-threatening symptomatic non-AIDS events requiring medical 
intervention) was found at the 5% level. As the majority of primary end-point events were 
observed at CD4 counts >500, and AIDS-related events were observed amongst individuals 
with full viral  suppression, the authors postulate that damage to the immune system is 
done early in infection and is not adequately captured by measuring CD4 count.  
The ANRS TEMPRANO trial also provided randomised evidence supporting immediate 
versus deferred ART initiation, though in this case using a 2x2 factorial trial design 
incorporating isoniazid preventive therapy and conducted in the Ivory Coast 259. The study 
team reported a 44% lower risk of the primary endpoint (a composite of AIDS and non-AIDS 
related events, all-cause mortality at 30 months) in those starting immediate ART arm 
versus the deferring (HR 0.56; 95% CI 0.41-0.76). Unlike in START where a CD4 threshold 
was used to define early versus deferred therapy, deferred ART was initiated in TEMPRANO 
according to WHO guidelines and these changed twice over the course of the study  
period 260,261. Nonetheless, when the study team restricted the analysis to individuals with 
CD4>500 at baseline to rule out any bias from the WHO guideline changes the effect of 
early ART on severe events remained unchanged.  
Understanding of the clinical benefits of initiating ART specifically in PHI also improved over 
the study period, thanks to further observational analyses indicating improved 
immunological recovery to normal levels with earlier treatment 262, reduced the HIV RNA 
and DNA reservoir size 263, lower T-cell activation 263 and protection of T-cell memory  
cells 264 thus improving dedicated immune response 265,266.  However the three randomised 
trials designed to evaluate the benefits of short-course ART in PHI that were published over 
the study period; ACTG A5217, Primo SHM and SPARTAC, all found modest but transient 
beneficial effects of early therapy. The ACTG A5217 trial randomised individuals presenting 
within 6 months of seroconversion to receive 36weeks of short-course ART or deferred 
ART. A higher proportion of the deferred treatment arm met criteria for antiretroviral re-
initiation at 72 weeks; 50% versus 10% in the early treatment arm, and median time to re-
initiation was  modestly higher in the early treatment arm 267. PRIMO SHM also found that 
individuals with PHI randomised to receive transient ART (of 24 or 60 weeks duration) had a 
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lower viral set point (4.0 and 4.3 log10 copies/mL, respectively) at 36 weeks post treatment 
interruption versus 4.8 in the deferred treatment group, though this effect was  
transient 268. They also found time to ART re-initiation was longer in the 24 and 60 week 
early treatment arms compared to the deferred treatment arms, with a hazard ratio risk of 
restarting 0.42 (95% CI 0.25-0.73) and 0.55 (0.32-0.95), respectively. The SPARTAC trial 
examined 12 and 48 week short-course ART in PHI, compared to no therapy 216. Compared 
to the no-early treatment arm, the time to needing long-term treatment after treatment 
interruption was delayed in the 48 week treatment arm, but this was only by an average of 
65 weeks, only 17 weeks more than the length of the short-course treatment itself.  
Importantly, timing of initiation was crucial, as higher CD4 and viral load benefits were seen 
the closer ART was initiated to HIV infection. In addition, further analyses of SPARTAC data 
have shown that those who spent longer on ART were more likely to control viral load after 
HIV infection 269. It is notable that across all trials, the beneficial effects of early ART were 
transient in the majority of individuals.  
Whilst the high proportion of men who believed in a health benefit of earlier ART was likely 
due to the wealth of observational data available in conjunction with the international 
guidelines recommending earlier ART, the in-depth interview study highlighted that MSM’s 
definition of health was not always in concordance with the medical definition of health. 
The clinical benefit of early ART, most commonly operationalised as maintenance of a high 
CD4 count, an undetectable viral load and absence of HIV-related morbidity and mortality, 
is what drives ART recommendations for the majority of clinicians 270. What was apparent 
from the in depth interviews, was that whilst men appreciated that these were important 
elements of good health as an HIV-positive man, they were also abstract concepts and were 
only as part of a wider concept of holistic health. Men talked about ART affording other 
health benefits by improving quality of life, giving more energy for socialising and exercising 
and improving mental health by reducing stress and anxiety of transmission and reducing 
HIV-related stigma. These perceived benefits can be as important in the decision to start 
ART as the clinical benefits, but are rarely considered in randomised controlled trials. So, 
whilst the START findings have resulted in a shift in the clinical recommendation of ART and 
in the attitudes of clinicians, it may not have had such a profound effect on patient 
attitudes, as many men believed in a health benefit of early ART prior to the START results.  
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7.1.3.4 Early ART was empowering and brought hope of a functional cure 
The in-depth interview study highlighted the role early ART could play in empowering MSM 
who were coming to terms with their HIV infection, thus increasing self-efficacy and 
agency. Men reported feeling a loss of control over their lives and bodies at this time due to 
the virus. Early ART could be perceived as an empowering force by virtue of it facilitating 
regaining the control lost by HIV infection, both of one’s body by fighting and controlling 
viral replication, and of one’s sex life, by easing the anxiety over infectiousness as 
previously discussed.  These findings were also notably similar to those reported by the 
recently diagnosed Australian MSM interviewed by Down et al, who reported a strong 
discourse of control amongst the men, with fighting the virus, taking charge of one’s body 
and being proactive all  cited as reasons to start early 226.  
ART was also empowering for a different reason for the men interviewed in this thesis. 
During 2013 and 2014, much mainstream media attention was given to the idea of early 
ART facilitating a functional cure to HIV, after publication of findings from the VISCONTI 
(Virological and Immunological Studies in Controllers after Treatment Interruption) cohort 
in 2013 214. VISCONTI involved follow up of a cohort of 14 seroconverters who maintained 
virological control for at least 24 months after stopping treatment initiated in PHI. Contrary 
to the “short-course” approach to treatment in PHI, typically lasting between 12 and 60 
weeks, the median time spent on ART amongst the VISCONTI cohort was 36.5 months, the 
range was 12-92 months. The authors noted the probability of post-treatment control at 12 
months after treatment interruption, in the French Hospital Database on HIV (FHDH ANRS 
CO4), was 15.3% (95% CI 4.4-26.3) and this remained stable at 24months.  Interestingly, the 
prevalence of post-treatment control in VISCONTI was notably higher than has been 
reported by the CASCADE collaboration, who found only 4% could maintain undetectable 
viral load for longer than 2 years following interruption of ART 271,272.  
Nonetheless, the widespread publication of the VISCONTI results in the mainstream media 
led to two interview respondents, who were highly knowledgeable about HIV and ART, 
starting early ART in the hope they may be able to achieve a functional cure. To these men, 
early therapy presented the hope that they too could be post-treatment controllers and 
achieve a functional cure. Interestingly these men were confident that there would be a 
cure in their lifetime, and there was a hope that by controlling the viral reservoir so early 
on, they would be in a better position to benefit from any future cure.  Whilst I did not 
estimate the prevalence of belief in a future HIV cure in the survey, a recent survey of 
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PLWH in the UK showed that overall support for HIV cure research was high (at 86% ) and 
that the majority of respondents expected an HIV cure to be found within 10 years 273,274.  
7.1.3.5 Healthcare providers attitudes to early ART were important in the decision to 
start 
Healthcare providers’ recommendation to start ART was highly associated with early 
initiation of ART in the survey. After adjusting for other associated factors, MSM were five-
times more likely to have started early ART if they reported their clinician had 
recommended it. The importance of the healthcare providers’, and in particular the HIV 
clinician’s, opinions on early ART was highlighted in the in-depth interview study and was 
one of the reasons I chose to enquire about it in the survey.  
As mentioned previously, the equipoise over clinical benefit of early ART over the study 
period, either in PHI or at high CD4 count, likely resulted in personal differences in the 
recommendation of early ART for clinical benefit. Certainly, the divergence of official 
recommendations between the US and UK around when to start ART was a source of 
consternation for some of the men interviewed who could not understand how this was 
possible given a shared evidence base on both sides of the Atlantic.  Clinicians themselves 
may have held favourable views towards early ART prior to the START results, but be 
employed by an NHS CCG with strict commissioning rules in place preventing the 
prescribing of ART in the absence of RCT evidence demonstrating clinical benefit.  
Suspicions were raised amongst the men interviewed over whether the additional financial 
cost that would be incurred by recommending earlier treatment was a prohibitive factor for 
the NHS and the UK government to adopt a test and treat strategy, or higher CD4 
threshold.   
Even from a TasP perspective, whilst the results from HPTN-052 and the PARTNER interim 
results provided evidence of a very low risk of sexual transmission of HIV if undetectable on 
ART for vaginal sex over the study period 215,230, questions still surrounded the risk of 
transmission from anal sex. The PARTNER 2 study aims to boost the number of MSM 
recruited and followed up to provide to reduce the confidence interval around the 
estimated probability of transmission through anal sex whilst undetectable on ART 275. 
Additionally, there is still no consensus on whether the presence of an STI increases the 
probability of transmission from PLWH with undetectable viral load though the absence of 
linked transmission events in PARTNER despite 18% of HIV-positive MSM reporting an STI 
 285 
 
during follow-up is encouraging 231. In addition, data from Australian ART prescribers 
showed that over half of the respondents agreed very strongly that clinical benefit should 
be the priority when considering TasP 270. With the uncertainty surrounding clinical benefit 
and questions remaining over the application of TasP findings to MSM it was 
understandable that many UK clinicians held differing opinions over whether to 
recommend early ART to an individual or not.  
The qualitative data in this thesis revealed that men’s trust in the opinion of their HIV 
clinician was usually unequivocal as they were regarded as the “experts”. These findings 
were mirrored in a qualitative study amongst 53 Australian MSM, who stressed how 
important their clinician’s expertise and advice was in the matter of when to start ART 226. 
Underlying the implicit trust was the assumption amongst the men that in any given 
situation, different clinicians will have the same opinions over early ART and will make the 
same recommendation. Frustrations arose for men when their opinions over early ART 
were not in alignment with their healthcare providers, and this could lead to a breakdown 
in trust and communication. In one example, a clinician was apparently dismissive of early 
ART when the patient requested it. In this case, the doctor allegedly told the patient the he 
regularly sees patients for whom “the last thing they want to do is be on treatment, they 
beg not to be on treatment”. This scared the patient into delaying ART until after AHI, 
causing regret and stress. Since 2012, BHIVA guidelines have stated that all healthcare 
professionals should discuss the evidence for TasP, and it should be made available to those 
who wish to start 229, but an audit of UK HCP recently highlighted that subtle assumptions 
are made in the interpretation of these guidelines. Whilst 98% of clinicians would discuss 
TasP with individuals diagnosed in PHI who reported sexual partners since their diagnosis, 
fewer (81%) reported they would if no sexual partners were disclosed 276.  
In the UK, HIV clinicians are the gatekeepers to early ART, and have a responsibility to 
present both its risks and benefits to PLWH.  The results of this thesis highlight that this 
discussion should include the potential benefits to individual wellbeing in the form of 
reduced stigma, anxiety and stress, and improved self-efficacy, in addition to the clinical 
benefits and reduced infectiousness, which can all assist with coming to terms with HIV 
diagnosis. Furthermore, the survey results have shown that this discussion is acceptable to 
patients at the point of diagnosis. Qualitative work with HIV Specialist Nurses has 
highlighted the complexity involved in implementing TasP in the UK, however, reporting 
that decisions to start TasP are largely made on an individualised, patient by patient  
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basis 277. Under these circumstances, assessing the complexity and diversity of patients’ 
social scenarios, relationships and beliefs was perceived to be difficult and time-consuming, 
with the current lack of guidance and evidence available on which to base 
recommendations troubling.   
7.1.3.6 Short-course treatment in PHI had mixed appeal to MSM with early HIV 
infection 
Analysis of data from the UK Register of HIV Seroconverters in workstream 1 highlighted a 
notable decrease in the proportion of people opting for the short-course approach from 
87% of those who started ART in PHI in 2006-7, to 11% in 2008-2010. From early in the in-
depth interview study, a belief that initiation of short-course ART in PHI was not good for 
one’s health was apparent amongst some respondents. Compared to the 61% of ART-naïve 
men in the survey who agreed with the statement “I am ready to start ART now”, only 35% 
agreed with the statement “I would start ART now if I only had to take it for a year” and 
further 28% of men were unsure or undecided.  
The observed pattern of decreased use of short-course ART since 2006-7 could be the 
effect of the Strategies for Management of Antiretroviral Therapy (SMART) trial findings 48. 
This trial of CD4-guided treatment interruptions was stopped early in 2006 after interim 
analysis indicated increased risk of disease progression, AIDS and death was higher in the 
treatment interruption arm. Of note, death from cardiovascular, renal and hepatic diseases, 
which are typically attributed to ART toxicity, were hypothesised to be lower amongst those 
in the episodic treatment arm due to the lower exposure to ART, but were in fact 1.7 times 
higher (95% CI 1.1-2.5). Whilst the relevance of the SMART findings to a treatment naïve 
EHI population has been questioned (95% of participants enrolled in SMART were ART 
experienced) they may be off-putting for PLWH considering short-course therapy and their 
clinicians. Notably though, the SPARTAC trial found no evidence of increased risk of death 
or adverse events in the treatment interruption arm over the average follow-up of 4.2  
years 216.  Men in the interview study certainly expressed confusion as to how the short-
course strategy can still be used given the SMART findings. However, short-course 
treatment also held some appeal amongst the men interviewed. As the commitment to 
start was for a short period with a tangible end date, it could mediate the fears surrounding 
the permanence of treatment and reduce the barrier of commencing lifelong therapy.   
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The changes to international treatment guidelines following the START trial results have 
brought the feasibility of observational research into short-course ART into question. Any 
subsequent observational research into the clinical benefit of treating primary HIV infection 
will likely be problematic due to the loss of the temporal distinction between treatment in 
PHI and treatment in chronic infection. There is, however, still much research interest into 
the role of early ART in affording a functional cure. The RIVER (Research In Viral Eradication 
of HIV Reservoirs) trial is currently recruiting to investigate whether a “kick and kill” 
approach can reduce the size of the viral reservoir by using a combination of vorinostat to 
activate dormant reservoir cells, HIV-vaccines to boost the immune system, and early ART 
to kill the activated reservoir cells 278.  
7.1.3.7 Fear of side effects, adherence, resistance, stigma and permanence of treatment 
are barriers to early ART 
Concern over the side effects of ART was reported by 70% of ART-naïve men who agreed 
with the statement “I am concerned about the possible side effects of ART”. Fear of side 
effects was repeatedly mentioned in the in-depth interviews and it was notable that they 
were regarded almost as inevitable. Interestingly, it was not entirely the side effects 
themselves that induced fear amongst the men, but the impact that they could have on life 
and work, as well as the associated increased visibility of being ill. These were at odds with 
the desire to maintain as normal a life as possible, and to hide one’s HIV status as well as 
possible by avoiding looking ill.  Interestingly, HIV resistance was rarely mentioned in the in-
depth interviews, and almost half of MSM responded that they were unsure or undecided 
whether “Starting ART now could reduce my treatment options”.  Those who discussed 
drug resistance in the interviews presented it as a confusing concept, with men unsure as 
to whether early treatment would increase or decrease the risk of drug resistance. This 
finding was backed up in the survey data with, 47% of men unsure as to whether starting 
ART early would affect their future treatment options.  
Horne et al 279 have suggested that patient’s beliefs towards early ART can be grouped into 
two categories: perceptions  of the personal needs for treatment, and concerns over 
adverse effects. Applying this “necessity-concerns” framework to a cohort of PLWH who 
had just been recommended treatment, the researchers found that those who expressed 
concerns about adverse events prior to starting ART were more likely to delay starting and 
once on ART had lower adherence at 12 months. Conversely, those scoring highly on 
perceived necessity were more likely to adhere to ART.  What was interesting in this thesis 
 288 
 
was the fact that despite 70% of ART-naïve men reporting concerns about drug side effects, 
61% agreed with the statement “I am ready to start ART now”, possibly indicating that the 
perceived benefits of treatment outweigh the concerns.  
For 11% of survey respondents, initiating ART was perceived to not fit into their lifestyle. 
The in-depth interviews highlighted that adhering to ART was perceived to be logistically 
problematic amongst those who performed shift work or travelled long haul regularly, 
especially when drugs had to be taken at regular intervals and with food. Regular air travel 
with work was also a problem, with concerns that airport security may unintentionally 
disclose men’s HIV status to colleagues.  
The workstream 2 survey demonstrated that over half of respondents disagreed with the 
statement “I would not start ART now as I would have to be on it for the rest of my life”, 
however, 1 in 5 men agreed. The lifelong permanence of treatment was deemed a sobering 
prospect for some men in the interviews, especially the younger ones who thought it a very 
abstract concept. Interestingly, the older men interviewed held a more pragmatic view of 
daily ART, which was seen as just another set of pills to take on top of their existing ones. 
What was clear was that although men were aware that ART was likely lifelong, there was 
also hope in the discovery of a cure for HIV in their lifetimes.  
The barriers identified to early ART in this thesis, are similar to those reported from a 
qualitative study using focus group discussions to assess acceptability to ART amongst 
members of MSM and black African MSW communities living in Scotland by Young et al 242.  
Additional barriers reported by the authors were the perception that taking daily ART was 
too much work and a lack of knowledge and awareness about TasP, which was likely to be 
more of an issue as half of the respondents were HIV-negative. 
 The utility of early ART in reducing onward transmission  7.1.4
In this section I use the biological parameters of the simple model of HIV transmission 
(R0=βcD) 
61,65 to describe the potential utility of early ART to reduce secondary transmission 
from MSM with EHI. The utility of ART to reduce secondary transmission is primarily 
dictated by the acceptability and uptake of ART, which was demonstrated to be high in this 
population, with 47% of respondents having started ART by the time of survey completion.  
Utility also depends on whether MSM present to clinic in time to reduce peak viraemia, 
which influences the per contact risk of transmission.  Through the use of secondary 
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analysis of epidemiological data from the UK Register of HIV Seroconverters, in workstream 
1, it was possible to characterise viral load at first clinic presentation amongst UK MSM, 
estimate peak viraemia and changes in viral load at first presentation over calendar time.  
The ability of ART to reduce secondary transmission also depends on sexual behaviour over 
the period of EHI, which forms the “c” parameter (defined by Boerma and Weir as the 
exposure of susceptible to infected individuals 65). Data from the cross-sectional survey 
permitted estimation of transmission-risk behaviours following HIV diagnosis, along with 
identification of factors associated with them, with the in-depth interviews aiding 
understanding of these risk behaviours.  
7.1.4.1 Peak viraemia is seen in men who present to clinic at around 30 days after date 
of seroconversion 
Modelling of viral load at first presentation by time since seroconversion estimated peak 
viraemia to coincide with MSM presenting to clinic at around 30 days after estimated date 
of seroconversion, with a steady-state plateau reached at around 100 days.  From a public 
health perspective, if investigating risk of HIV transmission for a single sexual act, these 
results indicate that the benefit of immediate TasP in UK MSM presenting in EHI wanes 
after 30 days post seroconversion and, by 100 days post-seroconversion, becomes no more 
than it would be for those presenting in chronic infection. Current HIV testing practices in 
the UK, as demonstrated by the MSM recruited to the UK Register, result in only 24% of 
those diagnosed in EHI presenting to clinic within 30 days of their seroconversion. Even if 
ART is initiated immediately amongst those who present within this time, the median time 
to achieving undetectable viral load is estimated at 12 weeks 219. Hence, achievement of 
undetectable viral load by the advent of peak infection is unlikely in all but a few of the men 
presenting to clinic under current testing strategies. Notable however, were the large 
proportion of men (nearly 40%) who presented to clinic between 6 and 12 months after 
seroconversion with a viral load over 5.0 log10 copies/mL, indicating that some individuals 
present a heightened transmission risk after 100 days post-seroconversion. There is 
inevitably benefit in initiating TasP in EHI regardless of timing of peak viral load if the 
cumulative protective benefit is considered, as any reduction in the period of infectiousness 
will constrain the number of potential transmission events.  
Under current UK testing guidelines compiled by BHIVA and BASHH, MSM are 
recommended to test  “annually or more frequently if clinical symptoms are suggestive of 
seroconversion or ongoing high risk exposure” 280, though no further guidance as to the 
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frequency is given in the document. BASSH and PHE more recently published 
recommendations that MSM at high risk of HIV acquisition, (defined as having UAI with new 
or casual partners, or engaging in ChemSex) test for HIV and other STIs every three  
months 281.  HIV testing coverage amongst MSM attending sexual health clinics remains 
high, with 87% of MSM attending sexual health clinics tested in accordance with BASSH and 
PHE recommendations in 2015, and 80% of GUM clinics meeting testing targets in this risk 
group 282. This accompanies reported increases in proportion of MSM in the community 
who report ever having an HIV test and testing in the last year, though the extent of this 
increase varies between sub-populations. NATSAL-3, a weighted probability survey 
conducted in the UK between 2010-2012, estimated 60% of MSM had ever HIV tested in 
the UK 283, an increase from 44% from NATSAL-2 conducted in 2000 184, although the 
proportion of those ever testing who reported testing in the last year remained similar 
between surveys at one in three. This compares to the 91% of MSM recruited from gay 
commercial venues in London in 2013 who reported ever testing and 60% who reported 
testing in the last year, up from 63% and 26% respectively in 2000 284.  Despite the observed 
increases over time in the proportion of men ever testing and those who test regularly, 
both amongst clinic attenders and in the wider community, HIV incidence remains high 
within the UK MSM population.  
Recent mathematical modelling studies support the findings from the thesis literature 
review that undiagnosed EHI is disproportionately responsible for the ongoing increase in 
incidence observed amongst MSM in the UK 285–288, though estimates of the proportion of 
new infections vary by model from to 10% (95% CI 3-28%) 288 to 48% for undiagnosed PHI 
(90% CI 34-63%) 286. These models suggest more frequent HIV testing, in combination with 
immediate ART initiation, could have a large impact on HIV incidence amongst MSM in the 
UK 285–288. This may only be possible with a culture shift towards more regular HIV testing 
and immediate treatment in the UK, as to achieve an incidence of 1 per 1,000 person-years 
90% of MSM would need to be diagnosed within 1 year of infection, and 90% of those 
diagnosed would need to be undetectable on ART 285. The “test and treat” model was 
implemented in San Francisco in 2010, and since then a decrease in the population-level 
time to reaching undetectable viral load has been observed from 13 months in 2008 to 5 
months in 2012 289 with a decrease in the number of new infections diagnosed from 522 in 
2008 to 302 in 2014 290.  
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One suggested method of increasing repeat testing is through active recall, where STI clinics 
actively contact MSM who are at high risk of HIV acquisition, by phone, email or SMS (short 
message service). A recent meta-analysis of 17 studies which concluded that active recall 
improved re-attendance and retesting rates, though the increases differed notably across 
studies from 18-89% 291.   The national rollout of PHE’s home-sampling initiative is designed 
to reach members of high-risk populations who may not attend an STI clinics 292. 
Additionally, home-testing kits were licensed in the UK in 2014, and kits went on sale in 
2015, though there are concerns over linkage to care, with fears that people who test 
positive may not present to clinic for treatment. 
Nearly two thirds of the survey respondents in this thesis reported feeling unwell in the 
months preceding their HIV diagnosis but only one third of men reported testing for HIV 
because they felt unwell. Of these, over half reported their symptoms were severe enough 
to disrupt their daily routine. Improvement of the awareness of HIV symptoms amongst 
both MSM, and amongst primary and secondary care-givers to whom MSM may present 
with HIV seroconversion-like symptoms, should be a priority to improve HIV diagnosis in 
EHI. Awareness of seroconversion symptoms is of particular importance given that 1 in 5 
men who reported seroconversion-like symptoms also reported UAI whilst unwell, and this 
was more likely to be with a regular partner. Outside of sexual health services in the UK, 
adherence to the BHIVA/BASHH testing guidelines has been demonstrated to be poor, with 
only 27% of individuals eligible for a test actually receiving one 293.  
One potential method of increasing HIV testing outside of sexual health services is by the 
routine use of opt-out testing, whereby patients attending primary care centres and 
hospitals are automatically offered an HIV test, with the patient actively having to refuse 
the test. Indeed, current BHIVA testing guidelines recommend opt-out HIV testing upon 
registration with a GP surgery in areas of the UK where HIV prevalence is exceeds 2 per 
1000 people 280. Whilst no randomised evidence exists in the UK to endorse opt-out 
methods, recent evidence from a US RCT showed opt-out HIV testing, compared to opt-in 
and active choice testing, in an A&E department increases the acceptance rate (66%, versus 
38% and 51%, respectively) 294. In the UK, observational studies have estimated test uptake 
to range from 70-96.7% in acute general medicine (AGM) hospital settings 295–299 and 
between 44.5-75.4% in primary care settings 295,300–302, with qualitative studies also 
indicating positive attitudes to opt-out testing amongst STI clinic attendees in the South 
East of England 303,304. The feasibility of implementation has also been reported to be 
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good 305, with evidence that coverage rates in primary care settings can be increased 
further with staff training and promotion of HIV testing in surgeries 300. In addition, 
implementing opt-out testing in AGM scenarios in geographical areas where HIV prevalence 
exceeds two per 1000 people has been shown by all studies to date to exceed the cost-
effectiveness threshold of one new diagnosis per 1,000 tests 297–299,305–307 and may be more 
cost effective than implementing universal testing in primary care settings 306.  
7.1.4.2 Increase in viral load at first presentation seen over calendar time 
Analysis of UK Register data highlighted a temporal increase in viral load at first 
presentation from 4.7 to 5.1 log10 copies/mL between 1997 and 2012, a difference of 
75,774 copies/mL. Given the known positive correlation between infectiousness and viral 
load 66 this increased viraemia may translate to an increased risk of transmission in EHI over 
time. 
Increasing initial viral loads have previously been identified amongst a European cohort of 
seroconverters, with those seroconverting in 2001-2 having a 0.626 (0.497-0.754) log10 
copies/mL higher initial viral load than those seroconverting in 1985-90 195. Increases in viral 
set-point have also been reported over time, from  4.05 log10 copies/mL in 1980 to 4.5 log10 
copies/mL in 2002 308. Upward trends in viral load in early infection, have been summarised 
in a meta-analysis which indicated an upward trend in viral load in early infection of 0.39 
 log10 copies/mL between 1985 to 2010 
309, though the authors note that the trend has 
decelerated between 2005 and 2010. Interestingly, this deceleration is reflected in my 
study findings, however no study published to date has included data collected after 2010, 
so it is not currently possible to corroborate the upward trend observed from 2010 
onwards.  
These observed increases in initial viral load and viral set point have led some researchers 
to propose an evolutionary hypothesis that HIV has evolved over time to maximise 
transmissibility, necessitating a trade-off between higher viraemia and disease duration 194. 
Under this theory, plasma viral load is defined as a heritable trait, and maximum 
transmissibility is achieved by balancing the highest possible viral load achievable with the 
longest possible duration of infection. This theory has been challenged by recent research 
indicating that only 6% (95% CI 3-9%) of the variance in viral load can be explained by the 
viral genotype 310, and that the remaining variance is likely due to a combination of host 
and environmental factors.  
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7.1.4.3 Attenuation of transmission risk following diagnosis  
Amongst the men surveyed, 57% of men attenuated their HIV transmission-risk between 
diagnosis and questionnaire completion, a median of 76 days (IQR 29-191).  36% of men 
reported total abstinence from AI since HIV diagnosis, and a further 21% reported 
exclusively using condoms for AI. This reduction in high-risk sex following diagnosis is in line 
with findings from a meta-analysis demonstrating HIV transmission risk in the US is highest 
amongst undiagnosed individuals compared to diagnosed with HIV 125. It is also broadly in 
line with findings reported previously amongst MSM with PHI in London 128, though the 
proportion of MSM attenuating their risk of transmission in that study was higher at 76%. 
This may be due to differences in the definition of “risk elimination” which was defined by 
Fox et al as absence of all of the following at 3 months post-diagnosis: UAI with a regular 
partner of unknown or negative HIV status, UAI with casual male partners, and incident  
STI 128. Time from diagnosis to questionnaire completion was also different due to the study 
design, with men surveyed up to 12 months post-diagnosis in my study compared to 3 
months post-diagnosis.  
Whilst attenuation of risk behaviour following diagnosis has been previously reported, 
there are concerns surrounding the duration of this reduction. Heijman et al, compared 
sexual behaviour in the 12 months prior to seroconversion to sexual behaviour reported 
every year up to 4 years following seroconversion amongst MSM participating in the 
Amsterdam Cohort Studies 311. The authors reported that prevalence of UAI in the ART era 
was significantly lower at 1 year post-diagnosis at 53% compared to 72% at 12 months pre-
diagnosis. However, by 4 years post-seroconversion this had increased to 61%, with the 
95% confidence interval including the pre-diagnosis prevalence 48-74%. Furthermore, this 
finding did not appear to be driven by individuals who were on ART; the results were 
unchanged after restricting the analysis only to individuals who were ART naïve at the time 
of their study visit. It is therefore important to note that any risk attenuation seen amongst 
the men in this thesis is likely to be transient. Given the 12 week period often cited 
between initiating ART and achieving viral suppression, there is a potential public health 
argument to initiate ART as soon as possible after diagnosis in order for viral suppression to 
be achieved over the transient period of risk attenuation, meaning individuals will likely be 
undetectable by the time of resumption of UAI post-diagnosis. 1 in 3 MSM reported 
engaging in high-risk sex after HIV diagnosis 
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Whilst the majority of men attenuated high transmission risk behaviours after diagnosis, 1 
in 10 men had reported engaging in serodiscordant UAI since being diagnosed with HIV. 
Sadly, the small number of survey respondents meant there was not sufficient power to 
identify risk factors for engagement in serodiscordant UAI alone. But also of concern, and 
reported by a far higher proportion of men, was the engagement in ChemSex (defined as 
the use of any of any the following drugs before or during sex: GHB/GBL, methedrone, 
methamphetamine, piperazines or ketamine).  The use of drugs during sex, especially in 
group sex scenarios, was highlighted in the in-depth interviews a situation where consistent 
condom use, strategic positioning and serosorting were often challenging due to loss of 
inhibitions and control. The cross-sectional survey indicated that attending sex parties and 
engaging in ChemSex were very popular practices amongst UK MSM in the 6 months before 
HIV diagnosis,  and remained so after diagnosis, with 1 in 3 MSM reporting ChemSex after 
diagnosis. As explained eloquently by one respondent in the in-depth-interviews, Chems 
are often a necessary part of group sex, especially when BDSM practices such as fisting are 
involved, due to the length of time it takes to prepare the body and the potential for 
boredom if not using drugs. The documented lack of awareness and control whilst on 
Chems, and it’s often co-occurrence with UAI, group sex and BDSM practises 312,313, likely 
results in a high HIV transmission-risk from men with EHI who engage in these behaviours.  
After controlling for differences in the time from diagnosis to questionnaire completion, 
men were more likely to have reported engagement in serodiscordant UAI or ChemSex, if 
they had previously received PEP, if they had engaged in ChemSex prior to diagnosis, and if 
they reported serodiscordant UAI, and higher partner numbers prior to diagnosis. These 
findings are similar to those of Fox et al, who reported MSM with continued transmission-
risk behaviour were more likely to have another STI, use ketamine and have more sexual 
partners at baseline 128. These findings would indicate that men at most risk of transmitting 
HIV after receiving their HIV diagnosis were those who were at highest risk of acquiring 
(and likely also transmitting) HIV prior to diagnosis. It also supports the proposed theory 
that a “core group” of MSM are at risk of acquiring and transmitting HIV have a prominent 
role in the sustained increase in incidence observed in the UK 314.  
Of those who engaged in serodiscordant UAI or ChemSex since diagnosis, 59% were on ART 
though no clinical measures were available to determine undetectability amongst these 
men.  This was higher than the proportion of men who did not engage in high-risk sex who 
were on ART (41%) though the difference was not found to be significant at the p<0.05 
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level. This could be because there is no true difference in the populations, or because the 
difference is too small to be detected within a study of this size (type II error).  Even if these 
men had undetectable plasma viral load on ART, their engagement in UAI puts them at risk 
of contracting an STI. Increasing rates of gonorrhoea and syphilis have been observed 
amongst HIV-positive MSM in the UK 315, alongside outbreaks of novel STIs such as shighella 
and lymphogranuloma venereum (LGV)  316,317. 
Both the Swiss Statement and the BHIVA position statement on TasP emphasise the 
importance of absence of STI as a condition for being uninfectious 5,217. The BHIVA 
statement goes one step further by defining the conditions under which absence of STI can 
be assumed (both partners have had a comprehensive negative STI screen, and neither 
partner has had sex with anyone else since the screen, and the screen is repeated for each 
individual exposure with every new sexual partner and a negative result is obtained within 
the relevant ‘window’ period for each STI before the couple have sex again). A strong 
correlation has been demonstrated between HIV viral load in blood plasma, the genital 
tract and semen, and viral shedding has been shown even when plasma viraemia remains 
undetectable in the presence of STIs 318–320, though Kelley et al reported no increase in 
rectal viral load in the presence of STI when viral load was undetectable in the blood 
plasma 73. With the very high rates of STI observed in this population of MSM (44% had an 
STI co-infection at the time of HIV diagnosis) it is unlikely that the assumption of absence of 
STI can be reliably implemented in the case of MSM who engage regularly in UAI, and/or 
ChemSex.  
Interestingly, UAI with serosorting for positive partners was reported by a minority of men 
after diagnosis (8%). This is considerably lower than the proportion of HIV-positive MSM 
who report serosorting in the community (64%) 284. This may be due to the emotional 
upheaval that follows diagnosis and the necessary self-efficacy and agency involved to be 
able to disclose HIV status to partners, in combination with felt stigma. For those men who 
did serosort for HIV-positive partners to eliminate risk of transmission, it was not without 
problems. Men in the interviews reported a social pressure to bareback when having sex 
with other known positive men or in group sex scenarios. Requesting to use condoms in 
these scenarios could be difficult as other positive MSM sometimes did not see the point, 
and could even result in sexual rejection.  
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One of the survey findings was that engagement in high risk sexual behaviour was 
associated with the two statements traditionally suggestive of HIV treatment optimism: 
“Better HIV treatment means that people are less worried about catching HIV” and “Being 
on ART and having an undetectable viral load means that HIV is unlikely to be passed to a 
sexual partner even through anal intercourse without a condom”. Greater HIV optimism 
has consistently been shown to be independently associated with engagement in high-risk 
sexual behaviour amongst MSM 3,321–323.  However, research from early to mid-2000 
amongst MSM in England and Scotland reported under a third of MSM surveyed to be 
optimistic about HIV treatment 323–325. This relatively low prevalence of treatment optimism 
resulted in a low (estimated at between 8-13%) population attributable risk of HIV 
treatment optimism on the increasing high-risk behaviour observed at this time 326, 
meaning that 92-87% of the observed increase in risk was likely due to other factors.  It is 
important to acknowledge though that the construct of treatment optimism is essentially a 
measure of men’s attitudes and beliefs towards ART and these are likely to change over 
time given the improvements in understanding and increased evidence of the efficacy and 
effectiveness of TasP. Given the RCT evidence of the efficacy of TasP afforded by  
HPTN-052 215, and the encouraging real-world effectiveness reported by the PARTNER  
study 230, it is unsurprising that a large proportion of MSM (around 55%) agreed with the 
HIV optimism statements in my survey. It remains to be demonstrated, however, that an 
increase in treatment optimism will result in a further increase in high-risk behaviour, i.e. 
risk compensation. Longitudinal analysis of the risk behaviour component of the START trial 
will shed light on whether increases in high-risk sexual behaviours are seen amongst 
individuals on ART, with only the ART-naïve baseline data published to date 327.  
 Strengths and weakness of the research design 7.2
 The mixed methods approach 7.2.1
This study is the first mixed methods design to address acceptability of early ART amongst 
MSM with EHI.  The combination of quantitative and qualitative methods has permitted me 
to get closer to a multidimensional understanding of the acceptability and utility of early 
ART in preventing secondary transmission in the UK.  Whilst the in-depth interviews 
revealed some of the social, cultural and psychological issues experienced during early 
infection in a small group of men from a central London HIV clinic, the survey permitted 
estimation the prevalence of attitudes, beliefs and acceptability towards early ART in a 
wider population more representative of MSM across the UK. Triangulation of the survey 
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and qualitative data has also facilitated understanding of the mechanisms and explanations 
for the findings. This has been particularly helpful in understanding mechanisms behind 
surprising results, such as the large proportion of men who started early ART primarily for 
health benefit, though it was not recommended for clinical benefit in UK treatment 
guidelines at the time due to the lack of randomised evidence.  
A recent review article by Young and McDaid highlighted the lack of research into the 
acceptability of PrEP and TasP 221, noting there is no widely accepted method of measuring 
acceptability. A multitude of methods were identified in the literature to measure the 
construct of acceptability, ranging from ART/PrEP uptake and adherence, to attitudinal 
measures investigating: stigma, risk perception, concerns or barriers and scepticism of risk 
reduction.  Of the three studies in the review investigating acceptability towards TasP, all 
were cross-sectional surveys and measured acceptability by assessing attitudinal measures 
only 222,223,225. Another strength of this thesis is that it combines measures of attitudinal 
constructs assessing acceptability from both a qualitative and quantitative perspective, 
along with estimation of ART uptake amongst those with EHI through use of data from the 
UK Register and the cross-sectional survey. From this perspective it measures both 
acceptability and the intention to initiate ART, along with the actual uptake of ART. 
A weakness of this thesis was the lack of investigation into healthcare providers’ views on 
early ART, resulting in a one-sided perspective of early ART. Given the weight reportedly 
placed in healthcare providers’ opinions towards early ART by the men interviewed and the 
survey respondents, conducting both qualitative and quantitative research into provider’s 
attitudes and acceptability towards early ART would have been beneficial, though not 
possible in this programme of work given the time and funding constraints.  
Adopting a sequential mixed methods design in workstream 2 allowed the cross-sectional 
survey to be guided by findings from the qualitative component, and resulted in themes of 
enquiry which I would not have considered myself, for example the belief that early ART 
makes it easier to disclose HIV. By piloting the resulting questionnaire using cognitive 
interviewing, it was possible to ensure men understood the questions and belief 
statements as was intended, and provided an opportunity for men to suggest solutions 
where problems existed. Nonetheless there were also disadvantages in using this study 
design. The sequential manner in which the qualitative and quantitative components of 
workstream 2 were planned proved to be problematic due to the length of time it took to 
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recruit MSM with EHI for in-depth interviews in the first phase. This resulted in only half of 
the interviews informing the design of the questionnaire for phase 2, the cross-sectional 
survey. The sequential design also increased the total duration of workstream 2, which in 
combination with a one-year maternity leave, and the fast-moving world of research of 
early ART, meant that pivotal study results and policy changes occurred over the course of 
the PhD. This likely resulted in shifts in attitudes amongst MSM with EHI over this time and 
rendered findings out of date relatively quickly.   
 The study population 7.2.2
Overall weaknesses were also apparent in the selection of the study population. The men 
recruited to the studies in this thesis were relatively well-educated, currently employed, 
predominantly white and of a fairly homogenous age range.  The relationship between 
virological rebound on ART and low socioeconomic status has previously been noted to be 
higher amongst people who are unemployed, non-university educated, those who did not 
own their own home and did not have a support network 328. These people are largely 
underrepresented in my study population, which brings to question representativeness of 
the findings of high acceptability of early ART to the wider UK MSM population. In addition, 
the ethics committee stipulated that only MSM without mental illness could participate in 
workstream 2 studies, which may have resulted in the exclusion of men who were 
depressed or who particularly struggled to come to terms with their HIV diagnosis. PLWH 
with depression are known to be less likely to adhere to ART 329, and it is also conceivable 
that they may be less likely to want to initiate early.  
The MSM eligible for this study (recent HIV seroconverters) are likely to be more health 
conscious than those diagnosed in chronic infection 212. This is due to the selection bias 
imposed by eligibility criteria for seroconverter cohorts, involving a negative antibody 
followed by a positive within 12 months (requiring more frequent than annual repeat 
testing) or awareness of HIV seroconversion symptoms leading to presentation during 
acute infection (which may be more likely amongst MSM more knowledgeable about HIV). 
The rollout of RITA assays by PHE, which has enabled detection of MSM who likely 
seroconverted in the last 6 months but may who not have presented for a previous HIV 
test, may reduce this bias somewhat. However, 70% of survey respondents were identified 
through repeat HIV tests, and only 15% through a RITA assay, so any effect would have 
been marginal. If current efforts to expand HIV testing to include irregular and first time 
testers are successful, the findings of this thesis may not be relevant to this new population 
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of MSM diagnosed in EHI. First time or irregular HIV testers, given their irregular, or total 
lack of, previous interaction with GUM services in the past, are likely to be less health 
conscious and have differing levels of HIV knowledge. As could be observed from the in-
depth interview study, knowledge and beliefs about ART are likely to influence attitudes 
and beliefs towards early HIV treatment. Indeed, repeat cross-sectional national survey of a 
wider population of HIV-positive, negative and untested MSM in Australia, conducted in 
2011 and repeated in 2013, found only around 3% of respondents believed that HIV 
treatment reduced risk of  transmission 224.  
Caution should also be used when triangulating results from the various workstreams and 
study phases, as respondents for the different phases of the studies were from different 
populations, though all men included in the PhD studies had confirmed laboratory evidence 
of recent seroconversion. The qualitative data was collected from men attending only one 
inner-London HIV clinic, whilst the survey recruited men from 16 HIV clinics across the UK, 
and the secondary analysis of UK Register data involved data from all of the UK Register HIV 
centres, including those who did not participate in the survey. The UK-wide 
representativeness of the survey cannot be guaranteed as no sampling procedure was put 
in place at either the clinic, or patient level to ensure a representative population. Instead a 
convenience approach had to be adopted for financial and logistical reasons, and this is 
noted as an important limitation to the study. In the qualitative study, whilst I intended to 
sample MSM for the interview using an age-quota, this was not possible due to recruitment 
problems and the low response rate. Recruitment of men from multiple HIV clinics, 
sampled across the UK and stratified on age, ethnicity and ART status would have resulted 
in a more representative sample of MSM in the qualitative study. In the case of this study, 
where there was no money and the limited resources of just myself to conduct the study, 
this approach would not have been possible so I can only acknowledge the limitations 
resulting from a sub-optimal sampling procedure. 
 Implications for practice and policy 7.3
The original reason for undertaking this PhD in 2008 was for the findings to inform the 
development of policy surrounding TasP in recent seroconverters, under the assumption of 
no clinical benefit to early ART. Whilst the release of the START trial results in 2015 resulted 
in the change of guidelines to recommend ART to all, irrespective of infection stage or CD4 
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count, there are still findings from this thesis which are applicable to clinical care under the 
new BHIVA guidelines.  
 Implications for HIV healthcare providers  7.3.1
The two key implications of these thesis findings for healthcare providers are:  
1) that the perceived psychological and emotional benefits of early ART to PLWH are 
important in the decision to start ART early, and that initiating early ART may 
facilitate adjustment to an HIV diagnosis, 
2) that men are able to come to terms with an offer of ART at the point of diagnosis, 
and that many expect it to be offered then. 
My experience from both the in-depth interviews, and as backed up by the survey data, 
was that most men were open to discussion about early ART at the point of diagnosis. 
Furthermore, for some men early ART is an essential step in dealing with HIV diagnosis by 
reducing the stigma and anxiety caused by being “infectious”, thus facilitating living a 
“normal” life.  To quote one of the survey respondents, who notably had not resumed 
sexual activity, “Being on Atripla straight away has helped me feel better about my status. 
Emotionally I manage better knowing I am not infectious”.  
Current BHIVA guidelines recommend the evidence for TasP is discussed with all PLWH  330. 
They also state that assessment of risk of transmission should also be performed at this 
time and ART is offered to all PLWH, though these recommendations are graded as “good 
practise points” based on the clinical experience of the writing team. There is however a 
notable absence in the guidelines pertaining to the timing of such a discussion after 
diagnosis. Healthcare providers occupy a position of trust and many men rely on their 
transparency and judgement, especially on very complex decisions such as when to start 
ART. The high acceptability of early ART and expectation of starting at diagnosis found 
amongst MSM in this thesis supports the need for presentation of the clinical and 
preventive evidence for early ART to all patients at diagnosis, regardless of reported sexual 
behaviour, only then can both parties make an informed decision on when to start.  
The findings that a core group of MSM who report ChemSex, PEP and high partner numbers 
prior to diagnosis are more likely to engage in high-risk sex after diagnosis have important 
implications for prevention. The prevention benefits of early ART should be discussed and 
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TasP offered as a matter of priority amongst men who report these behaviours at HIV 
diagnosis, as they may be more likely to continue engaging in these behaviours. Extended 
risk-reduction counselling should also be discussed and recommended to assist them with 
assessing transmission risk.  
 The importance of earlier diagnosis  7.3.2
The findings from this thesis demonstrating attenuation of high-risk behaviour following 
diagnosis underline the influence of early diagnosis on reducing transmission risk. This in 
combination with the finding that only 24% of MSM seroconverters enrolled in the UK 
Register first present to clinic in the 30 days preceding peak viraemia, indicate the need for 
improving the rate of very early detection of HIV. The reduction the HIV window period 
afforded by the 4th generation ELISA, which detects antigen as well as antibody, in addition 
to rollout of RITA methods to identify likely recent infection, will likely have increased 
identification of EHI. But more will need to be done to increase detection within the 30 day 
window for ART to influence peak viraemia.  
The post-diagnosis attenuation in risk behaviour reported by the men recruited to the study 
by Fox et al 128 used in a stochastic model by White et al 331 to predict the number of 
infections likely arising from the population in the event that: HIV infection remained 
undiagnosed, and pre-diagnosis sexual behaviour continued throughout PHI; or that the 
infection was diagnosed immediately so post-diagnosis sexual behaviour was assumed 
through the entirety of PHI. If HIV remained undiagnosed throughout PHI, the estimated 
number of infections arising from the 98 men was 33-45, with a 65% reduction in this 
number if diagnosis of HIV had been made immediately following infection. The authors 
also modelled varying proportions of post-diagnosis sexual behaviour in PHI according to 
different testing intervals, and found that monthly testing could reduce the number of 
onward transmission events over PHI by 49-52%.  
The best approaches to facilitate diagnosis of HIV in early infection are currently unknown, 
but suggestions include active recall by GUM clinics of MSM known to be at high risk of HIV 
acquisition every three months, the use of home sampling and home testing. Perhaps the 
largest challenge will be in encouraging those who have never HIV tested to test. The 
national rollout of PHE’s home-sampling initiative is designed to reach members of high-risk 
populations who may not attend STI clinics 292. Additionally, home testing kits were licensed 
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in the UK in 2014, and kits went on sale in 2015, though there are concerns over linkage to 
care, with fears that people who test positive may not present to clinic for treatment.  
 Recommendations for future research 7.4
Given the high acceptability and early uptake of ART amongst UK MSM observed in this 
thesis, one crucial piece of work will be to monitor adherence in those who initiate early 
ART. Men who initiate early ART, in the absence of HIV symptoms may not be as motivated 
to take their medications and transmissions may occur when ART adherence is sub-optimal; 
a recent phylogenetic analysis demonstrated a high proportion of transmission events were 
attributable not just to PHI, but to chronic infection when ART interruption had  
occurred 332. Amongst respondents to my cross-sectional survey, 5% (n=3) of the MSM who 
started ART had stopped by the time they completed the questionnaire, though no further 
information was provided by them as to the reason for terminating ART. Clearly, this has 
worrying implications for onward transmission, HIV resistance, and also potentially 
increases the risk for non-AIDS complications. Studies investigating the rate of treatment 
interruption and non-adherence are necessary amongst MSM who initiate ART in EHI, 
alongside qualitative investigation of the reasons behind poor adherence and ART 
discontinuation. 
As expected, time from questionnaire completion to HIV diagnosis was highly associated 
with engagement in high-risk sex after diagnosis, with men more likely to engage the longer 
time since diagnosis. A temporary abstinence and reduction in risk-behaviour is 
unsurprising given the emotional and social upheaval that was described in the interviews 
following receipt of an HIV diagnosis. Men expressed the need to assimilate and adjust to 
their HIV status before resumption of sex, with the added barriers of HIV-related stigma 
and anxiety over transmission resulting in long-term sexual abstinence in some cases. The 
cross-sectional study design of this PhD did not permit identification of the typical time 
from diagnosis to resumption of sexual behaviour, and how this may differ amongst men 
who engage in high transmission-risk behaviours. A deeper understanding of factors 
surrounding resumption of sex after diagnosis during EHI, and the part early ART may play 
in facilitating it, may be achieved by incorporating repeat interviews and surveys into a 
cohort of recent seroconverters. 
Whilst the majority of the men in the survey were amenable to early ART, 9% of men stated 
they would not have initiated ART at diagnosis if offered, and the same percentage agreed 
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with the statement “I would prefer to delay starting ART for as long as possible even if it 
meant a small increased risk of getting serious illness”. Given the START trial results, it is 
important to further understand the barriers to early ART amongst MSM who hold these 
views in order to maximise uptake of early ART, and reduce the morbidity and mortality 
associated with treatment delays. It would also be useful to estimate the transmission 
potential from men who are less likely to initiate early, given the longer period of 
infectiousness amongst them.  
That 1 in 10 men surveyed reported serodiscordant UAI and 1 in 3 reported ChemSex 
following HIV diagnosis, indicates the presence of a core group at high risk of transmitting 
HIV over EHI. From a public health perspective, these men may hold the key to maximising 
the impact of TasP on secondary transmission during EHI, however, they may also present 
potential problems over the effectiveness of TasP. Recurrent UAI episodes put these men at 
high risk of contracting other STIs, which may increase viral load in the genital tract even 
when plasma viraemia is undetectable 333,334. ChemSex is also known to influence risk 
perception, further undermining the ability to negotiate safer-sex. A deeper understanding 
of the reasons men engage in ChemSex and how it can be performed in as safer 
environment as possible is necessary to understand how TasP can be used effectively  
Finally, treatment optimism is known to be associated with high-risk behaviours, and is 
likely to have increased over time given the randomised evidence of health benefits of early 
treatment and TasP, and subsequent changes to national and international guidelines. 
Questions remain however, as to whether this increase in optimism has resulted in an 
increase in high-risk sexual behaviour, i.e. risk compensation. Sexual behaviour studies have 
repeatedly shown increases in UAI, however the plethora of risk-reduction practices now 
adopted by MSM go beyond the basic use of condoms. Even the measure of serodiscordant 
UAI is subject to elements of risk-reduction if undetectable viral load, PrEP, strategic 
positioning and withdrawal before ejaculation are factored into the equation.  Future work 
to assess the presence of risk-compensation is necessary, however such studies will be 
challenging given the many nuances of risk-reduction currently used by MSM in the UK. 
 Final conclusions 7.5
MSM in the UK continue to carry a disproportionate burden of HIV with a continued rise in 
the annual number of new diagnosis from 2,760 in 2009 to 3,360 in 2015, and accounted 
for over half of the new diagnoses in 2015 335. This has occurred despite a good cascade of 
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HIV care in the UK with increased frequency of HIV testing and high uptake of ART; PHE 
estimate that 91% of diagnosed PLWH in the UK who are retained in care are on ART,  of 
whom 95% are virally suppressed 335.  
The results presented in this thesis suggest that MSM diagnosed with EHI and attending UK 
clinics find early ART to be a largely acceptable prospect, with very few men stating they 
would not have taken ART at diagnosis if offered. Importantly, these findings pre-dated the 
results of the START trial, so acceptability is likely to have increased further with new 
evidence of clinical benefit at CD4>500 cells/mm3 and the subsequent changes to BHIVA 
guidelines. The qualitative and quantitative components of this PhD highlighted that men 
believed in a health benefit from early ART, even in the absence of RCT evidence at the 
time. Interestingly, the men’s definition of health transcended the traditional medical 
definition of health as the absence of disease, or the improvement of surrogate markers of 
HIV progression. In their opinion, reduced anxiety about transmission and lessening the 
stigma of being infectious were major health benefits of early ART, and could contribute to 
better mental health, though these benefits are often overlooked by the medical 
profession. Notably, very few men who reported initiating ART in EHI in the survey did so 
purely to reduce transmission and this tied in with findings from the qualitative work. 
Whilst evidence of an altruistic element of protecting one’s sexual partners did exist, it was 
often accompanied by the responsibility to protect one’s own self from the negative 
feelings of guilt from secondary transmission and, in a worst case scenario, the possibility of 
prosecution.   
Ultimately though, whilst this study indicates that acceptability and uptake of early ART 
may be high in the study population, much still needs to be done to optimise the number of 
men who are diagnosed in EHI. Further expansion of HIV testing, especially targeted to 
those at risk of seroconversion is necessary to maximise any impact of TasP in EHI, with the 
most benefit from a public health perspective theoretically gleaned if ART is initiated by 30 
days post-seroconversion as was identified in my statistical analysis. Presently, this factor 
limits the utility of early ART to prevent transmission from individuals in EHI, with only 1 in 
4 MSM recruited to the UK Register presenting within this window period. Additionally, if 
the increase in viral load at first presentation over calendar time observed in this study is 
validated by other studies, earlier initiation may become increasingly effective in curbing 
the relatively higher transmission risk presented by those with EHI now, as compared to in 
previous years.  
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Also mediating the prevention effect of ART in EHI, is the reported attenuation of high 
transmission-risk sexual behaviour after diagnosis, with over a third of men reporting no 
sex since diagnosis in the survey. The in-depth interview study provided insight that sexual 
abstinence as a result of HIV diagnosis can be due to fear and anxiety over transmission, as 
well as felt and enacted stigma. Though the majority of men presented little to no 
transmission risk following diagnosis, a persistent population of around 1 in 3 MSM 
reported engagement in ChemSex and/or serodiscordant UAI following diagnosis. This core 
group of men, who typically report higher partner numbers, engagement in ChemSex and 
PEP use prior to diagnosis, likely have a key role to play in sustaining the epidemic. 
Increasing the proportion of this core group who start TasP in EHI may have a large impact 
on secondary transmission.  
Being diagnosed with HIV was undeniably a stressful time for the men interviewed, with 
many issues to come to terms with, including poorer health, a new sexual identity and the 
potential breakdown of relationships. Whilst presenting work from this thesis at various 
conferences, I have had many discussions with HIV care providers over the appropriateness 
of discussing ART at diagnosis, and was surprised that a notable proportion found it an 
unsuitable time to discuss ART. I believe that the results of this thesis provide evidence that 
men are receptive to discussion about ART at diagnosis, and furthermore, that it can be 
discussed in the context of being an empowering force as well as a lifelong duty. By 
identifying the positive elements it can bring to people’s lives, such as facilitating status 
disclosure, or removing the stigma of infectiousness,  
 In conclusion, I have demonstrated that early ART initiation is acceptable at diagnosis 
amongst MSM with EHI attending HIV clinics in the UK, not only to reduce risk of 
transmission to partners but for personal health reasons. It is perceived by men to provide 
holistic health benefits beyond the typically measured surrogate markers of HIV 
progression, morbidity and mortality. Men believed early ART increased quality or life, 
improved mental health by reducing or removing the stigma associated with infectiousness 
and facilitated the living of a “normal” life. The utility of ART in EHI to curb incidence in UK 
MSM is currently hampered by the small proportion of MSM who present to clinic, and are 
diagnosed, before peak viraemia. Given the sexual risk attenuation observed following 
diagnosis in this MSM population, expansion of HIV testing will not only increase the 
detection of individuals at peak viraemia, but earlier diagnosis will likely lead to further 
transmission-risk attenuation over the period of high infectiousness. That said, a core-
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group, comprising 1 in 3 of the MSM surveyed, appear to present a significant transmission-
risk following HIV diagnosis. Immediate initiation of early ART amongst these men is 
recommended to maximise the public health benefit of TasP, although engagement in 
ChemSex and UAI amongst this core-group may reduce the effectiveness of TasP through 
affecting ART adherence, interactions between ART and recreational drugs and the 
increasing risk of concurrent STI which is known to increase viraemia in the genital tract. 
Real-world evidence into transmission risk from MSM with EHI on sub-optimal ART, either 
due to the presence of STI, through recreational drug use, or poor adherence, is needed to 
further understand the role these men can play in the onward transmission of HIV.  
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Appendix 7 – Search strategy for scoping literature review 
“What is the rationale for initiation of ART in early HIV 
infection?”  
The database searched listed below were conducted by me and the abstracts reviewed. In 
addition to the database searches listed below, abstracts for the following conferences 
were searched by hand from January 2008 to March 2010 to ensure the inclusion of 
recently collected data which may not have been published: International AIDS Society 
(IAS), AIDS, European AIDS Conference (EACS) and Conference on Retroviruses and 
Opportunistic Infections (CROI). 
References cited in the articles included in the literature review chapter were also checked 
to ensure studies were not overlooked.  
Clinical and prevention benefits of early ART 
Total abstracts searched: 5193 
Databases searched:  PubMed and Ovid (search formatted for PubMed listed below) 
Dates: Literature published up to March 2010 
Language: English 
  Boolean operator Search terms 
 hiv[tiab] OR human immunodeficiency virus[tiab] OR human immuno-
deficiency virus[tiab] OR acquired immunodeficiency[tiab] OR  acquired 
immuno-deficiency[tiab] 
AND Highly Active Antiretroviral Therapy [tiab] OR Anti-Retroviral Agents[tiab] 
OR ((anti) AND (hiv[tiab])) OR antiretroviral*[tiab] OR ((anti) AND 
(retroviral*[tiab])) OR HAART[tiab] OR ART[tiab] OR HIV treatment[tiab] 
OR TasP[tiab] OR (treatment as prevention[tiab]) 
AND seroconver*[tiab] or early[tiab] or primary[tiab] or acute[tiab] or 
recent[tiab] or prevent*[tiab]  
AND initiat*[tiab] or start*[tiab] or begin*[tiab] or commenc*[tiab] 
NOT perinatal[tiab] or mother to child[tiab] or mother-to-child[tiab] or 
vertical[tiab] or infant[tiab] or child[tiab] or ped*[tiab] or paed[tiab] 
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Attitudes and acceptability towards early ART 
Databases searched:  PubMed and Ovid (search formatted for PubMed listed below) 
Dates: Literature up to March 2010 
Language: English 
Total abstracts searched: 1545 
  
Boolean operator Search terms 
 HIV[tiab] OR human immunodeficiency virus[tiab] OR human immuno-
deficiency virus[tiab] OR acquired immunodeficiency[tiab] OR acquired 
immuno-deficiency[tiab] 
AND Highly Active Antiretroviral Therapy [tiab] OR Anti-Retroviral Agents[tiab] 
OR ((anti) AND (hiv[tiab])) OR antiretroviral*[tiab] OR ((anti) AND 
(retroviral*[tiab])) OR HAART[tiab] OR ART[tiab] OR HIV treatment[tiab] 
OR TasP[tiab] OR (treatment as prevention[tiab]) 
AND attitud*[tiab] OR belie*[tiab] OR accept*[tiab] OR barrier*[tiab] OR 
facilitat*[tiab] OR feasib*[tiab] OR adopt*[tiab] 
AND seroconver*[tw] or ((early[tw]) or (primary[tw]) or (acute[tw])) or 
prevent*[tiab] 
AND  MSM[tiab] or (men who have sex with men[tiab]) or gay[tiab] or 
bisexual[tiab] or homosexual[tiab] 
NOT (perinatal[tiab] or mother to child[tiab] or mother-to-child[tiab] or 
vertical[tiab](perinatal[tiab] or mother to child[tiab] or mother-to-
child[tiab] or vertical[tiab] or paed*[tiab] or child*[tiab]) 
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Appendix 8 – UK Register of HIV Seroconverters case report 
proforma 
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Appendix 9 – UK Register of HIV Seroconverters MREC 
approval letter 
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Appendix 10 – In-depth and cognitive interview study LREC 
approval letter 
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Appendix 11 – In-depth interview study final topic guide 
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Appendix 12 – In-depth interview study participant 
information sheet 
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Appendix 13 – In-depth interview study consent form 
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Appendix 14 – Extract from framework analysis for the in-
depth interview study 
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Appendix 15 – Cognitive interview study participant 
information sheet  
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Appendix 16 – Cognitive interview study consent form 
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Appendix 17 – Questionnaire change log from piloted to final 
version for cross-sectional survey 
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Appendix 18 – Final questionnaire used in cross-sectional 
survey 
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Appendix 19 – MREC approval letter for amendment of the 
UK Register of HIV Seroconverters protocol to include the 
cross-sectional survey 
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Appendix 20 – Participant information sheet for the cross-
sectional survey nested in the UK Register 
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Appendix 21 – Consent form for the cross-sectional survey 
nested in the UK Register 
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Appendix 22 – Sensitivity analysis: factors associated with cART initiation, excluding individuals 
diagnosed in primary HIV infection 
 
  
Unadjusted 
HR 95% CI p Adjusted
a
 HR 95% CI p 
Year of SC (continuous per year increase) 1.09 1.07, 1.12 <0.001 1.09 1.07, 1.12 <0.001 
Sex 
  
  
  
  
Male 1 -
0.534 
1 -
0.086 
Female 1.12 0.78, 1.61 2 0.91, 4.41 
Exposure group 
     
 
MSM 1 -
0.878 
1 -
0.196 MSW 0.97 0.70, 1.37 0.57 0.20, 3.24 
IDU 1.34 0.43, 4.18 0.81 0.28, 1.15 
Age at seroconversion (per 10 year increase) 1.11 1.01, 1.21 0.022 1.12 1.03, 1.22 0.011 
Analyses based on 767 individuals, contributing 2621 person years at risk, of whom 590 initiated ART. HR= Hazard ratio; CI=confidence interval; MSM=sex between men; MSW=sex between men and women; 
IDU=injecting drug use. a=adjusted for all other variables in the table 
 
  
  
 
4
1
7
 
Appendix 23 – Sensitivity analysis: factors associated with risk of cART initiation including CD4 at HIV 
diagnosis 
  Unadjusted HR 95% CI p Adjusted
a
 HR 95% CI p 
Year of seroconversion (per year increase) 1.04 1.02, 1.06 <0.001 1.04 1.02, 1.06 <0.001 
Sex 
  
  
  
  
Male 1.00 -
0.985 
1 -
0.335 
Female 1.00 0.77, 1.31 1.21 0.82, 1.79 
Exposure group 
     
 
MSM 1.00 -
0.859 
1 -
0.441 IDU 1.05 0.85, 1.29 0.85 0.63, 1.15 
MSW 0.87 0.36, 2.11 1.29 0.52, 3.20 
Age at seroconversion (per 10 year increase) 1.14 1.08, 1.22 <0.001 1.13 1.06, 1.20 <0.001 
HIV test  interval
b
       
<0.001 30 days or more 1.00 -  1 - 
<30 days 1.42 1.24, 1.63 <0.001 1.36 1.19, 1.56 
CD4 count at HIV diagnosis
c
 (continuous) 0.91 0.89, 0.92 <0.001 0.91 0.89, 0.92 <0.001 
Analyses based on 1353 individuals, contributing 3172 person years at risk, of whom 1026 initiated ART. HR= Hazard ratio; CI=confidence interval; MSM=sex between men; MSW=sex between men and women; 
IDU=injecting drug use. a=adjusted for all other variables in the table; b=interval between HIV antibody negative and positive tests; c=CD4 count modelled as square root transformed cells/mm3 
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Appendix 24 – Sensitivity analysis: Temporal trends in ART initiation, starting combinations and time to 
stopping ART in patients with primary HIV infection, excluding those enrolled in SPARTAC trial 
 
 
  
Calendar year of seroconversion
a
 
  
  1998-99 2000-01 2002-03 2004-05 2006-07 2008-09 2010-11 p-value 
N 61 98 107 113 116 139 232  
% (95% CI) initiating ART in PHI 27.9 50 32.7 9.7 7.8 13 19.8 <0.001
b
 
% (95% CI) of those starting ART in PHI who stop 
within 12 months
c
  
47.1 59.2 68.6 63.6 88.9 11.1 10.9 <0.001
d
 
ART=combination antiretroviral therapy; PHI=primary HIV infection; CI=confidence interval; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=non-nucleoside reverse transcriptase inhibitor; PI=protease 
inhibitor. a=Calendar year of seroconversion modelled as categorical year groups; b=p-value for heterogeneity from logistic regression model of effect of year group of seroconversion (categorical) adjusting for sex, 
exposure group (MSM, MSW, IDU), age at seroconversion (continuous, per 10 years) and HIV test interval (30 days or more, < 30 days); c=time to event analysis assessing time from ART initiation in PHI to stopping 
ART; based on 251 individuals starting ART in PHI, contributing 478 person-years at risk, of whom 168 stopped therapy; d p-value for heterogeneity in Cox proportional hazards model, modelling year group of 
seroconversion (categorical) and adjusting for sex, exposure group (MSM, MSW, IDU), age at seroconversion (continuous, per 10 years) and HIV test interval (30 days or more, < 30 days) 
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